<SEC-DOCUMENT>0001493152-21-011927.txt : 20210927
<SEC-HEADER>0001493152-21-011927.hdr.sgml : 20210927
<ACCEPTANCE-DATETIME>20210517170404
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001493152-21-011927
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		57
FILED AS OF DATE:		20210517
<PUBLIC-REL-DATE>20210927
DATE AS OF CHANGE:		20210518

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Hillstream BioPharma Inc.
		CENTRAL INDEX KEY:			0001861657
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				842642541
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-04884
		FILM NUMBER:		21932058

	BUSINESS ADDRESS:	
		STREET 1:		1200 ROUTE 22 EAST
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		302-743-2995

	MAIL ADDRESS:	
		STREET 1:		245 MAIN STREET
		STREET 2:		SUITE 204
		CITY:			CHESTER
		STATE:			NJ
		ZIP:			07930
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
confidentially submitted to the U.S. Securities and Exchange Commission on May 17, 2021 pursuant to the Jumpstart Our Business Startups
Act of 2012</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
Statement No. 333- </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
</FONT></B><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">WASHINGTON, D.C. 20549</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
S-1</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF 1933</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>HILLSTREAM
BIOPHARMA, INC.</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Exact name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>84-2642541</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of</FONT></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</FONT></P></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Primary
    Standard Industrial</FONT></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
    Code Number)</FONT></P></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer</FONT></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1200
Route 22 East, Suite 2000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bridgewater,
NJ 08807</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>(908) 955-3140</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address,
including zip code and telephone number, including area code of registrant&rsquo;s principal executive offices)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Randy
Milby<BR>
Chief Executive Officer<BR>
Hillstream BioPharma, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1200
Route 22 East, Suite 2000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bridgewater,
NJ 08807</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>(908) 955-3140</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name,
address, including zip code, and telephone number, including area code, of agent for service)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Copies
to:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jeffrey
J. Fessler, Esq.<BR>
Nazia J. Khan, Esq.<BR>
Sheppard, Mullin, Richter &amp; Hampton LLP<BR>
30 Rockefeller Plaza<BR>
New York, NY 10112-0015<BR>
Tel.: (212) 653-8700</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approximate
date of commencement of proposed sale to the public:<BR>
As soon as practicable after the date this registration statement becomes effective.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933 check the following box: [X]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
&ldquo;smaller reporting company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 23%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer [&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 21%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer [&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 23%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer [X]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 27%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company [X]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company [X]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CALCULATION
OF REGISTRATION FEE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Title of Each Class of Securities to be Registered</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Proposed <BR>
Maximum Aggregate <BR>
Offering Price<SUP>1</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Amount of Registration</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Fee<SUP>2</SUP></B></FONT></P>

</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 60%">Common stock, par value $0.0001 per share</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">$</TD><TD STYLE="text-align: right; width: 16%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">$</TD><TD STYLE="text-align: right; width: 16%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants to be issued to the representative of the underwriters <SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock underlying warrants to be issued to the representative of the underwriters <SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
    solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933,
    as amended. Includes shares of common stock that the underwriters have the option to purchase to cover over-allotments, if any.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calculated
    pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price of the securities registered hereunder
    to be sold by the registrant.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    registration fee required pursuant to Rule 457(g).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have agreed to issue to the representative of the underwriters warrants to purchase shares of common stock representing up to 5%
    of the common stock issued in the offering. The representative&rsquo;s warrants are exercisable at a per share exercise price equal
    to 125% of the public offering price per share of the common stock offered hereby. As estimated solely for the purpose of calculating
    the registration fee pursuant to Rule 457(g) under the Securities Act, the proposed maximum aggregate offering price of the representative&rsquo;s
    warrants is $ &nbsp;&nbsp;&nbsp;&nbsp;, which is equal to 125% of $ (5% of $&nbsp;&nbsp;&nbsp;&nbsp;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date
as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration
statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does
it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><B>PRELIMINARY
    PROSPECTUS</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><B>SUBJECT
    TO COMPLETION</B></FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><B>DATED
    MAY 17, 2021</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="logo_001.jpg" ALT="" STYLE="height: 63px; width: 130px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hillstream
BioPharma, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
is a firm commitment initial public offering of shares of common stock of Hillstream BioPharma, Inc. Prior to this offering, there has
been no public market for our common stock. We anticipate that the initial public offering price will be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to apply to list our shares on The Nasdaq Capital Market under the symbol &ldquo;HILS.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company&rdquo; as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have
elected to comply with certain reduced public company reporting requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
in our common stock involves risks. See &ldquo;Risk Factors&rdquo; beginning on page 12.</I> <B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per Share</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; text-align: justify">Price to the public</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Underwriting discounts and commissions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds to us (before expenses)<SUP>1</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
not include a non-accountable expense allowance equal to 1.0% of the gross proceeds of this offering payable to the underwriters. We
refer you to &ldquo;Underwriting&rdquo; beginning on page 110 of this prospectus for additional information regarding underwriting compensation.
The registration statement, of which this prospectus is a part, also registers for sale warrants to purchase shares of common stock to
be issued to the representative of the underwriters. We have agreed to issue the warrants to the representative of the underwriters as
a portion of the underwriting compensation payable to the underwriters in connection with this offering. We refer you to &ldquo;Underwriting&rdquo;
beginning on page 110 of this prospectus for additional information regarding underwriting compensation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted the underwriters a 45-day option to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock solely to cover over-allotments, if
any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters expect to deliver the shares on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-size: 10pt"><B>Quatramers:
    A Tunable, Tumor-Targeting Platform</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD ROWSPAN="5" STYLE="border: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_006.jpg" ALT="" STYLE="width: 194px; height: 345px"></FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P></TD>
    <TD STYLE="text-align: center; border-top: Black 1.5pt solid; border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_001.jpg" ALT="" STYLE="height: 68.8pt; width: 36.3pt"></FONT></TD>
    <TD STYLE="text-align: left; border-top: Black 1.5pt solid; border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>mRNA
    / DNA</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_002.jpg" ALT="" STYLE="height: 50.15pt; width: 78.65pt"></FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1.5pt solid; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Small
    molecules</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_003.jpg" ALT="" STYLE="height: 43.25pt; width: 54.75pt"></FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1.5pt solid; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proteins
    / Peptides / Cytokines</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_004.jpg" ALT="" STYLE="height: 54.75pt; width: 47.1pt"></FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1.5pt solid; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Antibody
    therapeutics: ADC / scFv</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_005.jpg" ALT="" STYLE="height: 56.55pt; width: 56pt"></FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1.5pt solid; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Multi-Therapeutics:
    combination of payloads</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_007.jpg" ALT=""></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TABLE
OF CONTENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_001">PROSPECTUS SUMMARY</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_002">RISK FACTORS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">12</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#g_001">INFORMATION REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#g_002">INDUSTRY AND MARKET DATA</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#g_003">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#g_004">DIVIDEND POLICY</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#g_005">CAPITALIZATION</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">51</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_003">DILUTION</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#g_006">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">54</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#hj_001">BUSINESS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">62</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_001">MANAGEMENT</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">92</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_002">EXECUTIVE AND DIRECTOR COMPENSATION</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: -10pt; text-align: center; font: 10pt Times New Roman, Times, Serif">96</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_003">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: -10pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_004">PRINCIPAL STOCKHOLDERS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">102</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_005">DESCRIPTION OF CAPITAL STOCK</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">103</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_006">SHARES ELIGIBLE FOR FUTURE SALE</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_007">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF OUR COMMON STOCK</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_008">UNDERWRITING</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_009">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_010">EXPERTS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_011">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: -10pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_007">INDEX TO FINANCIAL STATEMENTS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
have not, and the underwriters have not, authorized anyone to provide any information or to make any representations other than those
contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take
no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give to you. The
information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this
prospectus or any sale of our common stock.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
should rely only on the information contained in this prospectus. No dealer, salesperson or other person is authorized to give information
that is not contained in this prospectus. This prospectus is not an offer to sell nor is it seeking an offer to buy these securities
in any jurisdiction where the offer or sale is not permitted. The information in this prospectus is accurate only as of the date of this
prospectus, regardless of the time of delivery of this prospectus or of any sale of these securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All
trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. Solely for convenience,
the trademarks and trade names in this prospectus are referred to without the &reg; and <SUP>TM</SUP> symbols, but such references should
not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights
thereto.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_001"></A>PROSPECTUS
SUMMARY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following summary highlights selected information contained elsewhere in this prospectus and is qualified in its entirety by the more
detailed information and financial statements included elsewhere in this prospectus. It does not contain all the information that may
be important to you and your investment decision. You should carefully read this entire prospectus, including the matters set forth under
&ldquo;Risk Factors,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations,&rdquo;
and our financial statements and related notes included elsewhere in this prospectus. In this prospectus, unless context requires otherwise,
references to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; HSBP&rdquo; &ldquo;Hillstream BioPharma,&rdquo; or &ldquo;the Company&rdquo;
refer to Hillstream BioPharma, Inc. and its subsidiary.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a biotechnology company leveraging our tumor targeting proprietary platform, Quatramer&trade;, to develop a pipeline of novel product
candidates to treat rare and devastating cancers. Quatramer allows us to leverage and exploit key undruggable targets and novel emerging
pathways, such as Iron Medicated Cell Death (&ldquo;IMCD&rdquo;) in tumors and facilitate the delivery of potent drug payloads directly
to the tumor microenvironment (&ldquo;TME&rdquo;) while sparing healthy tissue. By efficiently  extending the circulation
half-life as well as targeting delivery to the tumor site, Quatramer traps payloads into the TME and exploits IMCD, an emerging orthogonal
anti-cancer approach which utilizes a fundamental recognized mechanism of tumor growth using iron transport, iron metabolism and iron-led
reactive oxygen species (&ldquo;ROS&rdquo;) production. We are building a portfolio of long-acting product candidates using Quatramers
including our most advanced product candidate, HSB-1216, a long-acting IMCD modulator of tumors. Our second product candidate, HSB-888,
is a dual-loaded IMCD modulator coupled with an ultra-low dose next generation anthracycline analogue for solid tumors which has a highly
synergistic tumor killing capacity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quatramers
are small ~100 nanometer sized particles with the ability to carry both payloads and exterior coatings incorporated in a proprietary
polymeric mixture which is designed with specific physico-chemical parameters to target specified cells or tissues and converge a therapeutic
payload at the site of disease to boost efficacy while abating adverse effects on healthy tissue. Quatramer is also highly modular and
tunable allowing us to design and develop various follow-on product candidates including (i) small proteins including cytokines/growth
factors (TNF-alpha, IL-2, IL-12 and IL-15), metabolic hormones (such as insulin) (ii) peptides (up to 40 amino acids long), (iii) oligonucleotides
such as ribonucleic acid (&ldquo;RNA&rdquo;) including messenger RNA (&ldquo;mRNA&rdquo;) and small interfering RNAs (&ldquo;RNAi&rdquo;),
complementary deoxyribonucleic acid (&ldquo;cDNA&rdquo;), as well as multiple cytokine and biologic products with potentially significant
advantages over existing and development-stage drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="formdrs_001.jpg" ALT="" STYLE="height: 203px; width: 330px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trident
Artificial Intelligence (&ldquo;TAI&rdquo; or &ldquo;Trident&rdquo;), our artificial intelligence platform, is a novel approach
to identify synthetic lethal sensitivities associated with degrees of cell plasticity using biomarkers that can be translated for patient
selection and stratification. TAI integrates diverse public datasets, such as The Cancer Genome Atlas as well as other available datasets,
which we intend to couple with data from our planned clinical programs in order to identify biomarkers and novel gene signatures to stratify
patients prospectively as we move compounds from bench to bedside.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
1: Our Platform Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_002.jpg" ALT="" STYLE="height: 307px; width: 320px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
most advanced product candidate is HSB-1216, which we intend to develop in the clinic in 2022 for multiple high unmet need solid tumors,
which exploits a key feature of certain tumors that rely on an excessive Labile Iron Pool (&ldquo;LIP&rdquo;) within the cell
to modify the dysregulated iron microenvironment of cancer. We have received orphan drug designation in small cell lung cancer
(&ldquo;SCLC&rdquo;) for HSB-1216&rsquo;s active payload, pHSB-1216.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
second product candidate, HSB-888, is in investigational new drug (&ldquo;IND&rdquo;) enabling studies and may be developed in
the clinic in 2022 for multiple sarcomas. The U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) has granted the payload of HSB-888,
pHSB-888, a rare pediatric disease designation and orphan drug designation for pediatric osteosarcoma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also plan to develop other Quatramer based compounds with therapeutic cargoes from our product pipeline, which include DNA-based contents
which hijack the tumor&rsquo;s genetic code and kill the tumor from within by generating an array of cancer killing cytokines, such as
tumor necrosis factor alpha (&ldquo;TNF-alpha&rdquo;) and potentially interleukin-2 (&ldquo;IL-2&rdquo;). The platforms&rsquo; tunability
stems from the fact that the system can be modified and adjusted to deliver single or multiple ratios of payloads in order to optimize
synergistic mechanisms of action in lower doses in order to eradicate rare cancers and devastating tumors with minimal or no treatment
options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
2: Quatramer is a tunable tumor-targeting platform</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #002060">
    <TD COLSPAN="3" STYLE="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: white"><B>Quatramer:
    A Tunable, Tumor-Targeting Platform</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD ROWSPAN="5" STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 33%; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #44546A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #44546A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #44546A"><IMG SRC="formdrs_003.jpg" ALT="" STYLE="height: 383px; width: 200px"></FONT></P></TD>
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #44546A"><IMG SRC="formdrs_004.jpg" ALT="" STYLE="height: 88px; width: 104px"></FONT></TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>mRNA
    or vector DNA</B> (TNF-alpha, IL-2, IL-15, IL-12)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #44546A"><IMG SRC="formdrs_005.jpg" ALT="" STYLE="height: 82px; width: 114px"></FONT></TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Small
    molecules</B>: degradation inhibitors, PI-3K (delta)/HDAC6 &amp; BCL-2 inhibitors, ferroptosis inducers</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #44546A"><IMG SRC="formdrs_006.jpg" ALT="" STYLE="height: 90px; width: 94px"></FONT></TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Large
    proteins</B>: large peptides BCL-2, MCL-1 and MUC1-C and several larger proteins such as insulin</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #44546A"><IMG SRC="formdrs_007.jpg" ALT="" STYLE="height: 98px; width: 96px"></FONT></TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Antibody
    based therapeutics</B>: scFv&rsquo;s, ADCs, ADNCs (antibody-drug nano-conjugate) systems can deliver greater toxin (DAR* &gt;100)
    to tumors vs. ADCs</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #44546A"><IMG SRC="formdrs_008.jpg" ALT="" STYLE="height: 94px; width: 94px"></FONT></TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Multi-Therapeutics</B>:
    combination of multiple payloads including DNA, mRNA, small molecules, proteins and antibodies possible</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Product Candidates and Research Programs</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are leveraging our proprietary technologies and developing multiple product candidates with differentiated profiles designed to address
rare and devastating cancers, as shown below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #002060">
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; border-right: white 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: white"><B>Pipeline</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%; border-right: white 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: white"><B>Drug
    / Mechanism</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; border-right: white 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: white"><B>Indication</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%; border-right: white 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: white"><B>IND
    Enabling</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; border-right: white 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: white"><B>Phase
    1 (ex-US)</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: white"><B>Phase
    1b/2</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HSB-1216</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Iron
    mediated <BR>
    Cell Death </FONT></TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solid
    tumors</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: white 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_009.jpg" ALT="" STYLE="height: 26px; width: 209px"></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: white 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HSB-888</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-1216
    and novel low dose anthracycline</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sarcomas</FONT></TD>
    <TD STYLE="border-right: white 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_009.jpg" ALT="" STYLE="height: 26px; width: 209px"></FONT></TD>
    <TD STYLE="border-right: white 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HSB-1218</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-viral
    / Iron mediated Cell Death</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVID-19</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: white 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_010.jpg" ALT="" STYLE="height: 26px; width: 93px"></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: white 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HSB-114</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TNF-alpha
    DNA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Metastatic
    Soft Tissue Sarcoma</FONT></TD>
    <TD STYLE="border-right: white 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_011.jpg" ALT="" STYLE="height: 26px; width: 86px"></FONT></TD>
    <TD STYLE="border-right: white 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-left: black 1pt solid; background-color: white"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HSB-510</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(NCATS-NIH
    CRADA)</FONT></P></TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bifunctional
    PI-3 Kinase (delta) &amp; HDAC-6 inhibitor</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solid
    tumors &amp;<BR>
    Lymphomas</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: white 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_012.jpg" ALT="" STYLE="height: 26px; width: 76px"></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: white 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-1216</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-1216
is an IMCD modulator delivered by our proprietary Quatramer carrier. We intend to submit an IND to the FDA and obtain clinical data to
support our strategy in 2022. In a compassionate use human study in Germany, pHSB-1216 was studied in seven patients with positive
results in heavily pretreated and therapy resistant cancers. By design, HSB-1216 is an injected product which circulates systemically
after a subcutaneous injection and concentrates in the TME of solid tumor masses. The localization of HSB-1216 has been demonstrated
in multiple <I>in vivo</I> models with pharmacodynamic signals showing significant decreases in tumor size after multiple weekly injections.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
3: Shifting the Intracellular Redox Balance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_013.jpg" ALT="" STYLE="height: 317px; width: 432px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a tumor concentrating therapeutic, HSB-1216 has the potential to be used in cancer patients who have failed standard-of-care therapies
for multiple rare solid tumors with devastating consequences due to a lack of therapies. We anticipate IND approval in the first half
of 2022 and top-line data readout of our first clinical program  in late 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-888</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemotherapy,
as an important part of antitumor treatment, exerts anticancer effects by killing cancer cells, and anthracycline-based regimens have
been and continue to be the mainstay of treatment for a vast majority of tumors. The clinical applications of anthracycline regimens,
above certain dose ranges have limited their use due to adverse events, including cumulative lifetime doses resulting in cardiotoxicity.
The nonspecific accumulation of anthracyclines, such as doxorubicin and similar agents in non-target tissues such as cardiac cells continue
to be a problem.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-888
is a dual-loaded IMCD modulator coupled with an ultra-low dose next generation anthracycline analogue for solid tumors. One
component compound in HSB-888 is a next generation anthracycline analogue approved and marketed in China and Japan which has potent
antitumor activity and indicated for multiple tumor types, with an improved therapeutic index compared to doxorubicin. We believe by
targeting the agent in our proprietary dual-loaded Quatramer with our novel IMCD modulator confers key benefits for multiple
reasons, including a synergistic ultra low-dose approach as well as leveraging a key differentiating mechanism of iron-mediation to
kill the tumor and reduce off target toxicities simultaneously.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-888
has the potential to be used in solid tumors whereby a potent anthracycline may be effective but prohibitive in current available forms
due to their off-target effects. We anticipate leveraging the human data available from Japanese and Chinese studies to potentially obtain
an IND approval in  2022 and top-line clinical data soon after.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>HSB-114</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">HSB-114 is a novel immunotherapeutic agent which
uses our non-viral Quatramer platform to deliver the human TNF-alpha gene to cancer cells to selectively increase intratumoral TNF levels
in tumors while managing the toxicity associated with such approaches remains a major unmet need. We believe we have developed a novel
approach to include a peptide-DNA complex which preferentially releases genetic material and localizes into the nucleus of the delivered
cancer cell and have demonstrated in pre-clinical oncology models using TNF to be highly effective in achieving a desired tumor response.
We believe this intratumoral expression of secreted cytokines, such as TNF, thus represents a novel approach for inducing anti-tumor
activity and potentially reprogramming the tumor immune microenvironment and intend to develop this technology further to strengthen
our pipeline.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
Programs</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
technology platform enables us to generate a pipeline of earlier-stage product candidates spanning multiple targets in oncology utilizing
diverse payloads to treat rare and devastating tumors. While the payloads in our most advanced product candidates, HSB-1216 and HSB-888,
are novel, and have pilot and extensive human data in multiple solid tumors, any solid tumor or non-oncologic disease requiring delivery
of a peptide, protein or biologic is conceivably a candidate for our technology. Our early-stage pipeline is focused on rare and devastating
diseases where our technology could potentially deliver meaningful benefit across a wide range of oncologic and viral diseases. We have
tested several peptides, nucleic acids, proteins, small molecules and antibody constructs against multiple targets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Strategy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to disrupt the biotechnology landscape by developing novel therapeutics by leveraging both our targeted-delivery Quatramer platform-based
therapeutics and our Trident platform and to address significant unmet medical needs, with a focus on treatments for cancer. We believe
that our technology has the potential to generate differentiated products that have massive potential to treat multiple unmet need, rare
and devastating tumors. We are prioritizing our efforts based on our assessments and expertise of clinical development and regulatory
strategy, unmet medical needs and market forces.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical components of our business strategy to achieve our goals include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Develop our drug candidate,
  HSB-1216, in solid tumors.</I></FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
from a compassionate use study in Germany led us to progress HSB-1216 into IND-enabling studies with the ultimate goal of launching a
Phase 1b/2a trial in 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Develop our combination
  drug candidate, HSB-888, for pediatric sarcomas.</I></FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-888
is currently in IND-enabling trials with the ultimate goal of achieving an IND from the FDA in 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Leverage Our Trident Artificial
  Intelligence Platform.</I></FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAI
is a deep learning engine that identifies synthetic lethal sensitivities associates with degree of cell plasticity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Develop and commercialize
  Quatramer in collaboration with leading pharmaceutical companies.</I></FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our internal development programs, we actively seek opportunities to collaborate with recognized biopharmaceutical companies
to develop Quatramer incorporating therapeutic payloads from their proprietary product portfolios.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Leverage our novel
  platform to develop a pipeline of high value Quatramer leads.</I></FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tunability of our technology allows us to efficiently expand our pipeline of Quatramer, both on our own and in collaboration with others,
through various combinations of targeted DNA encoded for anti-tumor cytokines and therapeutic payloads, which enables us to move into
other areas of oncology, including immuno-oncology whereby we could increase the effectiveness of immune checkpoint inhibitors (&ldquo;ICIs&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Commercialize proprietary
  Quatramer based products, including HSB-1216, directly in the United States and with collaborators outside the United States.</I></FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have retained the worldwide rights to HSB-1216 and our other proprietary pipeline and expect to maintain similar rights with respect
to other proprietary Quatramer we develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Continue to extend and
  protect our product technology and Quatramer through our intellectual property portfolio.</I></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek to protect our novel platform through issued U.S. and international patents as well as know-how and trade secrets relating
to the design and manufacturing of our technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Team</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
are led by a management team with extensive scientific, drug development, and commercialization experience across pertinent disciplines
including oncology; small molecule, peptide and antibody drug manufacturing and quality; clinical drug development, and commercialization.
Randy Milby, our Chief Executive Officer and Chairman of our board of directors and consultants have held assorted roles leading
research, clinical development, arterial intelligence, strategy, corporate development and operational functions at large biopharmaceutical
companies</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <FONT STYLE="background-color: white">public
biotechnology companies, and universities having worked at companies such as DuPont Merck Pharmaceuticals, Amgen, Exelixis,
Centocor (Johnson &amp; Johnson), Eisai, Salix Pharmaceuticals (Bausch Healthcare), Axsome Therapeutics, Harvard Medical
School and Dana-Farber Cancer Institute. We were founded by a core group of scientists from Harvard Medical School and Dana-Farber
Cancer Institute, who have extensive backgrounds in cancer biology, biopharmaceutical technologies, and delivery of pharmaceutical
products and successful exits to Genzyme (ILEX Oncology). Our Chief Executive Officer and consultants have been involved in the
discovery, development, manufacturing and commercialization of multiple marketed products across various therapeutic areas, including
Cabometyx<SUP>&reg;</SUP> (cabozantinib), Remicade<SUP>&reg;</SUP> (infliximab), Clolar<SUP>&reg;</SUP> (clofarabine), as well as product
candidates currently in development.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Platform Technologies</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Trident
Artificial Intelligence</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trident
is a deep learning engine that identifies synthetic lethal sensitivities associated with degree of cell plasticity using biomarkers that
can be translated for patient selection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Trident platform:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
    the ability to integrate diverse multi-omics datasets including not only genomics, epigenetics and transcriptomics but also emerging
    proteomics data which enable identification of dynamical re-wiring of intra-tumoral signaling circuitry;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
    the ability to identify biomarkers that robustly differentiate between progression of cancer plasticity and correlate it to degree
    of sensitivity to a synthetically lethal target that is induced with standard of care treatment and development of resistance; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Is
    a state-of-the-art convolutional neural network used to classify and select patients that are most likely to respond to treatment.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Quatramer
Technology</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key aspect of oncology treatment is that effective anticancer agents do not penetrate the tumor bed in order to kill cancer cells due
to the limitation of the microenvironment of the tumor. The TME is protected by multiple layers of collagen, proteoglycans, hyaluronans
and laminin layers shielding the tumor from the deployment of traditional treatments, including chemotherapy (novel small molecule and
immunotherapies). Parts of the tumor create an environment to survive despite reduced nutrient sources whereby hypoxic regions of the
tumor continue to thrive by incorporating a shift in metabolism, including iron dysregulation. Subsequently, any drug reaching the tumor,
is effluxed by transporter pumps upregulated by the cancer cells rendering any drug reaching the tumor ineffective. The TME continues
to thrive by the inability of immune cells normally designed to infiltrate and kill the tumor made ineffective by reducing their ability
to activate their killing effect of the cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
proprietary Quatramer technology overcomes the limitations which have hampered development of nanoscale and liposome derived products
as cancer therapeutics. Limitations include, but are not limited to, drug efflux, toxicity, eluding phagocytosis, physiological barrier
penetrance and immune responses. The Quatramer technology incorporates a therapeutic payload and is designed to be tunable while having
a prolonged circulation within the blood, allowing a targeting of diseased tissue or cells, while providing a controlled and timely release
of the therapeutic payload.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Characteristics
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">of our Quatramer technology:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prolonged
    circulation</B>: the stealth nature of Quatramer allows for a prolonged circulation time whereby there is accumulation at the site
    of disease prior to being cleared.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Targeted</B>:
    the size, shape and surface of Quatramer allows it to escape via gaps in the blood vessels in the TME allowing for release of the
    payload directly into cancerous cells.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Blocks
    drug efflux</B>: Quatramer composition offers reversal of p-glycoprotein mediated drug resistance in cells.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tunability</B>:
    Quatramer physicochemical characterization allows for optimizing size, shape and surface chemistry based on payload characteristics
    to render enhanced permeation and retention into the TME.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ease
    of manufacturing</B>: large scale production efficiency and analysis for uniform chemistry, manufacturing and control capability
    at lower costs.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Biodegradable</B>:
    chemical compositions listed in FDA Inactive Ingredients Database tuned to maximize nano-bio interfaces with limited or no environmental
    concerns.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payload
    versatility and flexibility</B>: combined with the tunability of Quatramer, the technology allows for a variety of delivery payloads
    including peptides, small molecules, nucleic acids and antibodies with the added flexibility of dual loaded payload therapeutics.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Associated with Our Business</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to execute on our business strategy is subject to a number of risks, which are discussed more fully in the section titled &ldquo;Risk
Factors.&rdquo; Investors should carefully consider these risks before making an investment in our common stock. These risks include,
among others, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
                                            have a limited operating history and as of May 11, 2021 we have not initiated, conducted
                                            or completed any clinical trials, and have no products approved for commercial sale, which
                                            may make it difficult for you to evaluate our current business and likelihood of success
                                            and viability.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to generate sufficient
    revenue to achieve and maintain profitability.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Even
    if this offering is successful, we will require substantial additional capital to finance our operations in the future. If we are
    unable to raise such capital when needed, or on acceptable terms, we may be forced to curtail, delay or discontinue one or more of
    development programs or future commercialization efforts.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern, which
    may hinder our ability to obtain future financing.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are substantially dependent on the success of our product candidates. If we are unable to complete development of, obtain approval
    for and commercialize our product candidates in a timely manner, our business may be harmed.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    delays in the commencement or completion, or termination or suspension, of our ongoing, planned or future clinical trials could result
    in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    outcome of pre-clinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the
    results of our clinical trials may not satisfy the requirements of the U.S. Food and Drug Administration or other comparable foreign
    regulatory authorities.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we experience delays or difficulties in enrolling patients in our ongoing or planned clinical trials, our receipt of necessary regulatory
    approval could be delayed or prevented.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing
    requirements to maintain regulatory approval. If our candidates prove to be ineffective, unsafe or commercially unviable, our entire
    technology platform and pipeline would have little, if any, value, which would have a material and adverse effect on our business,
    financial condition, results of operations and prospects.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse
    side effects or other safety risks associated with our drug candidates could delay or preclude approval, cause us to suspend or discontinue
    clinical trials or abandon further development, limit the commercial profile of an approved label, or result in significant negative
    consequences following marketing approval, if any.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    products may never achieve market acceptance.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that
    are more effective, safer or less expensive than the products we develop, our commercial opportunities will be negatively impacted.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    rely on third parties to manufacture our product candidates and conduct our pre-clinical studies and clinical trials. If these third
    parties do not successfully perform their contractual and regulatory duties or meet expected deadlines, we may not be able to obtain
    regulatory approval for or commercialize our drug candidates and our business could be substantially harmed.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we are successful in completing all pre-clinical studies and clinical trials, we may not be successful in commercializing one
    or more of our drug candidates.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    development and commercialization of pharmaceutical products are subject to extensive regulation, and we may not obtain regulatory
    approvals for our drug candidates on a timely basis, or at all.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    inability to protect our intellectual property and proprietary rights may have a material adverse effect on our business.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business may be adversely affected by the ongoing coronavirus pandemic.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may encounter difficulties in managing our growth, which could adversely affect our operations.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    employees, independent contractors, consultants, commercial partners, collaborators and vendors may engage in misconduct or other
    improper activities, including noncompliance with regulatory standards and requirements.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    has been no prior public market for our common stock, the stock price of our common stock may be volatile or may decline regardless
    of our operating performance and you may not be able to resell your shares at or above the initial public offering price.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over
    matters subject to stockholder approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Corporate History</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hillstream
BioPharma Inc. (&ldquo;HBI&rdquo;) was incorporated on March 28, 2017, as a Delaware C-corporation. On July 16, 2019, Hillstream
BioPharma Holdings, Inc. (&ldquo;Holdco&rdquo;) was formed as a Delaware C-corporation. On July 24, 2019, Holdco entered into a Contribution
and Exchange Agreement with Nanoproteagen LLC (&ldquo;Nanoproteagen&rdquo;) whereby the members of Nanoproteagen
exchanged 100% of their membership interests in Nanoproteagen for shares of Holdco common stock. Also on July 24, 2019,
the stockholders of HBI exchanged 100% of their shares of common stock for shares of common stock of Holdco. HBI and Nanoproteagen
became wholly-owned subsidiaries of Holdco. On August 7, 2019, pursuant to a certificate of amendment, Holdco&rsquo;s name was changed
to Hillstream BioPharma, Inc. and HBI&rsquo;s name was changed to HB Pharma Corp. On November 12, 2020, Hillstream BioPharma, Inc. entered
into a Share Exchange Agreement with Farrington Therapeutics LLC (&ldquo;Farrington&rdquo;), whereby the members of Farrington
exchanged their membership interest in Farrington for shares of common stock of Hillstream BioPharma, Inc.. Farrington became
a wholly-owned subsidiary of Hillstream BioPharma, Inc. At December 31, 2020, Hillstream BioPharma, Inc. has three wholly-owned subsidiaries:
HB Pharma Corp., Nanoproteagen and Farrington.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at 1200 Route 22 East, Suite 2000, Bridgewater, NJ 08807 and our telephone number is (908)
955-3140. Our website address is <I>www.hillstreambio.com</I>. The information contained on our website is not incorporated by reference
into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part
of this prospectus or in deciding whether to purchase our common shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Implications
of Being an Emerging Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a company with less than $1.07 billion in revenues during our last fiscal year, we qualify as an emerging growth company as defined in
the Jumpstart Our Business Startups Act (&ldquo;JOBS Act&rdquo;) enacted in 2012. As an emerging growth company, we expect to take advantage
of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    permitted to present only two years of audited financial statements, in addition to any required unaudited interim financial statements,
    with correspondingly reduced &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
    disclosure in this prospectus;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (&ldquo;Sarbanes-Oxley
    Act&rdquo;);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions
    from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute
    payments not previously approved.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may use these provisions until the last day of our fiscal year following the fifth anniversary of the completion of this offering. However,
if certain events occur prior to the end of such five-year period, including if we become a &ldquo;large accelerated filer,&rdquo; our
annual gross revenues exceed $1.07 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will
cease to be an emerging growth company prior to the end of such five-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
OFFERING</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock offered by us</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock to be outstanding immediately after this offering</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    shares
    (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    shares if the underwriters exercise their option in full).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    to purchase additional shares</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    underwriters have an option for a period of 45 days to purchase up to an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    shares of our common stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of proceeds</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    estimate that the net proceeds from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or approximately $&nbsp;&nbsp;&nbsp; if the underwriters exercise their
    over-allotment option in full, at an assumed initial public offering price of $ per share, the midpoint of the range set forth on
    the cover page of this prospectus, after deducting the underwriting discounts and commissions and estimated offering expenses payable
    by us. We intend to use the net proceeds from this offering to advance our product candidates, HSB-1216 and HSB-888, through pre-clinical
    activities, completion of human proof-of-concept Phase 1 studies and manufacturing as well as for general corporate and working
    capital purposes. We may also use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or products;
    however, we have no current commitments or obligations to do so. See &ldquo;Use of Proceeds&rdquo; for a more complete description
    of the intended use of proceeds from this offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriters&rsquo;
    warrants</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    the closing of this offering, we have agreed to issue &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    &nbsp;, as representative of the underwriters, warrants that will be
    exercisable during a four and one-half year period commencing six months from the effective date of this offering, entitling the
    representative to purchase 5% of the number of shares of common stock sold in this offering at a per share exercise price equal to
    125% of the public offering price per share in this offering. For additional information regarding our arrangement with the underwriters,
    please see &ldquo;Underwriting.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lock-up
    agreements</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    executive officers and directors have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities
    for a period of 12 months from the date of this prospectus, and all of our stockholders have agreed with the underwriters not to
    sell, transfer or dispose of any shares or similar securities for a period of 6 months from the date of this prospectus. For additional
    information regarding our arrangement with the underwriters, please see &ldquo;Underwriting.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    factors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    &ldquo;Risk Factors&rdquo; on page 12 and other information included in this prospectus for a discussion of factors to consider
    carefully before deciding to invest in shares of our common stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposed
    Nasdaq Capital Market symbol</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;HILS&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of our common stock to be outstanding after this offering is based on 167,833,334 shares of our common stock
outstanding as of May 11, 2021, and excludes as of that date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">28,264,150
    </FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">shares of common stock reserved for future
    issuance under our 2019 stock incentive plan;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">22,352,516 shares of common stock issuable upon
    exercise of outstanding options with a weighted average exercise price of $0.1534;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issuable upon the conversion of
    outstanding convertible notes in the aggregate amount of $3,129,956, including interest accrued thereon, assuming an initial
    public offering price of $ per share, the midpoint of the range set forth on the cover page of this prospectus; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issuable upon exercise of warrants
    to be issued to the representative of the underwriters as part of this offering at an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(assuming
    an initial public offering price of $ per share (the midpoint of the price range set forth on the cover page of this prospectus)).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Except
as otherwise indicated herein, all information in this prospectus assumes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">a
    -for-1 stock split of our common stock effected on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursuant
    to which (i) every&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of outstanding common stock was decreased to one share of
    common stock, (ii) the number of shares of common stock for which each outstanding option  to purchase common stock is
    exercisable was proportionally decreased on a 1-for &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; basis and (iii) the exercise price of each outstanding option  to
    purchase common stock was proportionally increased on a 1-for &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; basis (the &ldquo;Reverse Stock Split&rdquo;). No fractional shares
    will be issued as a result of the Reverse Stock Split. Any fractional shares resulting from the Reverse Stock Split shall be paid in
    cash<FONT STYLE="background-color: white">; and</FONT></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">no
    exercise by the underwriters of their option to purchase an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
Financial Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following tables set forth our consolidated financial data as of the dates and for the periods indicated. We have derived the summary
consolidated statements of operations data for the years ended December 31, 2020 and 2019 from our audited consolidated financial statements
included elsewhere in this prospectus. We have derived the summary consolidated statements of operations data for the three months ended
March 31, 2021 and 2020 and our balance sheet data as of March 31, 2021, from our unaudited interim consolidated financial statements
included elsewhere in this prospectus. The unaudited interim consolidated financial statements have been prepared on the same basis as
the audited consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal, recurring nature
that are necessary for a fair presentation of the unaudited interim consolidated financial statements. Our historical results are not
necessarily indicative of the results that may be expected in the future, and the results in the three months ended March 31, 2021 are
not necessarily indicative of results to be expected for the full year or any other period. The following summary financial data should
be read with &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and our consolidated
financial statements and related notes and other information included elsewhere in this prospectus.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statements of Operations Data:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: center; text-indent: -10pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">(in
thousands, except share and per share data)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: center; text-indent: -10pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended<BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Three Months Ended March 31,</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt"></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2021</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2020</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Consolidated Statements of Operations Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 36%; text-align: left">Research and development</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">847,272</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">368,732</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Acquired in-process research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">289,200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">429,403</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">671,879</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">625,807</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,808,351</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,423,942</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other Expense:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Interest Expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">246,534</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,074</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in redemption value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">362,486</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,458</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total other expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">609,020</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">101,532</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,417,371</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,525,474</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per common share &ndash; basic and diluted<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.01</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.01</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average common shares outstanding &ndash; basic and diluted<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">167,666,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">108,611,112</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    Note 2 to our consolidated financial statements appearing elsewhere in this prospectus for an explanation of the method used to calculate
    the basic and diluted net loss per share attributable to common stockholders and the number of shares used in the computation of
    the per share amounts.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Balance
Sheet Data:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
thousands)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;<B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&nbsp;</TD><TD COLSPAN="9" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>March 31, 2021 (unaudited) &nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;<B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Actual&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro Forma<SUP>(1)</SUP> </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro Forma,<BR> As Adjusted<SUP>(2)(3)</SUP> &nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%">Cash</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Working Capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total stockholders&rsquo; equity (deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    a pro forma basis to reflect ________________.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    a pro forma as adjusted basis to give further effect to (i) our issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering
    at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range listed on the cover page of
    this prospectus, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us and (ii)
    the conversion of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of principal amount and accrued interest of outstanding convertible notes into an aggregate
    of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock upon the closing of this offering based upon an assumed initial public offering price
    of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range listed on the cover page of this prospectus. Pro forma as adjusted
    balance sheet data is illustrative only and will change based on the actual initial public offering price and other terms of this
    offering determined at pricing.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
$1.00 increase (decrease) in the assumed initial public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share, the midpoint of the price range listed on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted
amount of each of cash, working capital, total assets and total stockholders&rsquo; equity (deficit) by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting
underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 100,000
shares in the number of shares offered by us at the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range
listed on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash, working capital,
total assets and total stockholders&rsquo; equity (deficit) by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. These unaudited adjustments are based upon available
information and certain assumptions we believe are reasonable under the circumstances.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_002"></A>RISK
FACTORS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
in our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with
all other information in this prospectus, including our financial statements and related notes and the &ldquo;Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations&rdquo; section of this prospectus before investing in our common stock.
Any of the risk factors we describe below could adversely affect our business, financial condition, results of operations or prospects.
The market price of our common stock could decline if one or more of these risks or uncertainties actually occur, causing you to lose
all or part of your investment in our common stock. Additional risks that we currently do not know about or that we currently believe
to be immaterial may also impair our business, financial condition, operating results and prospects.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to Our Financial Position and Need for Additional Capital</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects.
We commenced operations in 2017, have no products approved for commercial sale and have not generated any revenue. Drug development is
a highly uncertain undertaking and involves a substantial degree of risk. Since our inception, we have spent the first three years developing
and refining our Quatramer technology, and since 2019, we have focused our efforts on advancing the development of our product candidates,
HSB-1216, HSB-888 and HSB-1218.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Quatramer technology is new and unproven. We have not yet commenced human clinical trials for any of our product candidates, nor have
we demonstrated an ability to initiate or successfully complete any large-scale or pivotal clinical trials, obtain marketing approvals,
manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities
necessary for successful product commercialization. As a result, it may be more difficult for you to accurately predict our likelihood
of success and viability than it could be if we had a longer operating history.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan on filing an IND with the FDA for HSB-1216 in first half of 2022. Our other programs are in pre-clinical discovery and research
stages. As a result, we expect that it will take several years, if ever, before we have a commercialized product and generate revenue
from product sales. Even if we succeed in receiving marketing approval for and commercializing one or more of our product candidates,
we expect that we will continue to incur substantial research and development and other expenses in order to discover, develop and market
additional potential products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are leveraging our Trident platform in an attempt to identify synthetic lethal sensitivities associated with degree of cell plasticity
using biomarkers that can be translated for patient selection and stratification for the development of oncology drugs. While we believe
that applying our Trident platform is a precision oncology approach that identifies the mechanism of action, potential combination drug
usage and potentially responsive patient population, our approach is both innovative and in the early stages of development and therefore,
the cost and time needed to develop such platform difficult to predict, and our efforts may not result in the successful discovery and
development of biomarkers. We may also be incorrect about the effects of the biomarkers on our drug candidates on the diseases of our
defined patient populations, which may limit the utility of our approach or the perception of the utility of our approach. Furthermore,
our estimates of our defined patient populations available for study and treatment may be lower than expected, which could adversely
affect our ability to conduct clinical trials and may also adversely affect the size of any market for medicines we may successfully
commercialize. Our approach may not result in time savings, higher success rates or reduced costs as we expect it to, and if not, we
may not attract collaborators or develop new drugs as quickly or cost effectively as expected and therefore we may not be able to commercialize
our approach as originally expected.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Trident Artificial Intelligence platform may fail to help us discover and develop appropriate biomarkers for our potential drug candidates
which would limit our commercialization prospects and cause our losses to continue.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any biomarker discovery or drug development
that we are conducting using our Trident platform may not be successful in identifying biomarkers that have commercial value for our
products or therapeutic utility. Our Trident platform may initially show promise in identifying potential biomarkers for our drug candidates,
yet fail to stratify patients for clinical development or commercialization for a number of reasons, including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">research
    programs to identify new biomarkers will require substantial technical, financial and human resources, and we may be unsuccessful
    in our efforts to identify biomarkers. If we are unable to identify suitable biomarkers for pre-clinical and clinical development,
    our ability to stratify patients could be compromised, which could result in significant harm to our financial position and adversely
    impact our stock price;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-indent: -13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">biomarkers
    identified through our Trident platform may not demonstrate correlation to efficacy, safety or tolerability;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    data available for our Trident platform that seeks to correlate genomic or biomarker signatures with certain cancers may be influenced
    by the race of the patient which may limit the efficacy of our drug candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    regulatory pathway for the biomarkers may be too complex, expensive or otherwise difficult to &nbsp;navigate successfully; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competitors
    may develop alternative approaches that render our potential biomarkers non-competitive or less attractive.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development
of, and seek regulatory approvals for, our product candidates, and begin to commercialize approved drugs, if any. Typically, it takes
many years to develop a new drug from the time it is discovered to when it is available for treating patients. We may encounter unforeseen
expenses, difficulties, complications, delays and other unknown factors that may increase our expenses and adversely affect our ability
to generate revenue. The size of our future net losses will depend, in part, on our ability to manage these aspects of our business.
&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to generate sufficient
revenue to achieve and maintain profitability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never been profitable and have incurred significant losses in each year since inception. For the years ended December 31, 2020 and
2019 and the three months ended March 31, 2021, we reported a net loss of $2.4 million, $1.5 million and $ million, respectively. As
of December 31, 2020 and March 31, 2021, we had an accumulated deficit of $4.7 million and $ million, respectively. To date, we have
funded our operations primarily with proceeds from sales of shares of our convertible promissory notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur
may fluctuate significantly from quarter to quarter such that a period-to-period comparison of our results of operations may not be a
good indication of our future performance. The size of our future net losses will depend, in part, on the rate of future growth of our
expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse
effect on our working capital, our ability to achieve and maintain profitability and the performance of our stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
ability to generate revenue and achieve profitability depends significantly on our ability to achieve several milestones relating to
the discovery, development and commercialization of our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial condition and operating results have varied significantly in the past and are expected to continue to fluctuate significantly
due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations
include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
    our current research and development programs, including conducting laboratory, pre-clinical studies for product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate
    clinical trials for product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of our clinical trials through all phases of clinical development;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in the commencement, enrollment and timing of clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to secure and maintain collaborations, licensing or other arrangements for the future development and/or commercialization
    of our product candidates, as well as the terms of those arrangements;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain, as well as the timeliness of obtaining, additional funding to develop our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of clinical trials or marketing applications for product candidates that may compete with our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
    from existing products or new products that may receive marketing approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    side effects of our product candidates that could delay or prevent approval or cause an approved drug to be taken off the market;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delays in regulatory review and approval of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to identify and develop additional product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of patients or healthcare providers to obtain coverage or sufficient reimbursement for our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability, and the ability of third parties such as Clinical Research Organizations, or CROs, to adhere to clinical study and other
    regulatory requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of third-party manufacturers to manufacture our product candidates and key ingredients needed to conduct clinical trials
    and, if approved, successfully commercialize our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs to us, and our ability as well as the ability of any third-party collaborators, to obtain, maintain and protect our intellectual
    property rights;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    related to and outcomes of potential intellectual property litigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to adequately support future growth;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain key personnel to manage our business effectively; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to build our finance infrastructure and, to the extent required, improve our accounting systems and controls.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing
new products and services is a speculative and risky endeavor. Products or services that initially show promise may fail to achieve the
desired results or may not achieve acceptable levels of analytical accuracy or clinical utility. We may need to alter our products in
development and repeat clinical studies before we identify a potentially successful product or service. Product development is expensive,
may take years to complete and can have uncertain outcomes. Failure can occur at any stage of the development. If, after development,
a product or service appears successful, we may, depending on the nature of the product or service, still need to obtain FDA and other
regulatory clearances, authorizations or approvals before we can market it. The FDA&rsquo;s clearance, authorization or approval pathways
are likely to involve significant time, as well as additional research, development and clinical study expenditures. The FDA may not
clear, authorize or approve any future product or service we develop. Even if we develop a product or service that receives regulatory
clearance, authorization or approval, we would need to commit substantial resources to commercialize, sell and market it before it could
be profitable, and the product or service may never be commercially successful. Additionally, development of any product or service may
be disrupted or made less viable by the development of competing products or services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
potential products and services may fail any stage of development or commercialization and if we determine that any of our current or
future products or services are unlikely to succeed, we may abandon them without any return on our investment. If we are unsuccessful
in developing additional products or services, our potential for growth may be impaired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
cases where we are successful in obtaining regulatory approval to market one or more of our drug candidates, our revenue will be dependent,
in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the
ability to obtain coverage and reimbursement, and whether we own the commercial rights for that territory. If the number of our addressable
patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the treatment
population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of
such products, even if approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our research and development expenses to continue to be significant in connection with our continued investment in our ongoing
and planned clinical trials for our current product candidates and any future product candidates we may develop. Furthermore, if we obtain
regulatory approval for our product candidates, we expect to incur increased sales and marketing expenses. In addition, once we are a
public company, we will incur additional costs associated with operating as a public company. As a result, we expect to continue to incur
significant and increasing operating losses and negative cash flows for the foreseeable future. These losses have had and will continue
to have a material adverse effect on our stockholders&rsquo; equity, financial position, cash flows and working capital.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if this offering is successful, we will require substantial additional funding. If we are unable to raise capital on favorable terms
when needed, we could be forced to curtail, delay or discontinue our research or drug development programs or any future commercialization
efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently advancing our product candidates, HSB-1216 and HSB-888, through pre-clinical stage development. Developing cancer drugs is expensive and we expect our research and development expenses
to increase substantially in connection with our ongoing activities, particularly as we advance our product candidates in clinical studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, we had cash of $191,852. We estimate that the net proceeds from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million,
assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint
of the price range set forth on the cover of this prospectus, after deducting underwriting discounts and commissions and estimated offering
expenses payable by us. We expect that the net proceeds from this offering and our existing cash will not be sufficient to fund our current
operations through at least 12 months from the date of this prospectus. However, our operating plan may change as a result of many factors
currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings,
government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing
arrangements or a combination of these approaches. In any event, we will require additional capital to obtain regulatory approval for,
and to commercialize, our product candidates. Raising funds may present challenges including, but not limited to, as a result of COVID-19.
Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions
are favorable or if we have specific strategic considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to
develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient
amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights
of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may
cause the market price of our shares to decline. The sale of additional equity or convertible securities may dilute our stockholders.
The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive
covenants, such as limitations on our ability to make certain dividends, incur additional debt, limitations on our ability to acquire,
sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our
business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than
otherwise would be desirable, and we may be required to relinquish rights to some of our technologies or product candidates or otherwise
agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our
research or development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise
capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern, which
may hinder our ability to obtain future financing</I></B><B><I>.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial statements as of December 31, 2020 have been prepared under the assumption that we will continue as a going concern for the
next twelve months. Our independent registered public accounting firm included in its opinion for the year ended December 31, 2020 an
explanatory paragraph referring to our recurring losses from operations and expressing substantial doubt in our ability to continue as
a going concern without additional capital becoming available. Our ability to continue as a going concern is dependent upon our ability
to obtain additional equity or debt financing, reduce expenditures and to generate significant revenue. Our financial statements as of
December 31, 2020 did not include any adjustments that might result from the outcome of this uncertainty. The reaction of investors to
the inclusion of a going concern statement by our auditors, and our potential inability to continue as a going concern, in future years
could materially adversely affect our share price and our ability to raise new capital or enter into strategic alliances. Furthermore,
we also could be required to seek funds through arrangements with collaborative partners or otherwise that may require us to relinquish
rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to the Discovery and Development of Our Product Candidates</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are substantially dependent on the success of our product candidates, HSB-1216 and HSB-888, which are currently in pre-clinical </I></B><B><I>trials.
If we are unable to complete development of, obtain approval for and commercialize HSB-1216 or HSB-888 for one or more indications in
a timely manner, our business may be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future success is dependent on our ability to timely and successfully complete clinical trials, obtain marketing approval for and successfully
commercialize HSB-1216 and HSB-888, our product candidates which are in the pre-clinical stages of development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no products approved for sale. The success of our business, including our ability to finance our company and generate any revenue
in the future, will primarily depend on the successful development, regulatory approval and commercialization of HSB-1216 and HSB-888
as well as other product candidates, which may never occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we may also become dependent on other product candidates that we may develop or acquire; however, no product candidates based
on our Quatramer technology have been tested in humans and given our early stage of development, it may be many years, if at all, before
we may be able to demonstrate the safety and efficacy of our product candidates to warrant approval for commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical and commercial success of our current and any future product candidates will depend on a number of factors, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to raise any additional required capital on acceptable terms, or at all;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to complete IND-enabling studies and successfully submit an IND to the FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">timely
    completion of our pre-clinical studies and clinical trials, which may be slower or cost more than we currently anticipate and will
    depend substantially upon the performance of third-party contractors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    by the FDA or similar foreign regulatory agencies to conduct additional clinical trials or other studies beyond those planned to
    support approval of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    of our proposed indications and primary endpoint assessments relating to the proposed indications of our product candidates by the
    FDA and similar foreign regulatory authorities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to consistently manufacture our product candidates on a timely basis;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability, and the ability of any third parties with whom we contract, to remain in good standing with regulatory agencies and develop,
    validate and maintain commercially viable manufacturing processes that are compliant with current good manufacturing practices (&ldquo;cGMPs&rdquo;);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, efficacy and acceptable
    risk-benefit profile of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future
    approved products, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
    and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual
    obligations and with all regulatory requirements applicable to our current and future product candidates or approved products, if
    any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to successfully develop a commercial strategy and thereafter commercialize our product candidates in the United States and
    internationally, if approved for marketing, sale and distribution in such countries and territories, whether alone or in collaboration
    with others;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of coverage and adequate reimbursement from managed care plans, private insurers, government payors (such as Medicare
    and Medicaid) and other third-party payors for any of our product candidates that may be approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    convenience of our treatment or dosing regimen;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    by physicians, payors and patients of the benefits, safety and efficacy of our product candidates, if approved, including relative
    to alternative and competing treatments;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of physicians, operators of hospitals and clinics and patients to utilize or adopt our cancer therapeutics approach;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    demand for our current or future product candidates, if approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and enforce intellectual property rights in and to our product candidates; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals
or commercialize our current or future product candidates. Even if regulatory approvals are obtained, we may never be able to successfully
commercialize our product candidates. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through
the sale of our product candidates to continue our business or achieve profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Quatramer approach is based on novel ideas and technologies that are unproven and may not result in marketable products, which exposes
us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory
approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are using our Quatramer technology to develop product candidates to treat cancer. Our foundational science and product development approach
are based on our ability to target specified cells or tissues and converge a therapeutic payload at the site of disease to boost efficacy
while abating adverse effects on healthy tissue. We believe that this approach may offer an improved therapeutic effect by driving an
intense, focused attack selectively upon a patient&rsquo;s tumor. However, this approach to treating cancer is novel and the clinical
research that results in a product candidate has had limited testing in humans. We are currently in the process of validating
different tumor-specific therapeutic product candidates. We may spend substantial funds attempting to develop these products with the
Quatramer approach and never succeed in developing a marketable therapeutic.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
such, we cannot assure you that even if we are able to develop product candidates to treat cancer, such therapies would safely and effectively
treat cancers. We may spend substantial funds attempting to develop this approach and never succeed in developing a marketable therapeutic.
We are unable to predict when or if our drug candidates will prove effective or safe in humans or if we will obtain marketing approval.
Before obtaining marketing approval from regulatory authorities for the sale of any drug candidate, we must complete pre-clinical development
and then conduct extensive clinical trials to demonstrate the safety and efficacy of our drug candidates in humans. Clinical testing
is expensive, difficult to design and implement, can take many years to complete and is uncertain as to the outcome. A failure of one
or more clinical trials can occur at any stage of testing. The outcome of pre-clinical testing and early clinical trials may not be predictive
of the success of later clinical trials, and interim or preliminary results of a clinical trial do not necessarily predict final results.
In particular, the small number of patients in our early clinical trials may make the results of these trials less predictive of the
outcome of later clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to obtain
marketing approval or commercialize our drug candidates, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators
    or institutional review boards (&ldquo;IRBs&rdquo;)/ethics committees (&ldquo;ECs&rdquo;) may not authorize us or our investigators
    to commence a clinical trial or conduct a clinical trial at a prospective trial site;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols
    with prospective trial sites;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    trials for our drug candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to
    conduct additional clinical trials, delay clinical trials or abandon product development programs;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of patients required for clinical trials for our drug candidates may be larger than we anticipate, enrollment in these clinical
    trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate or
    the duration of these clinical trials may be longer than we anticipate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
    for clinical trial participants from investigational and approved therapies may make it more difficult to enroll patients in our
    clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    or third-party collaborators may fail to obtain the clearance or approval of companion diagnostic tests, if required, on a timely
    basis, or at all;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    third-party contractors may fail to meet their contractual obligations to us in a timely manner, or at all, or may fail to comply
    with regulatory requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may have to suspend or terminate clinical trials for our drug candidates for various reasons, including a finding that the participants
    are being exposed to unacceptable health risks;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    drug candidates may have undesirable or unexpected side effects or other unexpected characteristics, causing us or our investigators,
    regulators or IRBs/ECs to suspend or terminate the trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of clinical trials for our drug candidates may be greater than we anticipate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    supply or quality of our drug candidates or other materials necessary to conduct clinical trials for our drug candidates may be insufficient
    or inadequate and result in delays or suspension of our clinical trials; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    or a diagnostic development partner may fail to receive regulatory approval of a companion diagnostic for use with a marketed product.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product development costs will increase if we experience delays in pre-clinical studies or clinical trials or in obtaining marketing
approvals. We do not know whether any of our planned pre-clinical studies or clinical trials will begin on a timely basis or at all,
will need to be restructured or will be completed on schedule, or at all. For example, the FDA may place a partial or full clinical hold
on any of our clinical trials for a variety of reasons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
pre-clinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our
drug candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize
our drug candidates and may harm our business and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
delays in the commencement or completion, or termination or suspension, of our ongoing, planned or future clinical trials could result
in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
we can initiate clinical trials of a drug candidate in any indication, we must submit the results of pre-clinical studies to the FDA
along with other information, including information about the drug candidate&rsquo;s chemistry, manufacturing and controls and our proposed
clinical trial protocol, as part of an IND or similar regulatory filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining marketing approval from the FDA for the sale of our product candidate in any indication, we must conduct extensive clinical
studies to demonstrate safety and efficacy. Clinical testing is expensive, time consuming and uncertain as to outcome. In addition, we
expect to rely in part on pre-clinical, clinical and quality data generated by our contract research organizations (&ldquo;CROs&rdquo;)
and other third parties for regulatory submissions for our drug candidates. While we have or will have agreements governing these third
parties&rsquo; services, we have limited influence over their actual performance. If these third parties do not make data available to
us, or, if applicable, make regulatory submissions in a timely manner, in each case pursuant to our agreements with them, our development
programs may be significantly delayed and we may need to conduct additional studies or collect additional data independently. In either
case, our development costs would increase. We still need to receive FDA clearance of our IND for HSB-1216 and HSB-888 before we can
begin clinical trials and would require the same acceptance by the FDA prior to initiating any clinical trials in the United States for
any of our other drug candidates. The FDA may require us to conduct additional pre-clinical studies for any drug candidate before it
allows us to initiate clinical trials under any IND, which may lead to additional delays and increase the costs of our pre-clinical development
programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delays in the commencement or completion of our ongoing, planned or future clinical trials could significantly affect our product development
costs. We do not know whether our planned trials will begin on time or at all, or be completed on schedule, if at all. The commencement
and completion of clinical trials can be delayed for a number of reasons, including delays related to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA disagreeing as to the design or implementation of our clinical trials or with our recommended dose for any of our pipeline programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    FDA authorization to commence a trial or reaching a consensus with the FDA on trial design;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failing
    to obtain regulatory clearance or approval of companion diagnostics we may use to identify patients for enrollment in our clinical
    trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation
    and may vary significantly among different CROs and trial sites;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    approval from one or more IRBs/ECs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IRBs/ECs
    refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects,
    or withdrawing their approval of the trial;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    to clinical trial protocol;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    sites deviating from trial protocol or dropping out of a trial;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failing
    to manufacture or obtain sufficient quantities of drug candidate or, if applicable, combination therapies for use in clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    failing to enroll or remain enrolled in our trials at the rates we expect, or failing to return for post-treatment follow-ups;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    choosing an alternative treatment, or participating in competing clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
    of adequate funding to continue clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    experiencing severe or unexpected drug-related adverse effects;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence
    of serious adverse events in trials of the same class of agents conducted by other companies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting
    or being required to use clinical end points that require prolonged periods of clinical observation or analysis of the resulting
    data;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    facility manufacturing our drug candidates or any of their components being ordered by the FDA to temporarily or permanently shut
    down due to violations of cGMP regulations or other applicable requirements, or infections or cross-contaminations of drug candidates
    in the manufacturing process;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    changes to our manufacturing process that may be necessary or desired;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
    clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials
    on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices (&ldquo;GCPs&rdquo;) or other
    regulatory requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">us,
    or our third-party contractors not performing data collection or analysis in a timely or accurate manner or improperly disclosing
    data prematurely or otherwise in violation of a clinical trial protocol; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
    contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations
    of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all
    of the data produced by such contractors in support of our marketing applications.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs/ECs of the institutions in which such trials
are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA. Such authorities may impose such a suspension or
termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or
our clinical protocols, inspection of the clinical trial operations or trial site by the FDA resulting in the imposition of a clinical
hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a pharmaceutical, changes in governmental
regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory
requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require
us to resubmit our clinical trial protocols to IRBs/ECs for reexamination, which may impact the costs, timing or successful completion
of a clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of our scientific advisors or consultants who receive compensation from us are investigators for our clinical trial. Under certain circumstances,
we may be required to report some of these relationships to the FDA. Although we believe our existing relationships are within the FDA&rsquo;s
guidelines, the FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest
or otherwise affected interpretation of the study. The FDA may therefore question the integrity of the data generated at the applicable
clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection,
of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our product candidates. If we
experience delays in the completion of, or termination of, any clinical trial of our drug candidates, the commercial prospects of such
drug candidate will be harmed, and our ability to generate product revenues will be delayed. Moreover, any delays in completing our clinical
trials will increase our costs, slow down our development and approval process and jeopardize our ability to commence product sales and
generate revenues which may harm our business, financial condition, results of operations and prospects significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
outcome of pre-clinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results
of our clinical trials may not satisfy the requirements of the FDA, European Medicines Agency (&ldquo;EMA&rdquo;) or other comparable
foreign regulatory authorities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe
and effective for use in a diverse population before we can seek marketing approvals for their commercial sale. Success in pre-clinical
studies and early-stage clinical trials does not mean that future clinical trials will be successful. Product candidates in later-stage
clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA, EMA and other comparable foreign
regulatory authorities despite having progressed through pre-clinical studies and early-stage clinical trials. Regulatory authorities
may also limit the scope of later-stage trials until we have demonstrated satisfactory safety, which could delay regulatory approval,
limit the size of the patient population to which we may market our product candidates, or prevent regulatory approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product
candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences
in and adherence to the dose and dosing regimen and other trial protocols and the rate of dropout among clinical trial participants.
Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments and may be using
other approved products or investigational new drugs, which can cause side effects or adverse events that are unrelated to our product
candidates. As a result, assessments of efficacy can vary widely for a particular patient and from patient to patient and site to site
within a clinical trial. This subjectivity can increase the uncertainty of, and adversely impact, our clinical trial outcomes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain
approval to market any of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Interim,
topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes
available, and are subject to audit and verification procedures that could result in material changes in the final data.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may publicly disclose preliminary, interim or topline data from our clinical trials, such as the interim data from our
Phase 1b clinical trial of HSB-1216 or HSB-888. These interim updates are based on a preliminary analysis of then-available data, and
the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the
particular study or trial. For example, we may report tumor responses in certain patients that are unconfirmed at the time and which
do not ultimately result in confirmed responses to treatment after follow-up evaluations. We also make assumptions, estimations, calculations
and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate
all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions
or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject
to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously
published. As a result, topline data should be viewed with caution until the final data are available. In addition, we may report interim
analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete are subject to the
risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available.
Adverse changes between interim data and final data could significantly harm our business and prospects. Further, additional disclosure
of interim data by us or by our competitors in the future could result in volatility in the price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a
more extensive amount of available information. You or others may not agree with what we determine is the material or otherwise appropriate
information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with
respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If
the preliminary or topline data that we report differs from late, final or actual results, or if others, including regulatory authorities,
disagree with the conclusions reached, our ability to obtain approval for, and commercialize, HSB-1216 or HSB-888 or any other product
candidates may be harmed, which could harm our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we experience delays or difficulties in enrolling patients in our ongoing or planned clinical trials, our receipt of necessary regulatory
approval could be delayed or prevented.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to initiate or continue our ongoing or planned clinical trials for our product candidates if we are unable to identify
and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA. Patient enrollment is a significant
factor in the timing of clinical trials. Our ability to enroll eligible patients may be limited or may result in slower enrollment than
we anticipate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient
enrollment may be affected if our competitors have ongoing clinical trials for programs that are under development for the same indications
as our product candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in clinical trials of
our competitors&rsquo; programs. Patient enrollment for our current or any future clinical trials may be affected by other factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">size
    and nature of the patient population;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">severity
    of the disease under investigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    and efficacy of approved drugs for the disease under investigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    eligibility criteria for the trial in question as defined in the protocol;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">perceived
    risks and benefits of the product candidate under study;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&rsquo;
    and patients&rsquo; perceptions as to the potential advantages of the product candidate being studied in relation to other available
    therapies, including any new products that may be approved or other product candidates being investigated for the indications we
    are investigating;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&rsquo;
    willingness to screen their patients for biomarkers to indicate which patients may be eligible for enrollment in our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    referral practices of physicians;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to monitor patients adequately during and after treatment;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">proximity
    and availability of clinical trial sites for prospective patients; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may be late-stage cancer
    patients and will not survive the full terms of the clinical trials.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon
one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product
candidates and jeopardize our ability to obtain marketing approval for the sale of our product candidates. Furthermore, even if we are
able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining participation in our clinical
trials through the treatment and any follow-up periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
no regulatory authority has granted approval for a cancer therapeutic based on a Quatramer approach. We may never receive approval to
market and commercialize any product candidate. Even if we obtain regulatory approval, the approval may be for targets, disease indications,
lines of therapy or patient populations that are not as broad as we intended or desired or may require labeling that includes significant
use or distribution restrictions or safety warnings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not previously submitted a new drug application (&ldquo;NDA&rdquo;) to the FDA or similar regulatory approval filings to comparable
foreign authorities, for any product candidate, and we cannot be certain that our product candidates will be successful in clinical trials
or receive regulatory approval. Further, any future product candidates may not receive regulatory approval even if they are successful
in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations.
Even if we successfully obtain regulatory approvals to market a product candidate, our revenue will be dependent, in part, upon the size
of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets or patient subsets
that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if
approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to seek regulatory approval to commercialize our product candidates both in the United States and in selected foreign countries.
While the scope of regulatory approval generally is similar in other countries, in order to obtain separate regulatory approval in other
countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy. Other countries
also have their own regulations governing, among other things, clinical trials and commercial sales, as well as pricing and distribution
of our product candidates, and we may be required to expend significant resources to obtain regulatory approval and to comply with ongoing
regulations in these jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements
to maintain regulatory approval. If our candidates prove to be ineffective, unsafe or commercially unviable, our entire technology platform
and pipeline would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results
of operations and prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">HSB-1216, HSB-888, HSB-1218 are novel technologies,
making it difficult to predict the time, cost and potential success of these product candidates. We have not yet been able to assess
the safety and efficacy of any product candidates in humans. Our success depends on our ability to develop and commercialize product
candidates using our novel Quatramer technology. The novel nature of our technology makes it difficult to accurately predict the developmental
challenges we may face for product candidates as they proceed through research, pre-clinical or greenhouse studies and clinical or field
trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been a limited number of clinical trials of products created with induced ferroptosis and reverse epithelial-mesenchymal transition
(&ldquo;EMT&rdquo;), none of which has utilized our Quatramer technology, and no therapeutic product candidates created with induced
ferroptosis and reverse EMT technology have received marketing approval in the United States or Europe. Because our therapeutic research
programs are all in research or pre-clinical stages, we have not yet been able to assess the safety or efficacy of any product candidates
in humans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our product candidates do not achieve projected development milestones or commercialization in the announced or expected timeframes,
the further development or commercialization of such product candidates may be delayed, and our business may be harmed. Current or
future product candidates may not meet safety and efficacy requirements for continued development or ultimate approval in humans and
may cause significant adverse events or toxicities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Adverse
side effects or other safety risks associated with our drug candidates could delay or preclude approval, cause us to suspend or discontinue
clinical trials or abandon further development, limit the commercial profile of an approved label, or result in significant negative
consequences following marketing approval, if any.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
of our planned clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics.
Undesirable side effects caused by our drug candidates could result in the delay, suspension or termination of clinical trials by us
or the FDA for a number of reasons. Additionally, due to the high mortality rates of the cancers for which we are initially pursuing
development and the pretreated nature of many patients in our planned clinical trials of HSB-1216, a material percentage of patients
in these clinical trials may die during a trial, which could impact development of HSB-1216. If we elect or are required to delay, suspend
or terminate any clinical trial, the commercial prospects of our drug candidates will be harmed and our ability to generate product revenues
from this drug candidate will be delayed or eliminated. Serious adverse events observed in clinical trials could hinder or prevent market
acceptance of our drug candidates. Any of these occurrences may harm our business, prospects, financial condition and results of operations
significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
if our drug candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we
may elect to abandon or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other
characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations
for our drug candidates, if approved. We may also be required to modify our study plans based on findings in our clinical trials. Many
drugs that initially showed promise in early stage testing have later been found to cause side effects that prevented further development.
In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is possible that as we test our drug candidates in larger, longer and more extensive clinical trials, including with different dosing
regimens, or as the use of our drug candidates becomes more widespread following any regulatory approval, illnesses, injuries, discomforts
and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous
trials, will be reported by patients. If such side effects become known later in development or upon approval, if any, such findings
may harm our business, financial condition, results of operations and prospects significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if any of our drug candidates receive marketing approval, and we or others later identify undesirable side effects caused by
treatment with such drug, a number of potentially significant negative consequences could result, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw approval of the drug;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to recall a product or change the way the drug is administered to patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require additional warnings on the label, such as a &ldquo;black box&rdquo; warning or a contraindication, or issue
    safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information
    about the product;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to implement a Risk Evaluation and Mitigation Strategy (&ldquo;REMS&rdquo;) or create a medication guide outlining
    the risks of such side effects for distribution to patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
    restrictions may be imposed on the marketing or promotion of the particular product or the manufacturing processes for the product
    or any component thereof;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    drug could become less competitive; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation may suffer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could prevent us from achieving or maintaining market acceptance of our drug candidates, if approved, and could significantly
harm our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
sometimes estimate, or may in the future estimate, the timing of the accomplishment of various scientific, clinical, manufacturing, regulatory
and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific
studies or clinical trials, the submission of regulatory filings, the receipt of marketing approval or the realization of other commercialization
objectives.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
achievement of milestones such as the timing of the accomplishment of various scientific, clinical, manufacturing, regulatory and other
product development objectives may be outside of our control. All of these milestones are based on a variety of assumptions, including
assumptions regarding capital resources, constraints and priorities, progress of and results from development activities and the receipt
of key regulatory approvals or actions, any of which may cause the timing of achievement of the milestones to vary considerably from
our estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or our collaborators fail to achieve announced milestones in the expected timeframes, the commercialization of our product candidates
may be delayed, our credibility may be undermined, our business and results of operations may be harmed, and the price of our common
stock may decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
a product liability claim is successfully brought against us for uninsured liabilities, or such claim exceeds our insurance coverage,
we could be forced to pay substantial damage awards that could materially harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of any of our existing or future product candidates in clinical trials and the sale of any approved pharmaceutical products may expose
us to significant product liability claims. We currently do not have product liability insurance coverage but we intend to obtain such
insurance. Such insurance coverage may not protect us against any or all of the product liability claims that may be brought against
us in the future. We may not be able to acquire or maintain adequate product liability insurance coverage at a commercially reasonable
cost or in sufficient amounts or scope to protect us against potential losses. In the event a product liability claim is brought against
us, we may be required to pay legal and other expenses to defend the claim, as well as uncovered damage awards resulting from a claim
brought successfully against us. In the event our product candidate is approved for sale by the FDA or other regulatory agency and commercialized,
we may need to substantially increase the amount of our product liability coverage. Defending any product liability claim or claims could
require us to expend significant financial and managerial resources, which could have an adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
current and future products may never achieve significant commercial market acceptance.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends on the market&rsquo;s confidence that we can provide therapeutic products that improve clinical outcomes, lower healthcare
costs and enable better biopharmaceutical development. Failure of our products, or those jointly developed with our collaborators, to
perform as expected could significantly impair our operating results and our reputation. We believe patients, clinicians, academic institutions
and biopharmaceutical companies are likely to be particularly sensitive to defects, errors, inaccuracies, delays and toxicities in or
associated with our products. Furthermore, inadequate performance of these products may result in lower confidence in our immune medicine
platform in general.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not succeed in achieving significant commercial market acceptance for our current or future products due to a number of factors,
including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to demonstrate the clinical utility of our Quatramer platform and related products and their potential advantages over existing
    drug products to academic institutions, biopharmaceutical companies and the medical community;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability, and that of our collaborators, to secure and maintain FDA and other regulatory clearance, authorization or approval for
    our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    agreement by third-party payors to reimburse our products, the scope and extent of which will affect patients&rsquo; willingness
    or ability to pay for our products and will likely heavily influence physicians&rsquo; decisions to recommend our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rate of adoption of our Quatramer platform and related products by academic institutions, clinicians, key opinion leaders, advocacy
    groups and biopharmaceutical companies; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of our investments in product innovation and commercial growth.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
our customers and collaborators may decide to decrease or discontinue their use of our products due to changes in their research and
development plans, failures in their clinical trials, financial constraints, the regulatory environment, negative publicity about our
products, competing products or the reimbursement landscape, all of which are circumstances outside of our control. We may not be successful
in addressing these or other factors that might affect the market acceptance of our products and Quatramer technology. Failure to achieve
widespread market acceptance of our Quatramer platform and related products would materially harm our business, financial condition and
results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business may be adversely affected by the ongoing coronavirus pandemic.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outbreak of the novel Coronavirus (&ldquo;COVID-19&rdquo;) evolved into a global pandemic as COVID-19 spread to many regions of the world.
The extent to which COVID-19 impacts our business and operating results will depend on future developments that are highly uncertain
and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain COVID-19
or treat its impact, among others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
COVID-19 continue to spread, our business operations could be delayed or interrupted. For&nbsp;&nbsp; instance, our research and development
may be affected by the pandemic. Distribution of clinical trial materials, study monitoring and data analysis may be paused or delayed
due to changes in hospital or university policies, federal, state or local regulations, prioritization of hospital resources toward pandemic
efforts, or other reasons related to the pandemic. If COVID-19 continues to spread, some participants and clinical investigators may
not be able to comply with clinical trial protocols. For example, quarantines or other travel limitations (whether voluntary or required)
may impede participant movement, affect sponsor access to study sites, or interrupt healthcare services, and we may be unable to conduct
our research activities, including clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Infections
and deaths related to the pandemic may disrupt the United States&rsquo; healthcare and healthcare regulatory systems. Such disruptions
could divert healthcare resources away from, or materially delay FDA review and/or approval. It is unknown how long these disruptions
could continue, were they to occur. Any elongation or de-prioritization of clinical trials or delay in regulatory review resulting from
such disruptions could materially affect the development and study of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a shelter-in-place order or other mandated local travel restrictions, our employees conducting research and development
or manufacturing activities may not be able to access their laboratory or manufacturing space, and our core activities may be significantly
limited or curtailed, possibly for an extended period of time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
spread of COVID-19, which has caused a broad impact globally, including restrictions on travel and quarantine policies put into place
by businesses and governments, may have a material economic effect on our business. While the potential economic impact brought by and
the duration of the pandemic may be difficult to assess or predict, it has already caused, and is likely to result in further, significant
disruption of global financial markets, which may reduce our ability to access capital either at all or on favorable terms. In addition,
a recession, depression or other sustained adverse market event resulting from the spread of COVID-19 could materially and adversely
affect our business and the value of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ultimate impact of the current pandemic, or any other health epidemic, is highly uncertain and subject to change. We do not yet know
the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the
global economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor the
situation closely.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may expend our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications
that may be more profitable or for which there is a greater likelihood of success.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have limited financial and managerial resources, we focus on research programs and drug candidates that we identify for specific indications.
As a result, we may forego or delay pursuit of opportunities with other drug candidates or for other indications that later prove to
have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products
or profitable market opportunities. Our spending on current and future research and development programs and drug candidates for specific
indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market
for a particular drug candidate, we may relinquish valuable rights to that drug candidate through collaboration, licensing or other royalty
arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to
such drug candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be successful in our efforts to design additional potential drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key element of our strategy is to apply our knowledge and our understanding of the structure, biology and activity of ferroptosis to
develop drug candidates. The therapeutic design and development activities that we are conducting may not be successful in developing
drug candidates that are useful in treating cancer or other diseases. Our research programs may initially show promise in identifying
potential drug candidates, yet fail to yield drug candidates for clinical development for a number of reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    research methodology used may not be successful in identifying potential drug candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    drug candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are
    unlikely to be drugs that will obtain marketing approval or achieve market acceptance; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    drug candidates may not be effective in treating their targeted diseases.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
programs to identify and design new drug candidates require substantial technical, financial and human resources. We may choose to focus
our efforts and resources on a potential drug candidate that ultimately proves to be unsuccessful. If we are unable to identify and design
suitable drug candidates for pre-clinical and clinical development, we will not be able to obtain revenues from the sale of products
in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price.<B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are
more effective, safer or less expensive than the products we develop, our commercial opportunities will be negatively impacted.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis
on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product
candidates and processes competitive with ours. Any product candidates that we successfully develop and commercialize will compete with
existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently
under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop
product candidates. In addition, our products may need to compete with drugs physicians use off-label to treat the indications for which
we seek approval. This may make it difficult for us to replace existing therapies with our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, there is intense competition in the field of oncology. We have competitors both in the United States and internationally,
including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, emerging
and start-up companies, universities and other research institutions. We also compete with these organizations to recruit management,
scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business
plan. We will also face competition in establishing clinical trial sites, enrolling subjects for clinical trials and in identifying and
in-licensing new product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective,
have fewer side effects, are more convenient, have a broader label, are marketed more effectively, are more widely reimbursed or are
less expensive than any products that we may develop. Our competitors also may obtain marketing approval from the FDA, EMA or other comparable
foreign regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result in our competitors
establishing a strong market position before we are able to enter the market. Even if the product candidates we develop achieve marketing
approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced
competitiveness. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete,
less competitive or not economical. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our
products we develop may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to healthcare laws and regulations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our product candidates, if approved, or any other future product candidate will be subject to healthcare regulation and enforcement
by the federal government and the states and foreign governments in which we might conduct our business. The healthcare laws and regulations
that may affect our ability to operate include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Anti-Kickback Statute makes it illegal for any person or entity to knowingly and willfully, directly or indirectly, solicit,
    receive, offer, or pay any remuneration that is in exchange for or to induce the referral of business, including the purchase, order,
    lease of any good, facility, item or service for which payment may be made under a federal healthcare program, such as Medicare or
    Medicaid. The term &ldquo;remuneration&rdquo; has been broadly interpreted to include anything of value.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
    false claims and false statement laws, including the federal civil False Claims Act, prohibits, among other things, any person or
    entity from knowingly presenting, or causing to be presented, for payment to, or approval by, federal programs, including Medicare
    and Medicaid, claims for items or services, including drugs, that are false or fraudulent.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health
    Insurance Portability and Accountability Act of 1996 (&ldquo;HIPAA&rdquo;) created additional federal criminal statutes that prohibit
    among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program,
    including private third-party payors or making any false, fictitious or fraudulent statement in connection with the delivery of or
    payment for healthcare benefits, items or services.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and their implementing regulations,
    impose obligations on certain types of individuals and entities regarding the electronic exchange of information in common healthcare
    transactions, as well as standards relating to the privacy and security of individually identifiable health information.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which
    payment is available under Medicare, Medicaid or the Children&rsquo;s Health Insurance Program, with specific exceptions, to report
    annually to the Centers for Medicare &amp; Medicaid Services information related to payments or other transfers of value made to
    physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
many states have similar laws and regulations, such as anti-kickback and false claims laws that may be broader in scope and may apply
regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Additionally, we may be subject
to state laws that require pharmaceutical companies to comply with the federal government&rsquo;s and/or pharmaceutical industry&rsquo;s
voluntary compliance guidelines, state laws that require drug manufacturers to report information related to payments and other transfers
of value to physicians and other healthcare providers or marketing expenditures, as well as state and foreign laws governing the privacy
and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
to the extent that our product is sold in a foreign country, we may be subject to similar foreign laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and if we are
found to have improperly promoted off-label uses of our drugs or drug candidates, if approved, we may become subject to significant liability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to have improperly promoted off-label uses of our drugs or drug candidates, we may become subject to significant liability.
Such enforcement has become more common in the industry. The FDA and other regulatory agencies strictly regulate the promotional claims
that may be made about prescription drug products, such as our drug candidates. In particular, a drug may not be promoted for uses that
are not approved by the FDA or such other regulatory agencies as reflected in the drug&rsquo;s approved labeling. If we receive marketing
approval for our drug candidates for our proposed indications, physicians may nevertheless use our drugs for their patients in a manner
that is inconsistent with the approved label. However, if we are found to have promoted our drugs for any off-label uses, the federal
government could levy civil, criminal and/or administrative penalties, and seek fines against us. The FDA or other regulatory authorities
could also request that we enter into a consent decree or a corporate integrity agreement, or seek a permanent injunction against us
under which specified promotional conduct is monitored, changed or curtailed. If we cannot successfully manage the promotion of our drug
candidates, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to obtain or maintain Fast Track designation or accelerated approval for our drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a drug is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet
medical need for this condition, a drug sponsor may apply for FDA Fast Track designation. If we seek Fast Track designation for a drug
candidate, we may not receive it from the FDA. However, even if we receive Fast Track designation, Fast Track designation does not ensure
that we will receive marketing approval or that approval will be granted within any particular time frame. We may not experience a faster
development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition,
the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development
program. Fast Track designation alone does not guarantee qualification for the FDA&rsquo;s priority review procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to obtain or maintain orphan drug designation or exclusivity for our drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as &ldquo;orphan
drugs.&rdquo; Under the Orphan Drug Act, the FDA may designate a drug candidate as an orphan drug if it is intended to treat a rare disease
or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or if the disease
or condition affects more than 200,000 individuals in the United States and there is no reasonable expectation that the cost of developing
and making a drug product available in the United States for the type of disease or condition will be recovered from sales of the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphan
drug designation entitles a party to financial incentives, such as opportunities for grant funding towards clinical trial costs, tax
advantages and user-fee waivers. Additionally, if a product that has orphan designation subsequently receives the first FDA approval
for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity. This means that the
FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except
in certain circumstances, including proving clinical superiority (i.e., another product is safer, more effective or makes a major contribution
to patient care) to the product with orphan exclusivity. Competitors, however, may receive approval of different products for the indication
for which the orphan product has exclusivity, or obtain approval for the same product but for a different indication than that for which
the orphan product has exclusivity. In addition, exclusive marketing rights in the United States may be limited if we seek approval for
an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation
was materially defective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>A
Breakthrough Therapy designation by the FDA for our drug candidates may not lead to a faster development or regulatory review or approval
process, and it does not increase the likelihood that our drug candidates will receive marketing approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designation
as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our drug candidates meets the criteria
for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive
Breakthrough Therapy designation, the receipt of such designation for a drug candidate may not result in a faster development process,
review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval
by the FDA. In addition, even if one or more of our drug candidates qualify as breakthrough therapies, the FDA may later decide that
the drugs no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.
We may seek a breakthrough therapy designation for some of our drug candidates. A breakthrough therapy is defined as a drug that is intended,
alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical
evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant
endpoints, such as substantial treatment effects observed early in clinical development. For drugs and biologics that have been designated
as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient
path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough
therapies by the FDA are also eligible for accelerated approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Risks Related to Our Reliance on Third Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
rely on third parties to conduct our pre-clinical studies and clinical trials. If these third parties do not successfully perform their
contractual and regulatory duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our
drug candidates and our business could be substantially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have the ability to independently conduct all aspects of our pre-clinical testing or clinical trials. As a result, we have relied
upon and plan to continue to rely upon third-party medical institutions, clinical investigators, contract laboratories and other third
party CROs to monitor and manage data for our ongoing pre-clinical and clinical programs. We rely on these parties for the execution
of our pre-clinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible
for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards,
and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with current
GCPs, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic
Area and comparable foreign regulatory authorities for all of our drugs in clinical development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities enforce these current GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we
or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and
the FDA, the EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our
marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine
that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced
under cGMPs. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory
approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or
to do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under
our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our on-going clinical, nonclinical
and pre-clinical or clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected
deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure
to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated
and we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates. As a result, our results
of operations and the commercial prospects for our drug candidates would be harmed, our costs could increase and our ability to generate
revenues could be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for
whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. If the
third parties conducting our pre-clinical studies or our clinical trials do not perform their contractual duties or obligations, experience
work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy
of the clinical data they obtain is compromised due to their failure to adhere to our clinical trial protocols or to GCPs, or for any
other reason, we may need to enter into new arrangements with alternative third parties. Switching or adding additional CROs involves
additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work.
As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully
manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future
or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Manufacturing
pharmaceutical products is complex and subject to product loss for a variety of reasons. We contract with third parties for the manufacture
of our drug candidates for pre-clinical testing and clinical trials and expect to continue to do so for commercialization. This reliance
on third parties increases the risk that we will not have sufficient quantities of our drug candidates or products or such quantities
at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any manufacturing facilities. We produce very small quantities of small molecules for evaluation in our research programs
in our laboratory. We rely, and expect to continue to rely, on third parties for the manufacture of our drug candidates for pre-clinical
and clinical testing, as well as for commercial manufacture if any of our drug candidates obtain marketing approval. Some of our manufacturers
represent our sole source of supply, including the Israeli-based supplier of salinomycin, the active component of HSB-1216 and HSB-888
starting material, and a China-based supplier of pirarubicin, one of the active components of HSB-888. This reliance on third parties
increases the risk that we will not have sufficient quantities of our drug candidates or products or such quantities at an acceptable
cost or quality, which could delay, prevent or impair our development or commercialization efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be unable to establish any agreements with third-party manufacturers or to do so on favorable terms. Even if we are able to establish
agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reliance
    on the third party for regulatory, compliance and quality assurance;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">operations
    of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including
    the bankruptcy of the manufacturer or supplier or the issuance of an FDA Form 483 notice or warning letter;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possible breach of the manufacturing agreement by the third party;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possible misappropriation of our proprietary information, including our trade secrets and know how;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">carrier
    disruptions or increased costs that are beyond our control; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to deliver our drugs under specified storage conditions and in a timely manner.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have only limited supply arrangements in place with respect to our drug candidates, and these arrangements do not extend to commercial
supply. We acquire many key materials on a purchase order basis. As a result, we do not have long-term committed arrangements with respect
to our drug candidates and other materials. If we obtain marketing approval for any of our drug candidates, we will need to establish
an agreement for commercial manufacture with a third party; however, no assurance can be provided that we will be able to enter into
a commercial manufacture agreement on reasonable terms, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
manufacturers may not be able to comply with cGMPs or similar regulatory requirements outside of the United States. Our failure, or the
failure of our third-party manufacturers and suppliers, to comply with applicable regulations could result in sanctions being imposed
on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation,
seizures or recalls of drug candidates or products, operating restrictions and criminal prosecutions, any of which could significantly
and adversely affect supplies of our products. In addition, our third-party manufacturers and suppliers are subject to numerous environmental,
health and safety laws and regulations, including those governing the handling, use, storage, treatment and disposal of waste products,
and failure to comply with such laws and regulations could result in significant costs associated with civil or criminal fines and penalties
for such third parties. Based on the severity of regulatory actions that may be brought against these third parties in the future, our
clinical or commercial supply of drug and packaging and other services could be interrupted or limited, which could harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug candidates and any products that we may develop may compete with other drug candidates and products for access to manufacturing
facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers
that operate under cGMPs and that may be capable of manufacturing our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we prepare for later-stage clinical trials and potential commercialization, we will need to take steps to increase the scale of production
of our drug candidates. Even minor deviations from normal manufacturing processes could result in reduced production yields, product
defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our drug candidates or in the manufacturing
facilities in which our drug candidates are made, such manufacturing facilities may need to be closed for an extended period of time
to investigate and remedy the contamination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do
not currently have arrangements in place for redundant supply or a second source for bulk drug substance. If our current contract manufacturers
for pre-clinical and clinical testing cannot perform as agreed, we may be required to replace such manufacturers. Although we believe
that there are several potential alternative manufacturers who could manufacture our drug candidates, we may incur added costs and delays
in identifying and qualifying any such replacement manufacturer or be able to reach agreement with any alternative manufacturer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current and anticipated future dependence upon others for the manufacture of our drug candidates or products may adversely affect our
future profit margins and our ability to commercialize any products that obtain marketing approval on a timely and competitive basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
failure to find third party collaborators to assist or share in the costs of drug development could materially harm our business, financial
condition and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy for the development and commercialization of our proprietary drug candidates may include the execution of collaborative arrangements
with third parties. Existing and future collaborators have significant discretion in determining the efforts and resources they apply
and may not perform their obligations as expected. Potential third-party collaborators include biopharmaceutical, pharmaceutical and
biotechnology companies, academic institutions and other entities. Third-party collaborators may assist us in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">funding
    research, pre-clinical development, clinical trials and manufacturing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seeking
    and obtaining regulatory approvals; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    commercializing any future drug candidates.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to establish further collaboration agreements, we may be required to undertake drug development and commercialization
at our own expense. Such an undertaking may limit the number of drug candidates that we will be able to develop, significantly increase
our capital requirements and place additional strain on our internal resources. Our failure to enter into additional collaborations could
materially harm our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our dependence on licensing, collaboration and other agreements with third parties may subject us to a number of risks. These
agreements may not be on terms that prove favorable to us and may require us to relinquish certain rights in our drug candidates. To
the extent we agree to work exclusively with one collaborator in a given area, our opportunities to collaborate with other entities could
be curtailed. Lengthy negotiations with potential new collaborators may lead to delays in the research, development or commercialization
of drug candidates. The decision by our collaborators to pursue alternative technologies or the failure of our collaborators to develop
or commercialize successfully any drug candidate to which they have obtained rights from us could materially harm our business, financial
condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Commercialization of Our Drug Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we are successful in completing all pre-clinical studies and clinical trials, we may not be successful in commercializing one or more
of our drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we complete the necessary pre-clinical studies and clinical trials, the marketing approval process is expensive, time-consuming and
uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our drug candidates. If we are not
able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our drug candidates,
and our ability to generate revenue will be materially impaired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug candidates and the activities associated with their development and commercialization, including their design, testing, manufacture,
safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, export and import are subject
to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the EMA and similar regulatory authorities
outside of the United States. Failure to obtain marketing approval for a drug candidate will prevent us from commercializing the drug
candidate. We have not submitted an application for or received marketing approval for any of our drug candidates in the United States
or in any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party
clinical research organizations or other third-party consultants or vendors to assist us in this process. Securing marketing approval
requires the submission of extensive pre-clinical and clinical data and supporting information to regulatory authorities for each therapeutic
indication to establish the drug candidate&rsquo;s safety and efficacy. Securing marketing approval also requires the submission of information
about the drug manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our drug candidates
may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other
characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. New cancer drugs frequently are
indicated only for patient populations that have not responded to an existing therapy or have relapsed. If any of our drug candidates
receives marketing approval, the accompanying label may limit the approved use of our drug in this way, which could limit sales of the
drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years, if approval is obtained
at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the drug candidates
involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or
regulations, or changes in regulatory review for each submitted drug application, may cause delays in the approval or rejection of an
application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may
decide that our data is insufficient for approval and require additional pre-clinical, clinical or other studies. In addition, varying
interpretations of the data obtained from pre-clinical studies and clinical trials could delay, limit or prevent marketing approval of
a drug candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments
that render the approved drug not commercially viable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to develop satisfactory sales and marketing capabilities, we may not succeed in commercializing our drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no experience in marketing and selling drug products. We have not entered into arrangements for the sale and marketing of any of
our drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are risks involved with establishing our own sales and marketing capabilities. For example, recruiting and training a sales force is
expensive and time-consuming and could delay any product launch. If the commercial launch of a drug candidate for which we recruit a
sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily
incurred these commercialization expenses. These efforts are expected to be costly, and our investment would be lost if we cannot retain
or reposition our sales and marketing personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek to collaborate with a third party to market our drugs or may seek to market and sell our drugs by ourselves. If we seek to collaborate
with a third party, we cannot be sure that a collaborative agreement can be reached on terms acceptable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be sure that we will be able to acquire, or establish third party relationships to provide, any or all of these marketing and
sales capabilities. The establishment of a direct sales force or a contract sales force or a combination direct and contract sales force
to market our drugs will be expensive and time-consuming and could delay any drug launch. Further, we can give no assurances that we
may be able to maintain a direct and/or contract sales force for any period of time or that our sales efforts will be sufficient to generate
or to grow our revenues or that our sales efforts will ever lead to profits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
development and commercialization of pharmaceutical products are subject to extensive regulation, and we may not obtain regulatory approvals
for our drug candidates on a timely basis, or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
time required to obtain approval or other marketing authorizations by the FDA is unpredictable, and it typically takes many years following
the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities.
In addition, approval policies, regulations, and the type and amount of clinical data necessary to gain approval may change during the
course of a product candidate&rsquo;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval
for any product candidate, and it is possible that we may never obtain regulatory approval for any product candidates we may seek to
develop in the future. Neither we nor any current or future collaborator is permitted to market any drug product candidates in the United
States until we receive regulatory approval from the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to obtaining approval to commercialize any drug product candidate in the United States, we must demonstrate with substantial evidence
from well-controlled clinical trials, and to the satisfaction of the FDA, that such product candidates are safe, pure and effective for
their intended uses. Results from pre-clinical studies and clinical trials can be interpreted in different ways. Even if we believe the
pre-clinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA.
The FDA may also require us to conduct additional pre-clinical studies or clinical trials for our product candidates either prior to
or after approval, or it may object to elements of our clinical development programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates could fail to receive regulatory approval for many reasons, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may disagree with the design or implementation of our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate to the satisfaction of the FDA that a product candidate is safe and effective for its proposed indication;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of clinical trials may not meet the level of statistical significance required by the FDA for approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate that a product candidate&rsquo;s clinical and other benefits outweigh its safety risks;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical
    and commercial supplies; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data insufficient for approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the large number of products in development, only a small percentage successfully complete the FDA approval processes and are commercialized.
The lengthy approval and marketing authorization process as well as the unpredictability of future clinical trial results may result
in our failing to obtain regulatory approval and marketing authorization to market our product candidates, which would significantly
harm our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have invested a significant portion of our time and financial resources in the development of our pre-clinical product candidates. Our
business is dependent on our ability to successfully complete pre-clinical and clinical development, obtain regulatory approval for,
and, if approved, successfully commercialize HSB-1216, HSB-888, HSB-1218 and any future product candidates in a timely manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we eventually complete clinical testing and receive approval for HSB-1216, HSB-888, HSB-1218 and any future product candidates, the
FDA, may grant approval or other marketing authorization contingent on the performance of costly additional clinical trials, including
post-marketing clinical trials. The FDA, also may approve or authorize for marketing a product candidate for a more limited indication
or patient population than we originally request, and the FDA may not approve or authorize the labeling that we believe is necessary
or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable
regulatory approval or other marketing authorization would delay or prevent commercialization of that product candidate and would materially
adversely impact our business and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the FDA may change their policies, issue additional regulations or revise existing regulations, or take other actions, which
may prevent or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose
additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability
to maintain any marketing authorizations we may have obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Failure
to obtain marketing approval in foreign jurisdictions would prevent our drug candidates from being marketed abroad.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market and sell our drugs in the European Union and many other foreign jurisdictions, we or our potential third-party collaborators
must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies
among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required
to obtain FDA marketing approval. The regulatory approval process outside of the United States generally includes all of the risks associated
with obtaining FDA approval. In addition, in many countries outside of the United States, it is required that the drug be approved for
reimbursement before the drug can be approved for sale in that country. We or our potential third-party collaborators may not obtain
approvals from regulatory authorities outside of the United States on a timely basis, if at all. Approval by the FDA does not ensure
approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside of the United
States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, a failure or delay
in obtaining regulatory approval in one country may have a negative effect on the regulatory process in other countries. We may not be
able to file for marketing approvals and may not receive necessary approvals to commercialize our drugs in any market</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
drug candidate that we obtain marketing approval for could be subject to post-marketing restrictions or withdrawal from the market and
we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems
with our drugs, when and if any of them are approved.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">While
it is possible that one or more of our drug candidates may require a companion diagnostic to select the patients who will likely
respond to a cancer therapy involving one of our drug candidates that would require a PMA for the companion diagnostic as a
condition to obtaining marketing approval from the FDA, it is too early in our drug candidates development to identify which drug
candidate, if any, would require a PMA. According to FDA guidance, if the FDA determines that a companion diagnostic device is
essential to the safe and effective use of a novel therapeutic drug or indication, the FDA generally will not approve the
therapeutic drug or new therapeutic drug indication if the companion diagnostic is not also approved or cleared for that indication.
Under the Federal Food, Drug, and Cosmetic Act, (&ldquo;FDCA&rdquo;) companion diagnostics are regulated as medical devices, and the
FDA has generally required companion diagnostics intended to select the patients who will respond to cancer treatment to obtain
Premarket Approval (&ldquo;PMA&rdquo;) for the diagnostic. The PMA process, including the gathering of clinical and pre-clinical
data and the submission to and review by the FDA, involves a rigorous premarket review during which the applicant must prepare and
provide the FDA with reasonable assurance of the device&rsquo;s safety and effectiveness and information about the device and its
components regarding, among other things, device design, manufacturing and labeling. A PMA is not guaranteed and may take
considerable time, and the FDA may ultimately respond to a PMA submission with a &ldquo;not approvable&rdquo; determination based on
deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to
generate and that can substantially delay approval. As a result, if we are required by the FDA to obtain approval of a companion
diagnostic for a therapeutic drug candidate, and we do not obtain or there are delays in obtaining FDA approval of a diagnostic
device, we may not be able to commercialize the drug candidate on a timely basis or at all and our ability to generate revenue will
be materially impaired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
drug candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling,
advertising and promotional activities for such drug, will be subject to continual requirements of and review by the FDA and other regulatory
authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing
requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records
and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a drug
candidate is granted, the approval may be subject to limitations on the indicated uses for which the drug may be marketed or to the conditions
of approval, including the requirement to implement a REMS. New cancer drugs frequently are indicated only for patient populations that
have not responded to an existing therapy or have relapsed. If any of our drug candidates receives marketing approval, the accompanying
label may limit the approved use of our drug in this way, which could limit sales of the drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy
of the drug, including the adoption and implementation of REMS. The FDA and other agencies, including the Department of Justice(&ldquo;DOJ&rdquo;)
closely regulate and monitor the post-approval marketing and promotion of drugs to ensure they are marketed and distributed only for
the approved indications and in accordance with the provisions of the approved labeling. The FDA and DOJ impose stringent restrictions
on manufacturers&rsquo; communications regarding off-label use, and if we do not market our drugs for their approved indications, we
may be subject to enforcement action for off-label marketing. Violations of the FDCA and other statutes, including the False Claims Act,
relating to the promotion and advertising of prescription drugs may lead to investigations and enforcement actions alleging violations
of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws. In addition, later discovery of previously
unknown adverse events or other problems with our drugs, manufacturers or manufacturing processes, or failure to comply with regulatory
requirements, may have various consequences, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on such drugs, manufacturers or manufacturing processes;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    and warnings on the labeling or marketing of a drug;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on drug distribution or use;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    to conduct post-marketing studies or clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
    letters or untitled letters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of the drugs from the market;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to approve pending applications or supplements to approved applications that we submit;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recall
    of drugs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    restitution or disgorgement of profits or revenues;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or withdrawal of marketing approvals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">damage
    to relationships with any potential collaborators;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
    press coverage and damage to our reputation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to permit the import or export of our drugs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">drug
    seizure;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation
    involving patients using our drugs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Healthcare
Reform in the United States.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, there have been, and continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare
system that could affect the future results of pharmaceutical manufactures&rsquo; operations. In particular, there have been and continue
to be a number of initiatives at the federal and state levels that seek to reduce healthcare costs. Most recently, the Affordable Care
Act (&ldquo;ACA&rdquo;) was enacted in March 2010, which includes measures to significantly change the way healthcare is financed by
both governmental and private insurers. Among the provisions of the ACA of greatest importance to the pharmaceutical and biotechnology
industry are the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned
    among these entities according to their market share in certain government healthcare programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementation
    of the federal physician payment transparency requirements, sometimes referred to as the &ldquo;Physician Payments Sunshine Act&rdquo;;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    licensure framework for follow-on biologic products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness
    research, along with funding for such research;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment
    of a Center for Medicare Innovation at the Centers for Medicare &amp; Medicaid Services to test innovative payment and service delivery
    models to lower Medicare and Medicaid spending, potentially including prescription drug spending;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the
    average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs
    at 100% of the Average Manufacturer Price;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and
    biologics, including our product candidates, that are inhaled, infused, instilled, implanted or injected;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">extension
    of manufacturers&rsquo; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed
    care organizations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion
    of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals
    and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby
    potentially increasing manufacturers&rsquo; Medicaid rebate liability;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated
    prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&rsquo;s
    outpatient drugs to be covered under Medicare Part D; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion
    of the entities eligible for discounts under the Public Health program.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the provisions of the ACA have yet to be implemented, and there have been legal and political challenges to certain aspects of the
ACA. The Administration has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements
mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA.
While Congress has not passed repeal legislation, the Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January
1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health
coverage for all or part of a year that is commonly referred to as the &ldquo;individual mandate&rdquo;. Congress may consider other
legislation to repeal or replace elements of the ACA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the details regarding the implementation of the ACA are yet to be determined, and at this time, the full effect that the ACA would
have on a pharmaceutical manufacturer remains unclear. This uncertainty is heightened by President Biden&rsquo;s January 28, 2021 Executive
Order on Strengthening Medicaid and the Affordable Care Act which indicates that the incoming Biden Administration may significantly
modify the ACA and potentially revoke any changes implemented by the Trump Administration. It is also possible that President Biden will
further reform the ACA and other federal programs in manner that may impact our operations. The Biden Administration has indicated that
a goal of its administration is to expand and support Medicaid and the ACA and to make high-quality healthcare accessible and affordable.
The potential increase in patients covered by government funded insurance may impact our pricing. Further, it is possible that the Biden
Administration may further increase the scrutiny on drug pricing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Additionally,
on December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the tax penalty
on certain individuals who fail to maintain qualifying health coverage for all or part of a year, commonly referred to as the &ldquo;individual
mandate.&rdquo; Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit ruled that the individual mandate was
unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid
as well. The United States Supreme Court is currently reviewing this case, but it is unclear when a decision will be made. It is also
unclear how the Supreme Court ruling, other such litigation and the healthcare reform measures of the Biden administration will impact
the ACA. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative
or executive action, either in the United States or abroad. We expect that additional state and federal health care reform measures will
be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and
services. Moreover, the Biden administration, including his nominee for Secretary of DHHS, has indicated that lowering prescription drug
prices is a priority, but we do not yet know what steps the administration will take or whether such steps will be successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
there is uncertainty surrounding the applicability of the biosimilars provisions under the ACA. The FDA has issued several guidance documents,
but no implementing regulations, on biosimilars. A number of biosimilar applications have been approved over the past few years. The
regulations that are ultimately promulgated and their implementation are likely to have considerable impact on the way pharmaceutical
manufacturers conduct their business and may require changes to current strategies. A biosimilar is a biological product that is highly
similar to an approved drug notwithstanding minor differences in clinically inactive components, and for which there are no clinically
meaningful differences between the biological product and the approved drug in terms of the safety, purity, and potency of the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
states have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and
biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access,
and marketing cost disclosure and transparency measures, and to encourage importation from other countries and bulk purchasing. Legally
mandated price controls on payment amounts by third-party payors or other restrictions could harm a pharmaceutical manufacturer&rsquo;s
business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals
are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription
drug and other healthcare programs. This could reduce ultimate demand for certain products or put pressure product pricing, which could
negatively affect a pharmaceutical manufacturer&rsquo;s business, results of operations, financial condition and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, given recent federal and state government initiatives directed at lowering the total cost of healthcare, Congress and state
legislatures will likely continue to focus on healthcare reform, the cost of prescription drugs and biologics and the reform of the Medicare
and Medicaid programs. While no one cannot predict the full outcome of any such legislation, it may result in decreased reimbursement
for drugs and biologics, which may further exacerbate industry-wide pressure to reduce prescription drug prices. This could harm a pharmaceutical
manufacturer&rsquo;s ability to generate revenue. Increases in importation or re-importation of pharmaceutical products from foreign
countries into the United States could put competitive pressure on a pharmaceutical manufacturer&rsquo;s ability to profitably price
products, which, in turn, could adversely affect business, results of operations, financial condition and prospects. A pharmaceutical
manufacturer might elect not to seek approval for or market products in foreign jurisdictions in order to minimize the risk of re-importation,
which could also reduce the revenue generated from product sales. It is also possible that other legislative proposals having similar
effects will be adopted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
regulatory authorities&rsquo; assessment of the data and results required to demonstrate safety and efficacy can change over time and
can be affected by many factors, such as the emergence of new information, including on other products, changing policies and agency
funding, staffing and leadership. We cannot be sure whether future changes to the regulatory environment will be favorable or unfavorable
to our business prospects. For example, average review times at the FDA for marketing approval applications can be affected by a variety
of factors, including budget and funding levels and statutory, regulatory and policy changes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur
costs that could harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous foreign, federal, state and local environmental, health and safety laws and regulations, including those governing
laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve
the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste
products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination
or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held
liable for any resulting damages, and any liability could exceed our resources, including any available insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our leasing and operation of real property may subject us to liability pursuant to certain of these laws or regulations. Under
existing U.S. environmental laws and regulations, current or previous owners or operators of real property and entities that disposed
or arranged for the disposal of hazardous substances may be held strictly, jointly and severally liable for the cost of investigating
or remediating contamination caused by hazardous substance releases, even if they did not know of and were not responsible for the releases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could incur significant costs and liabilities which may adversely affect our financial condition and operating results for failure to
comply with such laws and regulations, including, among other things, civil or criminal fines and penalties, property damage and personal
injury claims, costs associated with upgrades to our facilities or changes to our operating procedures, or injunctions limiting or altering
our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain workers&rsquo; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting
from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain
insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal
of biological, hazardous or radioactive materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations.
These current or future laws and regulations, which are becoming increasingly more stringent, may impair our research, development or
production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we do not obtain patent term extension for any drug candidates we may develop, our business may be materially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, depending upon the timing, duration, and specifics of any FDA marketing approval of a drug candidate, the patent
term of a patent that covers an FDA-approved drug may be eligible for limited patent term extension, which permits patent term
restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent
Term Restoration Act of 1984, also known as the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the
expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory
review. Patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of drug
approval, and only one patent applicable to an approved drug may be extended and only those claims covering the approved drug, a
method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and other
non-United States jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when our
drug candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those drug candidates, there
is no guarantee that the applicable authorities will agree with our assessment of whether such extensions should be granted, and
even if granted, the length of such extensions. We may not be granted an extension because of, for example, failing to exercise due
diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply
prior to expiration of the relevant patents, or otherwise failing to satisfy applicable requirements. If we are unable to obtain any
patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing
drugs following the expiration of our patent rights, and our business, financial condition, results of operations, and prospects
could be materially harmed.<B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability
to protect our drugs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining
and enforcing patents in the pharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming
and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase
the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Recent
patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (the Leahy-Smith Act)
signed into law in September 2011, could increase those uncertainties and costs. The Leahy-Smith Act includes a number of significant
changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide
more efficient and cost-effective avenues for competitors to challenge the validity of patents. For example, the Leahy-Smith Act allows
third-party submission of prior art to the United States Patent and Trademark Office (&ldquo;USPTO&rdquo;) during patent prosecution
and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review,
inter parties review, and derivation proceedings. In addition, the Leahy-Smith Act has transformed the U.S. patent system from a &ldquo;first-to-invent&rdquo;
system to a &ldquo;first-to-file&rdquo; system in which, assuming that other requirements for patentability are met, the first inventor
to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent
the claimed invention. The first-to-file provisions, however, only became effective on March 16, 2013. Accordingly, it is not yet clear
what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation
could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the
prosecution of our or our collaboration partners&rsquo; patent applications and the enforcement or defense of our or our collaboration
partners&rsquo; issued patents, all of which could harm our business, results of operations, financial condition and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly
uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened
the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and
enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws
and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and
our ability to protect, defend and enforce our patent rights in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
or our future licensors may become involved in lawsuits to protect or enforce our patent or other intellectual property rights,
which could be expensive, time-consuming and unsuccessful.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
and other third parties may infringe, misappropriate or otherwise violate our or our future licensors&rsquo; issued patents or
other intellectual property. As a result, we or our licensors may need to file infringement, misappropriation or other intellectual property
related claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke such parties
to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their intellectual property. In addition,
in a patent infringement proceeding, such parties could counterclaim that the patents we or our licensors have asserted are invalid or
unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace.
Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty,
obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution
of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may institute
such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include
re-examination, post-grant review, inter parties review, interference proceedings, derivation proceedings, and equivalent proceedings
in foreign jurisdictions (e.g., opposition proceedings).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
adverse result in any such proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated or interpreted
narrowly, and could put any of our owned or in-licensed patent applications at risk of not yielding an issued patent. A court may also
refuse to stop the third party from using the technology at issue in a proceeding on the grounds that our owned or in-licensed patents
do not cover such technology. Furthermore, because of the substantial amount of discovery required in connection with intellectual property
litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during this
type of litigation. Any of the foregoing could allow such third parties to develop and commercialize competing technologies and products
and have a material adverse impact on our business, financial condition, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Third
parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property
rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our drug
candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property
and proprietary rights of third parties. There is considerable patent and other intellectual property litigation in the pharmaceutical
and biotechnology industries. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual
property rights with respect to our technology and drug candidates, including interference proceedings, post grant review, inter parties
review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the European
Patent Office.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability
of success might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive
and time-consuming, and our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting
these legal actions than we can. The risks of being involved in such litigation and proceedings may increase if and as our drug candidates
near commercialization and as we gain the greater visibility associated with being a public company. Third parties may assert infringement
claims against us based on existing patents or patents that may be granted in the future, regardless of merit. We may not be aware of
all such intellectual property rights potentially relating to our technology and drug candidates and their uses. Thus, we do not know
with certainty that our technology and drug candidates, or our development and commercialization thereof, do not and will not infringe,
misappropriate or otherwise violate any third party&rsquo;s intellectual property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we believe that third party intellectual property claims are without merit, there is no assurance that a court would find in our favor
on questions of misappropriation, infringement, validity, enforceability, or priority. A court of competent jurisdiction could hold these
third-party patents are valid, enforceable, and infringed, which could materially and adversely affect our ability to commercialize any
technology or drug candidate covered by the asserted third-party patents. In order to successfully challenge the validity of any such
U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present
clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction
would invalidate the claims of any such U.S. patent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to infringe, misappropriate or otherwise violate a third party&rsquo;s intellectual property rights, we could be
required to obtain a license from such third party to continue developing, manufacturing and marketing our technology and drug
candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were
able to obtain a license, it could be non-exclusive; thereby giving our competitors and other third parties access to the same
technologies licensed to us and could require us to make substantial licensing and royalty payments. We could be forced, including
by court order, to cease developing, manufacturing and commercializing the infringing technology or drug. In addition, we could be
found liable for significant monetary damages, including treble damages and attorneys&rsquo; fees, if we are found to have willfully
infringed a patent or other intellectual property right and could be forced to indemnify our collaborators or others. A finding of
infringement could prevent us from commercializing our drug candidates or force us to cease some of our business operations, which
could materially harm our business. In addition, we may be forced to redesign our drug candidates, seek new regulatory approvals and
indemnify third parties pursuant to contractual agreements. Claims that we have misappropriated the confidential information or
trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of
operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Intellectual property litigation or other legal proceedings relating to intellectual property could
cause us to spend substantial resources and distract our personnel from their normal responsibilities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant
expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public
announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors
perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or
proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future
sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings
adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because
of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual
property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings
could compromise our ability to compete in the marketplace.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with our obligations in our future intellectual property licenses and funding arrangements with third parties,
we could lose rights that are important to our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may be party to license and funding agreements
that impose diligence, development and commercialization timelines, milestone payment, royalty, insurance and other obligations on us.
If we fail to comply with such obligations, our counterparties may have the right to terminate our agreements or require us to
grant them certain rights. Such an occurrence could materially adversely affect the value of any drug candidate being developed under
any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our
having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including
our rights to important intellectual property or technology, which would have a material adverse effect on our business, financial condition,
results of operations, and prospects.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
these and other license agreements may not provide exclusive rights to use the licensed intellectual property and technology in all relevant
fields of use and in all territories in which we may wish to develop or commercialize our technology and drugs in the future. As a result,
we may not be able to prevent competitors from developing and commercializing competitive products and technology in fields of use and
territories not included in such agreements. In addition, we may not have the right to control the preparation, filing, prosecution,
maintenance, enforcement, and defense of patents and patent applications covering the technology that we may license from third
parties. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained,
and defended in a manner consistent with the best interests of our business. If our licensors fail to prosecute, maintain, enforce, and
defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated,
and our right to develop and commercialize any of our drugs that are the subject of such licensed rights could be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may need to obtain additional licenses from others to advance our research or allow commercialization of our drug candidates. It is possible
that we may be unable to obtain additional licenses at a reasonable cost or on reasonable terms, if at all, or such licenses may be non-exclusive.
The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies
may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These
established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development
and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license
rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make
an appropriate return on our investment or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights
we have, we may be required to expend significant time and resources to redesign our technology, drug candidates, or the methods for
manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis.
If we are unable to do so, we may be unable to develop or commercialize the affected technology and drug candidates, which could harm
our business, financial condition, results of operations, and prospects significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disputes
may arise regarding intellectual property subject to a licensing agreement, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of rights granted under the license agreement and other interpretation related issues;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing
    agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sublicensing of patent and other rights under our collaborative development relationships;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    diligence obligations under the license agreement and what activities satisfy those diligence obligations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors
    and us and our partners; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    priority of invention of patented technology.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any agreements under which we license intellectual property or technology from third parties may be complex,
and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation
disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology,
or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material
adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property
that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms,
we may be unable to successfully develop and commercialize the affected technology and drug candidates, which could have a material adverse
effect on our business, financial conditions, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
future licensors may rely on third-party consultants or collaborators or on funds from third parties such that our licensors
are not the sole and exclusive owners of the patents and patent applications we in-licensed. If other third parties have ownership rights
to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products
and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations,
and prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
spite of our best efforts, our future licensors might conclude that we have materially breached our license agreements and might
therefore terminate our license agreements, thereby removing our ability to develop and commercialize drug candidates and technology
covered by such agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the
intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products and technologies identical
to ours. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations,
and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to protect our intellectual property and proprietary rights throughout the world.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting, and defending patents on drug candidates in all countries throughout the world would be prohibitively expensive, and the
laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be
able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing
products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions
where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to
territories where we have patent protection or licenses but enforcement is not as strong as that in the United States. These products
may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them
from competing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets,
and other intellectual property protection, particularly those relating to pharmaceutical products, which could make it difficult for
us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary
rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial
costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or
interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against
us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.
Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant
commercial advantage from the intellectual property that we develop or license.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition,
many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent
owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to
grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and
our business, financial condition, results of operations, and prospects may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Managing Our Business and Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may encounter difficulties in managing our growth, which could adversely affect our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 11, 2021, we had 1 full-time employee. As our clinical development and commercialization plans and strategies develop, and as
we transition into operating as a public company, we will need to expand our managerial, clinical, regulatory, sales, marketing, financial,
development, manufacturing and legal capabilities or contract with third parties to provide these capabilities for us. As our operations
expand, we expect that we will need to manage additional relationships with various strategic collaborators, suppliers and other third
parties. Our future growth would impose significant added responsibilities on members of management, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    recruiting, integrating, maintaining and motivating additional employees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing
    our development and commercialization efforts effectively, including the clinical and FDA review process for our product candidates,
    while complying with our contractual obligations to contractors and other third parties; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">improving
    our operational, financial and management controls, reporting systems and procedures.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to continue to develop and, if approved, commercialize our product candidates will depend, in part, on our ability to effectively
manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities
in order to devote a substantial amount of time to managing these growth activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors
and consultants to provide certain services, including contract manufacturers and companies focused on research and development and discovery
activities. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available
to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage
our outsourced activities or if the quality, accuracy or quantity of the services provided is compromised for any reason, our clinical
trials may be extended, delayed or terminated, and we may not be able to obtain, or may be substantially delayed in obtaining, regulatory
approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing
consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors,
we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly,
may not achieve our research, development and commercialization goals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may acquire additional technology and complementary businesses in the future. Acquisitions involve many risks, any of which could materially
harm our business, including the diversion of management&rsquo;s attention from core business concerns, failure to effectively exploit
acquired technologies, failure to successfully integrate the acquired business or realize expected synergies or the loss of key employees
from either our business or the acquired businesses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which
could result in a material disruption of our product development programs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
internal computer systems and those of our current and any future collaborators and other contractors or consultants are vulnerable to
damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While
we have not experienced any such material system failure, accident or security breach to date, if such an event were to occur and cause
interruptions in our operations, it could result in a disruption of our development programs and our business operations, whether due
to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial
data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover
or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications,
or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed
and the further development and commercialization of our product candidates could be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss of
information maintained in the information systems and networks of our company and our vendors, including personal information of our
employees and study subjects, and company and vendor confidential data. In addition, outside parties may attempt to penetrate our systems
or those of our vendors or fraudulently induce our personnel or the personnel of our vendors to disclose sensitive information in order
to gain access to our data and/or systems. We may experience threats to our data and systems, including malicious codes and viruses,
phishing and other cyberattack. The number and complexity of these threats continue to increase over time. If a material breach of, or
accidental or intentional loss of data from, our information technology systems or those of our vendors occurs, the market perception
of the effectiveness of our security measures could be harmed and our reputation and credibility could be damaged. We could be required
to expend significant amounts of money and other resources to repair or replace information systems or networks. In addition, we could
be subject to regulatory actions and/or claims made by individuals and groups in private litigation involving privacy issues related
to data collection and use practices and other data privacy laws and regulations, including claims for misuse or inappropriate disclosure
of data, as well as unfair or deceptive practices. Although we develop and maintain systems and controls designed to prevent these events
from occurring, and we have a process to identify and mitigate threats, the development and maintenance of these systems, controls and
processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become
increasingly sophisticated. Moreover, despite our efforts, the possibility of these events occurring cannot be eliminated entirely. As
we outsource more of our information systems to vendors, engage in more electronic transactions with payors and patients, and rely more
on cloud-based information systems, the related security risks will increase and we will need to expend additional resources to protect
our technology and information systems. In addition, there can be no assurance that our internal information technology systems or those
of our third-party contractors, or our consultants&rsquo; efforts to implement adequate security and control measures, will be sufficient
to protect us against breakdowns, service disruption, data deterioration or loss in the event of a system malfunction, or prevent data
from being stolen or corrupted in the event of a cyberattack, security breach, industrial espionage attacks or insider threat attacks
which could result in financial, legal, business or reputational harm.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
current operations are concentrated in one location, and we or the third parties upon whom we depend may be adversely affected by earthquakes
or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster,
including earthquakes, outbreak of disease or other natural disasters.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication
failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing
facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business,
particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to
these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations.
Earthquakes or other natural disasters could further disrupt our operations, and have a material and adverse effect on our business,
financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented
us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities
or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult
or, in certain cases, impossible, for us to continue our business for a substantial period of time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event.
We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, could
have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that
we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you
that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities
of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for
a short period of time, any or all of our research and development programs may be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Unfavorable
global economic conditions could adversely affect our business, financial condition or results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. Portions
of our future clinical trials may be conducted outside of the United States and unfavorable economic conditions resulting in the weakening
of the U.S. dollar would make those clinical trials more costly to operate. Furthermore, the most recent global financial crisis caused
extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, including due to the impact
of the COVID-19 pandemic, could result in a variety of risks to our business, including a reduced ability to raise additional capital
when needed on acceptable terms, if at all. A weak or declining economy or international trade disputes could also strain our suppliers,
some of which are located outside of the United States, possibly resulting in supply disruption. Any of the foregoing could harm our
business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely
impact our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
increasing use of social media platforms presents new risks and challenges.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Social
media is increasingly being used to communicate about our clinical development programs and the diseases our therapeutics are being developed
to treat, and we intend to utilize appropriate social media in connection with our commercialization efforts following approval of our
product candidates, if any. Social media practices in the biopharmaceutical industry continue to evolve and regulations and regulatory
guidance relating to such use are evolving and not always clear. This evolution creates uncertainty and risk of noncompliance with regulations
applicable to our business, resulting in potential regulatory actions against us, along with the potential for litigation related to
off-label marketing or other prohibited activities. For example, patients may use social media channels to comment on their experience
in an ongoing blinded clinical trial or to report an alleged adverse event. When such disclosures occur, there is a risk that trial enrollment
may be adversely impacted, we fail to monitor and comply with applicable adverse event reporting obligations or that we may not be able
to defend our business or the public&rsquo;s legitimate interests in the face of the political and market pressures generated by social
media due to restrictions on what we may say about our product candidates. There is also a risk of inappropriate disclosure of sensitive
information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur
or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to
our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
estimates of market opportunity and forecasts of market growth included in this prospectus may prove to be inaccurate, and even if the
markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
opportunity estimates and growth forecasts included in this prospectus are subject to significant uncertainty and are based on assumptions
and estimates which may not prove to be accurate. The estimates and forecasts included in this prospectus relating to size and expected
growth of our target market may prove to be inaccurate. Even if the markets in which we compete meet the size estimates and growth forecasts
included in this prospectus, our business may not grow at similar rates, or at all. Our growth is subject to many factors, including
our success in implementing our business strategy, which is subject to many risks and uncertainties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
employees, independent contractors, consultants, commercial partners, collaborators and vendors may engage in misconduct or other improper
activities, including noncompliance with regulatory standards and requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial
partners, collaborators and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails
to comply with the laws of the FDA and other similar foreign regulatory bodies, provide true, complete and accurate information to the
FDA and other similar foreign regulatory bodies, comply with manufacturing standards we have established, comply with healthcare fraud
and abuse laws in the United States and similar foreign fraudulent misconduct laws, or report financial information or data accurately
or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those
products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance
with such laws will also increase. These laws may impact, among other things, our current activities with principal investigators and
research patients, as well as proposed and future sales, marketing and education programs. In connection with this offering, we will
adopt a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by our employees, independent
contractors, consultants, commercial partners and vendors, and the precautions we take to detect and prevent this activity may not be
effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or
lawsuits stemming from a failure to comply with these laws or regulations. If any actions are instituted against us and we are not successful
in defending ourselves or asserting our rights, those actions could result in the imposition of civil, criminal and administrative penalties,
damages, monetary fines, imprisonment, disgorgement, possible exclusion from participation in government healthcare programs, additional
reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations
of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and the curtailment
of our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Failure
to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil
or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and any potential collaborators may be subject to federal, state and foreign data protection laws and regulations (i.e., laws and regulations
that address privacy and data security). In the United States, numerous federal and state laws and regulations, including federal health
information privacy laws, state data breach notification laws, state health information privacy laws and federal and state consumer protection
laws (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related
and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health
information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy
and security requirements under the HIPAA, as amended by HITECH. Depending on the facts and circumstances, we could be subject to criminal
penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity
in a manner that is not authorized or permitted by HIPAA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">International
data protection laws, including Regulation 2016/679, known as the General Data Protection Regulation (&ldquo;GDPR&rdquo;) may also apply
to health-related and other personal information obtained outside of the United States. The GDPR went into effect on May 25, 2018. The
GDPR introduced new data protection requirements in the European Union, as well as potential fines for noncompliant companies of up to
the greater of &euro;20 million or 4% of annual global revenue. The regulation imposes numerous new requirements for the collection,
use and disclosure of personal information, including more stringent requirements relating to consent and the information that must be
shared with data subjects about how their personal information is used, the obligation to notify regulators and affected individuals
of personal data breaches, extensive new internal privacy governance obligations and obligations to honor expanded rights of individuals
in relation to their personal information (e.g., the right to access, correct and delete their data). In addition, the GDPR includes
restrictions on cross-border data transfer. The GDPR will increase our responsibility and liability in relation to personal data that
we process, and we may be required to put in place additional mechanisms to ensure compliance with the new EU data protection rules.
Further, the United Kingdom&rsquo;s vote in favor of exiting the EU, often referred to as Brexit, has created uncertainty with regard
to data protection regulation in the United Kingdom. In particular, it is unclear whether the United Kingdom will enact data protection
legislation equivalent to the GDPR and how data transfers to and from the United Kingdom will be regulated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts,
restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure
to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could
include civil, criminal, and administrative penalties), private litigation and/or adverse publicity and could negatively affect our operating
results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the
providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we
have violated individuals&rsquo; privacy rights, failed to comply with data protection laws, or breached our contractual obligations,
even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could harm
our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in U.S. tax law could adversely affect our financial condition and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative
process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive
application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes
are likely to continue to occur in the future. Future changes in U.S. tax laws could have a material adverse effect on our business,
cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisors regarding the
implications of potential changes in U.S. tax laws on an investment in our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Common Stock and this Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
has been no prior public market for our common stock, the stock price of our common stock may be volatile or may decline regardless of
our operating performance and you may not be able to resell your shares at or above the initial public offering price.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering there has been no public market for shares of our common stock. You may not be able to sell your shares quickly or at
the market price if trading in shares of our common stock is not active. The initial public offering price for our common stock will
be determined through negotiations with the underwriters, and the negotiated price may not be indicative of the market price of the common
stock after the offering. An active or liquid market in our common stock may not develop upon the completion of this offering or, if
it does develop, it may not be sustainable. As a result of these and other factors, you may be unable to resell your shares of our common
stock at or above the initial public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter
into strategic collaborations or acquire companies or products by using our shares of common stock as consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
price of our stock may be volatile, and you could lose all or part of your investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading price of our common stock following this offering is likely to be highly volatile and could be subject to wide fluctuations in
response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed
in this &ldquo;Risk Factors&rdquo; section and elsewhere in this prospectus, these factors include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    commencement, enrollment or results of clinical trials and pre-clinical studies of our drug candidates or those of our competitors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delay in identifying and advancing a clinical candidate for our other development programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delay in our regulatory filings for our drug candidates and any adverse development or perceived adverse development with respect
    to the applicable regulatory authority&rsquo;s review of such filings, including without limitation the FDA&rsquo;s issuance of a
    &ldquo;refusal to file&rdquo; letter or a request for additional information;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    results or delays in future clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    regulatory decisions, including failure to receive regulatory approval of for our drug candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in laws or regulations applicable to our drug candidates, including but not limited to clinical trial requirements for approvals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    developments concerning our manufacturers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         inability to establish collaborations, if needed;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         failure to commercialize our product candidates, if approved;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
                                         or departures of key scientific or management personnel;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
                                         serious safety concerns related to the use of our drug candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction
                                         of new products offered by us or our competitors;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
                                         of significant acquisitions, strategic partnerships, joint ventures or capital commitments
                                         by us or our competitors;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to effectively manage our growth;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
                                         or anticipated variations in quarterly operating results;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         cash position;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         failure to meet the estimates and projections of the investment community or that we
                                         may otherwise provide to the public;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">publication
                                         of research reports about us or our industry, or product candidates in particular, or
                                         positive or negative recommendations or withdrawal of research coverage by securities
                                         analysts;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                         in the market valuations of similar companies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                         in the structure of the healthcare payment systems;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overall
                                         performance of the equity markets;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
                                         of our common stock by us or our stockholders in the future;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading
                                         volume of our common stock;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                         in accounting practices;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ineffectiveness
                                         of our internal controls;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
                                         or other developments relating to proprietary rights, including patents, litigation matters
                                         and our ability to obtain patent protection for our technologies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
                                         lawsuits, including patent or stockholder litigation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
                                         political and economic conditions; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
                                         events or factors, many of which are beyond our control.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme
price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies,
including as a result of the COVID-19 pandemic. Broad market and industry factors may negatively affect the market price of our
common stock, regardless of our actual operating performance. If the market price of our common stock after this offering does
not exceed the initial public offering price, you may not realize any return on your investment in us and may lose some or all
of your investment. In the past, securities class action litigation has often been instituted against companies following periods
of volatility in the market price of a company&rsquo;s securities. This type of litigation, if instituted, could result in substantial
costs and a diversion of management&rsquo;s attention and resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have broad discretion in the use of the net proceeds from this offering and may not use them effectively.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management will have broad discretion in the application of the net proceeds to us from this offering and could spend the proceeds
in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management
to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause
the price of our common stock to decline and delay the development of our drug candidates. Pending their use, we may invest the
net proceeds from this offering in a manner that does not produce income or that loses value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not
anticipate declaring or paying any cash dividends for the foreseeable future. Furthermore, future debt or other financing arrangements
may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any return
to stockholders will therefore be limited to the appreciation of their stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters
subject to stockholder approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
following the completion of this offering, our executive officers, directors and their affiliates will beneficially hold, in
the aggregate, approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of our outstanding voting stock. These stockholders,
acting together, would be able to significantly influence all matters requiring stockholder approval. For example, these stockholders
would be able to significantly influence elections of directors, amendments of our organizational documents, or approval of any
merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals
or offers for our common stock that you may feel are in your best interest as one of our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
you purchase our common stock in this offering, you will incur immediate and substantial dilution in the book value of your shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial public offering price will be substantially higher than the pro forma as adjusted net tangible book value per share of our common
stock after this offering. Investors purchasing common stock in this offering will pay a price per share that substantially exceeds the
pro forma as adjusted net tangible book value per share after this offering. As a result, investors purchasing common stock in this offering
will incur immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, based on an assumed initial public offering
price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus
and the sale of shares of common stock in the Company, representing the difference between our pro forma as adjusted net tangible
book value per share after giving effect to this offering and the assumed initial public offering price. Further, investors purchasing
common stock in this offering will contribute approximately &nbsp;&nbsp;&nbsp;&nbsp;% of the total amount invested by stockholders since
our inception, but will own only approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the shares of common stock outstanding after this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
dilution is due to our investors who purchased shares prior to this offering having paid substantially less when they purchased
their shares than the price offered to the public in this offering. To the extent outstanding options are exercised, there will
be further dilution to new investors. As a result of the dilution to investors purchasing shares in this offering, investors may
receive significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation. For a
further description of the dilution that you will experience immediately after this offering, see the section entitled &ldquo;Dilution&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies
will make our common stock less attractive to investors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an emerging growth company, as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may
take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging
growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley
Act, reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements
and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of
any golden parachute payments not previously approved. We could be an emerging growth company for up to five years following the
year in which we complete this offering, although circumstances could cause us to lose that status earlier. We will remain an
emerging growth company until the earlier of (i) the last day of the fiscal year (a) following the fifth anniversary of the completion
of this offering, (b) in which we have total annual gross revenue of at least $1.07 billion or (c) in which we are deemed to be
a large accelerated filer, which requires the market value of our common stock that is held by non-affiliates to exceed $700.0
million as of the prior June 30th and (ii) the date on which we have issued more than $1.0 billion in non-convertible debt during
the prior three-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may choose to take advantage of some, but not all, of the available exemptions. We cannot predict whether investors will find
our common stock less attractive if we rely on certain or all of these exemptions. If some investors find our common stock less
attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards
apply to private companies, which may make our financial statements less comparable to companies that comply with new or revised
accounting pronouncements as of public company effective dates. We have chosen to take advantage of the extended transition periods
available to emerging growth companies under the JOBS Act for complying with new or revised accounting standards until those standards
would otherwise apply to private companies provided under the JOBS Act. As a result, our financial statements may not be comparable
to those of companies that comply with public company effective dates for complying with new or revised accounting standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Financial
reporting obligations of being a public company in the U.S. are expensive and time-consuming, and our management will be required
to devote substantial time to compliance matters.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a publicly traded company we will incur significant additional legal, accounting and other expenses that we did not incur as a
privately company. The obligations of being a public company in the U.S. require significant expenditures and will place significant
demands on our management and other personnel, including costs resulting from public company reporting obligations under the Exchange
Act and the rules and regulations regarding corporate governance practices, including those under the Sarbanes-Oxley Act, the
Dodd-Frank Wall Street Reform and Consumer Protection Act, and the listing requirements of the stock exchange on which our securities
are listed. These rules require the establishment and maintenance of effective disclosure and financial controls and procedures,
internal control over financial reporting and changes in corporate governance practices, among many other complex rules that are
often difficult to implement, monitor and maintain compliance with. Moreover, despite recent reforms made possible by the JOBS
Act, the reporting requirements, rules, and regulations will make some activities more time-consuming and costly, particularly
after we are no longer an &ldquo;emerging growth company.&rdquo; In addition, we expect these rules and regulations to make it
more difficult and more expensive for us to obtain director and officer liability insurance. Our management and other personnel
will need to devote a substantial amount of time to ensure that we comply with all of these requirements and to keep pace with
new regulations, otherwise we may fall out of compliance and risk becoming subject to litigation or being delisted, among other
potential problems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial
results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm
our business and the trading price of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate
disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls,
or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any
testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting
firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that
may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement.
Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have
a negative effect on the trading price of our stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be required to disclose changes made in our internal controls and procedures on a quarterly basis and our management will
be required to assess the effectiveness of these controls annually. However, for as long as we are an emerging growth company,
our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls
over financial reporting pursuant to Section 404. An independent assessment of the effectiveness of our internal controls over
financial reporting could detect problems that our management&rsquo;s assessment might not. Undetected material weaknesses in
our internal controls over financial reporting could lead to restatements of our financial statements and require us to incur
the expense of remediation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Substantial
amounts of our outstanding shares may be sold into the market when lock-up or market standoff periods end. If there are substantial sales
of shares of our common stock, the price of our common stock could decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
significant number of our outstanding shares of common stock held by our directors, executive officers and certain stockholders
are subject to contractual lock-up restrictions on resale that for a period of six months after the date of this prospectus as
more fully described in the section titled &ldquo;Underwriting&rdquo; in this prospectus. If these stockholders sell, or indicate
an intent to sell, substantial amounts of our common stock in the public market after the expiration of the applicable lock-up
period, the trading price of our common stock could decline significantly and could decline below the public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, subject to contractual lock-up restrictions discussed above, holders of approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock, including shares of common stock issuable under outstanding options, have the right to require us
to register these shares under the Securities Act pursuant to an Amended and Restated Investors&rsquo; Rights Agreement as more
fully described in section titled &ldquo;Description of Capital Stock&mdash;Registration Rights&rdquo; in this prospectus. If
our existing stockholders sell substantial amounts of our common stock in the public market, or if the public perceives that such
sales could occur, this could have an adverse impact on the market price of our common stock, even if there is no relationship
between such sales and the performance of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price
and trading volume could decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish
about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If
no securities or industry analysts commence coverage of our company, the trading price for our stock would likely be negatively
impacted. In the event securities or industry analysts initiate coverage, if one or more of the analysts who covers us downgrades
our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these
analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which
might cause our stock price and trading volume to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Certificate of Incorporation provides that the Court of Chancery of the State of Delaware will be the sole and exclusive forum
for substantially all disputes between the Company and its stockholders, which could limit stockholders&rsquo; ability to obtain
a favorable judicial forum for disputes with the Company or its directors, officers or employees.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation provides that unless we consent in writing to the selection of an alternative forum, the State of
Delaware is the sole and exclusive forum for: (i) any derivative action or proceeding brought on behalf of us, (ii) any action
asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of our Company to us or our stockholders,
(iii) any action asserting a claim against us, our directors, officers or employees arising pursuant to any provision of the Delaware
General Corporation Law (the &ldquo;DGCL&rdquo;) or our Certificate of Incorporation or Bylaws, or (iv) any action governed by
the internal affairs doctrine. This exclusive forum provision would not apply to suits brought to enforce any liability or duty
created by the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.
To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal
jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations
thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty
or liability created by the Securities Act or the rules and regulations thereunder. However, our Certificate of Incorporation
contains a federal forum provision which provides that unless we consent in writing to the selection of an alternative forum,
the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting
a cause of action arising under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
choice of forum provisions may limit a stockholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable
for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors,
officers and other employees. Alternatively, if a court were to find our choice of forum provisions contained in our Certificate
of Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such
action in other jurisdictions, which could harm our business, results of operations, and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
could be subject to securities class action litigation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, securities class action litigation has often been brought against a company following a decline in the market price
of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock
price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&rsquo;s
attention and resources, which could harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
is no guarantee that our common stock will be listed on Nasdaq.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to apply to have our shares of common stock listed on The Nasdaq Capital Market. Upon completion of this offering, we believe
that we will satisfy the listing requirements and expect that our common stock will be listed on The Nasdaq Capital Market. Such
listing, however, is not guaranteed. If the application is not approved, we will seek to have our common stock quoted on the OTCQB
maintained by the OTC Markets Group, Inc. Even if such listing is approved, there can be no assurance any broker will be interested
in trading our common stock. Therefore, it may be difficult to sell any shares you purchase in this offering if you desire or
need to sell them. Our lead underwriter, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, is not obligated to make a market in our common stock, and even after making a market,
can discontinue market making at any time without notice. Neither we nor the underwriters can provide any assurance that an active
and liquid trading market in our common stock will develop or, if developed, that the market will continue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="g_001"></A>INFORMATION
REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains forward-looking statements that involve risks and uncertainties. You should not place undue reliance on these
forward-looking statements. All statements other than statements of historical facts contained in this prospectus are forward-looking
statements. The forward-looking statements in this prospectus are only predictions. We have based these forward-looking statements
largely on our current expectations and projections about future events and financial trends that we believe may affect our business,
financial condition and results of operations. In some cases, you can identify these forward-looking statements by terms such
as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;depends,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;expects,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;ongoing,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo;
&ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; or the negative of
those terms or other similar expressions, although not all forward-looking statements contain those words. We have based these
forward-looking statements on our current expectations and projections about future events and trends that we believe may affect
our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial
needs. These forward-looking statements include, but are not limited to, statements concerning the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    projected financial position and estimated cash burn rate;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates regarding expenses, future revenues and capital requirements;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to continue as a going concern;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    need to raise substantial additional capital to fund our operation;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success, cost and timing of our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    dependence on third parties in the conduct of our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain the necessary regulatory approvals to market and commercialize our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ultimate impact of the current COVID-19 pandemic, or any other health epidemic, on our business, our clinical trials, our
    research programs, healthcare systems or the global economy as a whole;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential that results of pre-clinical and clinical trials indicate our current product candidates or any future product candidates
    we may seek to develop are unsafe or ineffective;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of market research conducted by us or others;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain intellectual property protection for our current and future product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to protect our intellectual property rights and the potential for us to incur substantial costs from lawsuits to enforce
    or protect our intellectual property rights;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possibility that a third party may claim we or our third-party licensors have infringed, misappropriated or otherwise violated
    their intellectual property rights and that we may incur substantial costs and be required to devote substantial time defending
    against claims against us;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reliance on third-party suppliers and manufacturers;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of competing therapies and products that are or become available;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to expand our organization to accommodate potential growth and our ability to retain and attract key personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential for us to incur substantial costs resulting from product liability lawsuits against us and the potential for these
    product liability lawsuits to cause us to limit our commercialization of our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
    acceptance of our product candidates, the size and growth of the potential markets for our current product candidates and
    any future product candidates we may seek to develop, and our ability to serve those markets; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    successful development of our commercialization capabilities, including sales and marketing capabilities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in &ldquo;Risk
Factors.&rdquo; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time.
It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the
extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any
forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and
circumstances discussed in this prospectus may not occur and actual results could differ materially and adversely from those anticipated
or implied in the forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected
in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance
or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required
by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements.
We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus
to conform these statements to actual results or to changes in our expectations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to
the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of
activity, performance and events and circumstances may be materially different from what we expect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="g_002"></A>INDUSTRY
AND MARKET DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains estimates and other statistical data made by independent parties and by us relating to market size and growth
and other data about our industry. We obtained the industry and market data in this prospectus from our own research as well as
from industry and general publications, surveys and studies conducted by third parties. This data involves a number of assumptions
and limitations and contains projections and estimates of the future performance of the industries in which we operate that are
subject to a high degree of uncertainty, including those discussed in &ldquo;Risk Factors.&rdquo; We caution you not to give undue
weight to such projections, assumptions and estimates. Further, industry and general publications, studies and surveys generally
state that they have been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness
of such information. While we believe that these publications, studies and surveys are reliable, we have not independently verified
the data contained in them. In addition, while we believe that the results and estimates from our internal research are reliable,
such results and estimates have not been verified by any independent source.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="g_003"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the net proceeds from our issuance and sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
our common stock in this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
million if the underwriters exercise their over-allotment option in full, based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range listed on the cover page of this prospectus, after
deducting underwriting discounts and commissions and estimated offering expenses payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds from this offering as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
                                            $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for pre-clinical activities and manufacturing related to our product candidate, HSB-1216;</FONT></TD></TR></TABLE>

<P STYLE="margin: 0 0 0 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
                                            $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for clinical trials related to or our product candidate, HSB-1216 through Phase 1 studies;
                                            and</FONT></TD></TR></TABLE>

<P STYLE="margin: 0 0 0 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
                                            $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for pre-clinical activities related to our product candidate, HSB-888.</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Any additional capital
that we raise pursuant to this offering will be used for general corporate and working capital purposes. We may also use a portion
of the net proceeds to in-license, acquire or invest in complementary businesses or products, however, we have no current commitments
or obligations to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
$1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint
of the price range listed on the cover page of this prospectus, would increase or decrease the net proceeds from this offering
by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the number of shares offered by us, as set forth on the
cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering
expenses payable by us. An increase (decrease) of 100,000 shares in the number of shares offered by us, as set forth on the cover
page of this prospectus, would increase (decrease) the net proceeds from this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million,
assuming no change in the assumed initial public offering price per share and after deducting underwriting discounts and commissions
and estimated offering expenses payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
expected use of the net proceeds from this offering and our existing cash represents our intentions based upon our current plans,
financial condition and business conditions. Predicting the cost necessary to develop product candidates can be difficult and
the amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress
of our development and commercialization efforts, the status of and results from clinical trials, any collaborations that we may
enter into with third parties for our product candidates and any unforeseen cash needs. As a result, our management will retain
broad discretion over the allocation of the net proceeds from this offering and our existing cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we expect to from time to time evaluate the acquisition of, investment in or in-license of
complementary products, technologies or businesses, and we could use a portion of the net proceeds from this offering for such
activities. We currently do not have any agreements, arrangements or commitments with respect to any potential acquisition, investment
or license.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending
our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments,
including short-term, investment-grade, interest-bearing instruments and government securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="g_004"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid or declared any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our
common stock in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development
and expansion of our business. Any future determination to pay dividends will be at the discretion of our board of directors and
will depend upon a number of factors, including our results of operations, financial condition, future prospects, contractual
restrictions, restrictions imposed by applicable law and other factors our board of directors deems relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="g_005"></A>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our cash and capitalization as of March 31, 2021:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    an actual basis;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    a pro forma basis to give effect to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    a pro forma as adjusted basis to give further effect to (i) our issuance and sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
    our common stock in this offering at an assumed initial public offering price of
    $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range listed on the
    cover page of this prospectus, after deducting underwriting discounts and commissions and our estimated offering expenses and (ii)
    the conversion of
    $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of
    principal amount and accrued interest of outstanding convertible notes into an aggregate of
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
    common stock upon the closing of this offering based upon an assumed initial public offering price of
    $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share,
    which is the midpoint of the price range listed on the cover page of this prospectus.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pro forma information in this table is unaudited and is illustrative only and our capitalization following the completion of this
offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing.
You should read this table in conjunction with the information contained in &ldquo;Use of Proceeds,&rdquo; &ldquo;Summary Financial
Data&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operation,&rdquo; as well
as the financial statements and the notes included elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><B>March 31, 2021</B></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in
    thousands, except share and per share data)</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Actual</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Unaudited)</B></FONT></P></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro
                                         Forma</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Unaudited)
                                         </B></FONT></P></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro
                                         Forma,</B></FONT></P>
                                                                                                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As</B></FONT></P>
                                                                                                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Adjusted<SUP>(1)</SUP></B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Unaudited)<BR>
                                         </B></FONT></P></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible notes</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Short term notes payable to related
    parties</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stockholders&rsquo; deficit:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preferred stock, par value $0.0001 per
    share; 10,000,000 shares authorized, issued and outstanding, actual; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized,  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;issued and outstanding, pro forma;
      &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized,   &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;issued and outstanding, pro forma as adjusted</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common stock, par value $0.0001 per
    share; 250,000,000 shares authorized,&nbsp;&nbsp;&nbsp;shares issued and outstanding, actual;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
    authorized,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma;&nbsp;&nbsp;&nbsp;shares authorized,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
    issued and outstanding, pro forma as adjusted</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional paid-in capital</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated deficit</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total stockholders&rsquo;
    deficit</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total capitalization</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 97%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;per share, which is the midpoint
    of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount
    of each of cash, total stockholders&rsquo; equity and total capitalization by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million,
    assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and
    after deducting underwriting discounts and commissions and estimated offering expenses payable by us. An increase (decrease)
    of 100,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase
    (decrease) the pro forma as adjusted amount of each of cash, total stockholders&rsquo; equity and total capitalization by
    $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming no change in the assumed initial public offering price per share and
    after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of our common stock to be outstanding after this offering is based on shares of our common stock outstanding
as of March 31, 2021, assumes no exercise by the underwriters of their over-allotment option and excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    shares of common stock reserved for future issuance under our 2019 Stock Incentive plan;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issuable upon exercise
    of outstanding options with a weighted average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issuable upon the
    conversion of outstanding convertible notes in the aggregate amount of $ &nbsp;&nbsp;, including interest accrued thereon, assuming an
    initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set
    forth on the cover page of this prospectus; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issuable upon exercise of
    warrants to be issued to the representative of the underwriters as part of this offering at an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    (assuming an initial public offering price of $ per share (the midpoint of the price range set forth on the cover page of this prospectus)).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_003"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our common stock, your ownership interest will be diluted to the extent of the difference between the initial public
offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock
immediately after this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2021, we had a historical net tangible book (deficit) of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share of common stock, based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding at March 31, 2021. Our historical
net tangible book value per share is the amount of our total tangible assets less our total liabilities at March 31, 2021, divided
by the number of shares of common stock outstanding at March 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
giving effect to the issuance in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , our pro forma net tangible
book value (deficit) as of March 31, 2021 was $ , or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
giving further effect to (i) the sale of shares of common stock in this offering at an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the offering price range set forth on the cover page of this prospectus,
and after deducting underwriting discounts and commissions and estimated offering expenses payable by us and (ii) the conversion of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of principal amount and accrued interest of outstanding convertible notes into an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock upon the closing of this offering based upon an assumed
initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range
listed on the cover page of this prospectus, our pro forma as adjusted net tangible book value at March 31, 2021 would have been
$&nbsp;&#8239;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock. This
represents an immediate increase in pro forma as adjusted net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
share to existing stockholders and immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to new investors purchasing
shares of common stock in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table illustrates this dilution on a per share basis:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Assumed initial public offering price per
    share</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Historical net tangible book value (deficit) per share as of
    March 31, 2021</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pro forma net tangible book value
    per share as of March 31, 2021</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Increase in pro
    forma as adjusted net tangible book value per share attributable to new investors in this offering</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pro forma as adjusted net tangible book
    value per share immediately after this offering</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dilution per
    share to new investors in this offering</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information discussed above is illustrative only, and the dilution information following this offering will be adjusted based
on the actual initial public offering price and other terms of this offering determined at pricing. A $1.00 increase (decrease)
in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price
range set forth on the cover page of this prospectus, would increase (decrease) our pro forma as adjusted net tangible book value
after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and the dilution to new investors purchasing common stock in
this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, assuming that the number of shares offered by us, as set forth on
the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering
expenses payable by us. An increase of 100,000 shares in the number of shares offered by us, as set forth on the cover page of
this prospectus, would increase our pro forma as adjusted net tangible book value after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share and decrease the dilution to new investors purchasing common stock in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share, assuming no change in the assumed initial public offering price per share and after deducting underwriting discounts
and commissions and estimated offering expenses payable by us. A decrease of 100,000 shares in the number of shares offered by
us would decrease the pro forma as adjusted net tangible book value after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
share and increase the dilution to new investors purchasing common stock in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
share, assuming no change in the assumed initial public offering price per share and after deducting underwriting discounts and
commissions and estimated offering expenses payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the underwriters exercise their option to purchase additional shares in full, the pro forma as adjusted net tangible book value
per share after giving effect to the offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. This represents an increase
in pro forma as adjusted net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to existing stockholders and dilution
in pro forma as adjusted net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to new investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of our common stock to be outstanding after this offering is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
our common stock outstanding as of March 31, 2021, assumes no exercise by the underwriters of their over-allotment option and
excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    shares of common stock reserved for future issuance under our 2019 Stock Incentive Plan;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    shares of common stock issuable upon exercise of outstanding options with a weighted average exercise price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    shares of common stock issuable upon the conversion of outstanding convertible notes in the aggregate amount of $ &nbsp;&nbsp;, including
    interest accrued thereon, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint
    of the price range set forth on the cover page of this prospectus; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    shares of common stock issuable upon exercise of warrants to be issued to the representative of the underwriters as part of this
    offering at an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (assuming an initial public offering price of
    $ per share (the midpoint of the price range set forth on the cover page of this prospectus)).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes, on the pro forma as adjusted basis described above, the total number of shares of common stock we
issued and sold, the total consideration we received and the average price per share (i) paid to us by existing stockholders or
(ii) to be paid by new investors purchasing our common stock in this offering at the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, before deducting underwriting discounts
and commissions and estimated offering expenses payable by us and (iii) the average price per share paid by existing stockholders
and by new investors who purchase shares of common stock in this offering:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares
    Purchased</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    Consideration</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average
    Price</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per
    Share</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing
    stockholders</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    investors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100.0</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100.0</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
$1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is
the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the total consideration
paid by new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million and, in the case of an increase, would increase the percentage
of total consideration paid by new investors by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; percentage points and, in the case of a decrease,
would decrease the percentage of total consideration paid by new investors by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; percentage points,
assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. An increase
(decrease) of 100,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase
(decrease) the total consideration paid by new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million and, in the case of an increase,
would increase the percentage of total consideration paid by new investors by percentage points and, in the case of a decrease
of 100,000 shares, would decrease the percentage of total consideration paid by new investors by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
percentage points, assuming no change in the assumed initial public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table above assumes no exercise of the underwriters&rsquo; over-allotment option in this offering. If the underwriters&rsquo;
over-allotment option is exercised in full, the number of common shares held by new investors purchasing common stock in this
offering would be increased to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of common stock outstanding after this offering, and the number
of shares held by existing stockholders would be reduced to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of common stock outstanding after
this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that stock options or warrants are exercised or convertible debt is converted, we issue new stock options under our
equity incentive plan, or we issue additional common stock in the future, there will be further dilution to investors participating
in this offering. In addition, if we raise additional capital through the sale of equity or convertible debt securities, the issuance
of these securities could result in further dilution to our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="g_006"></A>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>You
should read the following discussion and analysis of our financial condition and results of operations together with our financial
statements and the related notes included elsewhere in this prospectus. In addition to historical information, this discussion
and analysis contains forward-looking statements that are based on our current expectations, estimates and projections about our
business and operations and that involve risks, uncertainties and assumptions. Our actual results may differ materially from those
currently anticipated and expressed in such forward-looking statements as a result of a number of factors, including those which
we discuss under &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus. See &ldquo;Information Regarding Forward-Looking
Statements.&rdquo; All amounts in this report are in U.S. dollars, unless otherwise noted. </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a biotechnology company leveraging our tumor targeting proprietary platform, Quatramer&trade;, to develop a pipeline of novel
product candidates to treat rare and devastating cancers. Quatramer allows us to leverage and exploit key undruggable targets
and novel emerging pathways, such as IMCD in tumors and facilitate the delivery of potent drug payloads directly to the TME while
sparing healthy tissue. By efficiently  extending the circulation half-life as well as targeting delivery to the tumor
site, Quatramer traps payloads into the TME and exploits IMCD, an emerging orthogonal anti-cancer approach which utilizes a fundamental
recognized mechanism of tumor growth using iron transport, iron metabolism and iron-led ROS production. We are building a portfolio
of long-acting product candidates using Quatramers including our most advanced product candidate, HSB-1216, a long-acting IMCD
modulator of tumors. Our second product candidate, HSB-888, is a dual-loaded IMCD modulator coupled with an ultra-low dose next
generation anthracycline analogue for solid tumors which has a highly synergistic tumor killing capacity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quatramers
are small ~100 nanometer sized particles with the ability to carry both payloads and exterior coatings incorporated in a proprietary
polymeric mixture which is designed with specific physico-chemical parameters to target specified cells or tissues and converge
a therapeutic payload at the site of disease to boost efficacy while abating adverse effects on healthy tissue. Quatramer is also
highly modular and tunable allowing us to design and develop various follow-on product candidates including (i) small proteins
including cytokines/growth factors (TNF-alpha, IL-2, IL-12 and IL-15), metabolic hormones (such as insulin) (ii) peptides (up
to 40 amino acids long), (iii) oligonucleotides such as RNA including messenger mRNA and small RNAi, cDNA, as well as multiple
cytokine and biologic products with potentially significant advantages over existing and development-stage drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trident,
our artificial intelligence platform, is a novel approach to identify synthetic lethal sensitivities associated with degrees of
cell plasticity using biomarkers that can be translated for patient selection and stratification. TAI integrates diverse public datasets,
such as The Cancer Genome Atlas as well as other available datasets, which we intend to couple with data from our planned clinical programs
in order to identify biomarkers and novel gene signatures to stratify patients prospectively as we move compounds from bench to bedside.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to disrupt the biotechnology landscape by developing novel therapeutics by leveraging both our targeted-delivery Quatramer
platform-based therapeutics and our Trident platform and to address significant unmet medical needs, with a focus on treatments
for cancer. We believe that our technology has the potential to generate differentiated products that have massive potential to
treat multiple unmet need, rare and devastating tumors. We are prioritizing our efforts based on our assessments and expertise
of clinical development and regulatory strategy, unmet medical needs and market forces.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical components of our business strategy to achieve our goals include:</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Develop
drug candidate, HSB-1216, in solid tumors</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
from a compassionate use study in Germany led us to progress HSB-1216 into IND-enabling studies with the ultimate goal of launching
a Phase 1b/2a trial in 2022. These IND-enabling trials are pre-clinical in nature and include toxicology and pharmacokinetic profiling
as well as bioanalytical assay development. We have engaged in discussions with the FDA in 2020 and expect to use the 505(b)(1)
FDA approval pathway and conduct a Phase 1 trial to obtain initial pharmacokinetic and dosing information in patients. We intend
to evaluate the development of HSB-1216 in other high-unmet need oncology indications, including certain brain, breast and prostate
cancers, and in combination with other cancer therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Develop
our combination drug candidate, HSB-888, for pediatric sarcomas</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-888
is in IND-enabling trials with the ultimate goal of achieving an IND from the FDA in 2022. These trials are pre-clinical in nature
and include toxicology and pharmacokinetic profiling as well as bioanalytical assay development. Based on the data from these
trials, we plan to initiate discussions with the FDA in 2021 and expect to use the 505(b)(1) FDA approval pathway and conduct
a Phase 1 trial for obtaining initial pharmacokinetic data and determine the optimized dose in patients. We intend to demonstrate
the safety and efficacy in a Phase 2b program in a basket trial enrolling patients with recurrent cancers due to multiple sarcomas,
including Ewing&rsquo;s sarcoma, rhabdomyosarcoma and eligible osteosarcoma patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Leverage
Our Trident Platform</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAI
is a deep learning engine that identifies synthetic lethal sensitivities associates with degree of cell plasticity. We undertake
a multi-pronged approach to address each of the leading causes of tumor plasticity as the disease progresses including EMT, dedifferentiation/transdifferentiation,
and transient drug-induced tolerance and sensitivity. The platform builds on a deep foundation of diverse multi-modal and multi-omic
private and public datasets which include not only genomic and transcriptomic data from patient derived blood or biopsy samples
and sublines, and pan-cancer epigenetic and transcriptional drug response data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trends
and Uncertainties&mdash;COVID-19</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global COVID-19 pandemic continues to rapidly evolve, and we will continue to monitor the COVID-19 situation closely. The extent
of the impact of the COVID-19 on our business, operations, pre-clinical and clinical development timelines and plans remains uncertain,
and will depend on certain developments, including the duration and spread of the outbreak and its future impact on our clinical
trial enrollment, clinical trial sites, CROs, third-party manufacturers, and other third parties with whom we do business, as
well as its impact on regulatory authorities and our key scientific and management personnel. The ultimate impact of the COVID-19
pandemic or a similar health epidemic is highly uncertain and subject to change. To the extent possible, we are conducting business
as usual, with necessary or advisable modifications to employee travel and with many of our employees and consultants working
remotely. We will continue to actively monitor the rapidly evolving situation related to COVID-19 and may take further actions
that alter our operations, including those that may be required by federal, state or local authorities, or that we determine are
in the best interests of our employees and other third parties with whom we do business. At this point, the extent to which the
COVID-19 pandemic may affect our business, operations and clinical development timelines and plans, including the resulting impact
on our expenditures and capital needs, remains uncertain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Components
of Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Revenue</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not recognize revenues for the years ended December 31, 2020 and 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include personnel costs associated with research and development activities, including third-party contractors
to perform research, conduct clinical trials and manufacture drug supplies and materials. Research and development expenses are
charged to operations as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
accrue costs incurred by external service providers, including contract research organizations and clinical investigators, based
on estimates of service performed and costs incurred. These estimates include the level of services performed by third parties,
patient enrollment in clinical trials, administrative costs incurred by third parties, and other indicators of the services completed.
Based on the timing of amounts invoiced by service providers, we may also record payments made to those providers as prepaid expenses
that will be recognized as expense in future periods as the related services are rendered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred research and development expenses related to the development of HSB-1216. We expect that our research and development
expenses will increase as we plan for and commence our clinical trials of HSB-1216 and HSB-888.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot determine with certainty the duration and costs of future clinical trials of our product candidates, HSB-1216 and HSB-888,
or any other product candidates we may develop or if, when or to what extent we will generate revenue from the commercialization
and sale of any of our product candidates for which we obtain marketing approval. We may never succeed in obtaining marketing
approval for any of our product candidates. The duration, costs and timing of clinical trials and development of our current and
future product candidates will depend on a variety of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, rate of progress, expense and results of clinical trials of our current product candidates, as well as of any future
    clinical trials of our future product candidates and other research and development activities that we may conduct;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">uncertainties
    in clinical trial design and patient enrollment rates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    actual probability of success for our product candidates, including their safety and efficacy, early clinical data, competition,
    manufacturing capability and commercial viability;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    and changing government regulations and regulatory guidance; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and receipt of any marketing approvals.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant
change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory
authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of
clinical development of a product candidate, or if we experience significant delays in our clinical trials due to slower than
expected patient enrollment or other reasons, we would be required to expend significant additional financial resources and time
on the completion of clinical development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
and Administrative Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of compensation and consulting related expenses, <FONT STYLE="background-color: white">including
stock-based compensation</FONT>. General and administrative expenses also include professional fees and other corporate expenses,
including legal fees relating to corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance
costs; travel expenses and other operating costs that are not specifically attributable to research activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support
our continued research activities and development of our product candidates. Following this offering, we also expect to incur
increased expenses associated with being a public company, including expenses related to compliance with the rules and regulations
of the SEC and Nasdaq, additional director and officer insurance expenses, corporate governance expenses, investor relations activities
and other administrative and professional services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Acquired
In-process Research and Development Expense</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs incurred in obtaining technology licenses and asset purchases are charged to research and development expense
if the technology licensed has not reached technological feasibility which includes manufacturing, clinical, intellectual property
and/or regulatory success which has no alternative future use. The licenses purchased by us require substantial completion of
research and development and regulatory and marketing approval efforts in order to reach technological feasibility. As such, for
the years ended December 31, 2020 and 2019, the purchase price of licenses and assets acquired was classified as acquired in-process
research and development expenses in the consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Change
in Redemption Value</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for derivative instruments in accordance with Accounting Standards Codification (&ldquo;ASC&rdquo;) 815, <I>Derivative
and Hedging, </I>which establishes accounting and reporting standards for derivative instruments, including certain derivative
instruments embedded in other financial instruments or contracts, and requires recognition of all derivatives on the balance sheet
at fair value. Our derivative financial instrument consists of an embedded option in our convertible debt that we call the &ldquo;redemption
liability.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial fair value of the redemption feature relating to the convertible debt instruments is treated as a debt discount and amortized
over the term of the related debt using the straight-line method, which approximates the interest method. If a loan is paid in
full, any unamortized financing costs will be removed from the related accounts and charged to operations. Amortization of debt
discount is recorded as a component of interest expense. In accordance with ASU 2015-03, Interest &mdash; Imputation of Interest,
the unamortized debt discount is presented in the accompanying balance sheet as a direct deduction from the carrying amount of
the related debt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
redemption liability includes provision that provide the noteholder with certain conversion and put rights at various conversion or
redemption values as well as certain call options for us. The fair value of the redemption liability is determined based upon a
Probability-Weighted of Expected Returns model (&ldquo;PWERM&rdquo;). </FONT><FONT STYLE="font-size: 10pt">This PWERM was
determined to be the most appropriate method of estimating the value of possible redemption or conversion outcomes over time, since
we have not entered into a priced equity round through December 31, 2020. The significant assumptions utilized in these calculations
are the possible exit scenarios (either a conversion of the principal and accrued interest of the notes in the event of a Next
Equity Financing (as defined below), a repayment of the notes and accrued interest in the event of a Corporate Transaction (as defined in the notes) or
a repayment of the notes and accrued interest at maturity), the pre-money valuation of our common stock, the
probabilities of such exit events occurring and discounts/premiums available to the noteholders at such measurement dates. At
December 31, 2020, we assumed a 40% probability of a Next Equity Financing event occurring at IPO pricing, an increase from
9% at December 31, 2019. At December 31, 2020, we assumed a 5% probability of a Corporate Transaction, an increase from 1%
at December 31, 2019 (See Note 5 of our audited consolidated financial statements)</FONT><FONT STYLE="font-size: 8pt">.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Comparison
of the Years Ended December 31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth key components of our results of operations for the years ended December 31, 2020 and 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Consolidated Statement of Operations Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 52%; text-align: left">Research and development</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">847,272</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">368,732</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">478,540</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Acquired in-process research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">289,200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">429,403</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(140,203</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">671,879</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">625,807</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">46,072</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,808,351</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,423,942</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">384,409</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other Expense:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">246,534</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,074</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">171,460</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in redemption value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">362,486</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,458</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">336,028</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total other expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">609,020</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">101,532</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">507,488</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,417,371</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,525,474</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(891,897</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses increased by $478,540, or 129.8%, to $847,272 for the year ended December 31, 2020 from $368,732 for
the year ended December 31, 2019. The increase was primarily the result of an increase in pre-clinical related expense, license
expenses, and GMP manufacturing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Acquired
In-Process Research and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired
in-process research and development expense was $289,200 for the year ended December 31, 2020 and $429,403 for the year ended December
31, 2019, a decrease of $140,203. The in-process research and development expenses represent expenses incurred with the acquisition of
Farrington that closed during the year ended December 31, 2020, and the acquisition of Nanoproteagen and small molecule analogues
that closed during the year ended December 31, 2019. The expense amounts represent acquisition related costs which were approximately
$20,000 during the year ended December 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
and Administrative Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses increased by $46,072, or 7.4%, to $671,879 for the year ended December 31, 2020 from $625,807 for
the year ended December 31, 2019. The increase in general and administrative expenses was primarily due to an increase of $134,746
in legal expenses; $81,998 in expenses associated with accounting related fees; $61,439 in stock based compensation expense; and
$7,187 in insurance expenses. These increases were offset by decreases of $200,000 in payroll and related expenses; $25,298 of
various other expenses; and $14,000 related to travel expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Interest
Expense</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense increased by $171,460, or 228.4%, to $246,534 for the year ended December 31, 2020 from $75,074 for the year ended December
31, 2019. The increase in interest expense was primarily related to the convertible promissory notes which were exchanged on September
27, 2020 and had default interest rate of 20% and added an original issue discount of 37.5%. &nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Change
in Redemption Value</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in redemption value increased by $336,028 to $362,486 for the year ended December 31, 2020 from $26,458 for the year ended
December 21, 2019 as the probability of conducting a larger priced financing has increased since 2019 due to advancing manufacturing
processes and pre-clinical data readouts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception in 2017, we have devoted most of our cash resources to research and development, in-process research and development
and general and administrative activities. We do not currently have any approved products and have never generated any revenue
from product sales. To date, we have financed our operations primarily with proceeds from the sale of our convertible promissory
notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020 and March 31, 2021, we had cash of $191,852 and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , respectively. We have determined that our current levels
of cash will not be sufficient to meet our anticipated cash needs for our ongoing operations. We have incurred significant operating
losses since inception, and we expect to incur significant expenses and operating losses for the foreseeable future as we advance
the pre-clinical and clinical development of our product candidates. We expect that our research and development and general and
administrative costs will increase, including in connection with conducting pre-clinical studies and clinical trials for our product
candidates, engaging contract manufacturing organizations and building out internal capacity to have products manufactured to
support pre-clinical studies and clinical trials, expanding our intellectual property portfolio and general and administrative
support with respect to our operations. As a result, our independent registered public accounting firm has included, in its opinion
for the year ended December 31, 2020, an explanatory paragraph expressing substantial doubt about our ability to continue as a
going concern within one year from the date of this filing/ substantial doubt exists regarding the going concern assumption on
our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are seeking significant additional capital funding to advance our product candidates through pre-IND, manufacturing and clinical
trials as well as for general corporate and working capital purposes. However, there can be no assurance that such efforts
will be successful or that, in the event that they are successful, the terms and conditions of such financing will be favorable.
In consideration of our plans, substantial doubt cannot be alleviated with respect to our continued operations. Management&rsquo;s
plans, of which the raising additional capital is not within management&rsquo;s control and cannot be assured, do not alleviate
such substantial doubt with respect to our ongoing operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash
Flow Activities for the Years Ended December 31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a summary of our cash flows for the periods presented:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Years
    Ended December 31,</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net cash used in operating
    activities</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,078,432</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(706,113</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net cash provided by financing activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,232,003</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">708,385</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net increase in cash</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">153,571</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,272</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
Flows from Operating Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
used in operating activities for the year ended December 31, 2020 was $1,078,432 which consisted of the net loss of $2,417,371
partially offset by $1,031,622 in non-cash charges and other adjustments to reconcile net loss to net cash used in operating activities
and $307,317 in net increase in operating accounts. The non-cash charges consists of change in fair value of redemption liability
of $362,486, in-process research and development expense of $289,200, stock compensation expense of $234,580 and amortization
of debt discount of $145,356. The net increase in operating activities was primarily due to an increase of $306,570 in accounts
payable and accrued expenses and an increase in accrued interest of $101,093, partially offset by an increase of $100,346 in prepaid
expense and other current assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
used in operating activities for the year ended December 31, 2019 was $706,113 which consisted of the net loss of $1,525,474, partially
offset by $576,665 in non-cash charges and other adjustments to reconcile net loss to net cash used in operating activities and $242,696
in net increase in operating accounts. The non-cash charges consist of in-process research and development expense of $429,393, stock
compensation expense of $92,012, amortization of debt discount of $28,802 and change in fair value of redemption liability of $26,458.
The net increase in operating activities was primarily due to an increase of $213,524 in due to founder, accrued interest of $46,190,
a decrease in prepaid expenses and other current assets of $13,400 offset by a decrease in accounts payable and accrued expenses of $30,418.&rdquo;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
Flows from Financing Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
provided by financing activities for the year ended December 31, 2020 was entirely from net cash proceeds of $1,232,003 from the
issuance of convertible promissory notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
provided by financing activities for the year ended December 31, 2019 was from net cash proceeds of $580,885 from the issuance
of convertible promissory notes and $127,500 from the exercise of stock options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible
Promissory Notes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Commencing in May 2017, we issued convertible
promissory note to certain investors to help finance our operations. The principal amount of such notes range from $1,000
to $300,000. Interest on the unpaid principal balance accrues at a rate of 5% per annum, computed on the basis of the actual number of
days elapsed and a year of 365 days. Unless earlier converted into shares of our common stock or preferred stock (&ldquo;Equity
Securities&rdquo;), the principal and accrued interest shall be due and payable by us on demand by the holders at any
time after the earlier of (i) the maturity date of each note and (ii) the closing of the Next Equity Financing. &ldquo;Next
Equity Financing&rdquo; means the next sale or series of related sales of our Equity Securities pursuant to which we
receive gross proceeds of at least $5,000,000 for notes entered into in 2017 and through November 2020 and $7,500,000 for
notes entered into in December 2020 (including the aggregate amount of debt securities converted into Equity Securities upon conversion
or cancellation of notes).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In general, the maturity date was two years
from the date of issuance, except for the notes entered into in December 2020, in the aggregate principal amount of $418,000, which
have a maturity date of three years from the date of issuance. For notes entered into in 2017 and through September 2018,
the default interest rate of 20% was added to the notes for the period after the maturity date (&ldquo;default period&rdquo;).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
notes will automatically convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number
of shares of such Equity Securities to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid
accrued interest due on the note on the date of conversion by the lesser of (i) 80% of the price paid Equity Security by
the investors in the Next Equity Financing, or (ii) an equity valuation of $25 million ($50 million for notes issued after December
2020). No such Next Equity Financing has occurred through December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
prior to the closing of the Next Equity Financing or the maturity date of the notes, there is a sale, merger, consolidation, liquidation,
dissolution or closure of our Company (&ldquo;Corporate Transaction&rdquo;), the holders of the notes shall be entitled
to receive 150% of the principal amount of the notes, together with any interest accrued thereon. In the event that
there are insufficient funds available to pay the foregoing amount, the holders of the notes will receive a pro rata share of
available proceeds.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2020, we issued a related party note holder notes (&ldquo;Exchange Notes&rdquo;) in exchange for seven notes
payable which were in default (&ldquo;Original Notes&rdquo;) at such time by more than 90 days. The Original Notes had a principal of
approximately $265,000 and accrued interest of $37,000 at December 31, 2019. As of September 27, 2020, the aggregate outstanding principal
was approximately $265,000 and accrued interest (which included the default interest rate of 20% as described above) was approximately
$71,000. The Exchange Notes took the then principal and accrued interest of the Original Notes and added an original issue discount
of 37.5% to determine the new principal, which amounted to an aggregate of $537,968. The Company accounted for this transaction
as a debt extinguishment, and the incremental amount of the principal of the notes payable of $201,737 was recorded to accumulated deficit
(analogous to a &ldquo;deemed dividend&rdquo;), since the notes are with related parties, and included in the calculation of loss per
share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 27, 2020, we issued certain related
party note holders Exchange Notes in exchange for five notes payable which were in default. As of such date, the aggregate outstanding
principal and interest was approximately $26,000, which included the 20% default interest rate. The new Exchange Note in the
aggregate principal amount of approximately $26,000 had substantially the same terms as the Original Notes. There was no accounting
entries required upon the re-issuance of such Exchange Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective October 1, 2020, all notes which matured,
and were not repaid or converted, were rolled over on substantially the same terms as the Original Notes with a new two year term
(&ldquo;Rolled Over&rdquo;). In the fourth quarter of 2020, approximately $166,000 of such Original Notes were Rolled Over. Since
the terms of the new notes are not substantially different from the Original Notes, this was not accounted for as a debt modification
or debt extinguishment.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not have any off-balance sheet arrangements as of December 31, 2020 or 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Accounting Policies and Use of Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Use
of Estimates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and related disclosures in the financial statements and accompanying notes. Management
bases it estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation
process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select
an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: research
and development expense recognition, valuation of acquired technologies, valuation of common shares, allowances of deferred tax
assets, valuation of debt related instruments, accrued expenses and liabilities, and cash flow assumptions regarding going concern
considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Critical
Accounting Policies</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research
and development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug
supplies and materials. We accrues for costs incurred by external service providers, including contract research organizations
and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level
of services performed by third parties, patient enrollment in clinical trials, administrative costs incurred by third parties,
and other indicators of the services completed. Substantially all of the prepaid expenses at December 31, 2020 relate to the purchase
of an active pharmaceutical ingredient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acquired
in-process research and development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acquired, and may in the future acquire, rights to develop and commercialize new product candidates and/or other in-process
research and development assets. In accordance with Financial Accounting Standards Board&rsquo;s (&ldquo;FASB&rdquo;) ASC 730-10-25-1,
Research and Development, the up-front acquisition or licensing payments are expensed as acquired in-process research and development
provided that the drug has not achieved regulatory approval for marketing, and, absent obtaining such approval, have no alternative
future use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock-based
compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation represents the cost related to stock-based awards granted to employees, directors and consultants of our company
and our affiliates. We measure stock-based compensation costs at the grant date, based on the estimated fair value of the award
and recognize the cost  over the requisite service period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an
expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for
each stock-based award. The fair value of each option grant is estimated as of the date of grant using the Black-Scholes option-pricing
model. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards,
which is generally the vesting period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. We are a private
company and lack company-specific historical and implied volatility information. Therefore, we estimate our expected stock volatility
based on the historical data regarding the volatility of a publicly traded set of peer companies. The expected term of stock options
granted to non-employees is between 5 and 7 years. The risk-free interest rate is determined by reference to the U.S. Treasury yield
curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The fair value
of common stock is determined with the assistance of an independent third-party valuation expert when issuing stock options and computing
its estimated stock based compensation expense and value of shares issued in acquiring product candidates. The assumptions underlying
these valuations represented management&rsquo;s best estimates, which involved inherent uncertainties and the application of significant
levels of management judgment. In order to determine the fair value, we considered, among other things, contemporaneous valuations of
our common stock, our business, financial condition and results of operations, including related industry trends affecting our operations;
the likelihood of achieving various liquidity events; the lack of marketability of our common stock; the market performance of comparable
publicly traded companies; and U.S. and global economic and capital market conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
value measurements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
apply ASC 820, Fair Value Measurement (&ldquo;ASC 820&rdquo;), which establishes a framework for measuring fair value and clarifies
the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would
be received for an asset or paid to transfer a liability in our principal or most advantageous market in an orderly transaction
between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity
to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The fair value
of the redemption liability is determined based upon a PWERM. This PWERM was determined to be the most appropriate method of estimating
the value of possible redemption or conversion outcomes over time since we have not conducted a priced equity round through December
31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Debt
discount and derivate instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial fair value of the redemption value relating to the convertible debt instruments is treated as a debt discount and amortized
over the term of the related debt using the straight-line method, which approximates the interest method. If a loan is paid in
full, any unamortized financing costs will be removed from the related accounts and charged to operations. Amortization of debt
discount is recorded as a component of interest expense. In accordance with ASU 2015-03, Interest &mdash; Imputation of Interest,
the unamortized debt discount is presented in the accompanying balance sheet as a direct deduction from the carrying amount of
the related debt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for derivative instruments in accordance with ASC 815, Derivative and Hedging, which establishes accounting and reporting
standards for derivative instruments, including certain derivative instruments embedded in other financial instruments or contracts
and requires recognition of all derivatives on the balance sheet at fair value. Our derivative financial instrument consists of
an embedded feature contained in our convertible debt that is bifurcated and accounted for separately. See Note 4 of our audited
consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recently
Issued and Adopted Accounting Standards</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 2 to our audited consolidated financial statements included elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JOBS
Act</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company,&rdquo; as defined in the JOBS Act. Emerging growth companies can <FONT STYLE="background-color: white">take
advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised
accounting standards. In other words, an &ldquo;emerging growth company&rdquo; can delay the adoption of certain accounting standards
until those standards would otherwise apply to private companies. We have chosen to take advantage of the extended transition
periods available to emerging growth companies under the JOBS Act for complying with new or revised accounting standards until
those standards would otherwise apply to private companies provided under the JOBS Act. As a result, our consolidated financial
statements may not be comparable to those of companies that comply with public company effective dates for complying with new
or revised accounting standards.</FONT> For as long as we continue to be an emerging growth company, we also intend to take advantage
of certain other exemptions from various reporting requirements that are applicable to other public companies including, but not
limited to, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, exemptions
from the requirements of holding a nonbinding advisory stockholder vote on executive compensation and any golden parachute payments
not previously approved, exemption from the requirement of auditor attestation in the assessment of our internal control over
financial reporting and exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding
mandatory audit firm rotation or a supplement to the auditor&rsquo;s report providing additional information about the audit and
the financial statements (auditor discussion and analysis). After we become a reporting company under the Exchange Act, we will
remain an emerging growth company until the earliest of (i) <FONT STYLE="background-color: white">the date on which we are deemed
to be a large accelerated filer under the rules of the SEC</FONT>, (ii) the end of the fiscal year in which we have total annual
gross revenues of $1.07 billion or more during such fiscal year, (iii) the date on which we issue more than $1 billion in non-convertible
debt in a three-year period or (iv) the end of the fiscal year following the fifth anniversary of the date of the completion of
this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="hj_001"></A>BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Overview</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a biotechnology company leveraging our tumor targeting proprietary platform, Quatramer&trade;, to develop a pipeline of novel product
candidates to treat rare and devastating cancers. Quatramer allows us to leverage and exploit key undruggable targets and novel emerging
pathways, such as IMCD in tumors, and facilitate the delivery of potent drug payloads directly to the TME while sparing healthy tissue.
By efficiently extending the circulation half-life as well as targeting delivery to the tumor site, Quatramer traps payloads into the
TME and exploits IMCD, an emerging orthogonal anti-cancer approach which utilizes a fundamental recognized mechanism of tumor growth
using iron transport, iron metabolism and ROS production. We are building a portfolio of long-acting product candidates using Quatramers
including our most advanced product candidate, HSB-1216, a long-acting IMCD modulator of tumors. Our second product candidate, HSB-888,
is a dual-loaded IMCD modulator coupled with an ultra-low dose next generation anthracycline analogue for solid tumors which has a highly
synergistic tumor killing capacity. Our other product candidate, HSB-114 is a novel immunotherapeutic agent which uses our non-viral
Quatramer platform to deliver the human TNF-alpha gene to cancer cells to selectively increase intratumoral TNF levels in tumors
while managing the toxicity associated with such approaches. HSB-510 is an ongoing collaboration with the National Center for Advancing
Translational Sciences (&ldquo;NCATS&rdquo;), a part of the National Institutes of Health (&ldquo;NIH&rdquo;). We have analyzed novel
dual PI3K/HDAC inhibitors and a lead compound which showed good antiproliferative activity against multiple oncology cell lines was identified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quatramers
are small approximately100 nanometer sized particles with the ability to carry both payloads and exterior coatings incorporated
in a proprietary polymeric mixture which is designed with specific physico-chemical parameters to target specified cells or tissues
and converge a therapeutic payload at the site of disease to boost efficacy while abating adverse effects on healthy tissue. Quatramer
is also highly modular and tunable allowing us to design and develop various follow-on product candidates including (i) small
proteins including cytokines/growth factors (TNF-alpha, IL-2, IL-12 and IL-15), metabolic hormones (such as insulin) (ii) peptides
(up to 40 amino acids long), (iii) oligonucleotides such as RNA including mRNA and small RNAi, cDNA, as well as multiple cytokine
and biologic products with potentially significant advantages over existing and development-stage drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trident,
our artificial intelligence platform, is a novel approach to identify synthetic lethal sensitivities associated with degrees of
cell plasticity using biomarkers that can be translated for patient selection and stratification. TAI integrates diverse public datasets,
such as The Cancer Genome Atlas as well as other available datasets, which we intend to couple with data from our planned clinical programs
in order to identify biomarkers and novel gene signatures to stratify patients prospectively as we move compounds from bench to bedside.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="formdrs_014.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
1: Our Platform Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="formdrs_015.jpg" ALT="" STYLE="height: 303px; width: 316px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
most advanced product candidate HSB-1216, which we intend to develop in the clinic in 2022 for multiple high unmet need solid
tumors. HSB-1216 exploits a key feature of certain tumors that rely on an excessive LIP within the cell to modify the dysregulated
iron microenvironment of cancer. We have received orphan drug designation in SCLC for HSB-1216&rsquo;s active payload, pHSB-1216.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
second product candidate, HSB-888, is in IND-enabling studies, and we intend to develop such product candidate in the clinic in
2022 for multiple sarcomas. The FDA has granted the payload of HSB-888, pHSB-888, a Rare Pediatric Disease Designation and Orphan
Drug Designation for pediatric osteosarcoma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also plan to develop other Quatramer based compounds with therapeutic cargoes from our product pipeline, which include DNA-based
contents which hijack the tumor&rsquo;s genetic code and kill the tumor from within by generating an array of cancer killing cytokines,
such as tumor necrosis factor alpha or TNF-alpha and potentially IL-2. The platform&rsquo;s tunability stems from the fact that
the platform can be modified and adjusted to deliver single or multiple ratios of payloads in order to optimize synergistic mechanisms
of action in lower doses in order to potentially eradicate rare cancers and devastating tumors with minimal or no treatment
options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
2: Quatramer is a tunable tumor-targeting platform</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #002060">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: white"><B>Quatramer:
    A Tunable, Tumor-Targeting Platform</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD ROWSPAN="5" STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="drs_040.jpg" ALT="" STYLE="height: 375px; width: 196px"></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="drs_041.jpg" ALT="" STYLE="height: 88px; width: 104px"></FONT></TD>
    <TD STYLE="vertical-align: middle; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>mRNA
    or vector DNA</B> (TNF-alpha, IL-2, IL-15, IL-12)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="drs_042.jpg" ALT="" STYLE="height: 82px; width: 114px"></FONT></TD>
    <TD STYLE="vertical-align: middle; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Small
    molecules</B>: degradation inhibitors, PI-3K (delta)/HDAC6 &amp; BCL-2 inhibitors, ferroptosis inducers</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="drs_043.jpg" ALT="" STYLE="height: 90px; width: 94px"></FONT></TD>
    <TD STYLE="vertical-align: middle; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Large
    proteins</B>: large peptides BCL-2, MCL-1 and MUC1-C and several larger proteins such as insulin</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="drs_044.jpg" ALT="" STYLE="height: 98px; width: 96px"></FONT></TD>
    <TD STYLE="vertical-align: middle; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Antibody
    based therapeutics</B>: scFv&rsquo;s, ADCs, ADNCs (antibody-drug nano-conjugate) systems can deliver greater toxin (DAR* &gt;100)
    to tumors vs. ADCs</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="drs_045.jpg" ALT="" STYLE="height: 94px; width: 94px"></FONT></TD>
    <TD STYLE="vertical-align: middle; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Multi-Therapeutics</B>:
    combination of multiple payloads including DNA, mRNA, small molecules, proteins and antibodies possible</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Product Candidates and Research Programs</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are leveraging our proprietary technologies and developing multiple product candidates with differentiated profiles designed to
address rare and devastating cancers, as shown below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #002060">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: white 1pt solid; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: White"><B>Pipeline</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: white 1pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: White"><B>Drug
    / Mechanism</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: white 1pt solid; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: White"><B>Indication</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: white 1pt solid; width: 15%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: White"><B>IND
    Enabling</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: white 1pt solid; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: White"><B>Phase
    1 (ex-US)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: White"><B>Phase
    1b/2</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-1216</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iron
    Mediated <BR>
    Cell Death</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solid
    tumors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: white 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="drs_046.jpg" ALT="" STYLE="height: 26px; width: 209px"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: white 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-888</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-1216
    and novel low dose anthracycline</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sarcomas</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: white 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="drs_047.jpg" ALT="" STYLE="height: 26px; width: 208px"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: white 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-1218</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-viral
    / Iron Mediated Cell Death</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVID-19</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: white 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="drs_048.jpg" ALT="" STYLE="height: 26px; width: 94px"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: white 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-114</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TNF-alpha
    DNA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Metastatic
    Soft Tissue Sarcoma</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: white 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="drs_049.jpg" ALT="" STYLE="height: 26px; width: 86px"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: white 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-510</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(NCATS-NIH
    CRADA)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bifunctional
    PI-3 Kinase (delta) &amp; HDAC-6 inhibitor</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solid
    tumors &amp;<BR>
    Lymphomas</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: white 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="drs_050.jpg" ALT="" STYLE="height: 27px; width: 75px"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: white 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-1216</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-1216
is an IMCD modulator delivered using our proprietary carrier, Quatramer. We intend to submit an IND application to the FDA and obtain
clinical data to support our strategy in 2022. In a compassionate use human study in Germany, pHSB-1216 was studied in seven patients
with positive results in heavily pretreated and therapy resistant cancers. By design, HSB-1216 is an injected product which circulates
systemically after a subcutaneous injection and concentrates in the TME of solid tumor masses. The localization of HSB-1216 has been
demonstrated in multiple <I>in vivo</I> models with pharmacodynamic signals showing significant decreases in tumor size after multiple
weekly injections.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
3: Shifting the Intracellular Redox Balance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="formdrs_018.jpg" ALT="" STYLE="height: 420px; width: 600px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a tumor concentrating therapeutic, HSB-1216 has the potential to be used in cancer patients who have failed standard-of-care therapies
for multiple rare solid tumors with devastating consequences due to a lack of therapies. We anticipate an IND approval in the
first half of 2022 and top-line data readout of our first clinical program  in late 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-888</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemotherapy,
an important part of antitumor treatment, exerts anticancer effects by killing cancer cells, and anthracycline-based regimens
have been and continue to be the mainstay of treatment for a vast majority of tumors. The clinical applications of anthracycline
regimens, above certain dose ranges have limited use due to adverse events, including cumulative lifetime doses resulting in cardiotoxicity.
The nonspecific accumulation of anthracyclines, such as doxorubicin and similar agents in non-target tissues such as cardiac cells,
continue to be a problem.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-888
is a dual-loaded IMCD modulator coupled with an ultra-low dose next generation anthracycline analogue for solid tumors. One component
compound in HSB-888 is a next generation anthracycline analogue approved and marketed in China and Japan which has potent antitumor
activity and indicated for multiple tumor types, with an improved therapeutic index compared to doxorubicin. We believe targeting the
agent in our proprietary dual-loaded Quatramer with our novel IMCD modulator may confer key benefits for multiple reasons, including
a synergistic ultra low-dose approach as well as leveraging a key differentiating mechanism of iron-mediation to kill the tumor and reduce
off target toxicities simultaneously.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
4: Quatramer allows for combination ultra-low-dose synergistic killing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="formdrs_019.jpg" ALT="" STYLE="height: 295px; width: 670px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-888
has the potential to be used in solid tumors whereby a potent anthracycline may be effective but prohibitive in current available forms
due to their off-target effects. We anticipate leveraging the human data available from Japanese and Chinese studies to potentially obtain
an IND approval in 2022 and top-line clinical data soon after.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-510</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
an ongoing collaboration with the NCATS, part of the NIH, we analyzed novel dual PI3K/HDAC inhibitors and a lead compound which
showed good antiproliferative activity against multiple oncology cell lines. This compound obtained ideal pharmacokinetic properties
in our proprietary Quatramer, while maintaining specific HDAC6-PI3K&delta; specificity. We intend to continue our collaborative
effort with NCATS/NIH through our collaboration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
5: Targeted Dual PI-3K(&delta;)/HDAC6 Inhibitor Quatramer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="formdrs_020.jpg" ALT="" STYLE="height: 300px; width: 610px"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-114</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-114
is a novel immunotherapeutic agent which uses our proprietary Quatramer platform to deliver the human TNF-alpha gene to cancer
cells. Finding ways to selectively increase intratumoral TNF levels in tumors while managing the toxicity associated with such
approaches remains a major unmet need. We believe we have developed a novel approach to include a peptide-DNA complex which
preferentially releases genetic material and localizes into the nucleus of the delivered cancer cell and has demonstrated highly
effective in achieving a desired tumor response in pre-clinical oncology models using TNF. We believe this intratumoral expression
of secreted cytokines, such as TNF, represents a novel approach for inducing anti-tumor activity and potentially reprogramming
the tumor immune microenvironment, and we intend to develop this technology further to strengthen our pipeline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
6: Non-viral immunotherapeutic delivers TNF-alpha DNA into tumor genome via Quatramer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="formdrs_021.jpg" ALT="" STYLE="height: 325px; width: 500px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
Programs</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Our
technology platform enables us to generate a pipeline of early-stage product candidates spanning multiple targets in oncology
utilizing diverse payloads to treat rare and devastating tumors. While the payloads in our most advanced product candidates, HSB-1216
and HSB-888, are novel, and have pilot and extensive human data in multiple solid tumors, any solid tumor or non-oncologic disease
requiring delivery of a peptide, protein or biologic is conceivably a candidate for our technology. Our early-stage product candidates
are focused on rare and devastating diseases; however, we believe our technology could potentially deliver meaningful benefit
across a wide range of oncologic and viral diseases. We have tested several peptides, nucleic acids, proteins, small molecules
and antibody constructs against multiple targets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Platform Technologies</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Trident
Artificial Intelligence</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trident
is a deep learning engine that identifies synthetic lethal sensitivities associated with degree of cell plasticity using biomarkers
that can be translated for patient selection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
TAI platform:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
                                         the ability to integrate diverse multi-omics datasets including not only genomics, epigenetics
                                         and transcriptomics but also emerging proteomics data which enable identification
                                         of dynamical re-wiring of intra-tumoral signaling circuitry;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
                                         the ability to identify biomarkers that differentiate between progression of cancer plasticity
                                         and correlate it to degree of sensitivity to a synthetically lethal target that is induced
                                         with standard of care treatment and development of resistance; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Is
                                         a state-of-the-art convolutional neural network used to classify and select patients
                                         that are most likely to respond to treatment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
7: Trident Artificial Intelligence Platform</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><IMG SRC="formdrs_022.jpg" ALT="" STYLE="height: 165px; width: 500px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Quatramer
Technology</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key aspect of oncology treatment is  that effective anticancer agents do not penetrate the tumor bed in order to kill cancer
cells due to the limitation of the microenvironment of the tumor. The TME is protected by multiple layers of collagen, proteoglycans,
hyaluronans and laminin layers shielding the tumor from the deployment of traditional treatments, including chemotherapy (novel
small molecule and immunotherapies). Parts of the tumor create an environment to survive despite reduced nutrient sources whereby
hypoxic regions of the tumor continue to thrive by incorporating a shift in metabolism, including iron dysregulation. Any drug
that reaches the tumor is effluxed by transporter pumps upregulated by the cancer cells rendering any such drug that reaches the
tumor ineffective. The TME continues to thrive by the inability of immune cells normally designed to infiltrate and kill the tumor
made ineffective by a reduction in their ability to activate their killing effect of the cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
8: Tumor extracellular matrix reduces therapeutic efficacy to solid tumors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><IMG SRC="formdrs_023.jpg" ALT="" STYLE="height: 362px; width: 565px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
proprietary Quatramer technology in intended to overcome the limitations which have hampered development of nanoscale
and liposome derived products as cancer therapeutics. Limitations include, but are not limited to, drug efflux, toxicity, eluding
phagocytosis, physiological barrier penetrance and immune responses. Our Quatramer technology incorporates a therapeutic payload
and is designed to be tunable while having a prolonged circulation within the blood, allowing a targeting of diseased tissue or
cells, while providing a controlled and timely release of the therapeutic payload.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Characteristics
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">of our Quatramer technology include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prolonged
                                         circulation</B>: the stealth nature of Quatramer allows for a prolonged circulation time
                                         allowing for accumulation at the site of disease prior to being cleared.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Targeted</B>:
                                         the size, shape and surface of Quatramer allows it to escape via gaps in the blood vessels
                                         in the TME allowing for release of the payload directly into cancerous cells.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Blocks
                                         drug efflux</B>: Quatramer composition offers reversal of p-glycoprotein mediated drug
                                         resistance in cells.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tunability</B>:
                                         Quatramer physicochemical characterization allows for optimizing size, shape and surface
                                         chemistry based on payload characteristics to render enhanced permeation and retention
                                         into the TME.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ease
                                         of manufacturing</B>: large scale production efficiency and analysis for uniform chemistry,
                                         manufacturing and control capability at lower costs.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Biodegradable</B>:
                                         chemical compositions listed in FDA Inactive Ingredients Database tuned to maximize nano-bio
                                         interfaces with limited or no environmental concerns.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payload
                                         versatility and flexibility</B>: combined with the tunability of Quatramer, the technology
                                         allows for a variety of delivery payloads including peptides, small molecules, nucleic
                                         acids and antibodies with the added flexibility of dual loaded payload therapeutics.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Key Programs: HSB-1216 and HSB-888</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have leveraged our proprietary technologies and are developing multiple product candidates with differentiated profiles designed
to address rare and devastating cancers. HSB-1216 is an IMCD modulator delivered by our proprietary Quatramer platform, and we
intend to obtain clinical data to support our strategy in 2022. We anticipate an IND approval in the first half of 2022 and top-line
data readout of our first clinical program soon after in 2022. HSB-888 is a dual-loaded IMCD modulator coupled with an ultra-low
dose next generation anthracycline analogue for solid tumors. We anticipate leveraging the human data available ex-US to obtain
an IND approval in 2022 and top-line clinical data soon after.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-1216:
Our Novel Iron-Medicated Cell Death Modulator</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iron,
an important factor of many organisms, satisfies an assortment of vital living processes including DNA replication, protein synthesis
and cellular respiration, essential for normal growth and propagation. However, iron also produces ROS via a chemical process
in which there is a catalytic decomposition of hydrogen peroxide by ferrous ions, known as the Fenton reaction. This process may
cause damage to the membrane lipid and DNA caused by ROS, known as lysosomal membrane permeabilization (&ldquo;LMP&rdquo;) rupturing
and killing the cell by spilling its contents into the surrounding microenvironment and causing degradation in the surrounding
extracellular milieu. Emerging evidence suggests iron may have a twofold role on cells, both stimulating cell growth and causing
cell death, particularly a new form named ferroptosis, first described by the accumulation of iron-dependent lipid peroxides.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
9: Iron is a central player and is dysregulated in some tumors causing metastasis</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="formdrs_024.jpg" ALT="" STYLE="height: 305px; width: 620px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">research&nbsp; with pHSB-1216 targeting chemotherapy resistant tumors
suggests that it sequesters iron in the lysosomes of resistant tumor cells causing LMP of hard-to-treat cancer cells known as persister
cells causing them to rupture and stop replicating. We believe an area of high interest for the development of HSB-1216 could be SCLC
or triple-negative breast cancer or other rare cancers with high unmet need.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
10: pHSB-1216 Confers a Novel Selective Iron-induced Cell Death Resembling Ferroptosis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: -4.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: -4.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="formdrs_025.jpg" ALT="" STYLE="height: 200px; width: 580px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the standard limitations to achieving successful cancer therapies is the manifestation of multidrug resistance (&ldquo;MDR&rdquo;)
which is a cross-resistance to many commonly used drugs after repeat dosing. Extensive evidence to this point has shown that the
mechanisms related to tumor MDR are complex and there is an urgent need to decipher the nuances of this phenomenon and discover
new agents capable of evading resistance which can be applied to a clinical strategy in cancer. MDR can be developed by various
ABC transporters, including the well characterized ABCB1, also known as p-glycoprotein, which has been shown to be an important
protein of the cell membrane and can transport a variety of molecules across extra- and intra-cellular membranes. The protein
is an <FONT STYLE="background-color: white">adenosine triphosphate (&ldquo;</FONT>ATP&rdquo;) dependent drug efflux pump that
transports foreign substances out of the cell including drugs and xenobiotics with broad substrate specificity. pHSB-1216 has
been shown to block this ABC transporter in numerous studies as evidenced by drug efflux assays in MDR cell lines overexpressing
these proteins by inducing a conformational change on the transporter protein itself rendering it ineffective. This evidence may
also allow other traditional chemotherapies, such as paclitaxel which is highly effected by these transporters, to stay in the
cell and elicit anti-tumor effects in combination with HSB-1216.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-1216
in Oncology Indications</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug candidate, HSB-1216, has novel characteristics which may benefit patients with hard-to-treat recurrent tumors, such as SCLC and
TNBC in a number of ways. pHSB-1216, traditionally used as an anti-coccidial drug in livestock and poultry, has been shown to possess
anti-cancer effects in a chemical screen on the basis that it has more than 100-fold potency compared to paclitaxel, a commonly used
FDA-approved anti-cancer drug. The active compound is a monocarboxylic polyether compound first isolated from <I>Strepotmyces albus</I>
strain (Strain No. 80614) shown to eliminate self-renewing cancer cells which may remain dormant or undetectable in the presence of traditional
chemotherapeutics, such as paclitaxel or other agents commonly used as first-line agents in a variety of tumors. Salinomycin alone could
not be advanced further after its discovery as an anti-cancer agent for a variety reasons, including a short half-life along with a relatively
narrow therapeutic index and potential toxicities. Subsequently, other groups  have shown cytotoxicity of the compound on human
neuronal cells showing it had an increase on cytosolic Na<SUP>+</SUP> concentrations consequently resulting in elevated cytosolic Ca<SUP>2+</SUP>.
In addition, overdose or accidental ingestion of similar compounds has shown undesirable effects in cats, dogs, pigs, horses, as well
as humans<FONT STYLE="background-color: white">. </FONT>These results and other data suggest it may be prudent to develop tissue-specific
strategies to deliver the drug and prevent neuro-specific adverse events and capitalize on the specific mechanisms of pHSB-1216.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
data suggest that the specific mechanisms of pHSB-1216 are three-fold which include a novel selective iron-induced cell death
known as ferroptosis, an ability to reverse a phenomenon known as EMT, as well as an ability to evade the ATP-binding cassette
(&ldquo;ABC&rdquo;) transporters, of which the latter two are linked to multidrug resistance to commonly used cancer chemotherapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Clinical
Data with pHSB-1216</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
several reasons, the pHSB-1216 was not established as a human drug due to several published reports of in the past decades which
reveal considerable toxicity in mammals such as horses, pigs, cats and alpacas after accidental oral ingestion or inhalation. It has
been relegated to use in livestock as a coccidiostat and growth promoter. The European Food Safety Authority has declared an
acceptable daily intake (&ldquo;ADI&rdquo;) of 5 <FONT STYLE="background-color: white">&micro;g/kg</FONT>. Based on these findings,
the compound was therapeutically used in a &#8220;first-in-man&#8221; pilot clinical trial in Germany with a cohort of patients with
metastatic breast, ovarian and head and neck cancers in which tumor and metastatic regression were observed clinically in 4 patients
with metastatic breast cancer, 1 patient with metastatic ovarian cancer, and 2 patients with squamous cell carcinoma (1 of the head
and neck and the other of the vulva). Two of these cases are described in detail below showing that these promising results inducing
cancer regression of heavily pretreated and therapy-resistant tumor types may define HSB-1216 to have novel effects as a clinically
significant anticancer agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thirty
months prior to &nbsp;treatment with the pHSB-1216, a 40-year-old female patient was diagnosed with unilateral ductal breast carcinoma
(post-mastectomy and axillary lymph node dissection) and subsequently experienced a recurrence of the subcutaneous multifocal
thoracic tumor that was ER, PR, and HER2 negative (i.e., &ldquo;triple negative&rdquo;) with vertebral bone metastasis. After
all therapeutic options were exhausted, experimental treatment with pHSB-1216 was recommended. The patient received 12 systemic
administrations of intravenous (&ldquo;IV&rdquo;) treatment at a dose of 200 &micro;g&middot;kg<SUP>-1</SUP> given every other
day. After 12 cycles, there was a marked regression of the subcutaneous thoracic metastases (Figure 11). A biopsy of the metastatic
tissue, as investigated by molecular histopathology, demonstrated that approximately 85% of the cells had undergone apoptosis.
Additionally, serum levels of the tumor marker Ca 15-3 decreased from 14.3 U/mL before therapy to 7.2 U/mL after therapy. Similarly,
serum levels of Carcinoembryonic antigen (&ldquo;CEA&rdquo;), another tumor marker, declined from 50.8 ng/mL to 15.5 ng/mL posttreatment.
These results demonstrate that the drug was not only able to kill hard-to-treat cancers, but also more differentiated tumor cells
and more importantly, highly indolent tumor cells displaying efficient mechanisms of resistance to cytotoxic drugs, radiation,
and induction of apoptosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a second case study, 18 months prior to treatment with pHSB-1216, an 82-year-old female patient was diagnosed with advanced and
metastatic (pelvic lymphatic metastasis) squamous cell carcinoma of the vulva (after radical vulvectomy and bilateral lymph node
dissection). Given a poor therapeutic response to existing treatments at the time and exhaustion of therapeutic options, experimental
treatment of pHSB-1216 in combination with erlotinib was recommended for this patient. The patient received 14 IV administrations
of the drug at a dose of 200 &micro;g&middot;kg<SUP>-1</SUP> given every other day plus erlotinib 150 mg daily for 30 days. Significant
tumor regression was observed 30 days after combination therapy, based on clinical inspection of the tumor, as well as decreased
serum level of squamous cell carcinoma (SCC) antigen from 11.3 ng/mL before combination therapy to 0.13 ng/mL after therapy. Three
months post-treatment, SCC levels increased to 3.2 ng/mL, and clinical inspection demonstrated significant tumor progression.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
11: Breast Cancer Metastasis Regression by pHSB-1216 in a Pilot Clinical Trial</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="formdrs_026.jpg" ALT="" STYLE="height: 196px; width: 490px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
experiencing numerous marked adverse effects with erlotinib (including fatigue, anorexia, nausea, and inappetence), the patient
refused further treatment with erlotinib and was retreated with pHSB-1216 as monotherapy. The patient received 12 IV administrations
at a dose of 200 &micro;g&middot;kg<SUP>-1</SUP> given every other day, which resulted in no progression and stable disease for
2 weeks, 4 weeks, and 4 months post-treatment, based on clinical inspection of the local tumor and no marked changes in SCC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
12: Serum Levels of the Tumor Marker SCC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="formdrs_027.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
results demonstrate that the drug is able to induce partial clinical regression of heavily pretreated and therapy-resistant cancers,
particularly in combination with novel tumor-targeted drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>HSB-1216
Pre-Clinical Data</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pHSB-1216
has been shown to target elusive cancer cells in different types of human cancers, including gastric cancer, lung adenocarcinoma, osteosarcoma,
colorectal cancer, squamous cell carcinoma, and prostate, suggesting that the drug may be effective against side populations of many
types of human cancers. The drug is able to enhance the cytotoxic effects of conventional chemotherapeutics and novel tumor-targeted
drugs in regular cancer cells, potentially playing a central role for HSB-1216-based combination therapies in the future treatment
of cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Figure 13: HSB-1216 Inhibits Tumor Growth in SCLC Model</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="formdrs_028.jpg" ALT="" STYLE="height: 224px; width: 460px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">According to
the National Cancer Institute&rsquo;s Surveillance, Epidemiology and End Results, there are anticipated to be more than 230,000
new cases of lung cancer in the United States in 2021, and according to the American Cancer Society, SCLC comprises approximately</FONT>
10-15% <FONT STYLE="background-color: white">of all lung cancers. Although SCLC is responsive to chemotherapy, recurrence occurs rapidly,
with less than 7% of patients surviving over five years. Recently, SCLC has shown to be responsive to immunotherapy with approximately
</FONT>one-third <FONT STYLE="background-color: white">of patients responding to</FONT> PD-1/PD-L1 <FONT STYLE="background-color: white">therapy
and achieving a median overall survival of approximately eight months. The need to rapidly advance therapeutics is an urgent, unmet medical
need in these recurrent cases. In one pre-clinical mouse model of SCLC conducted by a third party in Asia, both pHSB-1216 as well as
HSB-1216 showed no antitumor activity <I>in vivo</I>, believed to be due to lab dilution errors of the test articles. The same articles
showed marked antitumor activity in a tumor sphere model owing to the potent effects of both compounds. Our previous studies with HSB-1216
has shown a profound inhibition of tumor growth as a once-weekly injectable product in a nude mouse xenograft models utilizing
an N-H69 SCLC cell line, with three 5 mg/kg doses administered over 3 weeks when compared to placebo.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
14: HSB-1216 is 2x-4x &gt; potent against chemo-resistant SCLC <I>in vitro</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="formdrs_029.jpg" ALT="" STYLE="height: 244px; width: 460px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-1216
is two to four times more potent in chemoresistant SCLC. Using chemoresistant cell lines for SCLC (NCI-H69AR), our approach demonstrates
an increased potency of our compound using our Quatramer formulation when compared to standard of care therapies for these resistant
tumor types.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-1216
Clinical Plan in Solid Tumors</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to submit an IND for HSB-1216 for solid tumors to the FDA by 2022 and plan to conduct a Phase 1 clinical trial to obtain human
pharmacokinetic data and dose optimization data on our formulation thereafter. Based on the data obtained from pre-clinical studies,
we believe a Phase 1b/2a basket trial can be conducted in the US with HSB-1216 where there are limited therapies. Even with the advent
of ICIs, there remains a large patient population which either does not benefit from allowing HSB-1216 to potentially prolong survival
in ICI failures as well as recurrent disease patients. We plan to engage in discussions with the FDA and conduct a Phase 1b/2a study
in this recurrent setting in 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-888:
Our Dual-Loaded IMCD modulator + Ultra-Low Dose Next Generation Anthracycline</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-888
has a component selected in pre-clinical screens for its similar cytotoxic activity to doxorubicin accompanied by its reduced
cardiac toxicity. The component drug has been in use in Japan for more than two decades, and clinical studies support its claim
of similar efficacy to doxorubicin but with reduced toxicity. We intend to obtain approval of this product in the United States
as a drug that can be used in the treatment protocol of recurrent osteosarcoma. HSB-888 combination could be a more efficacious,
safer, and more tolerable therapy which may improve response rates, overall survival, and quality of life. We are progressing
towards an IND filing and plan to initiate a clinical trial in recurrent pediatric osteosarcoma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
payloads of HSB-888 have been used clinically to treat tumors such as osteosarcoma, breast cancer, lymphoma and acute myeloid
leukemia in countries outside the US such as Germany, Japan, China and India. One component compound has shown lower cardiotoxicity
and greater antitumor effect than other anthracycline agents, commonly used in these tumors, due to the fact that it is taken
up by tumor cells to a higher degree than other drugs in its class. This rapid uptake into tumor cells causes targeted incorporation
into the cell&rsquo;s DNA and causes cell cycle arrest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
in multidrug-resistant cells, we believe HSB-888 can disrupt cell cycle kinetics. Currently, the most important impediment to
improving outcomes of patients with osteosarcoma is the clinical resistance to the primary chemotherapy, MAP, which is widely
used. One of HSB-888&rsquo;s payloads has been shown to be taken up by tumor cells approximately 170 times faster than doxorubicin
and distributes its DNA into tumor nucleus and intercalates. In MDR osteosarcoma cell lines (MG63/DOX), the drug was shown to
have a marked cell inhibitory effect in both resistant and sensitive cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a retrospective Chinese study of relapsed and refractory osteosarcoma, 3 of 23 evaluable patients who received only one payload
of HSB-888 with cisplatin, had partial responses, with one patient after 7 cycles achieving disease free progression for more
than 29 months. In another Chinese study, the <FONT STYLE="background-color: white">5-year disease-free survival (&ldquo;DFS&rdquo;)
rate of the patients treated with the drug was 70.2%, significantly higher than that of the DOX-based regimen-treated group (53.1%).
The drug decreased the lung metastatic rate significantly compared with the DOX-based regimen (19.1% vs. 36.7%, </FONT><I>p</I><FONT STYLE="background-color: white">=0.045),
as well as the relapse rate (31.9% vs. 49.0%, </FONT><I>p</I><FONT STYLE="background-color: white">=0.067). The compound also
showed lower rates of alopecia (63.8% vs. 85.7%, </FONT><I>P</I><FONT STYLE="background-color: white">=0.012), nausea and vomiting
(51.1% vs. 79.6%, </FONT><I>p</I><FONT STYLE="background-color: white">=0.003), and mucositis (48.9% vs. 75.6%, </FONT><I>p</I><FONT STYLE="background-color: white">=0.003).
It also resulted in lower cardiac toxicity and demonstrated that it is better than the DOX-based regimen in terms of the 5-year
DFS rate, pulmonary metastasis rate, relapse rate and side effects</FONT>. These data suggest that an updated regimen utilizing
HSB-888 delivering two payloads in refractory cases in a setting that would use high-dose methotrexate along with a platinum-drug
may be warranted, and we intend to study these patients in a clinical trial, due to the high unmet need in this population.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-888
Low Dose Strategy</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemotherapies
like anthracyclines, including doxorubicin and others in its class, have been used for decades as mainstay therapy in combination
with other drugs for multiple tumor types, including osteosarcoma as first-line therapy. The most important issue is that although
the regimen may benefit patients in this setting, there is a dose-limiting cumulative effect on the patient with these cytotoxic
approaches whereby, after a maximum accumulation of dose over multiple cycles, the class of drug can longer be used in the recurrent
setting for patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
components of HSB-888 are two anticancer drugs with distinct and complementary mechanisms of actions (ferroptosis and DNA intercalation)
which together constitute an active combination for treating osteosarcoma. We investigated whether the efficacy of this combination
could be improved by controlling drug ratios following <I>in vitro and vivo </I>administration. The combinations were evaluated
systematically for drug ratio-dependent synergy <I>in vitro </I>using multiple tumor cell lines. <I>In vitro </I>screening informatics
on drug ratio-dependent cytotoxicity identified a consistently antagonistic region between payloads at various molar ratios, which
also showed multiple synergistic ratios, dependent on the chemical characteristics of either DNA intercalating payload combined
with a ferroptosis inducer. Co-formulations of these two agents were developed that maintained a fixed drug ratio for stability
and release profiling over broad timelines. Drug ratio-dependent antitumor activity was demonstrated <I>in vitro </I>and <I>in
vivo </I>for these ratios and improved antitumor activity was observed for the Quatramer 1:3 molar ratio of DNA intercalator:ferroptosis
inducer (designated HSB-888) compared to drug cocktails in models tested. HS-888, is a fixed-ratio formulation of DNA intercalator
and ferroptosis inducer, and a near-clinical candidate for development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Furthermore,
our proprietary molar ratio as seen by its <I>in vitro</I> and <I>in vivo</I> efficacy profile enables a low dose to be administered
that is presumably 5-fold to 10-fold less than the traditional DNA intercalator therapy that is currently utilized in multiple
high unmet need tumor types. This low dose strategy may allow clinicians to treat a variety of tumor types requiring cytotoxic
chemotherapy without the burden of dose-limiting toxicities for traditional chemotherapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-888
Synergy and Combination Index</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Extensive
research suggests cancer drug combination may act in synergy, additively or antagonistic based on drug ratios of the separate
compounds combined. While this relationship can be evaluated readily</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>in
vitro</I> <FONT STYLE="background-color: white">where drug ratios can be controlled, the translation of such information</FONT>
<I>in vivo is </I><FONT STYLE="background-color: white">complex due to the fact that individual drugs administered separately
may be distributed, metabolized and eliminated differently. This prevents control of the drug ratio following administration and
may result in exposure of cancer cells to antagonistic drug ratios with a corresponding loss of therapeutic activity.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
approach with a combination payload in HSB-888 as a dual drug-loaded formulation with our Quatramer strategy circumvents multiple
hurdles when compared with administering compounds separately. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
distinguishing feature of our technology is our proprietary Quatramer delivery platform which maintains drug combinations at
the desired ratio after <I>in-vivo </I>administration. Drug combinations used to treat cancer are often encompassed with drugs
which are highly varied in chemical and physical composition as well as properties. Subsequently, formulating such drug combinations
with unrelated features into a single pharmaceutical approach that discharges both agents at the same or pre-determined different
rates in the body as well as in the tumor tissue of choice presents a significant technical challenge. We have developed the Quatramer
platform to provide versatility in controlling drug loading to specified drug loading and release rates with the precise retention
properties for therapeutic agents from drug classes important for unmet need pharmaceutical development to benefit cancer patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have specifically identified cell-based screens and identified synergistic drug combinations of HSB-1216 and HSB-888 which have
markedly different chemical attributes. With respect to our combination approach, we have controlled the ratio of the compounds
in the delivery when prepared, maintained the ratio of the compounds within the carrier system while circulating in the blood
and have ensured the release at the proper synergistic ratios when delivered to the tumor. This approach allows for the combination
product HSB-888 to have different physicochemical properties of the original drugs and allows for the co-formulation and coordinated
release of both drugs with widely different properties from the same particle.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
15: HSB-888 is 5 times more potent in synergy with HSB-1216</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="formdrs_030.jpg" ALT="" STYLE="height: 240px; width: 660px"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-888
Combination Drug Clinical Development Plan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to file an IND for HSB-888 in 2022 and thereafter progress our program into a Phase 1 study to identify the dose
of our formulation that would optimize the pharmacokinetic profile of the drug in line with the known cellular and human kinetic
profiles in Japanese and Chinese studies. We intend to work with the FDA to further progress a Phase 2b trial in a refractory
sarcoma setting in patients who would benefit due to the cumulative doses of anthracycline regimens these patients have already
received. We intend to develop our combination strategy that incorporates our Quatramer platform using HSB-888, a dual drug-loaded
formulation, that may be synergistic in mechanism to explore improved outcomes in these patients.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Recurrent
Sarcoma Market Potential</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sarcomas
in a broad sense are tumors which are mesenchymal in nature capable of forming in connective tissue, blood, lymphatic and vessels,
believed to also effect bone and soft tissue. They are rare and account for 1% of cancers, yet encompass about 13% of cases under
the age of 20. Most common in bone are osteosarcoma and Ewing&rsquo;s sarcoma, while those arising from soft tissue are commonly
rhabdomyosarcomas. Other sarcomas, such as desmoplastic small round cell and synovial sarcoma are more common into adolescence
and young adulthood. All of these tumors are treated with combination strategies including surgery, radiotherapy and traditional
chemotherapy of various kinds with 5-year survival rates of 60-70% depending on histology and metastatic disease at diagnosis.
Metastatic disease has a poor prognosis at about 20-30% 5-year survival, while recurrent disease is even worse at less than 20%.
Recurrent osteosarcoma, either initially non-respondent to treatment or returning after an initial response, occurs in about 30-50%
of patients with local disease and upwards of 80% in metastatic disease. The most frequent site of metastasis as well as recurrence
is the lungs, and often times these patients undergo surgical resection of the tumor prior to continuing on therapy. Research
has suggested that patients can benefit from multiple surgeries, but this does not obviate the need for systemic treatments to
mitigate or eradicate the disease in recurrent cases, a significant high unmet need. Other than palliative approaches using bone-seeking
radiopharmaceuticals, limited agents have been approved for this high unmet need tumor, predominantly in children and young adults.
<FONT STYLE="background-color: white">Vascular endothelial growth factor</FONT> inhibitors as well as <FONT STYLE="background-color: white">mechanistic
target of rapamycin</FONT> inhibitors and immunotherapy have been studied but none have been conclusive in elucidating a regimen
that could be FDA-approved for this disease. Ewing&rsquo;s sarcoma, the second most common bone sarcoma when it recurs, has a
dismal prognosis with a 5-year overall survival less than 10%. Frontline therapy consists of vincristine, doxorubicin, cyclophosphamide,
ifosfamide and etoposide in alternating cycles of interval compressed treatment. While chemotherapy regimens are used in frontline
treatment, there remains no standard backbone therapy for recurrent or refractory cases. Rhabdomyosarcoma, the most common soft
tissue tumor in young adults, has been historically treated with vincristine, actinomycin D, and cyclophosphamide as standard
of care for the last 50 years. Desmoplastic round cell tumors as well synovial sarcomas are much more aggressive sarcomas and
have had no new interventions in recurrent and refractory disease. All of these sarcomas, effecting younger patients, share the
commonality of very poor prognoses when the cancer recurs or becomes refractory to standard of care treatment protocols, creating
a vital urgency for novel treatments in these tumor types.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-510:
Our Novel Dual HDAC-PI3K Inhibitor</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2020, we renewed our Cooperative
Research and Development Agreement with NCATS. The agreement enables NCATS to use our Quatramer drug delivery platform
in formulations of HDAC-PI3K&delta; dual inhibitors for the treatment of rare cancers, including acute myeloid leukemia (&ldquo;AML&rdquo;)
and acute lymphoid leukemia (&ldquo;ALL&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
series of compounds were rationally designed and synthesized as novel dual PI3K/HDAC inhibitors by incorporating a <FONT STYLE="background-color: white">histone
deacetylase</FONT> pharmacophore into a PI3K inhibitor (Idelalisib) via an optimized linker. Several of these dual inhibitors
were highly potent (IC50 &lt; 10 nM) and selective against PI3K&gamma;, &delta; and HDAC6 enzymes and exhibited good antiproliferative
activity against multiple cancer cell lines. The lead compound induced necrosis in several mutant and FLT3-resistant AML cell
lines and primary blasts from AML patients, while showing no cytotoxicity against several select normal cells. Target engagement
of PI3K&delta; and HDAC6 by the lead were demonstrated in specific cells using the cellular thermal shift assay. The compound
also showed ideal pharmacokinetic properties in mice via intraperitoneal administration which provides a means to examine the
biological effects of inhibiting these two enzymes with a single molecule, either <I>in vitro</I> or <I>in vivo</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Studies
have shown that by disrupting multiple compensatory cytoprotective pathways, HDAC6-PI3K&delta; dual inhibitors have therapeutic
value. Our primary objective in conjunction with NCATS/NIH was encapsulation of NCATS&rsquo; developed HDAC6-PI3K&delta; dual
inhibitors into our proprietary, tumor infiltrating Quatramer platform to enhance delivery to malignant cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to continue our collaborative effort with NCATS/NIH through our Cooperative Research and Development Agreement, and we intend
to expand such agreement and execute a license to this novel HDAC-PI3K&delta; dual inhibitor to move the compound through further
pre-clinical testing and into IND-enabling work.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-114
(TNF-alpha DNA) for Metastatic Soft Tissue Sarcoma</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tumor
necrosis factor-&alpha; (TNF-&alpha;), identified in 1975, cloned in 1984 and named for its ability to induce necrosis of induced-sarcomas
in mice, is a chemokine with potent tumoricidal properties. However, severe systemic toxicity (capillary leakage, disseminated
coagulopathy, acidosis and shock) limited its use as an anticancer agent, until procedures were developed to use the cytokine
in the clinic where high concentrations were infused into isolated limbs of sarcoma and melanoma subjects. It has since been shown
that direct intratumoral injection can augment ICIs by slowing progression of tumors in various models, with unreliable efficacy
due to the fact that levels of TNF produced must be sufficient to attract specific T cells to the tumor via signaling, notwithstanding
TNF&rsquo;s direct antitumor necrotic effects. Despite the potential to activate tumor cell death, physiological intratumoral
levels of sufficient TNF concentrations are unlikely to induce cancer regression in patients utilizing the current strategies
available to deliver this potent cytokine. Finding ways to selectively increase intratumoral TNF levels in tumors while managing
the toxicity associated with such approaches remains a major unmet need.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-114
is a novel immunotherapeutic agent which uses our proprietary Quatramer technology to deliver the human TNF-&alpha; gene to cancer
cells. Previous immunotherapeutic strategies, including the payload of HSB-114,pHSB-114, used adenovector technology requiring
replication deficient gene deletions and complex manufacturing controls in order to deliver the gene to the desired cells, although
posed a theoretical risk of systemic toxicity and adjacent tissue damage due to overflow of TNF-&alpha; in blood from the tumor,
had some dose-limited toxicities. <FONT STYLE="background-color: white">In early phase trials of pHSB-114 in combination with
radiotherapy, significant clinical activity was observed in patients with metastatic melanoma, soft tissue sarcoma and locally
advanced esophageal cancer. Anti-tumor activity was also observed in patients with pancreatic, rectal, and head and neck cancers.
However, a Phase 3 trial in patients with locally advanced pancreatic cancer failed to demonstrate a survival benefit prompting
discontinuation of the development of this agent.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our novel non-viral immunotherapeutic TNF-&alpha; gene therapy, HSB-114, builds on the pHSB-114 clinical development program
with improved scalability and tunability providing efficacy with an overall enhanced safety profile to potentially minimize dose-limited
toxicities. We <FONT STYLE="background-color: white">have developed HSB-114 via a modified Quatramer delivery system which includes a
peptide-DNA complex designed for maintaining the balance of DNA condensation and intracellular release and nuclear localization. For
delivery <I>in vivo</I>, the system circumvents the challenge of DNA-nanoparticle serum interactions that have limited this field from
progressing without use of a viral vector delivery scheme. Our results demonstrate that this approach is highly effective in conferring
TNF-induced anti-tumor activity in the absence of toxicity (</FONT>Figure 4<FONT STYLE="background-color: white">). Our findings further
indicate that this system maybe broadly applicable for expression of intratumoral cytokines that promote immune recognition and destruction.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
16: Antitumor Activity of HSB-114</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><IMG SRC="formdrs_031.jpg" ALT="" STYLE="width: 570px"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Clinical
Data with pHSB-114</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
Phase 1 studies evaluated TNF-&alpha; gene transfer therapy using a radiation-inducible polymer combined with ionizing radiation
therapy in patients with soft tissue sarcoma and solid tumors This combination therapy optimizes the therapeutic index of TNF-&alpha;
by facilitating a synergistic supra-additive interaction between the two therapeutic modalities by selective destruction of the
tumor vasculature leading to tumor necrosis. Further, this strategy allows for direct cellular toxicity by locally targeted induction
of high concentrations of TNF-&alpha; within the tumor with minimal systemic toxicity. The studies, summarized below, provide
preliminary evidence that pHSB-114 + radiotherapy is feasible, well tolerated, and provides a potential alternative to isolated
limb perfusion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Phase
I Study in Soft Tissue Sarcoma of the Extremities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Phase 1 dose-escalation study evaluated pHSB-114 and concomitant ionizing radiation therapy for up to 5 weeks in 14 adult patients with
soft tissue sarcoma of an extremity. pHSB-114 was administered by intratumoral injection, twice weekly during the first week and once
weekly during weeks 2-5 of radiation therapy. Three escalating dose levels of pHSB-114 were administered, with 3-6 patients treated per
dose level, starting with a dose of 4 &times; 10<SUP>9</SUP> particle units (&ldquo;pu&rdquo;) and escalating in 1-log increments to
a dose of 4 &times; 10<SUP>11 </SUP>pu or until the maximal tolerated dose (&ldquo;MTD&rdquo;) was reached. There was no intrapatient
dose escalation. Concomitant single-daily fractionated radiation was administered 5 days per week (total dose, 36-50.4 Gy). Surgery was
performed in 11 patients whose tumor was resectable 3&ndash;9 weeks after radiotherapy ended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
objective tumor response was observed in 11 patients, or 85%; of these, 2 were complete responses and 9 were partial responses.
Of the 11 patients who had surgery, all were resected with negative margins. Pathological complete response was observed in 2
of the 11 patients. Of the 8 patients who had partial response, 4 had &ge; 95% tumor necrosis, which prognostically carries an
improved long-term survival. Of the 2 patients who did not have surgery and received pHSB-114 for palliation, 1 had stable disease
and the other had partial response. Tumor response assessment was not consistent between results obtained via computed tomography
(&ldquo;CT&rdquo;) and those obtained via histological assessment after resection, whereby CT scans showed less response than
pathological assessment in 9 of the 11 patients who had surgery, suggesting that the magnitude of the true anti-tumor response
rate of pHSB-114 with ionizing radiation may be underestimated by CT scans, particularly if performed shortly after the end of
treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-1218:
Research in Treating COVID-19</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coronaviruses
(&ldquo;CoVs&rdquo;) are important human and animal pathogens, and at the end of 2019, a novel coronavirus emerged as the cause of a
cluster of pneumonia cases in Wuhan, China. Since then the virus identified as severe acute respiratory syndrome coronavirus 2
(&ldquo;SARS-CoV-2&rdquo;) has been identified to causes the designated as COVID-19. According to GlobalData Inc. global cases of
COVID-19 have reached over 161,206,000, with more than 3,345,000 reported deaths and 109,626,000 estimated recoveries as of May 14,
2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
there are no specific clinical features which can reliably distinguish COVID-19 from other viral respiratory infections, development
of dyspnea, anosmia and myalgias were strongly associated with a positive microbiologic test. There has been much research on
finding effective vaccines and therapeutics against SARS-COV-2, including remdesivir, chloroquine or hydroxychloroquine, convalescent
plasma and other antibody based therapies, as well as IL-6 inhibitors, direct and indirect acting antivirals, immunomodulatory
agents as well as antibiotics including azithromycin, and anti-helminthics such as ivermectin are all in various stages of testing
and clinical development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
has been reported that CoVs present and adhere to host cells via Angiotensin-Converting Enzyme-2 (&ldquo;ACE-2&rdquo;) receptor-mediated
endocytosis, which is a pH-dependent process. In this process, Spike (S) protein plays a major role in receptor binding and membrane
fusion of SARS-CoV-2 for access into host cells. It is a large transmembrane protein on the surface of the virus consisting of
two subunits, including the S1 subunit necessary to fit with the ACE-2 receptor for viral entry. Subsequent to binding, SARS-CoV-2
enters the cytosol of the host cell, by pH-dependent proteolytic cleavage of spike protein by transmembrane protease serine 2,
a plasma membrane-anchored protease that participates in proteolytic cascades of several human proteins, including those relevant
to the normal function of the human prostate. This host protein primes the S1 subunit and promotes viral uptake and host cell
entry. Then, the combination of viral and host cell membranes occurs in acidified endosomes, permitting viral genomes to affect
host cells with the aid of the S2 subunit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-1218
uses our Quatramer tunable technology to encapsulate a potent antiviral and deploy the agent either systemically or in an inhaled formulation
to target SARS-CoV-2. Evidence suggests the payload of HSB-1218,pHSB-1218, inhibits replication of viral RNA in the cytoplasm by altering
the pH. We believe this product candidate has the potential to prevent the entry of SARS-CoV-2 into the cytosol and prevent membrane
fusion (a pH-dependent process). Further, it has been reported to interact with the S-protein, and impact ACE2 attachment and impede
the release of viral RNA into the cytoplasm identifying the active component as a <FONT STYLE="background-color: white">potential antiviral
agent against SARS-CoV-2.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
recent data supports the use of HSB-1218 with data generated in a BSL3 laboratory which grew SARS-CoV-2 virus in the commonly
used Vero E6 cell line. These cell lines were seeded into 96 well tissue culture plates and incubated overnight followed by the
addition of HSB-1218 and a 6 h SARS-CoV-2 challenge at various multiplicity of infection concentrations to measure the 50% tissue
culture infectious dose (&ldquo;TCID<SUB>50</SUB>&rdquo;). At concentrations of 1 and higher &micro;M doses, HSB-1218 significantly
reduced the production of infectious SARS-CoV-2 TCID<SUB>50 </SUB>values at 24 hours. We are continuing further mechanistic studies
in order to identify the antiviral effect of HSB-1218 against SARS-CoV-2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
17: HSB-1216 TCID<SUB>50</SUB>/mL in Vero E6 Cells at 24 hr</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><IMG SRC="formdrs_032.jpg" ALT="" STYLE="height: 160px; width: 670px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
believe HSB-1218, which utilizes our Quatramer delivery technology, may offer an approach for effective use of this agent as an
antiviral delivered to the site of infection in attacking SARS-CoV-2, and we intend to continue to develop this compound and seek
government and other funding to further develop this program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Iron
Mediated Cell Death Modulator Analogues Program</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, &nbsp;&nbsp;we acquired intellectual property and data related to analogues of pHSB-1216 with varying molecular
constructs with increased efficacy against a subgroup of tumors consisting of breast, pancreatic and prostate cancers. Several
lead analogues have demonstrated increased potency when compared to pHSB-1216, whereby the increased potency of these compounds
is expected to have ferroptotic effects greater than pHSB-1216 at micro-dosage levels, creating an increased therapeutic index
as novel small molecules. We expect to develop these advanced compounds as follow-on therapeutics to HSB-1216 to treat a variety
of high unmet needs, including orphan cancers, which are sensitive to the ferroptotic pathway.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trident
Artificial Intelligence Platform</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Overview</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tumor
cells are constantly undergoing phenotypic switching that may or may not be dependent on the drug target and without additional
secondary genetic mutations but are now understood to engage three different mechanisms: EMT, Dedifferentiation/Transdifferentiation
and Treatment-induced tolerance. These stepwise phenotypic transitions through a slow cycling state potentially induce a synthetic
lethal sensitivity of key driver functional pathways making them amenable to novel therapeutic strategies. These phenotypic transitions
present novel opportunities for targeting specific drug pathways and gene circuits which none of the conventional approaches are
designed to do.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize these dynamical aspects which make cancer a constantly evolving progressive disease and are taking a biomarker-guided
approach to drug development that will maximize treatment benefit for patients. We are developing TAI, a drug targeting technology
platform, to enable the development of rational therapeutic strategies to target the plasticity of cancer cells associated with
drug resistance. TAI aims to de-risk clinical development by applying state-of-the-art deep learning artificial intelligence technologies
to patient-based multi-modal datasets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Features
of Trident include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         ability to integrate diverse multi-omics datasets including not only genomics, epigenetics
                                         and transcriptomics but also emerging proteomics data which  enable identification
                                         of dynamical re-wiring of intra-tumoral signaling circuitry;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         ability to identify biomarkers that differentiate between progression of cancer plasticity
                                         and correlate it to degree of sensitivity to a synthetically lethal target that is induced
                                         with standard of care treatment and development of resistance; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State-of-the-art
                                         convolutional neural network used to classify and select patients that are most likely
                                         to respond to treatment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trident
is based on a deep learning engine that identifies synthetic lethal sensitivities associated with degree of cell plasticity using
biomarkers that can be translated for patient selection. Trident is designed to maximize enrichment for patients who are most
likely to respond to treatment and thus de-risks clinical development.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cell
plasticity is a leading contributor to drug resistance</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tumor
cells are constantly undergoing phenotypic switching that may or may not be dependent on the drug target and without additional
secondary genetic mutations. Three critical mechanisms are understood to be involved which are engaged more or less simultaneously.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
are EMT, dedifferentiation and transdifferentiation, and transient drug-induced tolerance. EMT is characterized by both morphological
and molecular changes characterized by loss of apical-basal polarity and epithelial cell junctions leading to changes in cellular
composition of basement membrane, altering intra- and inter- cellular signaling, and eventually resulting in metastasis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the same time, distinct compartments of the epithelium maintained by different pools of resident stem cells begin to transdifferentiate
or even reverse completely and dedifferentiate upon treatment. For instance, <FONT STYLE="background-color: white">epidermal growth
factor receptor</FONT> (&ldquo;EGFR&rdquo;)-driven non-small cell lung cancer are observed to convert towards a SCLC phenotype
upon EGFR inhibition and melanoma cells dedifferentiate progressively through transitory and neural crest-like states under BRAF
inhibitor treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
18: Trident maps the phenotypic transition of a tumor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="formdrs_033.jpg" ALT="" STYLE="width: 365px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Lastly, tumor cells undergo a slow-proliferating
drug-tolerant state, called drug-tolerant persisters, before further developing secondary mutational drug-resistance. This phenomenon
has been observed in glioblastomas, melanomas and non-small cell lung cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collectively,
these stepwise transitions through a slow cycling state potentially induce a synthetic lethal sensitivity of key driver functional
pathways making them amenable to novel therapeutic strategies. This presents a novel opportunity for drug targeting to identifying
treatment-induced, state-specific, synthetically lethal drug-target pairs.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conventional
approaches to drug targeting are limiting</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Conventional approaches to drug targeting
are not equipped to handle the challenges of identifying synthetic lethal drug-target pairs. Signature-reversion principles or
Guilt-by-association strategies used to uncover drug-drug or drug-disease similarity have yielded few successes due to large transcriptional
differences between in vitro long-lived cell lines and in vivo tumor macroenvironment. Chemical similarity approaches have their
pitfalls - errors in chemical structures as well as physiological effects that exist beyond the structural relationship limit
the use for drug targeting. Structure-based molecular docking virtual screens, for predicting drug-target pairs, are limited by
lack of widespread availability of 3D protein structures for drug targets and poor predictability of target binding affinity.
Pathway- or network-based approaches to integrate gene expression patterns, protein interactions and GWAS data help identify enrichment
of drug targets but do not yield biomarkers that can be translated for patient selection. None of these approaches are designed
to search for context-specific synthetic lethal targets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
19: Convention approach to identifying drug hits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="formdrs_034.jpg" ALT="" STYLE="height: 192px; width: 670px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Trident
is a Deep Learning Engine that identifies synthetic lethal sensitivities associated with degree of cell plasticity</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trident
takes a multi-pronged approach to address each of the leading causes of tumor plasticity as the disease progresses namely EMT,
dedifferentiation/transdifferentiation, and transient drug-induced tolerance and sensitivity. The platform builds on a deep foundation
of diverse multi-modal and multi-omic private and public datasets which include not only genomic and transcriptomic data from
patient derived blood or biopsy samples and sublines, and pan-cancer epigenetic and transcriptional drug response data from The
Cancer Genome Atlas, Cancer Cell Line Encyclopedia and Genomics of Drug Sensitivity in Cancer, but also human cancer proteome
datasets from emerging global efforts that include Human Cancer Proteome Project, The Cancer Proteome Atlas and The National Cancer
Institute&rsquo;s Clinical Proteomic Tumor Analysis Consortium. Inclusion of proteomics data is very critical for identifying
dynamical re-wiring of intra-tumoral signaling circuitry which is likely to be missed if one looks at the genomic and transcriptomic
level alone.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trident
is a deep learning engine that integrates <I>in vitro</I> and <I>in vivo</I> epigenetic, transcriptomic and proteomic data characterizing
genomic alterations, methylation states, cellular differentiation, and drug tolerance to identify:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biomarker
                                         fingerprints that deconvolve a heterogenous tumor biopsy into a discrete phenotypic state
                                         along a gradient of progressive cellular plasticity;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Network
                                         of dis-regulated functional pathways that underscore a patient&rsquo;s pathology; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indication-specific
                                         synthetic-lethal sensitivities to drugs.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trident
utilizes state-of-the-art convolutional neural networks to classify and select patients based on their tumor-derived multi-comic
profiles thus enabling a targeted synthetic-lethal approach to kill persistent tumor cell populations and treat patients in select
indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
20: Trident multi-pronged approach</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="formdrs_035.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Trident
maps the phenotypic tumor transition from a high-dimensional landscape onto a quantitative, measurable one-dimensional scale</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trident
traces the complex high-dimensional landscape of tumor progression to identify biomarkers that mark milestones in this continuum
and enable quantification of degree of plasticity along the trajectory. Trident&rsquo;s deep learning engine trains a model that
can reduce this high-dimensional information into a one-dimensional quantitative and measurable scale which provides the degree
of plasticity in a biopsy sample or cell line dataset. Trident&rsquo;s unbiased search in the vast repository of multi-modal datasets
enables identification of synthetic lethal sensitivities that correlate linearly but contrast with degree of plasticity. This
biomarker-guided, state-specific approach enables to successfully deconvolve signals from a heterogenous tumor biopsy into a discrete
phenotypic state along a gradient of progressive and divergent cellular plasticity and complementary synthetic lethal sensitivity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
21: Trident assesses phenotype of plasticity</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="formdrs_036.jpg" ALT=""></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Trident
is designed to de-risk clinical development and deliver on the promise of precision medicine</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trident
is designed to deliver on our ultimate goal, which is to identify and treat the right patients that are most likely to benefit
from treatment. Using Trident, biomarkers measured in patient blood/biopsy samples will assist in determining the degree of plasticity
for a specific patient, which will then directly inform about a patient&rsquo;s sensitivity to activation/inhibition of the synthetically
lethal target and probability of successful treatment. More than just de-risking clinical development, Trident aspires to deliver
on the promise of precision medicine by building a platform based on the robust foundation of patient-based biomarker research
and deep learning artificial intelligence technologies. Trident has successfully identified biomarkers correlating dedifferentiation
in melanoma with sensitivity to inhibitors of ferroptosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
22: Trident assesses biomarkers for clinical development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="formdrs_037.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quatramer
Technology</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Overview</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
proprietary Quatramer technology is based on know-how and permits manufacture of uniform size polymer aggregates that can be packaged
and tuned specifically to interact with pharmaceutical drugs, biological molecules and/or combinations of molecules to bypass
delivery problems. The system is biocompatible and can be tailored to form therapeutics which solubilize the drug in aqueous media
such as human plasma and blood which dramatically increases the amount of drug available at the disease site while administering
a lower dose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
23: Quatramer preferentially release payloads into tumors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="formdrs_038.jpg" ALT=""></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Studies
have shown that targeted delivery of drugs to a site of action, including tumors, is directly related to the length of time of
a circulating therapeutic in the bloodstream. This is an expected outcome as most drug delivery formulations delivering payloads
to sites of action are cleared extremely rapidly by the reticuloendothelial system (&ldquo;RES&rdquo;) in the liver. The stealth
nature of our technology allows for a prolonged circulation time whereby there is accumulation at the site of disease prior to
being cleared.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B>Figure 24: Quatramer
Multilayered core shell structure SEM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><IMG SRC="formdrs_039.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
size, shape and surface of our Quatramer allows it to escape via gaps in the blood vessels in the TME allowing for release of
the payload directly into cancerous cells. Furthermore, the system functions as a &ldquo;peeling onion&rdquo; in coordinated and
precise acidic versus basic conditions depending on the TME as well as inside cancerous cells. Certain portions of the technology
release a payload due to its own physicochemical characteristics while the core of the Quatramer system would release a different
payload depending on its own chemical and physical properties. This type of a profile for certain of our Quatramer therapeutics,
particularly our combination products, are specifically designed to cleave or disperse in response to external stimuli causing
internal changes for delivery and is a designed approach to our size tunable vehicles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
designed size tunable feature of certain of our Quatramer compositions offer further advantages, as certain cleaved materials
create a reversal of drug resistance in cells. <FONT STYLE="background-color: white">Drug resistance can be classified into two
categories: <I>de novo</I> resistance or acquired resistance. Cancer patients that exhibit <I>de novo</I> resistance do not respond
to chemotherapy from the start. However, in acquired resistance, the cancer cells initially respond to a drug but eventually acquire
resistance to it and the cells might also show cross-resistance to other structurally and mechanistically unrelated drugs, a phenomenon
commonly known as MDR whereby treatment regimens that combine multiple agents with different targets are no longer effective.
Our Quatramer technology circumvents this phenomenon upon cleavage of the payload from the system, whereby the remnants of the
system, such as certain hydrophobic chains flanked by hydrophilic chains which are not related to therapeutic efficacy, cause
drug efflux pump blockage and allow the payload to continue to be effective in MDR cellular systems both <I>in vitro</I> and <I>in
vivo</I>.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quatramer
physicochemical characterization allows for optimizing size, shape and surface chemistry based on payload characteristics to render
enhanced permeation and retention into the TME. Our scientific know-how and scientific expertise in developing Quatramer based
therapeutics has led to understanding the optimal conditions for encapsulating therapeutics of different physicochemical characteristics
into our proprietary delivery, and the combination of multiple materials used varies depending on the drug itself, causing a highly
specific tunability platform that can be scaled. The proprietary know-how behind our Quatramer structures with multiple layering
allows for therapeutics of different levels of hydrophilicity and hydrophobicity to interact within aqueous mediums of varied
acid-base conditions, including human serum and blood. The importance of the Quatramer structure extends the certain aspects of
the core and thereby has the capacity to increase drug uptake and sustain its release over long periods of time, including over
many days and weeks in both <I>in vitro</I> and <I>in vivo</I> systems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Quatramer technology has been designed to be a scalable process with production efficiency whereby the analysis of the output of a designed
chemistry, manufacturing and controls system creates a predictable and uniform product with controllable capability and cost efficiency.
Chemical compositions listed in the FDA Inactive Ingredients Database are tuned to maximize nano-bio interfaces with limited or no environmental
concerns due to the biodegradability of the entire system. Combined with the tunability of Quatramer, the technology allows for a variety
of delivery payloads including peptides, small molecules, nucleic acids and antibodies with the added flexibility of dual loaded payload
therapeutics. The payload diversity and flexibility of the system coupled with its numerous advantages allows for a targeted system with
prolonged circulation time, which takes advantage of an efficient EPR effect with numerous mechanistic features deployed at various conditions
with the TME as well as in intracellular environments, which makes the methodology of Quatramer therapeutics, a highly advantageous platform
to deliver low doses of therapeutics directly to tumors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our goal is to disrupt the biotechnology landscape
by developing novel therapeutics by leveraging both our targeted-delivery Quatramer platform-based therapeutics and our TAI platform
to address significant unmet medical needs, with a focus on treatments for cancer. We believe that our technology has the potential to
generate differentiated products that hav<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e the potential to
treat rare and devastating tumors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business strategy includes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Developing
    drug candidate, HSB-1216, in solid tumors.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
from a compassionate use study in Germany led us to progress HSB-1216 into IND-enabling studies with the goal of launching a Phase 1b/2a
trial in 2022. These IND-enabling trials are pre-clinical in nature and include toxicology and pharmacokinetic profiling as well as bioanalytical
assay development. We engaged in discussions with the FDA in 2020 and expect to use the 505(b)(1) FDA approval pathway and conduct a
Phase 1 trial to obtain initial pharmacokinetic and dosing information in patients. We intend to evaluate the development of HSB-1216
in other high-unmet need oncology indications, including certain brain, breast and prostate cancers, and in combination with other cancer
therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Developing
    our combination drug candidate, HSB-888, for pediatric sarcomas.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-888
is in IND-enabling trials with the goal of potentially obtaining an IND from the FDA in 2022. These trials are pre-clinical in nature
and include toxicology and pharmacokinetic profiling as well as bioanalytical assay development. Based on this data we plan to initiate
discussions with the FDA in 2021 and intend to use the 505(b)(1) FDA approval pathway and conduct a Phase 1 trial for obtaining initial
pharmacokinetic data and determine the optimized dose in patients. We intend to demonstrate the safety and efficacy in a Phase 2b program
in a basket trial enrolling patients with recurrent cancers due to multiple sarcomas, including Ewing&rsquo;s sarcoma, rhabdomyosarcoma
and eligible osteosarcoma patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Leveraging
    Our Trident Artificial Intelligence Platform.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAI
is a deep learning engine that identifies synthetic lethal sensitivities associated with degree of cell plasticity. We undertake a multi-pronged
approach to address each of the leading causes of tumor plasticity as the disease progresses including epithelial to EMT, dedifferentiation/transdifferentiation,
and transient drug-induced tolerance and sensitivity. The platform builds on a deep foundation of diverse multi-modal and multi-omic
private and public datasets which include not only genomic and transcriptomic data from patient derived blood or biopsy samples and sublines,
and pan-cancer epigenetic and transcriptional drug response data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Developing
    and commercializing Quatramer in collaboration with leading pharmaceutical companies.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our internal development programs, we actively seek opportunities to collaborate with recognized biopharmaceutical companies
to develop Quatramer incorporating therapeutic payloads from their proprietary product portfolios. We intend to establish collaborations
with industry leaders and strategic pharmaceutical organizations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Leveraging
    our novel platform to develop a pipeline of high value Quatramer leads.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tunability of our technology allows us to efficiently expand our pipeline of Quatramer, both on our own and in collaboration with others,
through various combinations of targeted DNA encoded for anti-tumor cytokines and therapeutic payloads, which enables us to move into
other areas of oncology, including immuno-oncology whereby we could potentially increase the effectiveness of ICIs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Commercializing
    proprietary Quatramer based products, including HSB-1216, directly in the United States and with collaborators outside the United
    States.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have retained the worldwide rights to HSB-1216 and our other proprietary pipeline and expect to maintain similar rights with respect
to other proprietary Quatramer we develop. We intend to build a focused oncology sales organization to market Quatramer in the United
States following FDA approval. Outside the United States, we expect to rely on collaborators to commercialize proprietary approved Quatramer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Continuing
    to extend and protect our product technology and Quatramer through our intellectual property portfolio.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek to protect our novel platform through issued U.S. and international patents as well as know-how and trade secrets relating to the
design and manufacturing of our technology. We expect to continue to file patent applications as we apply our technology to new targets
and therapeutic payloads. In addition, we believe the heightened regulatory requirements for generics of this technology may strengthen
the protection afforded by our intellectual property portfolio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Team</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">We are led
by a management team with extensive scientific, drug development, and commercialization experience across pertinent disciplines including
oncology; small molecule, peptide and antibody drug manufacturing and quality; clinical drug development, and commercialization. </FONT>Randy
Milby<FONT STYLE="background-color: white">, our Chief Executive Officer and Chairman of our board of directors and our consultants have
held assorted roles leading research, clinical development, strategy, corporate development and operational functions at large biopharmaceutical
companies</FONT>, <FONT STYLE="background-color: white">public biotechnology companies, and universities having worked at companies such
as Dupont Merck Pharmaceuticals, Amgen, Exelixis, Centocor (Johnson &amp; Johnson), Eisai, Salix Pharmaceuticals (Bausch Healthcare),
Axsome Therapeutics, Harvard Medical School and Dana-Farber Cancer Institute. We were founded by a core group of scientists from Harvard
Medical School and Dana-Farber Cancer Institute, who have extensive backgrounds in cancer biology, biopharmaceutical technologies, and
delivery of pharmaceutical products and successful exits to Genzyme (ILEX Oncology). Our Chief Executive Officer and consultants have
been involved in the discovery, development, manufacturing and commercialization of multiple marketed products across various therapeutic
areas, including Cabometyx<SUP>&reg;</SUP> (cabozantinib), Remicade<SUP>&reg; </SUP>(infliximab), Clolar<SUP>&reg;</SUP> (clofarabine),
as well as product candidates currently in development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong
emphasis on proprietary products and intellectual property. We face competition from m</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ajor
multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, emerging and
start-up companies, universities and other research institutions both in the United States and internally. Any drug candidates
that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available
in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical
testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions
in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number
of our competitors. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel
and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary
to, or necessary for, our programs. Earlier stage companies, such as smaller discovery phase biotechnology companies, may also prove
to be significant competitors, particularly through collaborative arrangements with large and established companies. Some of our competitors
include BridgeBio Pharma, Inc. (Ferro Therapeutic, Inc.), Bayer AG and The Broad Institute of MIT and Harvard, Moderna
Inc. and Takeda Pharmaceutical Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective,
have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors
also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours. In addition,
our ability to compete may be affected in many cases by insurers or other third-party payers seeking to encourage the use of generic
products. Generic products are currently on the market, including the therapeutics payload in HSB-1216 and/or HSB-888, for the
indications that we are pursuing, and additional products are expected to become available on a generic basis over the coming
years. If our drug candidates achieve marketing approval, we expect that they will be priced at a significant premium over competitive
generic products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
most common methods of treating patients with cancer are surgery, radiation and drug therapy, including chemotherapy and targeted drug
therapy. There are a variety of available drug therapies marketed for solid tumors. In many cases, these drugs are administered in combination
to enhance efficacy. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis, including
drugs in the same therapeutic class as the payloads contained in HSB-1216 and/or HSB-888. Many of these approved drugs are well established
therapies and are widely accepted by physicians, patients and third-party payers. In general, although there has been considerable progress
over the past few decades in the treatment of solid tumors and the currently marketed therapies provide benefits to many patients, these
therapies all are limited to some extent in their efficacy and frequency of adverse events, and none of them are successful in treating
all patients. As a result, the level of morbidity and mortality from solid tumor cancers remains high.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are also a number of products in late-stage
clinical development to treat solid tumors including, but not limited to, Merck &amp; Co Inc. (Keytruda), Bristol-Myers Squibb Co.
(Opdivo), AbbVie Inc. (Imbruvica), Roche Group (Tecentiq), Regeneron Pharmaceuticals, Inc. (Libtayo) and Eli Lilly &amp; Co (sintilimab).
These products in development may provide efficacy, safety, convenience and other benefits that are not provided by currently marketed
therapies. As a result, they may provide significant competition for our product candidates for which we obtain marketing approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
Property</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends on our intellectual property, and we strive to protect it, by, among other things, obtaining, maintaining,
defending, and enforcing our patents in the United States and internationally for our proprietary technology, improvements, platforms,
products and components thereof, novel biological discoveries, new therapeutic approaches and potential indications, and other
inventions that are important to our business. For our product candidates, generally we initially pursue patent protection covering
compositions of matter, methods of production, and methods of use. Throughout the development of our product candidates and technologies,
we will seek to identify additional means of obtaining patent protection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 5, 2021, our patent portfolio includes six patent families. These families include issued patents and pending applications related
generally to our polymeric nanoparticle technologies, methods of making our polymeric nanoparticle technologies, and methods of using
our polymeric nanoparticles therapeutically (<I>e.g</I>., for delivery of therapeutic compounds). Specifically, we own a patent portfolio
that currently includes 2 issued U.S. patents, 9 granted patents in foreign jurisdictions, and 28 patent applications pending worldwide.
Patent protection for the earliest-filed family is expected to expire in 2033, absent any applicable patent term adjustments or extensions,
with more recently-filed families expiring approximately between 2033 and 2041.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Certain of our
patents includes issued patents and patent applications in the United States, Europe, and Japan. Exemplary issued claims in this
family are directed to polymeric nanoparticles formed of the tetra block copolymer poly(lactic acid)-poly(ethylene glycol)-poly(propylene
glycol)-poly(ethylene glycol) PLA-PEG-PPG-PEG and related methods of using such compositions. The European patent is validated in seven
European countries: Switzerland, Germany, Spain, France, Italy, Netherlands and the United Kingdom. Patent protection under this family
is expected to expire in 2033, absent any applicable patent term adjustments or extensions.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other patents include pending patent applications
in the United States and each of China, Europe, Hong Kong, and Japan. Exemplary pending claims are directed to polymeric nanoparticles
comprising a PLA-PEG-PPG-PEG tetra block copolymer, anti-cancer/chemotherapeutic agents, and peptides, as well as related methods. Applications
maturing from this family are expected to expire in 2036, absent any applicable patent term adjustments or extensions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Other patents include
pending patent applications in the United States and each of China, Europe, Hong Kong, Japan, and Korea. Exemplary pending claims
are directed to polymeric nanoparticles comprising a block copolymer comprising PLA and PEG and an isolated nucleic acid or peptide of
a cytokine (<I>e.g.</I>, TNF-&alpha;), as well as related methods. Applications maturing from this family are expected to expire in 2037,
absent any applicable patent term adjustments or extensions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">Other patents include pending patent applications in the United States
and each of Australia, Canada, China, Europe, Japan, and Korea. Exemplary pending claims are directed to polymeric nanoparticles comprising
a PLA-PEG-PPG-PEG tetra block copolymer and bortezomib, as well as related methods. Applications maturing from this family are expected
to expire in 2038, absent any applicable patent term adjustments or extensions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">Other patents include pending
patent applications in the United States and each of Australia, Canada, China, Europe, Japan, and Korea. Exemplary pending claims are
directed to pharmaceutical compositions including polymeric nanoparticles comprising a PLA-PEG-PPG-PEG tetra block copolymer, and salinomycin
as well as related methods. Applications maturing from this family are expected to expire in 2039, absent any applicable patent term
adjustments or extensions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of individual patents depends on the legal term for patents in the countries in which they are obtained. In most countries,
including the U.S., the patent term is 20 years from the earliest filing date of a non-provisional patent application. In the
U.S., the term of a patent may be lengthened by patent term adjustment (&ldquo;PTA&rdquo;), which compensates a patentee for administrative
delays by the USPTO in examining and granting a patent or the term of a patent may be shortened if a patent is terminally disclaimed
over an earlier filed patent. The term of a patent that covers a drug or biological product may also be eligible for patent term
extension (&ldquo;PTE&rdquo;) after FDA approval for a portion of the term effectively lost as a result of the FDA regulatory
review period, subject to certain limitations and provided statutory and regulatory requirements are met. PTE can be for no more
than five years, typically only one patent per approved product can be extended, the extension cannot extend the total patent
term beyond 14 years from approval, and only those claims covering the approved drug, a method for using it or a method for manufacturing
it may be extended. In addition, the length of the adjustment or extension granted could be less than that requested, and we may
not receive the full PTA or PTE available if we fail to exercise due diligence during the testing phase or regulatory review process,
fails to apply within applicable deadlines, fails to apply prior to expiration of relevant patents, or otherwise fails to satisfy
applicable requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patents, we rely on trade secrets and know-how and continuing technological innovation to develop and maintain our
competitive position. However, trade secrets and know-how can be difficult to protect. We take measures to protect and maintain
the confidentiality of proprietary information in order to protect aspects of the business that are not amenable to, or that we
do not consider appropriate for, patent protection. We require employees, consultants, outside scientific partners, sponsored
researchers and other advisors to execute confidentiality agreements with us on or prior to the commencement of employment or
consulting relationships with us. These agreements also require such individuals to assign to us any inventions conceived in the
course of employment or consulting relationships with us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also filed a trademark application for &ldquo;HILLSTREAM BIOPHARMA&rdquo; for pharmaceutical preparations for use in cancer
treatment and therapies&rdquo;. We have filed a trademark application for &ldquo;QUATRAMER&rdquo; for nano particle technologies
and nanoparticle technologies for cancer therapy and treatment, namely, drug delivery agents in the form of nanoparticles that
provide controlled release of active ingredients for a wide variety of pharmaceuticals for the treatment of cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Manufacturing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own or operate any facilities in which we can formulate or manufacture our product candidates. We intend to rely on contract manufacturers
to produce all materials required to conduct pre-clinical studies and clinical trials under cGMPs, with oversight of these activities
by our management team. We have identified alternate sources of supply and other contract manufacturers that can produce materials for
our pre-clinical and clinical trial requirements on a timely basis. However, if an existing or future contract manufacture fails to deliver
on schedule, or at all, it may delay or interrupt the development process for our product candidates which may have an adverse effect
on our operating results and estimated timelines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Government
Regulations</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental
authorities in the U.S. and other countries extensively regulate the research, development, testing, manufacture, labeling, promotion,
advertising, distribution and marketing of pharmaceutical products such as those being developed by us. In the U.S., the FDA regulates
such products under the FDCA and implements related regulations. Failure to comply with applicable FDA requirements, both before
and after approval, may subject us to administrative and judicial sanctions, such as a delay in approving or refusal by the FDA
to approve pending applications, warning letters, product recalls, product seizures, total or partial suspension of production
or distribution, injunctions and/or criminal prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S.
Food and Drug Administration Regulation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>United
States Drug Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs, medical devices and combinations of drugs and devices, or combination products, under
the FDCA and its implementing regulations. Drugs are also subject to other federal, state and local statutes and regulations.
The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign
statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable
U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant
to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&rsquo;s refusal to approve
pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, requests for voluntary product
recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions,
fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement
action could have a material adverse effect on us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a drug may be marketed in the United States generally involves the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
    of extensive pre-clinical laboratory tests, animal studies and formulation studies in accordance with applicable regulations,
    including the FDA&rsquo;s Good Laboratory Practice regulations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an IND, which must become effective before human clinical trials may begin;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials in accordance with an applicable IND and other clinical study related
    regulations, sometimes referred to as GCPs to establish the safety and efficacy of the proposed drug for its proposed indication;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an NDA;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the product, or components
    thereof, are produced to assess compliance with the FDA&rsquo;s cGMP requirements;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    FDA audit of the clinical trial sites that generated the data in support of the NDA; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and approval of the NDA prior to any commercial marketing or sale.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
a pharmaceutical product candidate is identified for development, it enters the pre-clinical testing stage. Pre-clinical tests
include laboratory evaluations of product chemistry, toxicity, formulation and stability, as well as animal studies. An IND sponsor
must submit the results of the pre-clinical tests, together with manufacturing information, analytical data and any available
clinical data or literature, to the FDA as part of the IND. The sponsor must also include a protocol detailing, among other things,
the objectives of the initial clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to
be evaluated if the initial clinical trial lends itself to an efficacy evaluation. Some pre-clinical testing may continue even
after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns
or questions related to a proposed clinical trial and places the trial on a clinical hold within that 30-day period. In such a
case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also
may be imposed by the FDA at any time before or during clinical trials due to safety concerns or non-compliance, and may be imposed
on all drug products within a certain class of drugs. The FDA also can impose partial clinical holds, for example, prohibiting
the initiation of clinical trials of a certain duration or for a certain dose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCP regulations.
These regulations include the requirement that all research subjects provide informed consent in writing before their participation
in any clinical trial. Further, an IRB must review and approve the plan for any clinical trial before it commences at any institution,
and the IRB must conduct continuing review and reapprove the study at least annually. An IRB considers, among other things, whether
the risks to individuals participating in the clinical trial are minimized and are reasonable in relation to anticipated benefits.
The IRB also approves the information regarding the clinical trial and the consent form that must be provided to each clinical
trial subject or his or her legal representative and must monitor the clinical trial until completed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
new clinical protocol and any amendments to the protocol must be submitted for FDA review, and to the IRBs for approval. Protocols
detail, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria,
and the parameters to be used to monitor subject safety.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are typically conducted in three sequential phases that may overlap or be combined:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    1. The product is initially introduced into a small number of healthy human subjects or patients and tested for safety, dosage
    tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain early evidence on effectiveness. In
    the case of some products for severe or life-threatening diseases, especially when the product is suspected or known to be
    unavoidably toxic, the initial human testing may be conducted in patients.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    2. Involves clinical trials in a limited patient population to identify possible adverse effects and safety risks, to preliminarily
    evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage and
    schedule.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population
    at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit
    relationship of the product and provide an adequate basis for product labeling.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These studies are
used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances,
the FDA may mandate the performance of Phase 4 trials. Companies that conduct certain clinical trials also are required to register
them and post the results of completed clinical trials on a government-sponsored database, such as www.clinicaltrials.gov in the
United States, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progress
reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA,
and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events, findings
from other studies that suggest a significant risk to humans exposed to the product, findings from animal or in vitro testing
that suggest a significant risk to human subjects, and any clinically important increase in the rate of a serious suspected adverse
reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed
successfully within any specified period, if at all. The FDA or the clinical trial sponsor may suspend or terminate a clinical
trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable
health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial
is not being conducted in accordance with the IRB&rsquo;s requirements or if the product has been associated with unexpected serious
harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the
clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a
trial may move forward at designated check points based on access to certain data from the study. The clinical trial sponsor may
also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with clinical trials, companies usually complete additional animal studies and must also develop additional information about
the chemistry and physical characteristics of the product and finalize a process for manufacturing the product in commercial quantities
in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the
product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and
purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted
to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NDA
and FDA Review Process</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of product development, pre-clinical studies and clinical trials, along with descriptions of the manufacturing process,
analytical tests conducted on the drug, proposed labeling and other relevant information, are submitted to the FDA as part of
an NDA for a new drug, requesting approval to market the product. The submission of an NDA is subject to the payment of a substantial
user fee, and the sponsor of an approved NDA is also subject to an annual program user fee; although a waiver of such fee may
be obtained under certain limited circumstances. For example, the agency will waive the application fee for the first human drug
application that a small business or its affiliate submits for review.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA reviews all NDAs submitted before it accepts them for filing and may request additional information rather than accepting
an NDA for filing. The FDA typically makes a decision on accepting an NDA for filing within 60 days of receipt. The decision to
accept the NDA for filing means that the FDA has made a threshold determination that the application is sufficiently complete
to permit a substantive review. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act (&ldquo;PDUFA&rdquo;),
the FDA&rsquo;s goal to complete its substantive review of a standard NDA and respond to the applicant is ten months from the
receipt of the NDA. The FDA does not always meet its PDUFA goal dates, and the review process is often significantly extended
by FDA requests for additional information or clarification and may go through multiple review cycles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed product
is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMPs to assure and
preserve the product&rsquo;s identity, strength, quality and purity. The FDA may refer applications for novel drug products or
drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes
clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and
under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations
carefully when making decisions. The FDA will likely re-analyze the clinical trial data, which could result in extensive discussions
between the FDA and us during the review process. The review and evaluation of an NDA by the FDA is extensive and time consuming
and may take longer than originally planned to complete, and we may not receive a timely approval, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving an NDA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine
whether they comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and
facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
specifications. In addition, before approving an NDA, the FDA may also audit data from clinical trials to ensure compliance with
GCP requirements. After the FDA evaluates the application, manufacturing process and manufacturing facilities, it may issue an
approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing
information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete
and the application will not be approved in its present form. A Complete Response Letter usually describes all the specific deficiencies
in the NDA identified by the FDA. The Complete Response Letter may require additional clinical data and/or an additional pivotal
Phase 3 clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, nonclinical studies
or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the NDA, addressing all the deficiencies
identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may ultimately
decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive,
and the FDA may interpret data differently than we interpret the same data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no assurance that the FDA will ultimately approve a product for marketing in the United States, and we may encounter significant
difficulties or costs during the review process. If a product receives marketing approval, the approval may be significantly limited
to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value
of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product
labeling or may condition the approval of the NDA on other changes to the proposed labeling, development of adequate controls
and specifications, or a commitment to conduct post-market testing or clinical trials and surveillance to monitor the effects
of approved products. For example, the FDA may require Phase 4 clinical trials to further assess drug safety and effectiveness
and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. The
FDA may also place other conditions on approvals, including the requirement for a risk evaluation and mitigation strategy (&ldquo;REMS&rdquo;),
to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS;
the FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician communication
plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or
dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory requirements or if problems occur
following initial marketing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Orange
Book Listing and Paragraph IV Certification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
NDA submissions, including those under Section 505(b)(2), applicants are required to list with the FDA certain patents with claims
that cover the applicant&rsquo;s product. Upon approval, each of the patents listed in the application is published in <I>Approved
Drug Products with Therapeutic Equivalence Evaluations</I>, commonly referred to as the Orange Book. Any applicant who subsequently
files an ANDA or 505(b)(2) NDA that references a drug listed in the Orange Book must certify to the FDA that (1) no patent information
on the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the
date on which such patent expires; or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale
of the drug product for which the application is submitted. This last certification is known as a Paragraph IV Certification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an applicant has provided a Paragraph IV Certification to the FDA, the applicant must also send notice of the Paragraph IV Certification
to the holder of the NDA for the approved drug and the patent owner once the application has been accepted for filing by the FDA.
The NDA holder or patent owner may then initiate a patent infringement lawsuit in response to notice of the Paragraph IV Certification.
The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV Certification prevents the FDA from
approving the ANDA or 505(b)(2) application until the earlier of 30 months from the date of the lawsuit, the applicant&rsquo;s
successful defense of the suit, or expiration of the patent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reimbursement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
sales of any of our product candidates, if approved, will depend, at least in part, on the extent to which such products will
be covered by third-party payors, such as government health care programs, commercial insurance and managed healthcare organizations.
These third-party payors are increasingly limiting coverage and/or reducing reimbursements for medical products and services.
A third-party payor&rsquo;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate
will be approved. Further, one payor&rsquo;s determination to provide coverage for a drug product does not assure that other payors
will also provide coverage for the drug product. In addition, the U.S. government, state legislatures and foreign governments
have continued implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements
for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive
policies in jurisdictions with existing controls and measures, could further limit our future revenues and results of operations.
Decreases in third-party reimbursement or a decision by a third-party payor to not cover a product candidate, if approved, or
any future approved products could reduce physician usage of our products, and have a material adverse effect on our sales, results
of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the Medicare Part D program provides a voluntary outpatient drug benefit to Medicare beneficiaries for certain
products. We do not know whether our product candidates, if approved, will be eligible for coverage under Medicare Part D, but
individual Medicare Part D plans offer coverage subject to various factors such as those described above. Furthermore, private
payors often follow Medicare coverage policies and payment limitations in setting their own coverage policies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Healthcare
Laws and Regulations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our product candidates, if approved, or any other future product candidate will be subject to healthcare regulation and enforcement
by the federal government and the states and foreign governments in which we might conduct our business. The healthcare laws and
regulations that may affect our ability to operate include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Anti-Kickback Statute makes it illegal for any person or entity to knowingly and willfully, directly or indirectly,
    solicit, receive, offer, or pay any remuneration that is in exchange for or to induce the referral of business, including
    the purchase, order, lease of any good, facility, item or service for which payment may be made under a federal healthcare
    program, such as Medicare or Medicaid. The term &ldquo;remuneration&rdquo; has been broadly interpreted to include anything
    of value.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
    false claims and false statement laws, including the federal civil False Claims Act, prohibits, among other things, any person
    or entity from knowingly presenting, or causing to be presented, for payment to, or approval by, federal programs, including
    Medicare and Medicaid, claims for items or services, including drugs, that are false or fraudulent.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA
    created additional federal criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting
    to execute, a scheme to defraud any healthcare benefit program, including private third-party payors or making any false,
    fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and their implementing regulations,
    impose obligations on certain types of individuals and entities regarding the electronic exchange of information in common
    healthcare transactions, as well as standards relating to the privacy and security of individually identifiable health information.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for
    which payment is available under Medicare, Medicaid or the Children&rsquo;s Health Insurance Program, with specific exceptions,
    to report annually to the Centers for Medicare &amp; Medicaid Services information related to payments or other transfers
    of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their
    immediate family members.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
many states have similar laws and regulations, such as anti-kickback and false claims laws that may be broader in scope and may
apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Additionally,
we may be subject to state laws that require pharmaceutical companies to comply with the federal government&rsquo;s and/or pharmaceutical
industry&rsquo;s voluntary compliance guidelines, state laws that require drug manufacturers to report information related to
payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, as well as state
and foreign laws governing the privacy and security of health information, many of which differ from each other in significant
ways and often are not preempted by HIPAA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
to the extent that our product is sold in a foreign country, we may be subject to similar foreign laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>






















































<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 11, 2021, we employed 1 full-time employee and had no part-time employees. We are not a party to any collective bargaining agreements,
and we believe that we maintain good relations with our employee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Facilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters are located at 1200 Route 22 East, Suite 2000, Bridgewater, NJ 08807 pursuant to a monthly rental agreement. We
believe this to be sufficient to meet our needs for the foreseeable future and that any additional space we may require will be available
on commercially reasonable terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal
Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation
is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.
We are currently not aware of any such legal proceedings or claims that will have, individually or in the aggregate, a material adverse
effect on our business, financial condition or operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aR_001"></A>MANAGEMENT</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors
and Executive Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the name, age and position of each of our executive officers, key employees and directors as of May 11, 2021.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="text-align: left; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randy
    Milby</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman of the Board of Directors</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Randy
Milby</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randy
Milby has served as our Chief Executive Officer and Chairman of our board of directors since inception in 2017. Mr. Milby is an
experienced biopharmaceutical executive and served as the Chief Executive Officer and member of the board of directors at CorMedix
Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of
inflammatory and infectious diseases, from May 2012 to December 2012 and from January 2013 until September 2016, respectively. Mr. Milby has served in various other positions including, but
not limited to, Global Business Director &ndash; BioMedical and Global Business Director &ndash; Applied BioSciences of DuPont de
Nemours, Inc. ; Global Marketing Director of DuPont Crop Protection; Securities Analyst, Investment Research, Biotechnology of
Goldman Sachs ; and Senior Director of DuPont Merck Pharmaceuticals. Mr. Milby received his BS in pharmacy from The University of
Kansas and his MBA in finance/marketing from Washington University in St. Louis &ndash; Olin Business School. We believe Mr. Milby
is qualified to serve as a member of our board of directors because of his extensive experience in the biotechnology
industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Family
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our executive officers or directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Independence</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the consummation of this offering, our board of directors undertook a review of the independence of our directors and considered
whether any director has a relationship with us that could compromise that director&rsquo;s ability to exercise independent judgment
in carrying out that director&rsquo;s responsibilities. Our board of directors has affirmatively determined that
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
are each an &ldquo;independent director,&rdquo; as defined under the Nasdaq rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Committees
of Our Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors directs the management of our business and affairs, as provided by Delaware law, and conducts its business through
meetings of the board of directors and its standing committees. We will have a standing audit committee, compensation committee and nominating
and corporate governance committee. In addition, from time to time, special committees may be established under the direction of the
board of directors when necessary to address specific issues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Audit
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee will be responsible for, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving
    and retaining the independent auditors to conduct the annual audit of our financial statements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the proposed scope and results of the audit;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and pre-approving audit and non-audit fees and services;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    accounting and financial controls with the independent auditors and our financial and accounting staff;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving transactions between us and our directors, officers and affiliates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    procedures for complaints received by us regarding accounting matters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    internal audit functions, if any; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing
    the report of the audit committee that the rules of the SEC require to be included in our annual meeting proxy statement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the consummation of this offering, our audit committee will consist of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with serving as
chair. Our board of directors has affirmatively determined that
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
each meet the definition of &ldquo;independent director&rdquo; under the Nasdaq rules, and that they meet the independence standards
under Rule 10A-3. Each member of our audit committee meets the financial literacy requirements of the Nasdaq rules. In addition, our
board of directors has determined that &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
will
qualify as an &ldquo;audit committee financial expert,&rdquo; as such term is defined in Item 407(d)(5) of Regulation S-K. Our board
of directors will adopt a written charter for the audit committee, which will be available on our principal corporate website at <I>www.hillstreambio.com </I>concurrently
with the consummation of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Compensation
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee will be responsible for, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and recommending the compensation arrangements for management, including the compensation for our chief executive officer;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    and reviewing general compensation policies with the objective to attract and retain superior talent, to reward individual performance
    and to achieve our financial goals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering
    our stock incentive plans; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing
    the report of the compensation committee that the rules of the SEC require to be included in our annual meeting proxy statement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the consummation of this offering, our compensation committee will consist of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
with serving as chair. Our board has determined that
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
are each independent directors under Nasdaq rules. Our board of directors will adopt a written charter for the compensation
committee, which will be available on our principal corporate website at <I>www.hillstreambio.com</I> concurrently with the
consummation of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Nominating
and Governance Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
nominating and governance committee will be responsible for, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">nominating
    members of the board of directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    a set of corporate governance principles applicable to our company; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    the evaluation of our board of directors.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the consummation of this offering, our nominating and corporate governance committee will consist of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with serving as
chair. Our board has determined that
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
are each independent directors under Nasdaq rules. Our board of directors will adopt a written charter for the nominating and
governance committee, which will be available on our principal corporate website at <I>www.hillstreambio.com </I>concurrently with
the consummation of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Scientific
Advisory Board</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Scientific Advisory Board is composed of the
following members:<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Donald Kufe, MD &ndash; Chair of the Scientific Advisory Board; Dana-Farber
Cancer Institute/Harvard University</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Kwok-Kin Wong, MD, PhD &ndash; New York University
School of Medicine</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Paul Richardson, MD &ndash; Dana-Farber Cancer
Institute/Harvard University</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Surender Kharbanda, PhD - Dana-Farber Cancer
Institute</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Joseph Paul Eder, MD &ndash; Yale University/Yale
Cancer Center</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">David Weaver, PhD &ndash; FemtoDx</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Richard Stone, MD &ndash; Dana-Farber Cancer
Institute</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Jonathan Rayner, PhD &ndash; University of South
Alabama</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Code
of Business Conduct and Ethics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the completion of this offering, we will adopt a written code of business conduct and ethics that applies to our directors, officers
and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or
persons performing similar functions. A copy of the code will be posted on our website, <I>www.hillstreambio.com</I>. In addition, we
intend to post on our website all disclosures that are required by law or the Nasdaq rules concerning any amendments to, or waivers from,
any provision of the code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations
on Liability and Indemnification Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation, as amended (&ldquo;Certificate of Incorporation&rdquo;) and Bylaws contain provisions that limit the liability
of our current and former directors for monetary damages to the fullest extent permitted by Delaware law. Delaware law provides that
directors of a corporation will not be personally liable for monetary damages for any breach of fiduciary duties as directors, except
liability for:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    breach of the director&rsquo;s duty of loyalty to the corporation or its stockholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unlawful
    payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation
    Law; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    transaction from which the director derived an improper personal benefit.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the availability of equitable
remedies such as injunctive relief or rescission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and Bylaws provide that we are authorized to indemnify our directors and officers to the fullest extent
permitted by Delaware law. Our Bylaws also provide that we may advance expenses incurred by a director or executive officer in advance
of the final disposition of any action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee
or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted
to indemnify him or her under the provisions of Delaware law. Our Bylaws also provide our board of directors with discretion to indemnify
our employees when determined appropriate by our board of directors. We expect to enter into agreements to indemnify our directors, executive
officers and other employees as determined by the board of directors. With certain exceptions, we anticipate that these agreements
will provide for indemnification for related expenses, including, among other things, attorneys&rsquo; fees, judgments, fines and settlement
amounts incurred by any of these individuals in any action or proceeding. We believe that these provisions and agreements are necessary
to attract and retain qualified persons as directors and officers. We also intend to maintain obtain customary directors&rsquo; and officers&rsquo;
liability insurance upon consummation of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
limitation of liability and indemnification provisions in our Certificate of Incorporation and Bylaws may discourage stockholders from
bringing a lawsuit against our directors for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation
against our directors and officers, even though an action, if successful, might benefit us and other stockholders. Further, a stockholder&rsquo;s
investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers
as required by these indemnification provisions. At present, there is no pending litigation or proceeding involving any of our directors,
officers or employees for which indemnification is sought, and we are not aware of any threatened litigation that may result in claims
for indemnification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aR_002"></A>EXECUTIVE
AND DIRECTOR COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
Compensation Table</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the compensation awarded to, earned by or paid to our principal executive officer, who we also refer to as our
&ldquo;named executive officer&rdquo;, for the year ended December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name and Principal Position</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option<BR> awards<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left">Randy Milby, President and</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 9%; text-align: center">2020</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">193,627</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">193,627</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer<B><SUP>(1)(2)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    fiscal year 2020, in lieu of base salary, Mr. Milby was compensated with stock options to purchase 200,000 shares of common stock
    per month.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    the aggregate grant date fair value of stock options granted during the fiscal year calculated in accordance with FASB ASC Topic
    718. For a discussion of the assumptions made by us in determining the grant date fair value of our equity awards see Note 6 to our
    audited consolidated financial statements for the year ended December 31, 2020 included elsewhere in this prospectus.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employment
Agreements</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Employment
Agreement with Randy Milby</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2019, we entered into an employment agreement (&ldquo;Employment Agreement&rdquo;) with Randy Milby, to serve as our President
and Chief Executive Officer. Pursuant to the Employment Agreement, Mr. Milby with receive an annual base salary of $200,000. Mr. Milby
is also eligible to receive an annual target bonus of up to 100% of the Base salary, subject to the achievements to be mutually
agreed upon by the Board and Mr. Milby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2020, we amended the Employment Agreement
pursuant to which instead of a cash base salary, the Mr. Milby will be compensated with stock options to purchase
200,000 shares of common stock per month (at an exercise price based upon the most recent 409A valuation) per year effective January
1, 2020 until we receive a minimum of $3,000,000 of gross proceeds from the sale of the Company&rsquo;s securities, after which time,
cash compensation, pursuant to the Employment Agreement, shall be paid. In addition, if Mr. Milby raises more than $3,000,000, he will
receive a grant of options to purchase up to 20,000,000 shares of our common stock at an exercise price of $0.007.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective January 1, 2021, we further amended
the Employment Agreement with our Chief Executive Officer to provide a revised base salary pre-funding (as defined in the Employment
Agreement). In lieu of base salary, Mr. Milby will be compensated with stock options to purchase 500,000 shares of our common stock per
month at an exercise price of $0.2963 per share effective January 1, 2021 until funding meets or exceeds $5,000,000, after which time,
cash compensation, pursuant to the Employment Agreement, shall be paid. The amendment also provides for a future base salary after we
receive funding greater than $5,000,000, or we complete an initial public offering or similar transaction, as defined. In addition, if
Mr. Milby raises more than $5,000,000, he will receive a grant of stock options to acquire 20,000,000 shares of our common stock with
an exercise price based upon the most recent 409A valuation if the $5,000,000 is raised in a private transaction and an exercise price
equal to the initial public offering price if the $5,000,000 is raised in a public transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding
Equity Awards at December 31, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning outstanding equity awards held by our named executive officers as of December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">OPTION AWARDS</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Name</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Securities<BR> Underlying Unexercised<BR> Options (#) Exercisable</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Securities<BR> Underlying Unexercised<BR> Options (#) Unexercisable</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity Incentive <BR> Plan Awards:<BR> Number of Securities<BR> Underlying Unexercised<BR> Unearned Options (#)</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option<BR> Exercise<BR> Price ($)</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option<BR> Expiration<BR> Date</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 16%; font-weight: bold; text-align: left">Randy Milby</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">350,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000</FONT></TD><TD STYLE="width: 1%; text-align: left">(1)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.5000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 11%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/20/2023</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">206,875</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">83,125</FONT></TD><TD STYLE="text-align: left">(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.5000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/20/2023</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">515,625</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">484,375</FONT></TD><TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0030</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/31/2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000,000</FONT></TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0030</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/30/2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,219</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,781</FONT></TD><TD STYLE="text-align: left">(5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.1000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/17/2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,219</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,781</FONT></TD><TD STYLE="text-align: left">(6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.1000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/19/2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,719</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,281</FONT></TD><TD STYLE="text-align: left">(7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.1000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/05/2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">126,042</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73,958</FONT></TD><TD STYLE="text-align: left">(8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.1000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/13/2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">437,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">562,500</FONT></TD><TD STYLE="text-align: left">(9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.1000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/31/2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0119</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/31/2030</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0119</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">02/29/2030</TD><TD STYLE="text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0119</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/31/2030</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0119</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/30/2030</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0119</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/31/2030</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0119</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/30/2030</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0119</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/31/2030</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0119</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/31/2030</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0119</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/30/2030</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.1446</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/31/2030</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.1446</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/12/2030</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.1446</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/12/2030</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.1446</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/30/2030</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.1446</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/31/2030</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000
    of the options shall vest on the one year anniversary of the vesting staring date (June 20, 2018), with the remaining 400,000 of
    the options shall vest over period of 48 equal monthly installments.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000
    of the options shall vest on the one year anniversary of the vesting staring date (September 20, 2018), with the remaining 190,000
    of the options shall vest over period of 48 equal monthly installments.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%
    of the options shall vest on the one year anniversary of the vesting staring date (July 31, 2019), with the remaining 750,000 of
    the options shall vest over period of 48 equal monthly installments.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    of the options shall vest on the completion of an Initial Public Offering (&ldquo;IPO&rdquo;) or a public listing via reverse merger
    with a public company.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%
    of the options shall vest on the one year anniversary of the vesting staring date (September 17, 2019), with the remaining 37,500
    of the options shall vest over period of 48 equal monthly installments.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%
    of the options shall vest on the one year anniversary of the vesting staring date (September 19, 2019), with the remaining 37,500
    of the options shall vest over period of 48 equal monthly installments.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%
    of the options shall vest on the one year anniversary of the vesting staring date (November 5, 2019), with the remaining 18,750 of
    the options shall vest over period of 48 equal monthly installments.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000
    of the options shall vest on the one year anniversary of the vesting staring date (December 13, 2019), with the remaining 100,000
    of the options shall vest over period of 48 equal monthly installments.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%
    of the options shall vest on the one year anniversary of the vesting staring date (December 31, 2019), with the remaining 750,000
    of the options shall vest over period of 48 equal monthly installments.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2017
Stock Incentive Plan</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors and our stockholders approved the 2017 Stock Incentive Plan on March 30, 2017, under which we may grant equity incentive
awards in order to attract, motivate and retain the talent who are expected to make important contributions to the Company. The material
terms of the 2017 Plan are summarized below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Administration
of the Plan: </I></B>The Plan is administered by the Board of Directors (the &ldquo;Board&rdquo;). The Board may delegate any or all
of its powers under the Plan to one or more committees or subcommittees of the Board (a &ldquo;Committee&rdquo;). All references in the
Plan to the &ldquo;Board&rdquo; shall mean the Board or a Committee of the Board to the extent that the Board&rsquo;s powers or authority
under the Plan have been delegated to such Committee. The Board shall have authority to grant Awards and to adopt, amend and repeal such
administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Board may correct any defect, supply
any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem expedient to carry
the Plan into effect and it shall be the sole and final judge of such expediency. All decisions by the Board shall be made in the Board&rsquo;s
sole discretion and shall be final and binding on all persons having or claiming any interest in the Plan or in any Award. No director
or person acting pursuant to the authority delegated by the Board shall be liable for any action or determination relating to or under
the Plan made in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Eligibility
Participants: </I></B>The Plan authorizes the grant of stock options, restricted stock, restricted stock units and/or other stock-based
awards to employees, officers, directors, individual consultants and advisors of the Company. The Board determines, in its sole discretion,
who will receive awards under the Plan. Notwithstanding anything in the Plan or any Award documentation to the contrary, for so long
as the Company has elected Subchapter S status under Section 1362 of the Internal Revenue Code of 1986, as amended, no Award shall be
granted or exercised, as the case may be, if the result of such grant or exercise would result in the termination of such Subchapter
S status, unless such grant or exercise, as the case may be, is consented to by all stockholders of the Company. Any such purported grant
or exercise of an Award that does not comply with the foregoing shall be void and have no legal force or effect and shall not be recognized
on the books of the Company as effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Shares
Available Under the Plan: </I></B>The maximum number of shares of common stock that may be delivered to participants under the Plan is
2,500,000, subject to adjustment for certain corporate changes affecting the shares, such as stock splits. Shares subject to an award
under the Plan for which the award is canceled, forfeited or expires again become available for grants under the Plan. Shares subject
to an award that is settled in cash will not again be made available for grants under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Options:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General:
</I>The Board has the authority to grant options to purchase Common Stock and determine the number of shares of Common Stock to be covered
by each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise of each Option, including
conditions relating to applicable federal or state securities laws, as it considers necessary or advisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exercise
of Options:</I> An option may be exercised only in accordance with the terms and conditions for the option agreement as established by
the board or committee at the time of the grant. The option must be exercised by notice to us, accompanied by payment of the exercise
price. Payments may be made in cash or, at the option of the board or committee, by actual or constructive delivery of shares of common
stock to the holder of the option based upon the fair market value of the shares on the date of exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Expiration
or Termination</I>: Options, if not previously exercised, will expire on the expiration date established by the board or committee at
the time of grant; provided that such term cannot exceed ten years and that such term of an incentive stock option granted to a holder
of more than 10% of our voting stock cannot exceed five years. Options will terminate before the expiration date to the extend the vested
portion of the option is not exercised within 3 months of the termination date if the holder&rsquo;s service with us terminates before
the expiration date. The option may remain exercisable for specified periods after certain terminations of service, including terminations
as a result of death, disability or retirement, with the precise period during which the option may be exercised to be established by
the board or committee and reflected in the grant evidencing the award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Restricted
Shares and RSUs:</B> Eligible participants may be awarded grants of Restricted Stock Units, which represent the right to receive shares
of the Common Stock to be delivered when the Common Stock vests. The holders of Restricted Stock Units will have none of the rights of
a stockholder of the Company until such time or times as shares of the Common Stock have been issued to participant in settlement of
the award. The Board shall determine the participants to whom and the time or times at which grants of Restricted Stock Units shall be
awarded, the number of units to be awarded to any participant, the conditions for vesting, the time or times within which such awards
may be subject to forfeiture and restrictions on transfer and other terms and conditions of the awards. Each Restricted Stock Unit shall
at all times be equal in value to the fair market value of one share of the common stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Stock-Based Awards:</B> The plan administrator may grant or sell other awards that may be denominated or payable in, valued in whole
or in part by reference to, or otherwise based on or related to, common stock or factors that may influence the value of such shares.
In addition, the plan administrator may grant unrestricted shares to eligible participants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Material Provisions:</B> Awards will be evidenced by a written agreement, in such form as may be approved by the board or committee.
In the event of various changes to the capitalization of our company, such as stock splits, stock dividends and similar re-capitalizations,
an appropriate adjustment will be made by the board or committee to the number of shares covered by outstanding awards or to the exercise
price of such awards. The board or committee is also permitted to include in the written agreement provisions that provide for certain
changes in the award in the event of a change of control of our company, including acceleration of vesting. Except as otherwise determined
by the board or committee at the date of grant, awards will not be transferable, other than by will or the laws of descent and distribution.
Prior to any award distribution, we are permitted to deduct or withhold amounts sufficient to satisfy any employee withholding tax requirements.
The board also has the authority, at any time, to discontinue the granting of awards. The board also has the authority to alter or amend
the Plan or any outstanding award or may terminate the Plan as to further grants, provided that no amendment will, without the approval
of our stockholders, increase the number of shares available under the Plan or change the persons eligible for awards under the Plan.
No amendment that would adversely affect any outstanding award made under the Plan can be made without the consent of the holder of such
award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2019
Stock Incentive Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors and our stockholders approved the 2019 Stock Incentive Plan on July 24, 2019, under which we may grant equity incentive
awards in order to attract, motivate and retain the talent who are expected to make important contributions to the Company. The material
terms of the 2019 Plan are summarized below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Administration
of the Plan: </I></B>The Plan is administered by the Board of Directors (the &ldquo;Board&rdquo;). The Board may delegate any or all
of its powers under the Plan to one or more committees or subcommittees of the Board (a &ldquo;Committee&rdquo;). All references in the
Plan to the &ldquo;Board&rdquo; shall mean the Board or a Committee of the Board to the extent that the Board&rsquo;s powers or authority
under the Plan have been delegated to such Committee. The Board shall have authority to grant Awards and to adopt, amend and repeal such
administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Board may correct any defect, supply
any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem expedient to carry
the Plan into effect and it shall be the sole and final judge of such expediency. All decisions by the Board shall be made in the Board&rsquo;s
sole discretion and shall be final and binding on all persons having or claiming any interest in the Plan or in any Award. No director
or person acting pursuant to the authority delegated by the Board shall be liable for any action or determination relating to or under
the Plan made in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Eligibility
Participants: </I></B>The Plan authorizes the grant of stock options, restricted stock, restricted stock units and/or other stock-based
awards to employees, officers, directors, individual consultants and advisors of the Company. The Board determines, in its sole discretion,
who will receive awards under the Plan. Notwithstanding anything in the Plan or any Award documentation to the contrary, for so long
as the Company has elected Subchapter S status under Section 1362 of the Internal Revenue Code of 1986, as amended, no Award shall be
granted or exercised, as the case may be, if the result of such grant or exercise would result in the termination of such Subchapter
S status, unless such grant or exercise, as the case may be, is consented to by all stockholders of the Company. Any such purported grant
or exercise of an Award that does not comply with the foregoing shall be void and have no legal force or effect and shall not be recognized
on the books of the Company as effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Shares
Available Under the Plan: </I></B>The maximum number of shares of common stock that may be delivered to participants under the Plan is
90,666,666, subject to adjustment for certain corporate changes affecting the shares, such as stock splits. Shares subject to an award
under the Plan for which the award is canceled, forfeited or expires again become available for grants under the Plan. Shares subject
to an award that is settled in cash will not again be made available for grants under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Options:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General:
</I>The Board has the authority to grant options to purchase Common Stock and determine the number of shares of Common Stock to be covered
by each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise of each Option, including
conditions relating to applicable federal or state securities laws, as it considers necessary or advisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exercise
of Options:</I> An option may be exercised only in accordance with the terms and conditions for the option agreement as established by
the board or committee at the time of the grant. The option must be exercised by notice to us, accompanied by payment of the exercise
price. Payments may be made in cash or, at the option of the board or committee, by actual or constructive delivery of shares of common
stock to the holder of the option based upon the fair market value of the shares on the date of exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Expiration
or Termination</I>: Options, if not previously exercised, will expire on the expiration date established by the board or committee at
the time of grant; provided that such term cannot exceed ten years and that such term of an incentive stock option granted to a holder
of more than 10% of our voting stock cannot exceed five years. Options will terminate before the expiration date to the extend the vested
portion of the option is not exercised within 3 months of the termination date if the holder&rsquo;s service with us terminates before
the expiration date. The option may remain exercisable for specified periods after certain terminations of service, including terminations
as a result of death, disability or retirement, with the precise period during which the option may be exercised to be established by
the board or committee and reflected in the grant evidencing the award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Restricted
Shares and RSUs:</B> Eligible participants may be awarded grants of Restricted Stock Units, which represent the right to receive shares
of the Common Stock to be delivered when the Common Stock vests. The holders of Restricted Stock Units will have none of the rights of
a stockholder of the Company until such time or times as shares of the Common Stock have been issued to participant in settlement of
the award. The Board shall determine the participants to whom and the time or times at which grants of Restricted Stock Units shall be
awarded, the number of units to be awarded to any participant, the conditions for vesting, the time or times within which such awards
may be subject to forfeiture and restrictions on transfer and other terms and conditions of the awards. Each Restricted Stock Unit shall
at all times be equal in value to the fair market value of one share of the common stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Stock-Based Awards:</B> The plan administrator may grant or sell other awards that may be denominated or payable in, valued in whole
or in part by reference to, or otherwise based on or related to, common stock or factors that may influence the value of such shares.
In addition, the plan administrator may grant unrestricted shares to eligible participants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Material Provisions:</B> Awards will be evidenced by a written agreement, in such form as may be approved by the board or committee.
In the event of various changes to the capitalization of our company, such as stock splits, stock dividends and similar re-capitalizations,
an appropriate adjustment will be made by the board or committee to the number of shares covered by outstanding awards or to the exercise
price of such awards. The board or committee is also permitted to include in the written agreement provisions that provide for certain
changes in the award in the event of a change of control of our company, including acceleration of vesting. Except as otherwise determined
by the board or committee at the date of grant, awards will not be transferable, other than by will or the laws of descent and distribution.
Prior to any award distribution, we are permitted to deduct or withhold amounts sufficient to satisfy any employee withholding tax requirements.
The board also has the authority, at any time, to discontinue the granting of awards. The board also has the authority to alter or amend
the Plan or any outstanding award or may terminate the Plan as to further grants, provided that no amendment will, without the approval
of our stockholders, increase the number of shares available under the Plan or change the persons eligible for awards under the Plan.
No amendment that would adversely affect any outstanding award made under the Plan can be made without the consent of the holder of such
award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="aR_003"></A><B>CERTAIN
RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following includes a summary of transactions during our fiscal years ended December 31, 2020 and December 31, 2019 to which
we have been a party, including transactions in which the amount involved in the transaction exceeds the lesser of $120,000 or 1% of
the average of our total assets at year-end for the last two completed fiscal years, and in which any of our directors, executive officers
or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing
persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control
and other arrangements, which are described elsewhere in this prospectus. We are not otherwise a party to a related party transaction,
and no transaction is currently proposed, in which the amount of the transaction exceeds the lesser of $120,000 or 1% of the average
of our total assets at year-end for the last two completed fiscal years and in which a related person had or will have a direct or indirect
material interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Convertible Promissory Notes<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Commencing in May 2017, we entered into Subordinated
Convertible Promissory Note Agreements with our Chief Executive Officer for the aggregate principal amount of $2,116,944. The Convertible
Promissory Notes accrued interest at a rate of 5% per annum. Unless earlier converted into shares of Equity Securities (defined as the
Company&rsquo;s common stock or preferred stock), the principal and accrued interest shall be due and payable by the Company on demand
by the Holders at any time after the earlier of (i) the Maturity Date (as defined in each Agreement) and (ii) the closing of the Next
Equity Financing (defined as the next sale (or series of related sales) by the Company of its Equity Securities from which the Company
receives gross proceeds of not less than $5,000,000 for notes entered into in 2017 and through November 2020 and $7,500,000 for notes
entered into in December 2020 (including the aggregate amount of debt securities converted into Equity Securities upon conversion or
cancellation of promissory notes).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 27, 2020, we agreed to
provide a related party Noteholder &ldquo;Exchange Notes&rdquo; in exchange for seven notes payable which were in default
(&ldquo;Original Notes&rdquo;) at such time by more than 90 days. The Original Notes had a principal of approximately $265,000 and
accrued interest of $37,000 at December 31, 2019. As of September 27, 2020, the aggregate outstanding principal was approximately
$265,000 and accrued interest (which included the default interest rate of 20% as described above) was approximately $71,000. The
Exchanged Notes took the then principal and accrued interest of the Original Notes and added an original issue discount of 37.5% to
determine the new principal (which amounted to an aggregate of $537,968) of the Exchange Notes outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective October 1, 2020, all notes which matured,
and were not repaid or converted, were rolled over on substantially the same terms as the original notes with a new two year term. Effective
December 1, 2020, all notes which matured, and were not repaid or converted, were rolled over on substantially the same terms as the
original notes with a new three year term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Payments to the Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2020 and 2019, we owed our
Chief Executive Officer $200,000 and $255,068, respectively. The expenses were comprised of expenses paid by the Chief Executive Officer
on behalf of our Company of $55,068 (which was converted into a convertible promissory note in 2020) and $200,000 for accrued compensation
at December 31, 2019. At December 31, 2020, the balance comprised $200,000 for accrued compensation.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Related
Person Transaction Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, we have not had a formal policy regarding approval of transactions with related parties. Upon consummation of this
offering, we shall adopt a related person transaction policy that sets forth our procedures for the identification, review, consideration
and approval or ratification of related person transactions. The policy will become effective immediately upon the execution of the underwriting
agreement for this offering. For purposes of our policy only, a related person transaction is a transaction, arrangement or relationship,
or any series of similar transactions, arrangements or relationships, in which we and any related person are, were or will be participants
in which the amount involved exceeds the lesser of $120,000 or 1% of the average of our total assets at year-end. Transactions involving
compensation for services provided to us as an employee or director are not covered by this policy. A related person is any executive
officer, director or beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family
members and any entity owned or controlled by such persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the policy, if a transaction has been identified as a related person transaction, including any transaction that was not a related person
transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to
consummation, our management must present information regarding the related person transaction to our audit committee, or, if audit committee
approval would be inappropriate, to another independent body of our board of directors, for review, consideration and approval or ratification.
The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related
persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to
or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information
that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant stockholder to enable
us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition, under our
code of business conduct and ethics, our employees and directors will have an affirmative responsibility to disclose any transaction
or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related person transactions,
our audit committee, or other independent body of our board of directors, will take into account the relevant available facts and circumstances
including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risks, costs and benefits to us;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact on a director&rsquo;s independence in the event that the related person is a director, immediate family member of a director
    or an entity with which a director is affiliated;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of other sources for comparable services or products; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms available to or from, as the case may be, unrelated third parties or to or from employees generally.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
policy requires that, in determining whether to approve, ratify or reject a related person transaction, our audit committee, or other
independent body of our board of directors, must consider, in light of known circumstances, whether the transaction is in, or is not
inconsistent with, our best interests and those of our stockholders, as our audit committee, or other independent body of our board of
directors, determines in the good faith exercise of its discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="aR_004"></A><B>PRINCIPAL
STOCKHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information regarding the beneficial ownership of our common stock as of May 11, 2021 by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our named executive officers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    of our current directors and named executive officers as a group; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    stockholder known by us to own beneficially more than 5% of our common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the
securities. Shares of common stock that may be acquired by an individual or group within 60 days of May 11, 2021, pursuant to the
exercise of options or warrants, vesting of common stock or conversion of convertible debt, are deemed to be outstanding for the
purpose of computing the percentage ownership of such individual or group, but are not deemed to be outstanding for the purpose of
computing the percentage ownership of any other person shown in the table. Percentage of ownership is based on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock issued and outstanding as of May 11, 2021 assuming the conversion of all outstanding convertible
notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
noted otherwise, the address of all listed stockholders is c/o Hillstream BioPharma, Inc., 1200 Route 22 East, Suite 200, Bridgewater,
NJ 08807.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as indicated by the footnotes below, we believe, based on information furnished to us, that each of the stockholders listed has sole
voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community
property laws where applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of Shares<BR> Beneficially Owned</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage of Common<BR> Stock Beneficially Owned</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name of Beneficial Owner</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Prior to <BR> Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Before<BR> Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">After<BR> Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Directors and Named Executive Officers:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%; text-align: left">Randy Milby</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">All current named executive officers and directors as a group (1 person)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">5% or Greater Stockholders:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Highpoint Pharmaceuticals LLC (1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Kufe LLC (2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Donald Kufe</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Surender Kharbanda</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Varinder Kaur</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Bearing Circle Capital LLC (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Escape Investment LLC (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sireesh
    Appajosyula</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> is the Managing Member of Highpoint Pharmaceuticals
    LLC and in such capacity has the right to vote and dispose of the securities held by such entity. The address of Highpoint
    Pharmaceuticals LLC is 16192 Coastal Highway Lewes, DE 19958.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Donald
    W. Kufe is the Managing Director of Kufe LLC and in such capacity has the right to vote and dispose of the securities held by such
    entity. The address of Kufe LLC is 179 Grove Street, Wellesley, MA 02482.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandeep
Laumas is the Managing Member of Bearing Circle Capital LLC and in such capacity has the right to vote and dispose of the securities
held by such entity.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Veronica
    Todd</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> is the Managing Member of Escape Investment LLC and in such
    capacity has the right to vote and dispose of the securities held by such entity. The address of Escape Investment LLC
    is 245 Main Street, Suite 204, Chester, NJ 07930.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="aR_005"></A><B>DESCRIPTION
OF CAPITAL STOCK</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of this offering, our authorized capital stock will consist of 250,000,000 shares of common stock, par value $0.0001
per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 11, 2021, there were 9 record holders of our securities. As of May 11, 2021 there were 167,883,334 shares of common stock issued
and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following description of our capital stock and
provisions of our Certificate of Incorporation and to be effective upon the completion of this offering is only a summary. You should
also refer to our Certificate of Incorporation and Bylaws, copies of which are filed as an exhibit to the registration
statement of which this prospectus is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are authorized to issue up to a total of 250,000,000 shares of common stock, par value $0.0001 per share. Holders of our
common stock are entitled to one vote for each share held on all matters submitted to a vote of our stockholders. Holders of our common
stock have no cumulative voting rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
holders of our common stock have no preemptive or conversion rights or other subscription rights. Upon our liquidation, dissolution or
winding-up, holders of our common stock are entitled to share in all assets remaining after payment of all liabilities and the liquidation
preferences of any of our outstanding shares of preferred stock. Subject to preferences that may be applicable to any outstanding shares
of preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our
board of directors out of our assets which are legally available. Each outstanding share of our common stock is, and all shares of common
stock to be issued in this offering when they are paid for will be, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of a majority of the shares of our capital stock, represented in person or by proxy, are necessary to constitute a quorum for
the transaction of business at any meeting. If a quorum is present, an action by stockholders entitled to vote on a matter is approved
if the number of votes cast in favor of the action exceeds the number of votes cast in opposition to the action, with the exception of
the election of directors, which requires a plurality of the votes cast.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors will have the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred
stock in one or more series and to fix the designations, powers, preferences, privileges, and relative participating, optional, or special
rights as well as the qualifications, limitations, or restrictions of the preferred stock, including dividend rights, conversion rights,
voting rights, terms of redemption, and liquidation preferences, any or all of which may be greater than the rights of the common stock.
Our board of directors, without stockholder approval, will be able to issue convertible preferred stock with voting, conversion, or other
rights that could adversely affect the voting power and other rights of the holders of common stock. Preferred stock could be issued
quickly with terms calculated to delay or prevent a change of control or make removal of management more difficult. Additionally, the
issuance of preferred stock may have the effect of decreasing the market price of our common stock, and may adversely affect the voting
and other rights of the holders of common stock. At present, we have no plans to issue any shares of preferred stock following this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Options</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our 2017 and 2019 Stock Incentive Plans provide
for us to sell or issue shares of common stock or restricted shares of common stock, or to grant incentive stock options or nonqualified
stock options, SARs and RSU awards for the purchase of shares of common stock to certain service providers. As of May 11, 2021,
options to purchase 50,666,666 shares of our common stock were issued and outstanding. For additional information
regarding the terms of our plans, see &ldquo;Executive and Director Compensation&mdash;2017 Stock Incentive Plan and &ndash;
2019 Stock Incentive Plan&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exclusive
Forum</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Certificate of Incorporation provides
that unless we consent in writing to the selection of an alternative forum, the State of Delaware is the sole and exclusive forum for:
(i) any derivative action or proceeding brought on behalf of us, (ii) any action asserting a claim of breach of a fiduciary duty owed
by any director, officer or other employee of our Company to us or our stockholders, (iii) any action asserting a claim against us, our
directors, officers or employees arising pursuant to any provision of the DGCL or our Certificate of Incorporation or our Bylaws or (iv)
any action asserting a claim against us, our directors, officers, employees or agents governed by the internal affairs doctrine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the
exclusive forum for the resolution of any complaint asserting a cause of action arising under the Exchange Act or Securities Act. Any
person or entity purchasing or otherwise acquiring any interest in shares of our capital stock are deemed to have notice of and consented
to this provision</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Provisions of Delaware Law, our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Delaware
Law</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are governed by the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a publicly traded Delaware corporation from
engaging in a business combination with an interested stockholder for a period of three years after the date of the transaction in which
the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A business combination
includes mergers, asset sales or other transactions resulting in a financial benefit to the stockholder. An interested stockholder is
a person who, together with affiliates and associates, owns (or within three years, did own) 15% or more of the corporation&rsquo;s voting
stock, subject to certain exceptions. The statute could have the effect of delaying, deferring or preventing a change in control of our
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Board
of Directors Vacancies</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Bylaws authorize our board of directors
to fill vacant directorships. In addition, the number of directors constituting our board of directors may be set by resolution of the
incumbent directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Special Meeting of Stockholders</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Bylaws provide that special meetings of our stockholders
may be called by the chairman of the board of directors, the Chief Executive Officer, the secretary or any two directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Advance Notice Requirements for Stockholder
Proposals and Director Nominations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Bylaws provide that stockholders seeking
to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at our annual meeting
of stockholders, must provide timely notice of their intent in writing. To be timely, a stockholder&rsquo;s notice must be delivered
to the secretary at our principal executive offices not later than the close of business on the 60th day nor earlier than the
close of business on the 90th day prior to the first anniversary of the preceding year&rsquo;s annual meeting; provided, however,
that in the event the date of the annual meeting is more than 30 days before or more than 60 days after such anniversary date, or if
no annual meeting was held in the preceding year, notice by the stockholder to be timely must be so delivered not earlier than the close
of business on the 90th day prior to such annual meeting and not later than the close of business on the later of the 600th
day prior to such annual meeting or the 10th day following the day on which a public announcement of the date of such meeting is
first made by us. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from
making nominations for directors at our annual meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Authorized but Unissued Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our authorized but unissued shares of common stock
and preferred stock are available for future issuance without stockholder approval and may be utilized for a variety of corporate purposes,
including future public offerings to raise additional capital, corporate acquisitions and employee benefit plans. The existence of authorized
but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain control of
us by means of a proxy contest, tender offer, merger or otherwise. If we issue such shares without stockholder approval and in violation
of limitations imposed by The Nasdaq Capital Market or any stock exchange on which our stock may then be trading, our stock could be delisted.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Transfer
Agent and Registrar</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our common stock is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Market Listing</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to apply to have our shares of common stock listed for trading on The Nasdaq Capital Market under the symbol &ldquo;HILS.&rdquo;
No assurance can be given that such listing will be approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aR_006"></A>SHARES
ELIGIBLE FOR FUTURE SALE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there has been no public market for our common stock, and a liquid trading market for our common stock may not develop
or be sustained after this offering. Future sales of substantial amounts of our common stock in the public market, or the anticipation
of these sales, could materially and adversely affect market prices prevailing from time to time, and could impair our ability to raise
capital through sales of equity or equity-related securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
a limited number of shares of our common stock will be available for sale in the public market for a period of several months after completion
of this offering due to contractual and legal restrictions on resale described below. Nevertheless, sales of a substantial number of
shares of our common stock in the public market after such restrictions lapse, or the perception that those sales may occur, could materially
and adversely affect the prevailing market price of our common stock. Although we have applied to list our common stock on The Nasdaq
Capital Market, we cannot assure you that there will be an active market for our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the shares to be outstanding immediately after the completion of this offering, we expect that the shares to be sold in this offering
and the shares of common stock sold by the selling stockholders will be freely tradable without restriction under the Securities Act
unless purchased by our &ldquo;affiliates,&rdquo; as that term is defined in Rule 144 under the Securities Act. Certain of the remaining
shares of our common stock outstanding after this offering will be subject to a -day lock-up period under the lock-up agreements as described
below. These restricted securities may be sold in the public market only if registered or pursuant to an exemption from registration,
such as Rule 144 or Rule 701 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
144</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Affiliate
Resales of Restricted Securities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Affiliates
of ours must generally comply with Rule 144 if they wish to sell any shares of our common stock in the public market, whether or not
those shares are &ldquo;restricted securities.&rdquo; &ldquo;Restricted securities&rdquo; are any securities acquired from us or one
of our affiliates in a transaction not involving a public offering. All shares of our common stock issued prior to the closing of the
offering made hereby, are considered to be restricted securities. The shares of our common stock sold in this offering are not considered
to be restricted securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Non-Affiliate
Resales of Restricted Securities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
person or entity who is not an affiliate of ours and who has not been an affiliate of ours at any time during the three months preceding
a sale is only required to comply with Rule 144 in connection with sales of restricted shares of our common stock. Subject to the lock-up
agreements described below, those persons may sell shares of our common stock that they have beneficially owned for at least one year
without any restrictions under Rule 144 immediately following the effective date of the registration statement of which this prospectus
is a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is not an affiliate
of ours at the time such person sells shares of our common stock, and has not been an affiliate of ours at any time during the three
months preceding such sale, and who has beneficially owned such shares of our common stock for at least six months but less than a year,
is entitled to sell such shares so long as there is adequate current public information, as defined in Rule 144, available about us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resales
of restricted shares of our common stock by non-affiliates are not subject to the manner of sale, volume limitation or notice filing
provisions of Rule 144, described above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
701</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
701 generally allows a stockholder who purchased shares of our common stock pursuant to a written compensatory plan or contract and who
is not deemed to have been an affiliate of ours during the immediately preceding 90 days to sell these shares in reliance upon Rule 144,
but without being required to comply with the public information, holding period, volume limitation, or notice provisions of Rule 144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
701 also permits affiliates of ours to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements
of Rule 144. All holders of Rule 701 shares, however, are required to wait until 90 days after the date of this prospectus before selling
such shares pursuant to Rule 701 and until expiration of the -day lock-up period described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity
Incentive Awards</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to file a registration statement on Form S-8 under the Securities Act after the closing of this offering to register the shares
of common stock that are issuable pursuant to our 2014 Plan. The registration statement is expected to be filed and become effective
as soon as practicable after the completion of this offering. Accordingly, shares registered under the registration statement will be
available for sale in the open market following its effective date, subject to Rule 144 volume limitations and the lock-up arrangement
described above, if applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, each of our directors and executive officers, and our stockholders, have agreed, subject to certain limited exceptions, not
to offer, pledge, sell, contract to sell, grant any option to purchase, or otherwise dispose of our common stock or any securities convertible
into or exchangeable or exercisable for common stock, or to enter into any hedge or other arrangement or any transaction that transfers,
directly or indirectly, the economic consequence of ownership of the shares of our common stock, in the case of the Company and our stockholders
for a period of 180 days after the date of this prospectus, and in the case of our directors and executive officers for a period of 365
days after the date of this prospectus, without the prior written consent of &nbsp;&nbsp;&nbsp;, as representative of the underwriters. See &ldquo;Underwriting&mdash;Lock-up
Agreements.&rdquo; The underwriters do not have any present intention or arrangement to release any shares of our common stock subject
to lock-up agreements prior to the expiration of the 180- or 365-day lock-up period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aR_007"></A>MATERIAL
U.S. FEDERAL INCOME TAX CONSEQUENCES TO<BR>
NON-U.S. HOLDERS OF OUR COMMON STOCK</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the material U.S. federal income tax consequences to non-U.S. holders (as defined below) of the ownership and
disposition of our common stock but does not purport to be a complete analysis of all the potential tax considerations relating thereto.
This summary is based upon the provisions of the Internal Revenue Code Treasury regulations promulgated thereunder, administrative rulings
and judicial decisions, all as of the date hereof. These authorities may be changed, possibly retroactively, so as to result in U.S.
federal income tax consequences different from those set forth below. No ruling on the U.S. federal, state, or local tax considerations
relevant to our operations or to the purchase, ownership or disposition of our shares, has been requested from the IRS or other tax authority.
No assurance can be given that the IRS would not assert, or that a court would not sustain, a position contrary to any of the tax consequences
described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary also does not address the tax considerations arising under the laws of any non-U.S., state or local jurisdiction, or under U.S.
federal gift and estate tax laws, except to the limited extent set forth below. In addition, this discussion does not address tax considerations
applicable to an investor&rsquo;s particular circumstances or to investors that may be subject to special tax rules, including, without
limitation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks,
    insurance companies or other financial institutions, regulated investment companies or real estate investment trusts;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    subject to the alternative minimum tax or Medicare contribution tax on net investment income;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt
    organizations or governmental organizations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">controlled
    foreign corporations, passive foreign investment companies and corporations that accumulate earnings to avoid U.S. federal income
    tax;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">brokers
    or dealers in securities or currencies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">traders
    in securities that elect to use a mark-to-market method of accounting for their securities holdings;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    that own, or are deemed to own, more than five percent of our capital stock (except to the extent specifically set forth below);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
    expatriates and certain former citizens or long-term residents of the U.S.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">partnerships
    or entities classified as partnerships for U.S. federal income tax purposes or other pass-through entities (and investors therein);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    who hold our common stock as a position in a hedging transaction, &ldquo;straddle,&rdquo; &ldquo;conversion transaction&rdquo; or
    other risk reduction transaction or integrated investment;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as compensation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    who do not hold our common stock as a capital asset within the meaning of Section 1221 of the Internal Revenue Code; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    deemed to sell our common stock under the constructive sale provisions of the Internal Revenue Code.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
are urged to consult your tax advisor with respect to the application of the U.S. federal income tax laws to your particular situation,
as well as any tax consequences of the purchase, ownership and disposition of our common stock arising under the U.S. federal estate
or gift tax rules or under the laws of any state, local, non-U.S., or other taxing jurisdiction or under any applicable tax treaty.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Non-U.S.
Holder Defined</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this discussion, you are a non-U.S. holder (other than a partnership) if you are any holder other than:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    individual citizen or resident of the U.S. (for U.S. federal income tax purposes);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    corporation or other entity taxable as a corporation created or organized in the U.S. or under the laws of the U.S., any state thereof,
    or the District of Columbia, or other entity treated as such for U.S. federal income tax purposes;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    estate whose income is subject to U.S. federal income tax regardless of its source; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    trust (x) whose administration is subject to the primary supervision of a U.S. court and which has one or more &ldquo;U.S. persons&rdquo;
    (within the meaning of Section 7701(a)(30) of the Internal Revenue Code) who have the authority to control all substantial decisions
    of the trust or (y) which has made a valid election to be treated as a U.S. person.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if a partnership or entity classified as a partnership for U.S. federal income tax purposes holds our common stock, the tax
treatment of a partner generally will depend on the status of the partner and upon the activities of the partnership. Accordingly, partnerships
that hold our common stock, and partners in such partnerships, should consult their tax advisors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Distributions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in &ldquo;Dividend Policy,&rdquo; we have never declared or paid cash dividends on our common stock and do not anticipate paying
any dividends on our common stock in the foreseeable future. However, if we do make distributions on our common stock, those payments
will constitute dividends for U.S. tax purposes to the extent paid from our current or accumulated earnings and profits, as determined
under U.S. federal income tax principles. To the extent those distributions exceed both our current and our accumulated earnings and
profits, they will constitute a return of capital and will first reduce your basis in our common stock, but not below zero, and then
will be treated as gain from the sale of stock as described below under &ldquo;&mdash; Gain on Disposition of Common Stock.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion below on effectively connected income, backup withholding and foreign accounts, any dividend paid to you generally
will be subject to U.S. withholding tax either at a rate of 30% of the gross amount of the dividend or such lower rate as may be specified
by an applicable income tax treaty. In order to receive a reduced treaty rate, you must provide us with an IRS Form W-8BEN, IRS Form
W-8BEN-E or other appropriate version of IRS Form W-8 certifying qualification for the reduced rate. A non-U.S. holder of shares of our
common stock eligible for a reduced rate of U.S. withholding tax pursuant to an income tax treaty may obtain a refund of any excess amounts
withheld by timely filing an appropriate claim for refund with the IRS. If the non-U.S. holder holds the stock through a financial institution
or other agent acting on the non-U.S. holder&rsquo;s behalf, the non-U.S. holder will be required to provide appropriate documentation
to the agent, which then will be required to provide certification to us or our paying agent, either directly or through other intermediaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
received by you that are effectively connected with your conduct of a U.S. trade or business (and, if required by an applicable income
tax treaty, attributable to a permanent establishment maintained by you in the U.S.) are generally exempt from such withholding tax.
In order to obtain this exemption, you must provide us with an IRS Form W-8ECI or other applicable IRS Form W-8 properly certifying such
exemption. Such effectively connected dividends, although not subject to withholding tax, are taxed at the same graduated rates applicable
to U.S. persons, net of certain deductions and credits. In addition, if you are a corporate non-U.S. holder, dividends you receive that
are effectively connected with your conduct of a U.S. trade or business may also be subject to a branch profits tax at a rate of 30%
or such lower rate as may be specified by an applicable income tax treaty. You should consult your tax advisor regarding any applicable
tax treaties that may provide for different rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Gain
on Disposition of Common Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion below regarding backup withholding and foreign accounts, you generally will not be required to pay U.S. federal income
tax on any gain realized upon the sale or other disposition of our common stock unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    gain is effectively connected with your conduct of a U.S. trade or business (and, if required by an applicable income tax treaty,
    the gain is attributable to a permanent establishment maintained by you in the U.S.);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">you
    are a non-resident alien individual who is present in the U.S. for a period or periods aggregating 183 days or more during the taxable
    year in which the sale or disposition occurs and certain other conditions are met; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    common stock constitutes a U.S. real property interest by reason of our status as a &ldquo;U.S. real property holding corporation,&rdquo;
    (&ldquo;USRPHC&rdquo;) for U.S. federal income tax purposes at any time within the shorter of (i) the five-year period preceding
    your disposition of our common stock, or (ii) your holding period for our common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we are not currently and will not become a USRPHC for U.S. federal income tax purposes, and the remainder of this discussion
so assumes. However, because the determination of whether we are a USRPHC depends on the fair market value of our U.S. real property
relative to the fair market value of our other business assets, there can be no assurance that we will not become a USRPHC in the future.
Even if we become a USRPHC, however, as long as our common stock is regularly traded on an established securities market, such common
stock will be treated as U.S. real property interests only if you actually or constructively hold more than five percent of such regularly
traded common stock at any time during the shorter of the five-year period preceding your disposition of, or your holding period for,
our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are a non-U.S. holder described in the first bullet above, you will be required to pay tax on the net gain derived from the sale
under regular graduated U.S. federal income tax rates, and a corporate non-U.S. holder described in the first bullet above also may be
subject to the branch profits tax at a 30% rate, or such lower rate as may be specified by an applicable income tax treaty. If you are
an individual non-U.S. holder described in the second bullet above, you will be required to pay a flat 30% tax (or such lower rate specified
by an applicable income tax treaty) on the gain derived from the sale, which gain may be offset by U.S. source capital losses for the
year (provided you have timely filed U.S. federal income tax returns with respect to such losses). You should consult any applicable
income tax or other treaties that may provide for different rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Federal
Estate Tax</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock beneficially owned by an individual who is not a citizen or resident of the U.S. (as defined for U.S. federal estate tax
purposes) at the time of their death will generally be includable in the decedent&rsquo;s gross estate for U.S. federal estate tax purposes,
unless an applicable estate tax treaty provides otherwise. The test for whether an individual is a resident of the U.S. for U.S. federal
estate tax purposes differs from the test used for U.S. federal income tax purposes. Some individuals, therefore, may be non-U.S. holders
for U.S. federal income tax purposes, but not for U.S. federal estate tax purposes, and vice versa.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Backup
Withholding and Information Reporting</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
we must report annually to the IRS the amount of dividends paid to you, your name and address and the amount of tax withheld, if any.
A similar report will be sent to you. Pursuant to applicable income tax treaties or other agreements, the IRS may make these reports
available to tax authorities in your country of residence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
of dividends or of proceeds on the disposition of stock made to you may be subject to information reporting and backup withholding at
a current rate of 28% unless you establish an exemption, for example, by properly certifying your non-U.S. status on an IRS Form W-8BEN,
IRS Form W-8BEN-E or another appropriate version of IRS Form W-8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Backup
withholding is not an additional tax; rather, the U.S. federal income tax liability of persons subject to backup withholding will be
reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund or credit may generally be obtained
from the IRS, provided that the required information is furnished to the IRS in a timely manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Foreign
Account Tax Compliance</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Foreign Account Tax Compliance Act (&ldquo;FATCA&rdquo;) imposes withholding tax at a rate of 30% on dividends on and gross proceeds
from the sale or other disposition of our common stock paid to &ldquo;foreign financial institutions&rdquo; (as specially defined under
these rules), unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect
and provide to the U.S. tax authorities substantial information regarding the U.S. account holders of such institution (which includes
certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or
otherwise establishes an exemption. FATCA also generally imposes a U.S. federal withholding tax of 30% on dividends on and gross proceeds
from the sale or other disposition of our common stock paid to a &ldquo;non-financial foreign entity&rdquo; (as specially defined for
purposes of these rules) unless such entity provides the withholding agent with a certification identifying certain substantial direct
and indirect U.S. owners of the entity, certifies that there are none or otherwise establishes an exemption. The withholding provisions
under FATCA generally apply to dividends on our common stock, and under current transition rules, are expected to apply with respect
to the gross proceeds from the sale or other disposition of our common stock on or after January 1, 2019. An intergovernmental agreement
between the U.S. and an applicable foreign country may modify the requirements described in this paragraph. Non-U.S. holders should consult
their tax advisors regarding the possible implications of this legislation on their investment in our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Each
prospective investor should consult its tax advisor regarding the particular U.S. federal, state and local and non-U.S. tax consequences
of purchasing, holding and disposing of our common stock, including the consequences of any proposed change in applicable laws.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aR_008"></A>UNDERWRITING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into an underwriting agreement, dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, with &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, acting as the sole book-running manager (sometimes referred to as the
&ldquo;Representative&rdquo;). Subject to the terms and conditions of the underwriting agreement, each of the underwriters named below
have agreed to purchase, and we have agreed to sell to it, the number of shares of common stock listed next to its name at the public
offering price, less the underwriting discounts and commissions, as set forth on the cover page of this prospectus and as indicated below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriters</B></FONT></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<BR> Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 84%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriting agreement provides that the obligations of the underwriters to pay for and accept delivery of the shares of common stock
offered by this prospectus are subject to various conditions and representations and warranties, including the approval of certain legal
matters by its counsel and other conditions specified in the underwriting agreement. The shares of common stock are offered by the underwriters,
subject to prior sale, when, as and if issued to and accepted by the underwriters. The underwriters reserve the right to withdraw, cancel
or modify the offer to the public and to reject orders in whole or in part. The underwriters are obligated to take and pay for all of
the shares of common stock offered by this prospectus if any such shares are taken.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the underwriters and certain of their affiliates and controlling persons (within the meaning of Section 15 of
the Securities Act or Section 20 of the Exchange Act), among others, against specified liabilities, including liabilities under the Securities
Act, and to contribute to payments the underwriters may be required to make in respect thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discounts
and Commissions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters propose to offer the shares of common stock directly to the public at the public offering price set forth on the cover page
of this prospectus. After the offering to the public, the offering price and other selling terms may be changed by the underwriters without
changing the proceeds we will receive from the underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the public offering price, underwriting commissions and proceeds before expenses to us. The underwriting commissions
are 7.0% of the public offering price. We have also agreed to pay a non-accountable expense allowance to the Representative equal to
1.0% of the gross proceeds received at the closing of the offering. We have paid a $35,000 advance to the Representative upon execution
of our engagement letter with the Representative, and will pay an additional $15,000 upon filing of this Registration Statement, which
shall be applied against actual out-of-pocket-accountable expenses, which will be returned to us to the extent such out-of-pocket accountable
expenses are not actually incurred in accordance with FINRA Rule 5110(g)(4)(A).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Per Share</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Without<BR> Over-Allotment<BR> Option</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total With Full<BR> Over-Allotment<BR> Option</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: justify">Public offering price</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Underwriting discount (7%)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Non-accountable expense allowance (1%)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Proceeds, before expenses, to us</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>&nbsp;</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also agreed to pay certain of the Representative&rsquo;s expenses relating to the offering, including the fees and expenses of the
Representative&rsquo;s legal counsel, data services and communications expenses, road show expenses, market making and trading and clearing
firm expenses, and for the Representative&rsquo;s use of Ipreo&rsquo;s book-building, prospectus tracking and compliance software for
this offering, totaling $207,500.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
total estimated expenses of the offering, including the non-accountable expense allowance, registration, filing and listing fees, printing
fees and legal and accounting expenses, but excluding underwriting discounts and commissions, are approximately $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-Allotment
Option</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted a 45-day option to the Representative to purchase up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common
stock from us solely to cover over-allotments, if any, at the public offering price less underwriting discounts and
commissions.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Representative&rsquo;s
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
closing of this offering, we have agreed to issue to the Representative, or its designees, as compensation warrants to purchase a number
of shares of common stock equal to 5% of the aggregate number of shares of common stock sold in this offering (the &ldquo;Representative&rsquo;s
Warrants&rdquo;). The Representative&rsquo;s Warrants will be exercisable at a per share exercise price equal to 125% of the public offering
price per share in this offering. The Representative&rsquo;s Warrants are exercisable at any time and from time to time, in whole or
in part, during the four and one-half year period commencing 180 days from the effective date of the registration statement of which
this prospectus is a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Representative&rsquo;s Warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to FINRA
Rule 5110(e)(1). The Representative (or permitted assignees under Rule 5110(e)(2)) will not sell, transfer, assign, pledge, or hypothecate
these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call
transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period of 180
days from the effective date of the registration statement. In addition, the warrants provide for registration rights upon request, in
certain cases. The one-time demand registration right provided will not be greater than five years from the effective date of the registration
statement in compliance with FINRA Rule 5110(g)(8)(C). The unlimited piggyback registration right provided will not be greater than seven
years from the effective date of the registration statement in compliance with FINRA Rule 5110(g)(8)(D). We will bear all fees and expenses
attendant to registering the securities issuable on exercise of the warrants other than underwriting commissions incurred and payable
by the holders. The exercise price and number of shares issuable upon exercise of the warrants may be adjusted in certain circumstances
including in the event of a stock dividend or our recapitalization, reorganization, merger or consolidation. However, the warrant exercise
price or underlying shares will not be adjusted for issuances of shares of common stock at a price below the warrant exercise price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discretionary
Accounts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to &ldquo;lock-up&rdquo; agreements, we, our executive officers and directors, and our stockholders, have agreed, without the prior written
consent of the Representative, not to, directly or indirectly, offer to sell, sell, pledge or otherwise transfer or dispose of any of
shares of (or enter into any transaction or device that is designed to, or could be expected to, result in the transfer or disposition
by any person at any time in the future of) our common stock, enter into any swap or other derivatives transaction that transfers to
another, in whole or in part, any of the economic benefits or risks of ownership of shares of our common stock, make any demand for or
exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration
of any shares of common stock or securities convertible into or exercisable or exchangeable for shares of common stock or any other of
our securities or publicly disclose the intention to do any of the foregoing, subject to customary exceptions, for, with respect to the
Company and our stockholders, a period of 180 days from the date of this prospectus, and with respect to our executive officers and directors,
a period of 365 days from the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Right
of First Refusal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted the Representative a right of first refusal, for a period of eighteen (18) months from the closing of the offering, to act
as sole and exclusive investment banker, book-runner, financial advisor, underwriter and/or placement agent, at the Representative&rsquo;s
sole and exclusive discretion, for each and every future public and private equity and debt offering, including all of our equity linked
financings (each, a &ldquo;Subject Transaction&rdquo;), or any successor (or any of our subsidiaries), on terms and conditions customary
to the Representative for such Subject Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasdaq
Capital Market</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to apply to have our shares of common stock listed on the Nasdaq Capital Market under the symbol &ldquo;HILS.&rdquo; Our
application might not be approved and the consummation of this offering is contingent upon such approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price
Stabilization, Short Positions and Penalty Bids</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to facilitate the offering of our securities, the underwriters may engage in transactions that stabilize, maintain or otherwise
affect the price of our securities. In connection with the offering, the underwriters may purchase and sell our securities in the open
market. These transactions may include short sales, purchases on the open market to cover positions created by short sales and stabilizing
transactions. Short sales involve the sale by the underwriters of a greater number of shares of securities than they are required to
purchase in the offering. &ldquo;Covered&rdquo; short sales are sales made in an amount not greater than the underwriters&rsquo; option
to purchase additional shares of securities in the offering. The underwriters may close out any covered short position by either exercising
the over-allotment option to purchase shares or purchasing shares in the open market. In determining the source of shares of securities
to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase
in the open market as compared to the price at which they may purchase shares through the over-allotment option to purchase shares. &ldquo;Naked&rdquo;
short sales are sales in excess of the over-allotment option to purchase shares. The underwriters must close out any naked short position
by purchasing securities in the open market. A naked short position is more likely to be created if the underwriters are concerned that
there may be downward pressure on the price of our securities in the open market after pricing that could adversely affect investors
who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of securities made by the underwriters
in the open market before the completion of the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
to other purchase transactions, the underwriters&rsquo; purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our securities or preventing or retarding a decline in the market price of our securities. As result,
the price of our securities may be higher than the price that might otherwise exist in the open market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters make no representation or prediction as to the direction or magnitude of any effect that the transactions described above
may have on the price of our securities. In addition, neither we nor the underwriters make any representation that the underwriters will
engage in these transactions or that these transactions, once commenced, will not be discontinued without notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Offer, Sale and Distribution of Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus in electronic format may be made available on the websites maintained by the underwriters or selling group members, if any,
participating in the offering. The underwriters may agree to allocate a number of shares of securities to underwriters and selling group
members for sale to their online brokerage account holders. Internet distributions will be allocated by the underwriter and selling group
members that may make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format,
the information on any underwriter&rsquo;s website and any information contained in any other website maintained by an underwriter is
not part of this prospectus or the registration statement of which this prospectus forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the underwriters and/or their affiliates may provide in the future, various advisory, investment and commercial banking
and other services to us in the ordinary course of business, for which they will receive customary fees and commissions. However, except
as disclosed in this prospectus, we have no present arrangements with the underwriters or any of their affiliates for any further services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pricing
of the Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public offering price was determined by negotiations between us and the Representative. Among the factors considered in determining the
public offering price were our future prospects and those of our industry in general, our sales, earnings and certain other financial
and operating information in recent periods, and the price-earnings ratios, price-sales ratios, market prices of securities, and certain
financial and operating information of companies engaged in activities similar to ours. Neither we nor the underwriters can assure investors
that an active trading market for the shares will develop or that, after the offering, the shares will trade in the public market at
or above the public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offer
Restrictions Outside the United States</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered
by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be
offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with
the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result
in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are
advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus.
This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in
any jurisdiction in which such an offer or a solicitation is unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Canada</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors,
as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted
clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale
of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements
of applicable securities laws. Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies
for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies
for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&rsquo;s
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&rsquo;s
province or territory for particulars of these rights or consult with a legal advisor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>China</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this document does not constitute a public offer of the securities, whether by way of sale or subscription, in the People&rsquo;s
Republic of China (excluding, for purposes of this paragraph, Hong Kong Special Administrative Region, Macau Special Administrative Region
and Taiwan). The securities may not be offered or sold directly or indirectly in the PRC to legal or natural persons other than directly
to &ldquo;qualified domestic institutional investors.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>United
Kingdom</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the information in this document nor any other document relating to the offer has been delivered for approval to the Financial Services
Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as
amended (&ldquo;FSMA&rdquo;)) has been published or is intended to be published in respect of the securities. This document is issued
on a confidential basis to &ldquo;qualified investors&rdquo; (within the meaning of section 86(7) of FSMA) in the United Kingdom, and
the securities may not be offered or sold in the United Kingdom by means of this document, any accompanying letter or any other document,
except in circumstances which do not require the publication of a prospectus pursuant to section 86(1) FSMA. This document should not
be distributed, published or reproduced, in whole or in part, nor may its contents be disclosed by recipients to any other person in
the United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) received in connection with the
issue or sale of the securities has only been communicated or caused to be communicated and will only be communicated or caused to be
communicated in the United Kingdom in circumstances in which section 21(1) of FSMA does not apply to our Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United Kingdom, this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters
relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial
Promotions) Order 2005 (&ldquo;FPO&rdquo;), (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high
net worth companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated (together
&ldquo;relevant persons&rdquo;). The investments to which this document relates are available only to, and any invitation, offer or agreement
to purchase will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document
or any of its contents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Hong
Kong</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the information in this document nor any other document relating to the offer has been delivered for registration to the Registrar of
Companies in Hong Kong, and its contents have not been reviewed or approved by any regulatory authority in Hong Kong, nor have we been
authorized by the Securities and Futures Commission in Hong Kong. This document does not constitute an offer or invitation to the public
in Hong Kong to acquire shares. Accordingly, unless permitted by the securities laws of Hong Kong, no person may issue or have in its
possession for the purpose of issue, this document or any advertisement, invitation or document relating to the shares, whether in Hong
Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong other
than in relation to shares which are intended to be disposed of only to persons outside Hong Kong or only to &ldquo;professional investors&rdquo;
(as such term is defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (&ldquo;SFO&rdquo;) and the subsidiary
legislation made thereunder) or in circumstances which do not result in this document being a &ldquo;prospectus&rdquo; as defined in
the Companies (Winding Up and Miscellaneous Provisions) Ordinance of Hong Kong (Cap. 32 of the Laws of Hong Kong) (the &ldquo;CO&rdquo;)
or which do not constitute an offer or an invitation to the public for the purposes of the SFO or the CO. The offer of the shares is
personal to the person to whom this document has been delivered by or on behalf of our company, and a subscription for shares will only
be accepted from such person. No person to whom a copy of this document is issued may issue, circulate or distribute this document in
Hong Kong or make or give a copy of this document to any other person. You are advised to exercise caution in relation to the offer.
If you are in any doubt about any of the contents of this document, you should obtain independent professional advice. No document may
be distributed, published or reproduced (in whole or in part), disclosed by or to any other person in Hong Kong or to any person to whom
the offer of sale of the shares would be a breach of the CO or SFO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aR_009"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the issuance of the common stock offered by us in this offering will be passed upon for us by Sheppard, Mullin, Richter &amp;
Hampton LLP, New York, New York. Certain legal matters in connection with this offering will be passed upon for the underwriters by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aR_010"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of Hillstream BioPharma, Inc. as of and for the years ended December 31, 2020 and 2019, included in
this registration statement, of which this prospectus forms a part, have been audited by Mayer Hoffman McCann P.C., independent registered
public accounting firm, as set forth in their report (which includes an explanatory paragraph related to the existence of substantial
doubt about the Company&rsquo;s ability to continue as a going concern) appearing elsewhere herein, and are included in reliance upon
such report given on the authority of such firm as experts in auditing and accounting in giving said report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aR_011"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the common stock offered by this
prospectus. This prospectus, which is part of the registration statement, omits certain information, exhibits, schedules and undertakings
set forth in the registration statement. For further information pertaining to us and our common stock, reference is made to the registration
statement and the exhibits and schedules to the registration statement. Statements contained in this prospectus as to the contents or
provisions of any documents referred to in this prospectus are not necessarily complete, and in each instance where a copy of the document
has been filed as an exhibit to the registration statement, reference is made to the exhibit for a more complete description of the matters
involved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may read and copy all or any portion of the registration statement without charge at the public reference room of the SEC at 100 F Street,
N.E., Washington, D.C. 20549. Copies of the registration statement may be obtained from the SEC at prescribed rates from the public reference
room of the SEC at such address. You may obtain information regarding the operation of the public reference room by calling 1-800-SEC-0330.
In addition, registration statements and certain other filings made with the SEC electronically are publicly available through the SEC&rsquo;s
website at <I>http://www.sec.gov</I>. The registration statement, including all exhibits and amendments to the registration statement,
has been filed electronically with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of this offering, we will become subject to the information and periodic reporting requirements of the Exchange Act, and,
accordingly, will be required to file annual reports containing financial statements audited by an independent public accounting firm,
quarterly reports containing unaudited financial data, current reports, proxy statements and other information with the SEC. You will
be able to inspect and copy such periodic reports, proxy statements and other information at the SEC&rsquo;s public reference room, and
the website of SEC referred to above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_007"></A>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEX
TO FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B>&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_001">Report of Independent Registered Public Accounting Firm</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_002">Consolidated Balance Sheets as of December 31, 2020 and 2019</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_003">Consolidated Statements of Operations for the Years Ended December 31, 2020 and 2019</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</FONT>4</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_004">Consolidated Statements of Changes in Stockholders&rsquo; Deficit for the Years Ended December 31, 2020 and 2019</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</FONT>5</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_005">Consolidated Statements of Cash Flows for the Years Ended December 31, 2020 and 2019</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</FONT>6</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_006">Notes to Consolidated Financial Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</FONT>7</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 119; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="pri_001"></A><B>Report
of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To the Board of Directors and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Stockholders of Hillstream BioPharma, Inc.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Hillstream BioPharma, Inc. (&ldquo;Company&rdquo;) as of December 31, 2020 and 2019, and the related consolidated statements
of operations, changes in stockholders&rsquo; deficit, and cash flows for each of the two years in the period ended December 31, 2020,
and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of
its operations and its cash flows for each of the two years in the period ended December 31, 2020, in conformity with accounting principles
generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Going Concern Uncertainty</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company
has incurred recurring negative cash flows from operations and is dependent on additional financing to fund operations. These conditions
raise substantial doubt about the Company&rsquo;s ability to continue as a going concern. Management&rsquo;s plans in regard to these
matters are also described in Note 1 to the financial statements. The financial statements do not include any adjustments to reflect
the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that
might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These financial statements are the responsibility
of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s
internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well
as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>/s/ Mayer Hoffman McCann P.C.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have served as the Company&rsquo;s auditor since 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">San Diego, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">May 17, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_002"></A>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
BALANCE SHEETS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    assets:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">191,852</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,281</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and other current assets</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">102,946</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,600</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current assets</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">294,798</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,881</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    assets</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">294,798</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,881</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities
    and Stockholders&rsquo; Deficit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    liabilities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">514,828</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">241,409</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    interest</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73,066</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61,429</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
    to founder</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,000</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">255,068</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,777</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,626</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redemption
    liability</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,325,288</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">126,183</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term
    portion of convertible notes, net</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">563,425</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">430,600</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current liabilities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,725,384</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,130,315</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    notes, net, less short term portion</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,286,942</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">532,766</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,012,326</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,663,081</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments
    and contingencies (See Note 10)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&rsquo;
    deficit:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
    stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2020 and 2019</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock, $0.0001 par value, 250,000,000 shares authorized, 167,833,334 and 165,833,334 shares issued and outstanding as of December
    31, 2020 and 2019, respectively</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,783</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,583</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid-in capital</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">970,296</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">446,716</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,704,607</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,085,499</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stockholders&rsquo; deficit</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,717,528</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,622,200</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities and stockholders&rsquo; deficit</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">294,798</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,881</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying footnotes
are an integral part of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_003"></A>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
STATEMENTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the years ended</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    expenses:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">847,272</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">368,732</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired
    in-process research and development</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">289,200</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">429,403</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">671,879</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">625,807</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating expenses</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,808,351</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,423,942</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    from operations</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,808,351</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,423,942</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    Expense:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">246,534</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,074</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in redemption value</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">362,486</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,458</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    other expenses</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">609,020</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101,532</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,417,371</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,525,474</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss per share:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.01</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.01</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average number of common shares outstanding:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">167,666,667</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">108,611,112</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_004"></A>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS&rsquo; EQUITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE YEARS ENDED DECEMBER 31, 2020 AND 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paid-in</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&rsquo;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Par
    Value</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2018</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61,666,667</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,167</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,620</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(560,025</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(501,238</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of shares for the acquisition of NanoProteagen LLC</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61,666,667</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,166</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">178,834</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">185,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    based compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">92,012</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">92,012</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    of stock options</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,500,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,250</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">123,250</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">127,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,525,474</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,525,474</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2019</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">165,833,334</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,583</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">446,716</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,085,499</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,622,200</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of shares for the acquisition of Farrington Therapeutics LLC</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">200</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">289,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">289,200</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    based compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">234,580</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">234,580</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deemed
    dividend upon debt exchange</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(201,737</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(201,737</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,417,371</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,417,371</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2020</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">167,833,334</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,783</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">970,296</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,704,607</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,717,528</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The accompanying footnotes
are an integral part of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_005"></A>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Consolidated
Statement of Cash Flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">For the years ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash flows from operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 64%; text-align: left">Net loss</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 14%; font-weight: bold; text-align: right">(2,417,371</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">(1,525,474</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">In-process R&amp;D expense</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">289,200</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">429,403</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Amortization of debt discount</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">145,356</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,802</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Stock based compensation</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">234,580</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92,012</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Change in fair value of redemption liability</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">362,486</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,458</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Changes in operating accounts:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Changes in prepaid expenses and other current assets</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(100,346</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Changes in accounts payable and accrued expenses</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">306,570</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,428</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Changes in accrued interest</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">101,093</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,190</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Changes in due to founder</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">213,524</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Net cash used in operating activities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(1,078,432</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(706,113</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash flows from financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Proceeds from convertible notes</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,232,003</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">580,885</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Proceeds from exercise of stock options</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">127,500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,232,003</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">708,385</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net increase in cash</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">153,571</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,272</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Cash - beginning of year</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">38,281</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">36,009</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Cash - end of year</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">191,852</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">38,281</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental disclosure of non-cash investing and financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Acquisition of in-process R&amp;D expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Shares issued upon acquisition</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">289,200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">185,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Assumed accounts payable upon acquisition</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">174,393</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deemed dividend</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">201,737</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued interest roll-over to new notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">89,456</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Due to founder converted to note payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">55,068</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying footnotes
are an integral part of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_006"></A>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <FONT STYLE="font-variant: small-caps"><B>1
- Description of Business and Liquidity</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Hillstream BioPharma Inc.
(&ldquo;HBI&rdquo;) was incorporated on March 28, 2017, as a Delaware C-corporation. On July 16, 2019, Hillstream BioPharma Holdings,
Inc. (&ldquo;Holdco&rdquo;) was formed as a Delaware C-corporation. On July 24, 2019, Holdco entered into a Contribution and Share Exchange
Agreement with Nanoproteagen LLC (&ldquo;Nanoproteagen&rdquo;) pursuant to which the members of Nanoproteagen exchanged
100% of their membership interests in Nanoproteagen for shares of Holdco common stock. Also on July 24, 2019, the
stockholders of HBI exchanged 100% of their shares of common stock for shares of common stock of Holdco. HBI and Nanoproteagen
became wholly-owned subsidiaries of Holdco.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 7, 2019, Holdco&rsquo;s name was changed
to Hillstream BioPharma, Inc. and HBI&rsquo;s name was changed to HB Pharma Corp. On November 12, 2020, Hillstream BioPharma, Inc. entered
into a Share Exchange Agreement with Farrington Therapeutics LLC (&ldquo;Farrington&rdquo;) pursuant to which the members of Farrington
exchanged their membership interest in Farrington for shares of common stock of Hillstream BioPharma, Inc. Farrington became a wholly-owned
subsidiary of Hillstream BioPharma, Inc. At December 31, 2020, Hillstream BioPharma, Inc. has three wholly-owned subsidiaries: HB Pharma
Corp., Nanoproteagen and Farrington.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a biotechnology company leveraging a tumor targeting proprietary platform, Quatramer, to develop a pipeline of novel product
candidates to treat rare and devastating cancers. Quatramer are designed with specific physico-chemical parameters to target specified
cells or tissues and converge a therapeutic payload at the site of disease to boost efficacy while abating adverse effects on healthy
tissue. The Company is building a portfolio of long-acting product candidates based on Quatramer, initially in the oncology space. The
Company is advancing its product candidates, including novel small molecules and proprietary DNA expression vectors which encode inflammatory
cytokines directly into the tumor&rsquo;s genome. The first product candidate, HSB-1216, is in investigational new drug enabling studies
for solid tumors with an enhancement for small cell lung cancer (&ldquo;SCLC&rdquo;) and triple-negative breast cancer. The Company has
achieved orphan drug designation in SCLC for HSB-1216&rsquo;s payload. The Company&rsquo;s second product candidate, HSB-888, is a dual-loaded
Iron Medicated Cell Death modulator coupled with an ultra-low dose next generation anthracycline analogue for solid tumors which has
a highly synergistic tumor killing capacity. HSB-888, can be developed in the clinic for sarcomas, including pediatric osteosarcoma.
The U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) has granted HSB-888 the Rare Pediatric Disease Designation and Orphan Drug
Designation for pediatric osteosarcoma. The Company plans to develop other Quatramer based compounds with therapeutic cargoes from the
product pipeline, which include DNA-based contents which the Company believes hijacks the tumor&rsquo;s genetic code and kill the tumor
from within by generating an array of cancer killing cytokines, such as tumor necrosis factor alpha and interleukin-2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and going concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared on the basis that the Company is a going concern, which contemplates,
among other things, the realization of assets and satisfaction of liabilities in the normal course of business. For the year ended December
31, 2020, the Company has incurred operating losses in the amount of approximately $2.4 million and has an accumulated deficit of approximately
$4.7 million at December 31, 2020. The Company has financed its working capital requirements to date primarily through the issuance of
promissory notes payable. Substantially all of the debt is with stockholders of the Company, who may extend the maturity date or convert
the debt into equity at some point, although there are no agreements in place to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
additional financing to support the successful development of the Company&rsquo;s contemplated plan of operations, and its transition,
ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. Such funding is necessary
to conduct the clinical trials and pre-clinical activities to support the development of the Company&rsquo;s product candidates. The
Company is applying for government program facilities and grants, although there is no assurance that such funds will be received. The
Company is pursuing additional capital funding or other strategic transactions, and the Company will continue to seek funds through debt
or equity financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements,
or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
1 - Description of Business and Liquidity (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and going concern (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
sources of financing. However, there can be no assurances that such financing or other strategic transactions will be available on acceptable
terms, or at all. If the Company is unable to obtain additional funding, the development of its product candidates will be impacted and
the Company would likely be forced to delay, reduce, or terminate some or all of its development programs. See Note 11 for funds raised
subsequent to December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2020, and with the funds raised through the date of issuance of these financial statements, the Company has not raised sufficient
funds to finance the operating requirements for at least the next 12 months from the issuance date of these financial statements. These
factors raise substantial doubt regarding the Company&rsquo;s ability to continue as a going concern. The consolidated financial statements
do not include any adjustments that may result from the outcome of these aforementioned uncertainties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
risks and uncertainties</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
there can be no assurance that the Company&rsquo;s products, if approved, will be accepted in the marketplace, nor can there be any
assurance that any future products can be developed or manufactured at an acceptable cost and with appropriate performance
characteristics, or that such products will be successfully marketed, if at all. The Company is subject to risks common to
biopharmaceutical companies including, but not limited to, the development of new technological innovations, dependence on key
personnel, protection of proprietary technology, compliance with government regulations, product liability, uncertainty of market
acceptance of products and the need to obtain additional financing. The Company is dependent on third party suppliers, in some cases
single-source suppliers. The Company&rsquo;s products require approval or clearance from the FDA prior to commencing commercial
sales in the United States. Approvals or clearances are also required in foreign jurisdictions in which the Company may license or
sell its products. There can be no assurance that the Company&rsquo;s products will receive all of the required approvals or
clearances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVID-19</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, a novel strain of coronavirus (&ldquo;COVID-19&rdquo;) was reported globally. The World Health Organization has declared
COVID-19 to constitute a &ldquo;Public Health Emergency of International Concern&rdquo; on January 30, 2020 and a global pandemic on
March 11, 2020. In March 2020, individual states mandated &ldquo;stay at home orders&rdquo;, restricted access to hospitals, prohibited
elective surgeries and instituted other restrictions in connection with the COVID-19 outbreak. The extent of the impact of COVID-19 on
the Company&rsquo;s operational and financial performance will depend on future developments, including access to products, potential
disruption in global freight networks, domestic and foreign government actions and changes in demand based on the duration and severity
of the COVID-19 outbreak. To date, the Company&rsquo;s operations have not been materially affected by COVID-19.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
2 - Basis of Presentation and Summary of Significant Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
of presentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (&ldquo;GAAP&rdquo;). The Company operates in one segment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principles
of consolidation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of Hillstream BioPharma, Inc. and its wholly-owned subsidiaries, HB Pharma Corp.,
Nanoproteagen and Farrington. All significant intercompany balances and transactions have been eliminated in consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
2 - Basis of Presentation and Summary of Significant Accounting Policies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
of estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and related disclosures in the financial statements and accompanying notes. Management bases its estimates
on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often may yield
a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that
range of reasonable estimates. Estimates are used in the following areas, among others: research and development expense recognition,
valuation of common shares and stock options, allowances of deferred tax assets, valuation of debt related instruments, accrued expenses
and liabilities, and cash flow assumptions regarding going concern considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company from time to time during the period covered by these financial statements may have had bank account balances in excess of federally
insured limits. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit
risk beyond the normal credit risk associated with commercial banking relationships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and
development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies
and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical
investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed
by third parties, patient enrollment in clinical trials, administrative costs incurred by third parties, and other indicators of the
services completed. Substantially all of the prepaid expenses at December 31, 2020 relate to the purchase of an active pharmaceutical
ingredient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acquired
in-process research and development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has acquired, and may in the future acquire, rights to develop and commercialize new product candidates and/or other in-process
research and development assets. In accordance with Financial Accounting Standards Board&rsquo;s (&ldquo;FASB&rdquo;) Accounting Standards
Codification (&ldquo;ASC&rdquo;) 730-10-25-1, <I>Research and Development,</I> the up-front acquisition or licensing payments are expensed
as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing, and, absent
obtaining such approval, has no alternative future use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
based compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation costs resulting from the issuance of stock based awards to employees, non-employees and directors as
an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each
stock based award. The fair value of each option grant to employees, non-employees and directors is estimated as of the date of grant
using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on a straight-line
basis over the requisite service period of the awards, which is generally the vesting period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Note
2 - Basis of Presentation and Summary of Significant Accounting Policies (continued)</B></FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
based compensation (Continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company is
a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock
volatility based on the historical data regarding the volatility of a publicly traded set of peer companies. The expected term of stock
options granted is between 5 and 7 years. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in
effect at the time of grant of the award for time periods approximately equal to the expected term of the award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
stock valuations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was required to periodically estimate the fair value of common stock with the assistance of an independent third-party valuation
expert when issuing stock options and computing its estimated stock based compensation expense and value of shares issued in acquiring
product candidates. The assumptions underlying these valuations represented management&rsquo;s best estimates, which involved inherent
uncertainties and the application of significant levels of management judgment. In order to determine the fair value, the Company considered,
among other things, contemporaneous valuations of the Company&rsquo;s common stock, the Company&rsquo;s business, financial condition
and results of operations, including related industry trends affecting its operations; the likelihood of achieving various liquidity
events; the lack of marketability of the Company&rsquo;s common stock; the market performance of comparable publicly traded companies;
and U.S. and global economic and capital market conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset-and-liability method in accordance with ASC 740, <I>Income Taxes</I> (&ldquo;ASC 740&rdquo;).
Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial
statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is
recognized in the period that includes the enactment date. A valuation allowance is recorded if it is &ldquo;more likely than not&rdquo;
that some portion or all of the deferred tax assets will not be realized in future periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and
clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement.
The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical
merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely than-not threshold
are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the
taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that
the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties
related to tax positions in income tax expense. As of December 31, 2020 and 2019, the Company had no unrecognized uncertain income tax
positions, and therefore no amounts have been recognized in the consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
2 - Basis of Presentation and Summary of Significant Accounting Policies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
value measurements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies ASC 820, <I>Fair Value Measurement </I>(&ldquo;ASC 820&rdquo;), which establishes a framework for measuring fair value
and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that
would be received for an asset or paid to transfer a liability in the Company&rsquo;s principal or most advantageous market in an orderly
transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an
entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs
reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained
from sources independent of the reporting entity. Unobservable inputs reflect the entity&rsquo;s own assumptions based on market data
and the entity&rsquo;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to
be developed based on the best information available in the circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the Company&rsquo;s prepaid expenses, accounts payable and accrued expenses approximate fair value because of the short-term
maturity of these financial instruments. The redemption feature of the debt instruments is recorded at fair value (See Note 5).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input
that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify; text-indent: -41.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 - Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are
observable inputs, such as quoted prices in active markets for identical assets or liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-align: justify; text-indent: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify; text-indent: -41.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 - Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying
terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted
intervals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-align: justify; text-indent: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 - Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little
or no market data exists for the assets or liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
2 - Basis of Presentation and Summary of Significant Accounting Policies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Debt
discount and derivative instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial fair value of the redemption feature relating to the convertible debt instruments is treated as a debt discount and amortized
over the term of the related debt using the straight-line method, which approximates the interest method. If a loan is paid in full,
any unamortized financing costs will be removed from the related accounts and charged to operations. Amortization of debt discount is
recorded as a component of interest expense. In accordance with Accounting Standards Update (&ldquo;ASU&rdquo;) 2015-03, <I>Interest
&mdash; Imputation of Interest</I>, the unamortized debt discount is presented in the accompanying balance sheet as a direct deduction
from the carrying amount of the related debt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for derivative instruments in accordance with ASC 815, Derivative and Hedging, which establishes accounting and reporting
standards for derivative instruments, including certain derivative instruments embedded in other financial instruments or contracts and
requires recognition of all derivatives on the balance sheet at fair value. The Company&rsquo;s derivative financial instrument consists
of an embedded feature contained in the Company&rsquo;s convertible debt that is bifurcated and accounted for separately. See Note 4
- Debt for further details.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
loss per share</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reports earnings (loss) per share in accordance with ASC 260-10, <I>Earnings Per Share</I>, which provides for calculation of
basic and diluted earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available
to common stockholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential
dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives
effect to common stock equivalents; however, potential common shares are excluded if their effect is anti-dilutive. Management concluded
that the deemed dividend (see Note 4) is analogous to a return on equity classified preference shares, the deemed dividend is added to
the net loss for purposes of the basic and diluted loss per share calculation. Accordingly, the numerator of the loss per share calculation
(basic and diluted) is $2,619,108.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities not included in the computation of earnings (loss) per share at December 31, 2020 and 2019 included options to purchase
17,840,016 and 12,550,000 shares of common stock, respectively. The number of shares issuable upon the conversion of convertible debt
and accrued interest is not included in the denominator since their inclusion would be anti-dilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Recent
accounting pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company has evaluated all recent accounting pronouncements, and believes that none of them will have a material effect on the Company&rsquo;s
financial position, results of operations or cash flows except as discussed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Note
2 - Basis of Presentation and Summary of Significant Accounting Policies (continued)</B></FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accounting
policies being evaluated</B>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the FASB issued ASU 2016-02, <I>Leases (Topic 842</I>), which replaces the existing guidance in ASC 840 - Leases. This
ASU requires a dual approach for lessee accounting under which a lessee would account for leases as finance leases or operating leases.
Both finance leases and operating leases will result in the lessee recognizing a right-of-use asset and a corresponding lease liability.
For finance leases, the lessee would recognize interest expense and amortization of the right-of-use asset, and for operating leases,
the lessee would recognize a straight-line total lease expense. This ASU is effective for fiscal years beginning after December 15, 2022
and for interim periods within those fiscal years. The Company is currently evaluating the impact of this adoption on its consolidated
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the FASB Issued ASU 2019-12, &ldquo;<I>Income Taxes, (Topic 740): Simplifying the Accounting for Income Taxes</I>&rdquo;.
This standard removes certain exceptions to the general principles and improves consistent application of and simplify GAAP for other
areas of Topic 740 by clarifying and amending existing guidance. This standard is effective for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2021. The Company is currently evaluating the impact this standard will have on its
consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB recently issued ASU 2020-06, <I>Debt &ndash; Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging
&ndash; Contracts in Entity&rsquo;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&rsquo;s
Own Equity</I>, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity.
The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the
existing guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately
from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded
conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments
revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that
are both indexed to the issuer&rsquo;s own stock and classified in stockholders&rsquo; equity, by removing certain criteria required
for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification
(and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract.
The amendments in ASU 2020-06 further revise the guidance in ASC 260, <I>Earnings Per Share</I>, to require entities to calculate diluted
earnings per share (&ldquo;EPS&rdquo;) for convertible instruments by using the if-converted method. In addition, entities must presume
share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments are effective
for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December
15, 2020. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accounting
principles adopted</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2018, the FASB issued ASU 2018-13, <I>Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements
for Fair Value Measurement</I>. This amendment modifies the disclosure requirements for fair value measurements. The guidance is effective
for all entities for fiscal years ending after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted.
The guidance was adopted as of January 1, 2019. The impact on the Company&rsquo;s financial position, results of operations and cash
flows was immaterial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
3 - Acquisitions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Nanoproteagen</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 24, 2019, Holdco issued 61,666,667 shares of common stock to acquire 100% of the Membership Interests of Nanoproteagen, an
early stage biotech company. On the date of the transaction, Nanoproteagen had no assets on its books and accounts payable of
$174,393 which were assumed by the Company. The transaction did not meet the definition of a business combination for financial reporting
purposes, since there were no business inputs, employees acquired, processes or outputs at the time of the transaction. The fair value
of the common stock issued was approximately $185,000, for which the single asset was recognized as a component of acquired in-process
research and development expense in the accompanying consolidated statements of operations, summarized as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 78%; text-align: justify">Fair value of shares issued</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">185,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Liability assumed</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">174,393</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Purchase price</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">359,393</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
fees and other costs of approximately $20,000, related to this transaction, were included as a component of acquired in-process research
and development expense in the accompanying consolidated statements of operations. The previous license in place between the Company
and Nanoproteagen was cancelled as a result of this transaction without further consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Farrington</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 12, 2020, the Company acquired 100% of
the member interests of Farrington, an early stage biotech company which owned a next generation anthracycline, HSB-888, for pediatric
osteosarcoma. Pursuant to the Exchange Agreement, the Company issued 2,000,000 shares of its common stock to the seller as consideration
for the purchase. The transaction did not meet the definition of a business combination for financial reporting purposes, since there
were no business inputs, employees acquired, processes or outputs at the time of the transaction. The fair value of the common stock
issued was estimated to be $289,200, for which the single asset was recognized as a component of acquired in-process research and development
expense in the accompanying consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>Note 4 -
Convertible Notes - Related Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Commencing in May 2017, the Company entered into
Subordinated Convertible Promissory Note Agreements (the &ldquo;Agreements&rdquo;) with certain lenders (together, the &ldquo;Holders&rdquo;
or individually, the &ldquo;Holder&rdquo;), pursuant to which the Company issued Subordinated Convertible Promissory Notes (individually
the &ldquo;Note&rdquo; or together the &ldquo;Notes&rdquo;) to the Holders, principally all to the Chief Executive Officer and founder
of the Company (See Note 9). Interest on the unpaid principal balance accrues at a rate of 5% per annum, computed on the basis of the
actual number of days elapsed and a year of 365 days. Unless earlier converted into shares of the Company&rsquo;s common stock or preferred
stock (collectively, the &ldquo;Equity Securities&rdquo;), the principal and accrued interest shall be due and payable by the Company
on demand by the Holders at any time after the earlier of (i) the Maturity Date (as defined in each Agreement) and (ii) the closing of
the Next Equity Financing. &ldquo;Next Equity Financing&rdquo; means the next sale, or series of related sales, by the Company of its
Equity Securities pursuant to which the Company receives gross proceeds of not less than $5,000,000 for Notes issued in 2017 and through
November 2020 and $7,500,000 for Notes issued in December 2020 (including the aggregate amount of debt securities converted into Equity
Securities upon conversion or cancellation of the Notes).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>HILLSTREAM BIOPHARMA, INC.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Note
4 - Convertible Notes - Related Parties (continued)</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, the stated Maturity Date was two years from the date of issuance, except for the notes entered into in December 2020 (in the
aggregate principal amount of $418,000) which have a stated maturity date of three years. For Notes entered into in 2017 and through
September 2018, the default interest rate of 20% was added to the Notes for the period after the Maturity Date (&ldquo;default period&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes will automatically convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares
of such Equity Securities to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued
interest due on the Note on the date of conversion by the lesser of (i) 80% of the price paid per share for Equity Securities by the
investors in the Next Equity Financing, or (ii) an equity valuation of $25 million ($50 million for notes issued after December 2020).
No Next Equity Financing has occurred through December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
embedded features contained in the Notes in the aggregate are embedded derivative instruments, which were recorded as a debt discount
and derivative liability at the issuance date at their estimated fair value of $1.073 million. Accretion of debt discount for the Notes
was recorded as interest expense was approximately $175,000 for the year ended December 31, 2020. Accrued interest expense associated
with the Notes at December 31, 2020 and 2019 amounted to approximately $73,100 and $61,400, respectively. Interest expense, including
accretion of the debt discount, amounted to approximately $246,000 and $75,000 for the years ended December 31, 2020 and 2019, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, all convertible debt instruments which had matured had been rolled over into new notes as described below. The
convertible debt balance at December 31, 2020 and 2019 is summarized as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify">Principal amount outstanding</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">2,598,340</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">1,020,076</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Less: debt discount, net of accretion</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(747,973</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(56,710</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Carrying value</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,850,367</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">963,366</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">563,425</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">430,600</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Long term portion</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,286,942</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">532,766</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Total carrying value</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,850,367</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">963,366</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exchange
notes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 27, 2020, the Company agreed to issue
a related party Note holder notes (&ldquo;Exchange Notes&rdquo;) in exchange for seven Notes payable which were in default (&ldquo;Original
Notes&rdquo;) at such time by more than 90 days. The Original Notes had a principal amount of approximately $265,000 and accrued interest
of $37,000 at December 31, 2019. As of September 27, 2020, the aggregate outstanding principal was approximately $265,000 and accrued
interest, which included the default interest rate of 20% as described above, was approximately $71,000. The Exchange Notes took the
then principal and accrued interest of the Original Notes and added an original issue discount of 37.5% to determine the new principal
amount which amounted to an aggregate of $537,968. The Company accounted for this transaction as a debt extinguishment, and the
incremental amount of the principal of the Exchange Notes payable of $201,737 was recorded to accumulated deficit (analogous to a &ldquo;deemed
dividend&rdquo;), since the Exchange Notes are with related parties, and included in the calculation of loss per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 27, 2020, the Company issued certain
related party Noteholders notes (&ldquo;September Exchange Notes&rdquo;) in exchange for five Notes payable, which were
in default. As of such date, the aggregate outstanding principal and interest was approximately $26,000, which included the default interest
rate of 20% as described above. The September Exchange Notes in the aggregate principal amount of approximately $26,000 were issued with
substantially the same terms as the Original Notes. There was no accounting entries required upon the re-issuance of such Exchange Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Roll-over notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective October 1, 2020, all notes which matured,
and were not repaid or converted, were rolled over on substantially the same terms as the Original Notes with a new two year term
(&ldquo;Rolled Over&rdquo;). In the fourth quarter of 2020, approximately $166,000 of such Original Notes were Rolled Over. Since the
terms of the new notes are not substantially different from the Original Notes, this was not accounted for as a debt modification
or debt extinguishment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
5 - Redemption Liability</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the redemption liability is calculated under Level 3 of the fair value hierarchy, determined based upon a Probability-Weighted
Expected Returns Method (&ldquo;PWERM&rdquo;).</FONT> This PWERM was determined to be the most appropriate method of estimating the
value of possible redemption or conversion outcomes over time, since the Company has not entered into a priced equity round through December
31, 2020. The significant assumptions utilized in these calculations are the possible exit scenarios (either a conversion of the principal
and accrued interest of the Notes in the event of a Next Equity Financing, a repayment of the Notes and accrued interest in the event
of a Corporate Transaction (as defined in the Notes) or a repayment of the Notes and accrued interest at maturity), the pre-money valuation
of the Company&rsquo;s common stock, the probabilities of such exit events occurring and discounts/premiums available to the noteholders
at such measurement dates. At December 31, 2020 the Company assumed a 40% probability of a Next Equity Financing event occurring at IPO
pricing, an increase from 9% at December 31, 2019. At December 31, 2020, the Company assumed a 5% probability of a Corporate Transaction,
an increase from 1% at December 31, 2019. The calculation of the redemption liability also used the following assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 11pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 11pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Assumed ranges pre-money valuation at time of Next Equity Financing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5
                                       &ndash; 50 million</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5
                                       &ndash; 50 million</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%; text-align: left">Discount rate</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.86-
                                            11.13</FONT></TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">6.29</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected coupon interest rate on Notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected term to exit event</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.0-3.0
                                            years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.0
                                            years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the redemption liability is
re-measured at each period and is summarized as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify">Beginning balance</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">126,183</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">38,574</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Initial embedded redemption value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">836,619</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,151</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Change in fair value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">362,486</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,458</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Ending balance</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,325,288</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">126,183</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in fair value of $362,486 and $26,458 for the years ended December 31, 2020 and 2019, respectively, is recorded as a component
of other expense in the accompanying consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
6 - Stock Based Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Company&rsquo;s 2017 Stock Incentive Plan (the &ldquo;2017 Stock Incentive Plan&rdquo;) the Company may grant incentive stock options,
non-statutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock, restricted stock, performance
shares and performance units to employees, directors and consultants of the Company and its affiliates. Up to 2,500,000 shares of the
Company&rsquo;s common stock may be issued pursuant to the 2017 Stock Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2019, the Company authorized a new plan (the &ldquo;2019 Stock Incentive Plan&rdquo;). The 2019 Stock Incentive Plan reserved 7,500,000
shares of Company&rsquo;s common stock for issuance in the form of incentive stock options, non-statutory stock options, rights to purchase
common stock, stock appreciation rights, restricted stock, restricted stock, performance shares and performance units to employees, directors
and consultants of the Company and its affiliates. Pursuant to the written consent of HBI dated July 16, 2019, the 2017 Stock Incentive
Plan and all outstanding option agreements were assigned to Holdco. On August 30, 2019, the Company authorized an additional 68,000,000
shares of the Company&rsquo;s common stock which may be issued pursuant to the 2019 Stock Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
6 - Stock Based Compensation (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has granted options to acquire 2,450,000 shares of common stock at $0.50 per share under the 2017 Stock Incentive Plan, and 50,000
remain available for issuance. At each of December 31, 2020, 2019, and 2018, there were options outstanding to acquire 2,450,000 shares
of common stock. As of December 31, 2020, all such options were fully vested, and the weighted average remaining contractual life for
such options is approximately 7.0 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has granted options to acquire 57,890,016 shares of common stock under the 2019 Stock Incentive Plan, and 17,609,984 remain available
for issuance. The shares issued in 2020 and 2019 and the shares exercised under the 2019 Stock Incentive Plan are included in the table
below. At December 31, 2020, there are stock options outstanding to acquire 15,390,016 shares of common stock with a weighted average
exercise price of $0.008 and a weighted average contractual term of 7.82 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes stock based activities under the 2017 Stock Incentive Plan and 2019 Stock Incentive Plan:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares Underlying Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Weighted</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Average</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Exercise Price</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Contractual Terms</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: justify">Outstanding at December 31, 2018</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">2,450,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">0.500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: right">9.2 years</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,600,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.008</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(42,500,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.003</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Forfeited/cancelled</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Outstanding at December 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,550,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">0.122</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 1.5pt">9.4 years</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,290,016</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.087</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Forfeited/cancelled</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Outstanding at December 31, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">17,840,016</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">0.110</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 2.5pt">8.8 years</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Exercisable options at December 31, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,176,581</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.170</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">8.8 years</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Vested and expected to vest at December 31, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,365,016</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.120</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">8.8 years</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
6 - Stock Based Compensation (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock option awards is estimated at the date of grant using the Black-Scholes option-pricing model. The estimated fair
value of each stock option is then expensed over the requisite service period, which is generally the vesting period (ranging between
immediate vesting and 4 years). The determination of fair value using the Black-Scholes model is affected by the Company&rsquo;s share
price as well as assumptions regarding a number of complex and subjective variables, including expected price volatility, risk-free interest
rate and forfeitures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
options granted during the years ended December 31, 2020 and 2019 were valued using the Black-Scholes option-pricing model with the following
weighted average assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify">Expected volatility</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">83.0</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">92.4</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.7</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.8</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Expected dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Expected life of options in years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Estimated fair value of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.093</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.003</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant date fair value of stock options granted during 2020 and 2019 was approximately $0.058 and $0.002, respectively.
The weighted average fair value of stock options vested in 2020 and 2019 was approximately $0.052 and $0.0021, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
based compensation expense was approximately $234,000 ($124,000 included in research and development expense and $110,000 included in
general and administrative expenses) and approximately $92,000 ($43,000 included in research and development expense and $49,000 included
in general and administrative expenses) for the years ended December 31, 2020 and 2019, respectively, and is included in the accompanying
consolidated statements of operations. The intrinsic value of stock options outstanding at December 31, 2020 was approximately $517,000
and was negligible at December 31, 2019. The intrinsic value of stock options exercised during 2019 was negligible. At December 31, 2020,
total unrecognized compensation cost related to non-vested options was approximately $92,000 and is expected to be recognized over the
remaining weighted average service period of approximately 2.0 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
in the above table are stock options granted in 2019 to purchase 6,100,000 shares of common stock at an exercise price of $0.003 per
share and stock options granted in 2020 to purchase 375,000 shares of common stock at an exercise price of $0.20 per share, which vest
upon a specified performance condition. Since the occurrence of this condition was not considered probable as of December 31, 2020 or
2019, the Company has not recognized any expense for such grants in December 31, 2020 or 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
7 - Stockholders&rsquo; Deficit</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to an amendment to the Company&rsquo;s Certificate of Incorporation filed in April 2019, the Company increased the number of authorized
shares of common stock to 250 million shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2020 and 2019, the Company issued 2,000,000 shares of common stock and 61,666,667 shares of common stock,
respectively, for the Farrington and Nanoproteagen acquisition transactions described in Note 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
2019, the founder and a consultant exercised stock options to purchase an aggregate of 42,500,000 shares of the Company&rsquo;s common
stock for total proceeds of $127,500 (See Note 6).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
8 - Income Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not have any significant current income taxes due because of the losses generated in each period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. The Company&rsquo;s deferred tax assets relate primarily to its net operating
loss carryforwards and other balance sheet basis differences. In accordance with ASC 740, the Company recorded a valuation allowance
to fully offset the gross deferred tax asset because it is not more likely than not that the Company will realize future benefits associated
with these deferred tax assets at December 31, 2020 and 2019. The valuation allowance increased by approximately $589,000 and $407,000
for the years ended December 31, 2020 and 2019, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
components of the Company&rsquo;s deferred tax assets at December 31, 2020 and 2019 are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Deferred tax assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: justify">Federal net operating loss carryforward</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">424,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">149,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify">State net operating loss carryforward</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">182,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: justify">Capitalized R&amp;D costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">199,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">106,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify">Acquired In-process R&amp;D</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">205,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">134,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: justify">R&amp;D Credit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Accrued expenses and other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">99,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">98,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total deferred tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,175,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">586,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,175,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(586,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Deferred tax asset, net of valuation allowance</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax benefit for the years ended December 31, 2020 and 2019 differ from the amounts computed by applying the U.S. Federal income
tax rate of 21% to loss before income tax benefit as a result of non-deductible expenses, tax credits generated and increases in the
Company&rsquo;s valuation allowance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify">Income tax benefit at the federal statutory rate</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">(508,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">(320,000</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: justify">Permanent differences and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">117,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify">State income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(167,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(144,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: justify">R&amp;D Credit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(31,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Change in Valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">589,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">462,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Effective income tax expense</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 8 - Income taxes (continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2020, the Company had available net operating loss carryforwards of approximately $2,020,000 for federal income tax purposes,
all of which was generated after 2017 and can be carried forward indefinitely under the Tax Cuts and Jobs Act. At December 31, 2020,
the Company had approximately $66,000 of federal research and development (&ldquo;R&amp;D&rdquo;) tax credit carry-forwards. If not utilized,
the federal R&amp;D credits will begin to expire in 2038.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2020, the Company had available net operating loss (&ldquo;NOL&rdquo;) carryforwards for state tax purposes of approximately
$2,020,000 generated from 2018 to 2020 with a 20 year life which will begin to expire in 2038, unless previously utilized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sections
382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state regulations, contain provisions that may limit the NOL
carryforwards available to be used to offset income in any given year upon the occurrence of certain events, including changes in the
ownership interests of significant stockholders. In the event of a cumulative change in ownership in excess of 50% over a three-year
period, the amount of the NOL carryforwards that the Company may utilize in any one year may be limited. Although the Company has not
undertaken a formal analysis, it is likely that such an ownership change occurred during 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (&ldquo;CARES Act&rdquo;). The CARES
Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund
a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19
pandemic, some of the more significant provisions which are expected to impact the Company&rsquo;s financial statements include removal
of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years,
and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and
Jobs Act. The Company has concluded that the CARES Act did not have a material impact on its financial position, results of operations,
or cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 27, 2020, the United States enacted the Consolidated Appropriations Act which extended many of the benefits of the CARES Act
that were scheduled to expire. The Company evaluated the impact of the Consolidated Appropriations Act on its consolidated financial
statements and related disclosures, and concluded that the impact is immaterial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
9 - Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in Note 4, the Company entered into the Notes with the Holders commencing in May 2017. The Holders of substantially all of
the Notes are the Company&rsquo;s founder and Chief Executive Officer and third parties that are family members of the founder and Chief
Executive Officer. &nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the above Notes, the Company has amounts due to the founder and Chief Executive Officer that totaled $200,000 and $255,068
at December 31, 2020 and 2019, respectively. The balance comprised of expenses paid on behalf of the Company by the Chief Executive Officer
of $55,068 (which was converted into a convertible promissory note in 2020) and $200,000 for accrued compensation (See Note 10) at December
31, 2019. At December 31, 2020, the balance comprised $200,000 for accrued compensation (See Note 10). There are no established terms
for repayment of such amounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
10 - Commitments And Contingencies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Small
molecule analogues</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2019, the Company acquired a series of small molecule analogues pursuant to an asset purchase agreement (&ldquo;APA&rdquo;).
Pursuant to the APA the Company is required to make a payment of $50,000 upon the raising of at least $2 million in funding, and
up to $1.75 million based upon successfully meeting clinical and sales milestones. As of December 31, 2020, such fund raising requirement
was not met, no payments were made under pursuant to the APA. The Company included, in accounts payable at December 31, 2019 and 2020,
the $50,000 required initial payment. Milestone based payments, if any, will be expensed as incurred. The $50,000 consideration is recognized
as a component of acquired in-process research and development expense in the accompanying consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employment
agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2019, the Company entered into a three year employment agreement with its Chief Executive Officer which provides a specified
base salary and bonus annually. The employment agreement also provides the Chief Executive Officer with certain benefits while employed
and if employment cease. The Company has accrued $200,000 related to the Chief Executive Officer&rsquo;s base salary as per the employment
agreement which is included in due to founder in the accompanying consolidated balance sheet as of December 31, 2019, which remains outstanding
as of December 31, 2020. No bonus was approved by the Board of Directors of the Company for the years ended December 31, 2020 or 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2020, the Company amended the employment
agreement pursuant to which, in lieu of a cash base salary, the Chief Executive Officer will be compensated with stock options to purchase
200,000 shares of common stock per month (at an exercise price based upon the most recent fair value of the common stock) effective January
1, 2020 until the Company receives a minimum of $3,000,000 of gross proceeds from the sale of the Company&rsquo;s securities,
after which time, cash compensation, pursuant to the employment agreement, shall be paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the Chief Executive Officer acts as the &ldquo;finder&rdquo; of an investor who purchases more than $3,000,000 of the Company&rsquo;s
equity, he will receive a grant of options to acquire 20,000,000 shares of common stock of the Company at an exercise price of $0.007
per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
11 - Subsequent Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events through May 17, 2021, the date on which these financial statements were issued. No significant
subsequent events through this date would have had a material impact on the Company&rsquo;s consolidated financial statements as of and
for the years ended December 31, 2020 and 2019 other than described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employment
agreement amendment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 1, 2021, the Company amended the employment agreement with its Chief Executive Officer to provide a revised base salary pre-funding
(as defined in the employment agreement). In lieu of cash base salary, the Chief Executive Officer will be compensated with stock options
to purchase 500,000 shares of the Company&rsquo;s common stock per month (at an exercise price based upon the most recent fair value
of the common stock of the Company) effective January 1, 2021 until funding meets or exceeds $5,000,000, after which time, cash compensation,
pursuant to his employment agreement, shall be paid. &nbsp; The amended employment agreement also provides for a future base salary for
the Chief Executive Officer after the Company receives funding greater than $5,000,000, or completes an initial public offering or similar
transaction, as defined.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the Chief Executive Officer acts as the &ldquo;finder&rdquo; of an investor who purchases more than $5,000,000 of the Company&rsquo;s
equity, he will receive a grant of stock options to acquire 20,000,000 shares of common stock of the Company at an exercise price equal
to the most recent fair value of the Company&rsquo;s common stock. This clause replaces the previous &ldquo;finder&rdquo; fee agreement
mentioned in Note 10.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
11 - Subsequent Events (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible
notes payable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
January 1, 2021 to May 10, 2021, the Company entered into Subordinated Convertible Promissory Note Agreements with the Chief Executive
Officer pursuant to which the Company issued subordinated convertible promissory notes in the principal amount of for $360,000 and $153,025,
to its Chief Executive Officer and other investors, respectively. Interest on the unpaid principal balance accrues at a rate of 5% per
annum, computed on the basis of the actual number of days elapsed and a year of 365 days. Unless earlier converted into shares of Equity
Securities (as defined in Note 4), the principal and accrued interest shall be due and payable by the Company on demand by the holders
at any time after the earlier of (i) three years or (ii) the closing of the Next Equity Financing (as defined in Note 4).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
notes will automatically convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares
of such Equity Securities to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued
interest due on the note on the date of conversion by the lesser of (i) 80% of the price paid per share for Equity Securities by the
investors in the Next Equity Financing or (ii) an equity valuation of $50 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
option plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2021, the stockholders of the Company approved an increase in the number of shares authorized for issuance under the 2019 Stock
Incentive Plan by 15,166,666 shares. From January 1, 2021 to May 14, 2021, stock options to acquire an aggregate of 4,512,500 shares
of common stock were granted at an exercise price of $0.2963 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, the Company modified the stock option exercise price for stock options granted during 2020, increasing the exercise price
of such stock options from $0.0068 or $0.0984 to $0.0019 or $0.1146 per share. The increase in the stock option exercise price will be
accounted for as a modification in 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Shares
of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="logo_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PRELIMINARY PROSPECTUS</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 (25 days after the date of this prospectus), all dealers that effect transactions in these securities, whether or not participating
in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealers&rsquo; obligation
to deliver a prospectus when acting as an underwriter and with respect to their unsold allotments or subscriptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 141 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II&mdash;INFORMATION NOT REQUIRED IN PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
13. Other Expenses of Issuance and Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth all expenses, other than the underwriting discounts and commissions, payable by the registrant in connection
with the sale of the securities being registered. All the amounts shown are estimates except the SEC registration fee and the FINRA filing
fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Amount to</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">be paid</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 86%; text-align: left">SEC registration fee</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">*</TD><TD STYLE="width: 1%; text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">FINRA filing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">The Nasdaq Capital Market initial listing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Transfer agent and registrar fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Printing and engraving expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Miscellaneous</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>*</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    be filed by amendment.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
14. Indemnification of Directors and Officers</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
102 of the DGCL permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders
for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to
act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a
stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our Amended and Restated Certificate
of Incorporation provides that no director of the Company shall be personally liable to it or its stockholders for monetary damages for
any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the
DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or
a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in
related capacities against expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably
incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party
to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and
in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding,
had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation,
no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable
to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the
adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity
for such expenses which the Court of Chancery or such other court shall deem proper.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 142; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
consummation of this offering, our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws will provide indemnification
for our directors and officers to the fullest extent permitted by the DGCL. We will indemnify each person who was or is a party or threatened
to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of us)
by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to
serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership,
joint venture, trust or other enterprise (all such persons being referred to as an &ldquo;Indemnitee&rdquo;), or by reason of any action
alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&rsquo; fees), judgments, fines and
amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom,
if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests,
and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful.
Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws will provide that we will indemnify any Indemnitee
who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the
Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as
a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture,
trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including
attorneys&rsquo; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection
with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably
believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue
or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication
but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to
the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses
(including attorneys&rsquo; fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee
under certain circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the consummation of this offering, we intend to enter into separate indemnification agreements with each of our directors and executive
officers. Each indemnification agreement shall provide, among other things, for indemnification to the fullest extent permitted by law
and our Amended and Restated Certificate of Incorporation against any and all expenses, judgments, fines, penalties and amounts paid
in settlement of any claim. The indemnification agreements shall provide for the advancement or payment of all expenses to the indemnitee
and for the reimbursement to us if it is found that such indemnitee is not entitled to such indemnification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we carry officer and director insurance for claims based on acts or omissions of such officers and directors in their capacity
as such.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
any underwriting agreement we enter into in connection with the sale of common stock being registered hereby, the underwriters will agree
to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities
Act against certain liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
15. Recent Sales of Unregistered Securities</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is information regarding securities issued by us since during the prior three years that were not registered under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From May 2018 to December 2018, the Company issued
convertible promissory notes in an aggregate principal amount of $274,316 to certain investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From May 2018 to December 2018, the Company
granted stock options to purchase an aggregate of 1,290,000 shares of its common stock at a weighted-average exercise price of $0.50
per share to employees, directors and&nbsp;non-employee&nbsp;service providers pursuant to its 2017 Stock Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2018, the Company issued an aggregate
of 25,666,667 shares of its common stock in connection with the stock purchase agreement to acquire HSB-1216.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">From January
2019 to December 2019,</FONT><FONT STYLE="font-size: 8pt"> </FONT><FONT STYLE="font-size: 10pt"> the Company issued convertible
promissory notes in an aggregate principal amount of $580,885 to certain investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">From January 2019
to December 2019,</FONT><FONT STYLE="font-size: 8pt"> </FONT><FONT STYLE="font-size: 10pt">the Company granted stock options
to purchase an aggregate of 52,600,000 shares of its common stock at a weighted-average exercise price of $0.008 per share to employees,
directors and&nbsp;non-employee&nbsp;service providers pursuant to its 2019 Stock Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2019, the Company issued an aggregate of 61,666,667 shares of its common stock in connection with the Contribution and Exchange
Agreement pursuant to which the members&nbsp;of Nanoproteagen exchanged 100% of their membership interest in Nanoproteagen for shares
of the Company&rsquo;s common stock and Nanoproteagen became a wholly-owned subsidiary of the Company.</FONT></P>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From January 2020 to December 2020, the Company issued
convertible promissory notes in an aggregate principal amount of $1,287,068 to certain investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From January 2020 to December 2020, the Company
granted stock options to purchase an aggregate of 5,290,016 shares of its common stock at a weighted-average exercise price of $0.087
per share to employees, directors and&nbsp;non-employee service providers pursuant to its 2019 Stock Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2020, the Company issued an aggregate of 2,000,000 shares of its common stock in connection with the stock exchange agreement
with Farrington pursuant to which Farrington became a wholly-owned subsidiary of the Company.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">From January 2021
to May 14, 2021, the Company issued convertible promissory notes in an aggregate principal amount of $513,025 to certain investors</FONT><FONT STYLE="font-size: 8pt"></FONT><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif">From January 2021 to May 14, 2021, the Company
granted stock options to purchase an aggregate of 4,512,500 shares of its common stock at a weighted-average exercise price of $0.2963
per share to employees, directors and&nbsp;non-employee&nbsp;service providers pursuant to its 2019 Stock Incentive Plan.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing offers, sales and issuances
were exempt from registration under Section 4(a)(2) of the Securities Act or Rule 701 of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
16. Exhibits and Financial Statement Schedules</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Underwriting Agreement</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate
    of Incorporation</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
    to Certificate of Incorporation</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
    to Certificate of Incorporation</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen
    Stock Certificate evidencing the shares of common stock</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Underwriter Warrant</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Sheppard, Mullin, Richter &amp; Hampton, LLP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1+*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
    Agreement by and between the Company and Randy Milby dated January 1, 2019</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2+*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
    to Employment Agreement by and between the Company and Randy Milby dated January 1, 2020</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3+*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
    to Employment Agreement by and between the Company and Randy Milby dated January 1, 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">10.4+*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Amendment to Employment Agreement by and between the
    Company and Randy Milby dated January 20, 2021</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5+*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hillstream
    BioPharma, Inc.</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 2017 Stock Incentive Plan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6+*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hillstream
    BioPharma, Inc.</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 2019 Stock Incentive Plan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Subordinated Convertible Promissory Note&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Mayer Hoffman McCann P.C., independent registered public accounting firm</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Sheppard, Mullin, Richter &amp; Hampton, LLP (included in Exhibit 5.1)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    be filed by amendment.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    a management contract or any compensatory plan, contract or arrangement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Financial
Statement Schedules</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedules
have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements
or notes thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
17. Undertakings</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates
in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Insofar as indemnification for liabilities arising under the Securities
Act may be permitted to directors, officers and controlling persons of Hillstream BioPharma, Inc. pursuant to the foregoing provisions,
or otherwise, Hillstream BioPharma, Inc. has been advised that in the opinion of the SEC such indemnification is against public
policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such
liabilities (other than the payment by Hillstream BioPharma, Inc. of expenses incurred or paid by a director, officer or controlling
person of Hillstream BioPharma, Inc. in the successful defense of any action, suit or proceeding) is asserted by such director, officer
or controlling person in connection with the securities being registered, Hillstream BioPharma, Inc. will, unless in the opinion of its
counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction, the question whether such
indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such
issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The undersigned hereby further undertakes that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
For purposes of determining any liability under the Securities Act the information omitted from the form of prospectus filed as part
of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by Hillstream BioPharma, Inc. pursuant
to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time
it was declared effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
For the purpose of determining any liability under the Securities Act each post-effective amendment that contains a form of prospectus
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial <I>bona fide</I> offering thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement on Form S-1
to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Bridgewater, State of New Jersey, on the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; day
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
    BIOPHARMA, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randy
    Milby</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer <I>(Principal Executive Officer and Principal Accounting and Financial Officer)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-1 has been signed by the following
persons in the capacities and on the dates indicated below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 36%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 42%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer&nbsp; and Chairman of the Board of Directors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;,
    2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randy
    Milby</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Executive Officer and Principal Accounting and Financial Officer)</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 146; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>












































</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo_001.jpg
<TEXT>
begin 644 logo_001.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !B ,P# 2(  A$! Q$!_\0
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M51_PDFL_]!K4_P#P-E_^*K.HHY5V T?^$DUG_H-:G_X&R_\ Q5'_  DFL_\
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M\0VL&@K+##J=]).D;F7!90Q.#CC-?,S^L?V=JX\MEWOT^1V+E]KYGSC^Q_\
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M1ZTK_@?_ *+:CN&FFFYS^J:?)I.I7=E*09+>5HF*]"0<9JM6WXW_ .1RUO\
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M.BT3O_7<B$7>_FSJ:^5/V,?B;HVF^ _&<'B3Q=96]^OC/6 D>K:F@E6(3 (
M)'R%X..WI7U77QA^QW\$/AY\2/!7C75O$_@O0O$6IKXUUB 7FHV,<\H19_E3
M<P)P,GCWKFH*'L*G/M>.WS+E?F5O,[3P)XNA\3?MV^+ETO75U;15\#VK(EG>
M^?;++]K(8@*Q4/C&3UP17TW7R=\*O!/AWX>_MX^,=&\,:-8:!I@\"VL_V+3H
M%ACWM=_,^U0!DX'/L*^L:G&<O-'EVY5^04[V=^Y\^_M?ZM?:UI/@KX9:/?76
MGZKX\UR&QEN;%RDT%A#^_NY58$%2$15S_MU9_8S\8:AK7PEF\-:]/)/XF\%:
MG=>&]1:XD+RN8'/E2,3R=T1CY/7!KSG4M#\2?M _M<>+-4\*^,&\(VOPXL(M
M!@U*&PBO2]W< RW2A)?E!"B-2PYX [FI/A?I>N? +]L*^\/^)?$C>)H?B9H_
M]H1:I)916?F:A9_*R>7'\F[R#G(Y/&>:[73C]7]C=<R7-;6]]^UOA\^AG=\_
M-TV_KYGUW7R)XD^'FD_&']N#Q5X>\4RZI>:+I_@^RO;:QMM5N;6*.9IV4OB*
M1>2#7UW7QYKWPK\*?%[]O#QEI7BW2UU>RMO!=C<10FXEA*.;AUW9C93T)'6N
M3!OE<W>WN[K?=>AI4Z>IT/[-L]YX3_:"^)WP\T/Q%J7BGX>Z+965S;R:E>->
MMI=])N\RS6=B21M&[822O ZYS]15\O\ [+5JGP?^,/Q/^"D$F=#TK[-X@\/I
M*H\U;2Y!$J,^-T@248#-D\\FOJ"IQG\6Z[+7OHM?5]1T_A/A.Q^(&L>$?VWO
M$7BBXU6\?PE>>)X/ UW9R7#&W@DFT^*6WD"$[5/G1[20/XCZUV_[?'B35M9T
M"P^'OAW4+K3[Z?3M1\3ZG<6,S12Q6-A;LZC<I! DG,2^^TBN.M?AM+\8/AC^
MU/'I_P VL'QO>76E3+RR7=C'"T.WW+)M_P"!5J?"/4)?V@? _P 9?C'>P/&F
MM>&6\-:3'+P8X(+-FNBH[![J23_OV*]=J*G&M_(DOG96_-_^ G/K9Q[GT]\$
M]4;6O@WX$U"21II+K0;&9Y'8LS,UNA))/4YS7:5X_P#L?ZG_ &Q^R[\+[K=O
MSH%JF<Y^Z@7_ -EJ;]JSXFO\)?@)XLURU;&K26W]GZ9&#AGO)R(H0OJ0S[O^
M FO$E2<L0Z4=[V_$Z5*T.9GR]I_Q%UV/XXV/QVDU>\/@35O&TW@=;-KAQ:+I
MXB%O#=;,[>;J-V+8_G7WW7Q;K7[&?C^/]FE_ L?Q0FN-.L]*$D'AU="M0GVF
M/]^L8N!^\SYP^_G=SGVKZ%_9I^**_&3X&^$/%3/NO+NR6.^7()2ZC_=S ^AW
MHQQ[BNW&*%2"J4VFHOETOM]F^BUW,J=T[/KK_F:NK_!GX?ZYX@?4]2\#>&]0
MU*9C)+>76D6\LSO_ 'F=D))XZDUV=K:P6-M%;VT,=O;Q*$CBB4*B*.@ ' %%
M%9XK^' J&[):S/#OAO2?"NF_8=%TNRT>Q\QI/LUA;I!'O8Y9MJ #)/)/>BBN
M*/\ #EZK]33JC3KB/'OPN\&>-+JUN_$/A'0M>NT8(L^IZ;#<R*OH&=20***Z
M<%_&1%3X3KM-TVST>QALK"T@L;*!=D5O;1B..-?15   ^E6:**XY_$S1;%"U
MT'3+'5+W4[;3K2WU*^"+=7D4"K-<!!A!(X&6VC@9)QVJ_1155-UZ+\A(*S]&
M\/Z7X=MY8-)TVSTN":9[B2.S@2%7E8Y=R% RQ/4GDT441^"7R![H6/0-+BUN
M764TVT35Y81;2:@L"BX>('(C,F-Q4'G;G&:OT445-UZ($9^D^']+T)KQM-TV
MSTYKR=KJY-K D1GF;[TC[0-SG RQY-)J/A[2M6OM/O;[3+.]O-/=I+.XN+=)
M)+9F&&:-B,H2."1BBBMO^7K]/T%T-&J$>@:7#K4VL1Z;:)J\T*V\NH+ HN'B
M!R$:3&XJ#R 3BBBL:>TO0;Z"'P_I?]N#6O[-M/[8\C[+_:'D+]H\G.[R_,QN
MV9YVYQGFM"BBBIT] 74HZ5H>FZ$MRNFZ?:Z>MU.UU.+6!8A+,WWI'V@;G.!E
MCR<4ECH.F:7I?]F66G6EGIN&7['! J0X8DL-@&.223QSDT45K/=^J_42Z#](
MT>P\/Z;;Z=I=C;:;I]NNR&TLX5BBB7T5%  'L!4>L>']+\10P0ZKIMGJ<4$R
M7,,=Y DRQRK]V10P.&'9AR***2_C?,/LFA6?H?AW2O#-F]IH^F6>DVKR-,T%
:C;I"AD8Y9RJ@#<3U/4T45G'^'+Y?J/JC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_006.jpg
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %W ,0# 2(  A$! Q$!_\0
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M9 '4_H*7*[ASJQJ451N;]1<QVMNZ/<,X#*.=B]235VE8JXM%)2]J0PHI*!0
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MT82;E#8NA.<?<GNSKAR!D8]J44R)71,22;V[MC%/KD.P6BBB@ HHHH ****
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M/;TKHM.MS::?! PP47!YJRRAE*L,J1@@]ZB5>6RV1<</'=[LR]-LCIER\5N
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MKJ$D\P1X452VW(<DYV!^F/0XH N>8W_/%_S7_&CS&_YX2?FO^-244 1F1O\
MGBY_%?\ &J\ESB^M8#$X9][#.,8 Y[^X_.KE9Z_O?$$A[6]L%'U=B3^B+^=
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M#/'[WQ Q[6]L!^,C<_\ HL?G6A6?IO[RXU"X_OW!1?H@"_\ H0:M"@ HHHH
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M54$ @@C(/:@#EX')!^RW$<ZH,$1L&Q@YQCMP>IK2T2W@B^TR1VZ12L^V1D&
M^.GU^M3W.BZ?=,)&ME25?NRQ?(X_$<U:M[=;:%8U9WP,;G.6/U- $PHH%% "
M5E:I;L%:82B.$ ,^[IUZ^M:M(0#U /UH YNVM;JX&Z&U**P&9;DXSSG.SJ>W
M7%:<6BP;UDNV-U(N-OF*-J_11Q6E37W;3L^]VH JSWJP2+ (69WR$4=_\!5?
M[-<2*_F7SJLO"HF!L^AZFJT4[M?RL_.&*AMV1]!6D+A60,ZKN'.>PJ[VV(MS
M:LI;+F"0>5=/+A>(I.A_X$.E7[.[^V1LWE/$5;:5<8(/^%5@Y$DC.Q*<$?+P
M/\:1<)?0DL5!!5N< \9']:&[[A:VJ+.IP-<Z7=PI]]XF"^S8X_6N=:X.NZK(
M]P[#3;&**80*<":1@'W,>X4;<#UYKK*Y6 )''JT.!F._SP#@ A<#CL!@?A54
MNK(J]$69)7N6+LQ&YLHBG(/?&/7UJ$0-%+]UD);*9&,?0U)S)9W(CC9Y'@VQ
MHC;2>>0#5#3+IPMU8^4[1 ;R[\-&^, 8^H P*BIB?9U52MHRH8?VE-U+ZHT9
M$_M+3Y;:4E;B!?.@N,Y9&'0_7CGL:G\.W+:C#-J+@!IMB\=/E09_\>+TRR"_
MVD"QW!48M@'K[_K4_AI0NAQ,@VQN[O&OHI8D5I46A%-Z_P!=#6JK>7T=G&68
M%SG&U<9)]![U:K U%%6^D\Q6?=R!O &,>C<=C^513BI.S-*DG&-T5]KS),TY
MQ)*^_:O(]@.Y(''YTYXG$[,RLOF< ,N/\]:=*RKI]](HD9DB"J(3\PSU(]/_
M *U9^EW6$N;=09+8J&:1\@H<>_3'],YI3Q7)6C2MO_7Z"AAN>DZC>QKV%P8;
ME5:-F78P4@Y. <X_GTK;5E= RG*D9!KC+[5+:SXDD473KFW@;.7/OMY7(R!7
M51W3B.W#VDJ22 90 $1_4]*TJPV9%*>Z+.1G&1GTI:H/:%'9C;I.I);.<./\
M:1$LG<+^\C/9&8K6=D:\S-"BF1Q)$NU!A>N,T^I*%%% HH 2BBB@ I&7<I7)
M&>,CK2T4 <D0;:\E16+;7(8ELGKFKT%PLH;S&5HST!%6M2TDW+*]OMC8<M@?
M>]JP?*GCD;?"ZE&*DE20/<'TK1J^J(32T9N&Z4;V<[4'W>,FF6\HNKF*,*9!
M%\SD]LCC\:S8+>YN67RD;:Q'SL" 1[5T-A8)8JX5RY<Y+'J:5K;A?FT1; P,
M"N>F:+2]4NHKT>79:BX=+@=%DP%*,>V<9!^M=#4<\$5U \$\:R1.,,C#((I1
ME;<)QNM#"FMIK9G9E:6'.5D'11CC '/X]Z%6>9L)!)(^"3YAQCT//>IUT![0
M8TW4KJU3.?*<^:GX!N1^=/71[J1<7FL7<H)R5B"Q#]!G]:VYX]S'DEV_(H3Q
M3RE])LY"US,@^V7(X$"'L!_>(S@?C7100QVUO'!$NV.-0BCT &!3+2SM[&#R
M;:,(F<GN6/J3U)J>LISOHC:$.75A6;JUMYL22(0'WJI)Z;<UI4R6-9HFC<95
MA@U,79W*DKJQSUM,[()AOMR,A >I4'H1TYP:#"US*1NC\L,KR,"%+<\C\:T6
MTLLY+.K9_B;.?RS5JWL8K=MX4%_7;C'T%;.I&]UN8*G+9[',:0LLVKWVK75K
M;031R-;6S*659QVY/';'UK9>]L=+M4O9H9()+C@QN<MGJ1C/\JO?8+<M-N3<
MDP&^,\KQGD#UYK&\5SB!+1FARH8GS^08ST^5AP"?>N?%U^6FY1-\-1O-19KV
M.I6^H"3R20T1 =6ZC(R/TJRZ+(NUU##T(S7"6>J-I=RT6G_O8"28XHH69I?0
MLW<D]3VKO%)* E=I(R1Z5AAJ_M5KNC>O2Y'Y,7H,4445T&(HHH%% "4444 %
M%%% !1CVHHH  H4    = **** "BBB@ HHHH **** "BBB@ HHHH *"H8$$
M@]C110!F6F@V5G??:XA*9.=H:0E5SUP*TZ**F$(P5HJQ4I2D[R=PHHHJB1:*
%** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img_001.jpg
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" ", $H# 2(  A$! Q$!_\0
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M;SX"^//^)AHNO6^G-,[0KY@L-5AC4_,P7=:W,:9.]-PW>7'O_H_*Y.:^4_\
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M?V+_ (->/O\ @YZ_X*T^*OVQ?VE[/48_V?/A;>1V^D^%YYG$,]H)&:QTA6'
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M2?\ !(OXL>%/!NG276M>&]/MO%&F6\*[GD.G7"7$JJ.[&V%R HY8X'>O!/\
M@W-\;?LQ_P#!2[_@C;X7_9F_:"^''AGQPWPDUA]$UWPWXHTN*\A78\L^GW?E
M2J0!]GF,:L0?FAD'&* )%_X/&?\ @DH%PVA?%S/?_BBK;_Y,I?\ B,:_X))?
M] +XN?\ A%VW_P F5]??\.:/^"36W<W_  3@^#.?[H^'=A^7^K_^M3A_P1D_
MX),,-R_\$Y/@OC_LGMA_\:H ^/\ _B,:_P""27_0"^+G_A%VW_R91_Q&-?\
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M+I62<1W5H=TUJS8$D0*;C^_V_P!&]><_M6?LJ? W]M/X%Z_^SG^T9X(M]?\
M"OB*U\J\LYOEDA<<QSPOUBFC;#I(O*L,^N0#Q3X\_MZ?%KQC^P[I?[<7_!+C
MX1^'_CYIMW9'47\/Q^()M/OKRP"G>+4+#(6O(GRKVL@23*R*H,@6-OR]?_@\
M%_;(AD:*7_@D;=!E8A@WB/4P0<].=.XKS#Q)X!_X*8_\&FW[1=YX\^&@NOBK
M^S#XLUE&ODN-R6DC,0JQW14,-,U-5PB7 'DW "Y5P/)B_;3_ ()U?\%3?V/_
M /@IU\*8_B-^S)\0X[B_M;='\1>#=3V0:QH;MQMN+?<?D)^[,A>)^=KD@@ '
MY,_\1A/[8G_2(ZY_\*34O_E=1_Q&$?MB]O\ @D;<\]/^*DU+_P"5U?OB'#8(
M[U\]?\%#/^"G/[(7_!,SX5/\4/VG_B7'8SSPN=!\)Z:PFUC6Y!_!;6VX$@'
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M]Q_R8M\'?Q^&.D__ "/2_P##NK_@GY_T8M\&_P#PV.D__(] 'YII_P 'K/\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img_002.jpg
<TEXT>
begin 644 img_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Z %L# 2(  A$! Q$!_\0
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MY\0\[:,!L'D9 '%=K16D*CBK %<Q>Z=<Z?JTMQ::9_:%G<R+<-"LBH8;A?\
MEH-Q ^8=?<>]=/14QDX@8/\ ;.L_]"Q=?^!4/_Q54]3N=4U2R-M-X6NF3<K[
M#=PA7*G(#?-RN0,BNJHJE-)W4?S S=$TY]-T\+.XDNYG,US*/XY&ZX]AP![
65I445#;;NP"BBBD 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img_003.jpg
<TEXT>
begin 644 img_003.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "& *D# 2(  A$! Q$!_\0
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M, .R+#AT0%OF^4[3FQI?[4,/P?\  7AZV^._P\U[PU?:A-#8:='=+!,DSE>
M98I6CC957+"0H3@[0W-5?'R?M*?%CXA>%OB'\(;32K/PO8K,9[?7=0>*6X9P
M MR@A23*[-ZA689W9QS7YK6EE_\ 9\)81U7CW&G*:C=56KJ_/?2V^GR1[$5/
MF]ZW)K;L>^QE=G(KS']KS7=1\+_L_>(O$?A_1+G4=6L88KC1[6Q4M.UTLR&)
MHEP3(ZMAA&N6?:4'+5BZ]^U]IW@+XPZ/\"?B/X,FTO6-7M5FL[I;Q9+6\!?9
MBW8 ,[!OO*RH5&#R"#7RMI__  4G^,?Q-_;N^(/[&?PT^#]OXH\9>$-0O?\
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ME-ZVDF]4I=SA/VC?VH?V(/\ @HQ^PQJ'P\M/B9"UI\0EBTVSM0VV\L+\,UQ
M9D##RMCVV_+-M8(,%@XS\Q_\.0?^">/_ $=1X[_\*&T_^1Z^UOBCX+FU/Q_X
M?_9A^$WP$T/5/AKI5G&FL0Z?I]BMKH-WOS$62;&"L67580S@M\PPP#=#_P .
MTOV5_P#H2%_[XC_^(KX+B"7'&99Q4CE7+[*G:-Y0T;M=N+OJOR/ML!Q1B,EC
M.GEU:=*G*3DH\RNO5VWLCZ,HHHK]M/AR.YE\F(R'M67-=ZM<?O;*Q\R/)Y\P
M#O[GVJ_J;C[&]5] <#0X23_>_P#0S0!@^-/A]X%^*NA_\(;\5_ FE:YI\DB2
MMI^KV<5S#O0Y5MK@C<#R#U%+XHU=_ WA.\OO#GAQKB'2=/>2/3;&-0S+'&2(
MXUX&2%V@<"KVF7*W=]-J+/F-GQ'@Y&!_^JHM0U2RT;4&U74+N.&S\MOM$TTF
MU(@!G<2>  .OH,FN=T*7.YQ2YVK7LK^@I\TH<L6?&/Q9_:$_:*_:%^%WAOXS
M>$?@M=Z%H_AOQ9;2ZO'9S#4-0N%Y!\A8D5@L1QOPP).1@A<GRKXB?%OQG_P3
M^OKC]KKX\:MJ/V4R?9-+T?\ X0!X9+J&6X:2*$WL>V&*68_-*9 6! 8[C@#]
M'M8\3>&K[PK9^*=.UVRFTNX"74.HPW"M;O"R%A*) =I0J00V<$'-<Q^T!>?L
MW:G\&[I_VC[?PMJ7@N\,2W4/B:WANK&Y8L/+&R4,KDMC: "<XQ7Y[F'!>7XG
M.)8W$8J3FHJ\;J*O%W4FE;;;\S?*<13RUTJF8.4X0OSN_+S1>]^GIV/@3]@[
M]O+]GO\ X*I_M#Z7XX^)7[*?B.?X@>$_$EQ_PC>J:';LUAX?T?:9;5M3F6Y5
M)G6>)\9C.V25"B8WO79?\%E/BAXF_97\7^&_VF/'6B:=J/P\\E-%AM[/*7T.
MLR^<ZR/M WQ&*/@.X4%"",LH.S^Q7XHT/X6^,=4\0? []G#7+C2_$##3[BX\
M.Z3MM'L;+S9+*4S.45I3!=!<R$.R)&@X0&NS\5?&GX7?MF^.?^%5_$/X>7$*
M>$]>EV^!_%4("7]\NV&&6^@<;'B43>?'$=X9O*EZHN/%S_/.$L_R.>#S&E*G
M[2:A?D<5.2>C35]'W3U/<5'(8<0?7,#1<</)J3BI)R:M;65M^W8U/@9XX^)?
M[:7_  3K_M+X'ZM>> _$6KZ:\7A?5M:\M9?)$FZ"Y,=L[FU2>'&$!,D2OCYB
MN3Z9^Q1^S&G[,GP:L_"_B&WTF?Q5>!I_%&M:=&S/J%TSNY>2>0"6?!=OGDP2
M23@9Q5K]F_\ 9Y\ ?LM^'[GPQX/US5)[21T6./5+[S5MHT+;8HN!M0%SZGD9
M)XKJ/&_QH^'?@B_&E>(O$L4-Y)8SWD-G&K2320Q#+NJ("Q&<#IR3@9-?99;1
MP6"PE&MF,84ITH\J7-=1C>T;<VMVK:_(^>Q6&HU<TEB:/-LTE=VM>^VS?G8\
MH_;2^&O[.OQK:;0/$?BF"S^(_@WP^_B#06T[5A!J-C;-(T:RE,X>"26,Q_.K
M D';AAD8G[1G[-5AI_PXTWXS_!:ZUF3Q!X-T=I(]+TEUD_MQ7$1D\U<$^8P7
M<70!VR>I(KPW3;[XC?M#?MA^.O@S^T_X>OO#3^+=)T]O!-Y8"--2ATNVOY+N
MR8* Z@)*DKS!B1G@C@8]I\'Z1\;/V4OC9I_@F :YX\\.>+&9SK47AMBVG2B3
M&RX> [%^4[O-944@8 SDGX7/L1E^9YM4JT\!ST6E2JSM^\C*]XM12]Z.SW]1
MY3C*F+PO.U*#4FDI*UTG:_HSW_X&^.]1^)WPZT_QAJGAR\TQKI,K:WUF]O)M
M'&3&_P R?0\U'K_[//P0\2?%;3/CEX@^&FD7?B[1K5K;3/$$UFINH(3N^0/C
M) +OC.=N]\8W-G<\6^+=$\%>&[_Q;XFU2#3],TRQEO-2OKE]L=M!&A>21CV5
M5!)^E>1>'_VKO!G[16C2:)^S[J-YJ4E]:%)=8FM)+:#3DD#+',S.%9F;:QC5
M,EBI)VC)'Z1*M@\IRVEA\34]I-17+S6YI-=;=_EH%3"K&7<H)Q33[I/HSS[_
M (*G_#O2H_@WI7Q-T;PY/;KHGBJ&Z\0:QH5Q';7EO:R0S0-(,C]\3))$NWEO
MFR,D5YK\,/VEOBO\--$TD:)\3_"<'PWTW7M!\-W&N:A>HDFF0S6B((!;%$1)
MHFV!RS$;27P1PFI^U!\#/CI\,/V/)/@P_P :]/UY=6UK3U:Z;1OL^H/';7*W
M8CM(WG<37,@M^6PQ&TD(>67X/_9E_P"">'CS]IOXZ^+OV;O&WQD\9^./AQIO
MCRSU7Q%XAL;Z&VELM2_L[S5>;S))&$WDW[PMB,>;Y2GY0BA?S:-*./XNCBZT
M)0JJ"<J4)/2TG&+ERI7B[J]W\CWL#A^'L/@IU<;5E3]Z*7+!R<E)ZVCM=;W?
M0_27XH^(K?\ 8F^)K_M-_M ?'M=0\"^(M4M[)IKC2T673KF2!DC.]6.8"4QM
M1 P+ G< 37E=Y\5_V2_CW\0/&=]\!?$$'@[Q%JNL0K;>/+'5+XP7[X5]WE1,
M(O+N<>6Z#!D&YFRX&,W]OS]CSXC:WI/@#]FG5=,NM>_9VT.&WD\1:MKOBB)+
MZWO#,+:TB#[%F$,"L)"X+LVX+Q@[O*_^"F/@']F7]B7PIX1^&GP$^$LVDV/A
M9K/5_%VM6]I-"HM[B9K*QFEOV&R65KG*LJDR!3N8!5)'7Q)PSCZF%KX?*:5I
M)^VDG[SDVFFD[MK1:VLUT9QX[,<GP.!4X*=2JFTU%+X+KE=M[]];'Z!_L_\
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M%1\@D1N?+SW96\YL/VH/AK!/I&K:;\+]0U#QU#XSMQX@U>/2VNIXK:"' ;:
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M_ G]D_QS\0_C3IL&IZ!;>&+Q+[09-0AMWUE7A=38Q&5U5I903&J@[F+ +DD
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M>SKUERUY1BG%/FE%2>ETOQ9\'4C'+^7&8VBXU6_9^[>771;?-Z:%G]I/X<?
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26#_PF]E_SPF_[Y'^-%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img_004.jpg
<TEXT>
begin 644 img_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #A .$# 2(  A$! Q$!_\0
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M1110 51UG4XM&T6\U*;_ %=M"TA'J0.!^)P*O5Y?\:]:^RZ#9Z1&V)+V7S)
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M$@1%'8 8 KQ#X*Z)]JUV[UB1<QV<?EQD]/,?K^2C_P >KW.N7,:O-44%T.G
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M%1BHKH%%%%04%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img_005.jpg
<TEXT>
begin 644 img_005.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "/ (T# 2(  A$! Q$!_\0
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M[7]3'+Z_LL1ROL?C)_P4/U>;7/V]?C-?SJV[_A9^N0?,?^>5[+&,?@M?6/\
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M'IEQH/A7SO\ B9>-+ZW*JR=Q:(P_>N1D;B-@X/)XK]2/V>_V=_A-^RS\-8O
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M>Y%]M_O/7PN5>\IUFI6Z*Z15T[2;73;2.RLDC2&) D4<<8554>@'I[8Q5Q$
67KTIXV]12U\CZGM\L8JR04444#/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_007.jpg
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $3 1X# 2(  A$! Q$!_\0
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M.H **** "M:+P]=RO,BR0[HB%.6/)(SQQ635XZQ?F,I]HX(P2%4$\8Y.,DX
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ME56=@JJ68\  9)KJ;/P9(V&O;@(/[D7)_,__ %ZZ.QTJSTY<6\(5N[GEC^-
M'+:7X3GN,2WQ,$7]P??/^%=?:VD%E (;>)8T'8=_KZU/10 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A 8$$ @]
MC110!4ETK3Y_]99P$^NP _G59O#>D-ULQ^#L/ZT44 )_PC.C_P#/G_Y%?_&I
M$\/Z4A!%E&?]XD_S-%% %R*TMH/]3;Q1X_N(!4U%% !1110 4444 %%%% !1
1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>formdrs_001.jpg
<TEXT>
begin 644 formdrs_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #, 4L# 2(  A$! Q$!_\0
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M\EL4DB$WEM%M8*ZJV"#QD9&3UJ2Y\::[=Z9*;2S-K-'<V8^T2VL\4;K+,$9
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MMGW.^LE=-=4OR_S1GRZ;HD-U#;237"S3?ZM3>3?-U_VO8_D:L?V!IH_Y^?\
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M7'&0.>33/^$4UO\ Y\O_ "*G^-'_  BFM_\ /E_Y%3_&D_8M_%^(U[=*W+^
M^?78)R$:VD\GR7B(#J&Y8-D87 Z>E1QZS"MXT\EKN_<I&OS E2H R,@CG'IW
MI?\ A%-;_P"?+_R*G^-'_"*:W_SY?^14_P :$Z"TNOO!^W;NXO[@GUX33B06
MY&#.<;_^>@QZ=JD@\0B.!(6A<*B( T;+NW*",\J>N?PJ/_A%-;_Y\O\ R*G^
M-'_"*:W_ ,^7_D5/\:/W%K77WCOB+WL_N*5]?&]2W!4@Q(5))SN)8MG]:IUL
M_P#"*:W_ ,^7_D5/\:/^$4UO_GR_\BI_C6BJ4DK*2^\RE2JR=W%_<=-X'_Y
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M$<C7;QO@CKTZX^8"FE=V ]/HHHI %%%% !1110 4444 %%%% !1110 4444
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M ****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 -=%D0HZAE/4$9!K'N_"/AR]=I+C0]/=VZO]G4,?J0,UM44FD]RX5)P=
MX-KT=CF#\/?"_P#!ISQ#LL-W-&H_!7 H/P^\.MS);W<C?WFU"X)_]#KIZ*GV
M<.QK];Q'\[^\YZ'P+X6@.5T&Q8YSF2(/_P"A9K:MK.ULT"6MM# @XVQ(%'Z5
M/15**6R,YUJD_CDWZM_YA1113,PHHHH **** "BBB@ HHHH **** "BBB@ H
1HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>formdrs_002.jpg
<TEXT>
begin 644 formdrs_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Q 3X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BFNZ1HSR,JHHR68X %<KJOCJSMMT=@GVF0<;SP@_J?\\U<*<ZCM
M%$3J1@KR9UE8]]XHTBP)62[620?P1?.?TX'YUYQJ.NZEJA/VFY<H?^6:G:GY
M#^M9M=]/ =9O[CBGCOY%]YW5W\0E&19V)/HTS8_0?XUDS^.-9ESL:"'_ '(\
M_P#H6:YNBNJ.%HQ^R<LL35EU-9_$^M.V3J$H/M@?R%1?V_J__02NO^_AK.HK
M3V5-?97W&?M9]V::>(M80Y&HW!^KY_G5N'QEK<6,W2R =GC7^@K!HI.C3>\4
M-5JBVDSLK;X@W2X%U912#UC8J?US6_9>,](O,*\K6SGM,N!^8XKRZBL9X*E+
M;0VAC*L=]3VZ*:*>,20R)(AZ,C @_B*?7BUG?W>GR^;:7$D+]]IX/U'0UU-K
M\0+J. I<VD<TH'RNK;?S'^&*XJN"G#6.OYG92QD)NTM/R/0*RKWQ'I5CD27:
M.X_@B^<_IT_&O/M1\1:CJN1+.5B/_+*/Y5_'U_&LROG,1F;A)PA'5=_\CZ3#
M94IQ4YRT?;_,[.\\>MDBRLQCLTQ_H/\ &L>?Q;K,^<70B4]HT _7K6)17FSQ
MM>>\ONT/3IX'#PVC]^I<DU749L^9?7+ ]C*V/YU7:>9CEI7)]V-1T5@ZDWNW
M]YT*G!;)?<B1;B9/NS2#Z,:L1:MJ,)S'?7*^PE.*IT4*I-;-_>P=.#W2^Y&W
M#XMUF''^E"11VD0']<9K8M?'K# N[('U:%L?H?\ &N,HK>&-KPVE]^ISU,#A
MY[Q^[0]3L/$FEZA@1W(CD/\ !+\I_P #^!K6KQ:M/3?$&HZ60()RT0_Y92?,
MO_UOPKT*.:]*J^:_R/.K91UI2^3_ ,SU:BN=TGQ?97[+%<#[+.>!N/R,?8_X
MUT5>K3JPJKF@[H\BK2G2ERS5F%%%%:&84444 %%%% !1110 4444 %96M:_9
MZ+#F9M\S#Y(5/S'Z^@]ZSO$OBJ/2U:UM"LEX1R>HB^OO[5YQ//+<S---(TDC
MG+,QR37;A\(ZGO3T1QXC%*'NQW-'5_$%_K+_ +^3;"#\L*<*/\3]:RJ**]6,
M8Q5HH\R4G)WDPHHHJB0HHHH **** "BBB@ HHHH **** %!(/%2*X/!ZU%17
MGX[+J&,C::L^CZ_\'T/0P.95\'*\'==4]O\ @>I8HJ)'QP:EKX7'8&K@ZG)4
MVZ/H_P"NQ]W@<?2QE/GI[]5U7]=PHHHKB.T**** "BBB@ HHHH *W=%\47FE
M,L4A,]KT\MCRH_V3V^G2L*BM*=6=*7-!V9G5I0JQY9JZ/7[#4;74[83VLH=>
MX[J?0CM5JO(-/U"YTRZ6XMI"K#J.S#T(KTO1=<MM9M]T?R3J/WD1/(]QZBOH
M<)CHU_=EI+^MCYS&8"6'?-'6/Y>IJ4445W'GA1110 4444 %<OXK\3#3(C96
MC@WCCYF'_+(?XUH>(]<31=/+C!N9,K"A]?4^PKRF65YI7EE<O(Y+,Q/))KMP
MF'YWSRV./%8CD7)'<:S%F+,223DD]Z2BBO6/*"BIIK2YMU#36\L2G@%T*@_G
M3'ADC5&DC=0XRI92-P]1ZT70[,913Y89(7V2QO&V,X=2#BI/L-WYWD_99_-V
M[MGEG./7'I1=!9D%%6'T^]C7=):7"KD#+1D<GIVILUI<VX!GMY8@> 70K_.E
MS+N%GV(:*DC@FE1WCB=U09<JI(4>_I1%;S3[O)ADDVC)V*3@?A3N@LR.BG1Q
MO+((XT9W/15&2?PJ6.RNY2PCM9G*':VV,G!]#0VEN"39!14ZV5V\KQ+:S-(G
MWE$9)7ZCM43QO$Y21&1AU5A@BBZ"S&T444Q!1110 4]'QP>E,HKFQ6%IXJDZ
M51:/\/-'1A<54PM55:;U7X^3+%%1QMV/X5)7YYC<)/"5G2G\GW7<_1L%C*>+
MHJK#YKL^P4445R'4%%%% !1110 4444 %3V=W/8W27-NY21#D'^A]J@HIIN+
MNA2BI*SV/5]%UF#6;(2QX65>)(\\J?\ "M*O)-)U.;2;]+F+D#AT[,O<5ZI9
MW<-]:1W,#;HY!D'^GUKZ7!8M5X6?Q+^KGS&.P;P\[Q^%[?Y$]%%%=IP!4<\T
M=O!)-*P6.-2S,>P%25Q7CS5=D46F1/R_[R;'IV'Y\_@*TI4W4FHHSJU%3@Y,
MY/6M4DUC4Y;I\A3\L:'^%1T%9]%%>]&*BDD>'*3D[L*Z?P5#$U_=7#!6E@@+
MQ*>>?7_/K7,5<TS4[G2;P75J5W@%2&&0P/8U-6+E!Q1=*2C-29T_A[4KO7%U
M&SU-S<6YMR^YE&$8$8Z#\?PJCXF_Y ^@?]>G]%J2V\5VQ$T%SI4$5O<IMG-H
M-CL>>??KT^O-5H/%$EO MJ;2WNX("?LQN4RZ<_+G'''^37,H34^91MY?*QT.
M<'#E<K^?SN;NHV'V_P >V49!*1P)*^.P4D_SP/QJ7Q'-J4.G0ZO$KVMS$[PN
M!@_NV;Y2?R7\ZY0>)+\7-[<GRS/=IY9DP08U]$P>.WY"HXM>ODL+JSE<7$5P
M &\\EBN.Z\\'_"DJ$[QO;2W_  ?Z\@=>%I6OK?\ X']>9U'B#4;M?%%A8B8_
M9G:!FCP,$[^OZ"M+5Y7CL-<>2Z^U0^7Y:VR(,P$C&3^>:X2\URYOM5@U"5(A
M-#LVA0=IVG(SS4Z>);Q+Z]NC%;M]L39-$RDH1C'3.>F>_>E]6E:-ELOU_K4?
MUB-Y7Z_Y'6^%[2:RT6S46[.MZ[/.21\B%2%_/C\S5+PVAT.YUY9,[;783GJ5
M!8Y_$5S5WX@U"ZEB=9?LRQ(J)';DJ@ Z<9J>?Q/>7#7K-!;*UY$L4I5".!D
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M.GW13]2M?L6IW5MVBE91],\?I3%^Z/I67$DTZ%.W5_I_P3IX:@U7J-]%^O\
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MH YVBMK0]"&IM,;AWB2,A.!R6].?2GV^B6R6EQ=WUQ*D,4QB4QIDG!QD]<4
M85%2W"1)<2+!(9(@?E<C&1]*BH *Z_P9:$1W%XP^\1&O\S_2N152[!5!+$X
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MC=;868>1([AA+\YW'/7'7CTYK/HH L7UR+R]DN%B$0<@[1].O0=>OXU7HHH
M**** "NV\+Z+]EB%]<+^^D'[M3_"OK]3_*L_PWH'VEEOKM/W(.8T(^^?4^W\
MZ[2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""[M(+ZV
M:"X0.C?F#ZCWK@-8T2?2ILG+V['Y) /T/H:]&IDL4<T;1RHKHPP589!H \HH
MKI]8\*R0EI]/!DCZF+JR_3U_G]:YD@J2""".H- "4444 %%%% !1110 4444
M %%%% !1110 445-;6L]W,(K>)I'/910!#73Z!X:,^V[OD(BZI$>K>Y]JTM&
M\,166V>[VRW'4+U5/\370T ( %    '  [4M%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5F:GH5GJ8+2)LF[2IP?Q]:TZ* /
M/M1\,W]CET7[1"/XHQR/J.M8W2O6JI7FDV-_DW%LC,?XQPWYB@#S*BNON?!:
M$DVMV5]%D7/ZC_"LF?POJL!.V%95'>-Q_(X- &-15J73KV 9EM)T'J8SC\ZK
M%67J"/J* $HHIRQNQ 5&.>F!0 VBKT6CZE-C993X/<H0/UK1M_".HRG][Y4
M_P!IMQ_2@# I\44D\@CBC9W/15&2:[2T\'6<1#7,LDY_NCY5_P ?UK=M[2WM
M$V6\*1+_ +*XS]?6@#D-.\(3S8>^?R4_N+RQ_H/UKK;.QMK"'RK:)47N1U/U
M/>K%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>formdrs_003.jpg
<TEXT>
begin 644 formdrs_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %W ,0# 2(  A$! Q$!_\0
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M-).'QY(W(@.W!S\SKGD8'-3^)-=3P]H\MZ81/*H8QP;]ADVJ6;G!Z*K'IVH
MUZ*P+O7KT7^GV6GZ=#<37=JUT?.NC$$52@QD(V3\X].E2:EK-]I>B17<^GP&
M\DGC@%NER2@+R! =^S/<'[M &W16(FOR6PNUU>R^R26MJ;MS%+YR-&,YVG"G
M(QTP.HZU/IE]J=XV^[TZ&WMY%#Q/'=>8V#T##:,'Z$_X@&I1110 4444 %%%
M% !1110 4444 %%%% ')Z;JNG^&[C4K#5[N*R=[V:ZA>X(19DD;?E2>"025(
MZC'3D52:W?6]#\9S6/[UK]W2"(<,2D*Q\@]"2IQGJ,&NX*AL9 .#D9J%;*U6
M^:]6",73IY;2A<,RYR 3WH Y76-6L-?T:'2M.N5GOI9K9C;+Q)&JRHS%U/*X
M .<U;_TG4_%-[<6R6LD-A%]B'FE@0[[7D' P>/*_6NE  )( R>I]:6@#A)'>
M'X;:_I,Q3S]+MY[4A,D! FZ/KU^1E_6M'Q6GF>%]/3<R[KRR&Y3@C]ZG(KJJ
M* .:L(XM'\4WEO<2O*]W;">*YG<L^R,X>//0*NY6 ']X^YK*2PU/5O#-Y?V\
M5F9;^;^T8&9G#97:8<C']U(\CZUW5% '%SM:^)=>TI@2;:_T6X.1D$!FB_$$
M9JG/->ZUX<UF>\B83:?I5Q9L & >Y*'S& (Y& N#_M&O0** //\ 5SIR:YX?
M.J:B]A!_9<H$JW;6Y+9BXW @^O'M[5H^(9+.[\)6'V"]-S;&_M$2X6;S&.)U
M&=_.3[GO77T4 <O:)!HWB2^@NWDG^UVHGCGF)DD*(=KQ]/NC<I ']X^YJKHL
MUE#KUK;^&]1^UZ7*LAN;=)#+%;8 VE&YV9.!LSC'( P<]E2  9P ,G)Q0 M%
M%% !1110 4444 %%%% !1110 444&@ HI*4T %%)10 M%9MO>K:R_8[HM&^\
MK$[#Y9 >1@^OM3[>_&^:"Z(BEAY)8X4H3PP-5RLGF1?IJR*[,H/*G!'I5'^V
M=/9ML=P)3_TR4M_*L.\\00VT^HV\;GSI6 B)4\< ,?HO>G&G*704JD8[LZB&
M:.>,21ME3D9^E/R!UK'M]8L+6&.!Q- J#:&>%@I]\U+=W\<L=JMK*D@GG5-R
MMD =3^@I<KN'.K&I15&YOU%PEK;NCW#. RCG8O4DU=I6*N+124O:D,*:6P5'
MJ<?I2TQ_OQ_[W]#0!)1110 4444 %%%% !1110 4&B@T )3998X8R\C!4'4G
MH*=4-W-#!;L]P0(CA6)''/'/M0#)@<]*;)(D4;22.J(HR68X %9!N?[(6.1[
M@S::_P JL!N,1[<CJ#TK'U&[GU F;"2QJ"T<?)BC _B?^^_^ST%:1IN3,I55
M%>9=U'5(]2@:U6-1;S*5BDESND;L44<X!_BK&M;6YNM4_P")A*Q9B\"F3#,'
M4 A2/N^I!]Z;IMU*+T/*Q+R ;IY"-[>WL/85IZ@C&ZF>(8>:);J+WEBZC\5K
MJE3=+3N<BJ*MKV,5+R5;L0RLQ7S-I4N0!^5:E_9VQU5U$"<R6HR1ZDD_GBLK
M6HU^U)>1\+,!)'CH<UK.9#JD3R<MYEL3Z=&K:LERQE'0QI-\THO4K:K']EU4
MQ6DUQ'DY($IP23TQ3M8M9HKJ,6UW)YUJBNS;1DNYPJC'&3SSZ4[9]J\4KO\
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M=22V<X<?XTB)9.X7]Y&>R,Q6L[(UYF:%%,CB2)=J#"]<9I]24***!10 Q/\
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=SUP*TZ**F$(P5HJQ4I2D[R=PHHHJB1:*** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>formdrs_004.jpg
<TEXT>
begin 644 formdrs_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !8 &@# 2(  A$! Q$!_\0
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)110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>formdrs_005.jpg
<TEXT>
begin 644 formdrs_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !2 '(# 2(  A$! Q$!_\0
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MVE:E#=7*1C_19XHRYD3L#CN.E=;15QG96:N@.<_X22_G_P"//P_?/Z&7$?\
M.C[5XKN/]7I]C;#_ *;3%C^E='13YXK:* Q]"TF?3_M5S>S)->W<F^5T&  .
M H]A6Q1142DY.[ ****0!1110 4444 %%%% !1110 4444 %%%% !1110 44
-44 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>formdrs_006.jpg
<TEXT>
begin 644 formdrs_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !: %X# 2(  A$! Q$!_\0
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5HH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>formdrs_007.jpg
<TEXT>
begin 644 formdrs_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !B & # 2(  A$! Q$!_\0
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..1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>formdrs_008.jpg
<TEXT>
begin 644 formdrs_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !> %X# 2(  A$! Q$!_\0
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)BLBPHHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>formdrs_009.jpg
<TEXT>
begin 644 formdrs_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  : -$# 2(  A$! Q$!_\0
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M/H3BD\^'_GK'_P!]"O,OB+_R,<7_ %[+_P"A-7(T >]^?#_SUC_[Z%'GP_\
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CRJH'4YKK-&T:UT.Q6VMER3S)(1\SGU/^%:-% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>formdrs_010.jpg
<TEXT>
begin 644 formdrs_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  : %T# 2(  A$! Q$!_\0
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M?\\Y_P#OZ:ZBB@#E_P#A -"_YYS_ /?TT?\ " :%_P \Y_\ OZ:ZBB@#E_\
MA -"_P"><_\ W]-'_" :%_SSG_[^FNHHH \^\/\ @I9-2FN[Z,BSBF800OUD
2 )P3[?S^G7T$  8 P*** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>formdrs_011.jpg
<TEXT>
begin 644 formdrs_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  : %8# 2(  A$! Q$!_\0
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&13J* /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>formdrs_012.jpg
<TEXT>
begin 644 formdrs_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  : $P# 2(  A$! Q$!_\0
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=!QWA'PB--5+^_0&\(RD9Z1#_ .*_E78T44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>formdrs_013.jpg
<TEXT>
begin 644 formdrs_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" $] ; # 2(  A$! Q$!_\0
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MM4 >&X39(/<CZ^E.,*B;YEH.I&FHKEW-ZBBBF8!1110 4444 %%%% !1110
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M5G6=,BN)%NY;BY0IL4)"Y&>3VSU);]!6!ML)[F.)KV_5G!!CV'+ )T !].>
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M4 :5M:PVD?EP($3.<#\OZ5-110 5FZC?7=K.H@MVDCV9)\IF&?JIS^AK2HH
MY'6/$1-G''/ J%W&?F9?T=165XO\1VS>'F@B::)W95!4JP('494G%=CKJ%]-
M) ^ZP-<GXYL7N] AEM;2)T#!YF6,;P,>O7&>M;TK-HYJ]U%GGD+M,/(B8*)V
M52[-@#GO7J>D/I_@72!::AJ'FW3'>T:$OCTVKV%>86QALKBTNKF$36XER81P
M6VX[UZO=^&=.\3S0:HTTHCFB4E8R/FX]?T_"M:KV4MC#"I<MX;^9SFI^)O\
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MEZ?@>]34 %%%1SW$-M$9+B5(HQU9V"@?B: )*Q+M3IVI>?C]Q/PWL:4^(A=
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MI+"8%F6.-E^8%RNXY[ #CG-9LHV:*C@:5H5,Z*DG=5;(_.I*0!1110 4444
M%%%-9E12S$ #J30 ZF22I$,R.JCW-5&N9KGBV&R/_GHPZ_05"RVUN^9F,TQ]
M?F/Y5:CW(<^Q9.HQGB)))?\ =7C\Z;]INF^Y;*H_VWIHEN).(K?8/60X_2D=
M[FV DF\MX\X;:.5]Z=D3=C]]Z?\ GBOYFC-]_?A_[Y--G9WFBAC?8'R2PZX'
MI2_V>O\ SWGSZ[Z- U#S+X=H&_,4HN[E?OVN?]QZ/L+#[MU,/QS39(+B%&>.
MX+[1G:XZT:![R)!J40XE#Q'_ &UJQ'*DJYC<,/8U!&XFA5\<,,X-0FVMY'S&
MP1_6-L&ERHKF9H451$ES;_>'GIZCAA_C5F"YCN 3&W(ZJ>HJ7%H:DF2T444B
M@HHHH **** "BBB@ HHHH *R+\B/Q-I+GC>D\6?<A6Q_XZ:UZQ?$ZF*QM[]?
M^7"X2X;_ '/NO_XZQ/X4 ;5%("& (.0>012T %%%% !1110 4444 %)2USD^
MF7DB()/-:+S9R4CP&4-NP02>>M7&*EN[$RDULCHLCCD<TM<LVG7KSVS"UVE
MFTJJJ% D)YY^4XZXSZ5IW4$W]H6,KQR3-'O#O'PH!4@<$]>E4Z:74E3;Z&KD
M>M&X;MN1G&<5S7V&5M-E*V%Q%(;B-U@5AA0I'/WN> <^]7;2"^35KN4J=L@;
MYI,;>/\ 5A<<XQG/O0Z:2W!3;>QLT5C9\1^FD_G)1GQ'Z:3^<E9&ALT5C9\1
M^FD_G)1GQ'Z:3^<E %C7YYK30+ZXMFV310LZ-CH0,U?C;=&K>H!KF=FHOI/B
M4:H!N96\O9N\O;Y(^[N[9SGWS6_IS^9IEJ_]Z%#^@H LTE+10 4444 %%%%
M!1110 UW6-"[G"@9)J@ UZWF3#; .40]_<T^Z_TFY6#_ )9I\TGOZ"FR*;JX
M\@'$2#,F._H*TBK&<G?0BN];TW3POVJ\ACW<*,Y)_ 4NC3V]U \L#I*2QS(I
MSN%<CXKM9K#6YKIK)I[6>-$0JN0@'WA[$\_G6SX*TZ6T@N[AX'MH;B0-# _5
M5QU/UK:5.*I\R9G&4G.UCIJ1T61&1AE6&#2T5SFQ4@LY(YD:20,L0(08Y_&K
M=4KG6+&SO!:W$ZQS%/,PW0+G&<_6F0:]IMQ/Y,5W$9,@*,_>R,\>M#=P2L:%
M1W!(MI2.NTU477+%HED:;9O&Z-7&&=<9# =P15BTOK:_B,EK*LBCAL'H?0T
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MK(UFR/\ RVQ]5-/&JV3=+A/UHLPNBG_96J?]!^?_ ,!HO_B:/[*U3_H/S_\
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ME6=:VSR7L42\R' X_O$X_K104I0O+J>1#&U(R;>I[C!H5K:QND!>-6D>3"$
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M(/F+.N?YBKLNE6$\K2RV-M)(WWG:)23^.*9-I]K#:RM;V-L9%0E%$2\G' H
MYZZ72Y+B:3_A*(D\YPS*)U[*%P,,..,X]S5?S[$7@<^+8B%!*#?G:WTW=/\
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MP&(17TZI ZR0IM!",H4<9[<'CMN-=)110 4444 %%%% !1110 4444 %%%%
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G10!DZ+IUW8R3M>2K*SJBAP22^,\GWY _"M:BB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>formdrs_014.jpg
<TEXT>
begin 644 formdrs_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "[ 3P# 2(  A$! Q$!_\0
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M4<FNYH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% VN!EBO/'4C.U!(TUO%*\,D#N@9HI"I9"1]T[21D=."1Z$T 24444 %%%%
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M&6R_E12!E49W*T98,".>#['!!%%U+X7LKJ2VGLK42QXWA;$L%R-W)"D= 3]
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M"MH$FE2(1NB."ML6^5@Q!P%X&$8GT YQ5NUCTZ]MEG@MHC&Q(&Z#8002"""
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MM?\ GVA_[]BN:NZ#:Y/F:KVEO>^1SGB37-)O="G@M=4LIYF*[8XKA&8X8$X
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M&5/L^G*PY$(/S28[%S^@'K7)4<ZTDV]"Z4[7JR^S^+Z?YOT.KMK>*TM8;:!
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M/;'%(#:HJO9WD=[%))%@JDLD)(=6^9&*GE21U!X/(Z$ \58H **** "BBB@
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7 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>formdrs_015.jpg
<TEXT>
begin 644 formdrs_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Q 3X# 2(  A$! Q$!_\0
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M8!MOM_2J/C5V TR&5C-*D)9KG: LN<=,?0_G60NNSQB_6*VM8DO4".D:$*H
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M+=VS6\9 ,B"1QTSG"J2!ZY KG=F[J9T*ZT<#?M=!TR6[,4EIMMU,7DSF1O\
M2<J2W.<'U^7&,5SNNVL%K>0K;QJB/ DA*,2C$CDJ2<X^O/%68O"UU/=26\5W
M:/)$$+\N N[IU7TYJ)_#=W$CR3RP0Q(&+N[-A<-M[#)R1Q@=*J#C&5W.Y,U)
MQLH6,>BI)XC!.\1='VG&Z-MRGW!J.NDY@HHHI@%%%% !1110 4444 %%%% $
MR'*_2G5%&<-CUJ6OSS.,+]7Q<DMGJOG_ ,&Y^B9/BOK&$BWNM'\O^!8****\
ML]0**** "BBB@ HHHH **** .G\$WYM]5:T9OW=PO _VAR/TS^E>A5XW;3O:
MW,5Q&</&X<?4&O8()EN+>.9/NR*&'T(S7O955YJ;IOI^I\]FU'EJ*HNOYHX'
MQ_=^9J5O:@\0Q[C]6/\ @!^=<A6QXIG\_P 2WK9X5PG_ 'R /Z5CU]G0CRTH
MH^-KRYJDF%%%%;&04444 %%%% #XI##,DJ@%D8,,],BM2W\17MK)(\26X:2Y
M-PY:/=DG/'/0<GISR>:R**F4(RW149RCLS=;Q9J#R!W2W;&0 5/"E0"O7('
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M:2QM'(BNC##*PR"*=10!YQXI\+'32;VR4M:$_,G4Q'_"N5KV^2-)8VCD4,C
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M444 %%%% !7H_@JV\G01(1S-(S_@./Z5YRJEV"J,L3@ =Z]?L+466GV]L/\
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MJ6J[=?\ @GO87-(S]VMH^_3_ (!!12D$'!&#25Y;33LSUTTU=!1112 ****
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M@$G@9J187;MCZU;  Z#%%=-/*8+XY7_ Y:F<3?\ #C;UU(5MU'WCFI0 !@#
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M;9T.XCKC![4 ;FF/-'>3SVVI6@@>9VFAE?HN[[P_#O\ 2I9-3LK6VO9+.6,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>drs_040.jpg
<TEXT>
begin 644 drs_040.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %W ,0# 2(  A$! Q$!_\0
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M-).'QY(W(@.W!S\SKGD8'-3^)-=3P]H\MZ81/*H8QP;]ADVJ6;G!Z*K'IVH
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MQ6DUQ'DY($IP23TQ3M8M9HKJ,6UW)YUJBNS;1DNYPJC'&3SSZ4[9]J\4KO\
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M=22V<X<?XTB)9.X7]Y&>R,Q6L[(UYF:%%,CB2)=J#"]<9I]24***!10 Q/\
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=SUP*TZ**F$(P5HJQ4I2D[R=PHHHJB1:*** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>drs_041.jpg
<TEXT>
begin 644 drs_041.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !8 &@# 2(  A$! Q$!_\0
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MNL:#DLYP!^)KS2?X(Z+#,TVA:OK&BLQSMM;DE/R//ZTP?!>&]D7^W?%6N:M
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M=:I=)RC%>B @\]Q]3[4 =S\.-*;1OAYH=E(NV1;57<>C/\Q_G748I$144*H
M4#  ["G4 )BEQ110 4444 %%%% !1110 4444 17-O%=VTMM.@>*5"CJ>X(P
M16?H'AS2?#.G"QTBSCM;?.XA>2Q]23R:** -6BBB@ HHHH **** "BBB@ HH
%HH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>drs_042.jpg
<TEXT>
begin 644 drs_042.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !2 '(# 2(  A$! Q$!_\0
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+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>drs_043.jpg
<TEXT>
begin 644 drs_043.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !: %X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH ***K7=XEH8 T<C^=*(AL7.TGN?0<4; W8LT4@-+F@ HHHH **** "BBB@
M HJ.*>*>,20R+(AZ,AR#5%-:L9;:69+A0(RZG(Y^4X) ZD9J7)+=BN6+G4+:
MUR)9/G"[MB@LQ'3.!S7/^)KVVO-#::UU9K=H9DR8TWG(=01LZ_Y-1PZE93W=
MFUR\OVZX3YGMF*@J"2ORYSM/8]ZIO?RV.LPFST86SN&C5;N4*'4L.0<G:<GI
M]:XWB')VT:V\RX6NC=MIKJRMGD\Y+VT=3)'<*2S%F/"X&?EYZYIL'B +;B"\
M AU$JX2(H2)64<E0.W(XSFN>TO2]6O+QI].U>&*UAO7$D!1G4,#R$ST'MR*W
M+""SM!?:W!#>2R2EV:)Q\V0<-M!..=HJZ<I/X=(Z[_U<348M\S'_ &R_O)K:
MS2;R)&@WSRK%E<D=%.?E(//-;T*-'!&CR-*RJ 9& RQ'<XP,GVK-T6.86IFN
MDC2XN',K!$VX!/R@^X&,UJUM24K7D[W$TD] HHHK4 IKJKH590RD8((R#3JC
M=DR(RV&8' S@GZ4 <UKAFTJVN_*O_LEK<+B-E@W^4_?IT!S^=9=IX@TN*TBA
MCAGL5@#+-</;XW%2,]N02<YSWJ=+FYB,FG7DTMQ?).ZV<;#<K19PI<KUZ=3S
M^-8VHV'B"^UE[:Y$RS2NHM[BW 0*B#)8C/J>ON*\FNY*;Y=;;=>MW_PV]BHI
M.Z31$RO9W]@VB1%]0E4*$DB*@+G)+.0>!R?TK>_X1LG5%O-?,5R-V8#$K?)*
MV 6(S[<=A6.EO>K=2WEY"LER(FM\(<+&JD$ KG.>O/\ A7074BZUJ$?V9IH)
M(RJAHLI(JG.20>J],$=S6-&<$WR-MIZ+:_R?^9<EMY?U]Q7N=)DT4V.S4)L;
MU@1XU"_.QZLHP#QQQ6A86$EPWFLTT.G21%&LVP,R;SE_49';/_UZ-W/<7L%[
M;17EG?7-A()D@R SL,D!_0#U%5[#4]3U?4=/CNQ;22&%;@K;L6@W9[L,X(SQ
MZXKJAR0ESI.SZ?GU_P"'%[UGL=D\L4"J))$10>"S8Z]*LYK#F@<2W7FV'VB>
M0 I)&H  [#)/4=:T+2Q-M*TK7-Q*S(JD2OD#'<#H#793JN4K6,WH7:***V *
MPM3T62:^BOX)96N$)7#3L@6,X)"@<9.!UK=J.>1HH6=(FE(_@4@$_GQ4RCS)
MH+V/.=3N;K2O$=O>12SVYGB7[2D-OO$*[USN//7.<GTI^J7LSW=I<0ZC<&X^
MS2V@96";G#!]V!_LC.*Z64QR:;)/<I<3"]=76$J(Y57(PN ><5RM_?16?B"T
MDTRW6Y@D+SRSE I4EMI R "0!C'M7!-5*4/==E^)5-QD]$S=T""&7PX)9$74
M+Z,-%<RS?*9#GG)(P>/PJWI4GV*\N1?3I"9 #!#+(I9%&>!@#(_.FKKEC'8V
M\*))?P2#9/(BKA,\_,I/?GIZ5E6FNV9DNM/&E @K++!*<&/8&"C+'H<GMV]*
M+Q4X\K5[?UM_5P7[QMKH4GG/VIKS4])8&1EMQ=V9V/-(Q(Y!Q@ #'6MG29=1
M6U:\N;>+3?+B!AMF*[6!&/F(YST[<9-9,@UG1KW1M%O6AOA=S-(MQEPR2@%L
MG'49/L/SKH)XQ#I[KJ,A>XM$1?M)D4&4L0=OMD@#!K.*M=VU[[>O^?F5+1*Z
M^=S<MDN0SM<2HV[&U47&WCGGO5FJUC<O=6_F26TMNVXKLEQGCOP3Q5FO3C:V
MAG>X44450!1110!R/B#PW)<ZE!J<5RT26<;%$4@-N/8$]!^G-2:#I:VRI8K;
MN+2"-XR3<>8%DSDG!Y#'.?;^?2W$"75M)!(/D=2IXS_.L2QTE[>[<+'=0QS.
M\EPQG#K*WW0<=@0,\8KCE149\R3=_/0N]UN<18Z8CZE))-/(-,T^Z<17,DY;
M9A=JJR_7N#Z"NE;0-&>RMEEOI?)FG'D/&Y0ASDD9]"1T]JW[?0]/MH$ACME$
M:2&51Z,:CO-#@OM3BN)XH)(%C*M&\>3NR-K ]L<U,,,U_$2E^GIZ?>$Y\RY7
M\)78#3M5:5Q/=L(5&YG4^4,XZ'&,]<^U:7]EVIO&N_+_ 'K??Y.U^F"1TR,#
M!K/N/"6EW)EW)*HG %QME;=* <@%LY&#Z8K<4!5"CH!@5TTX<K:Z$R46D+11
A16H@HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>drs_044.jpg
<TEXT>
begin 644 drs_044.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !B & # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
..HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>drs_045.jpg
<TEXT>
begin 644 drs_045.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !> %X# 2(  A$! Q$!_\0
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MBJ-MO;(?FE;U/]37H:4+0@KS9CK/5['/:+\%]'M45]6N9;V;NJG8@_QKJX?
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$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>drs_046.jpg
<TEXT>
begin 644 drs_046.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  : -$# 2(  A$! Q$!_\0
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M\(!H7_/.?_OZ:ZBB@#E_^$ T+_GG/_W]-'_" :%_SSG_ ._IKJ** .7_ .$
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8#9>5%AYGYEF(Y8_T'M6M10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>drs_047.jpg
<TEXT>
begin 644 drs_047.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  : - # 2(  A$! Q$!_\0
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M ,C'%_U[+_Z$U<C0![_17@%% 'O]%> 44 >_T5X!10![_17@%% 'O]%> 44
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>drs_048.jpg
<TEXT>
begin 644 drs_048.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  : %X# 2(  A$! Q$!_\0
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M?\\Y_P#OZ:ZBB@#E_P#A -"_YYS_ /?TT?\ " :%_P \Y_\ OZ:ZBB@#E_\
MA -"_P"><_\ W]-'_" :%_SSG_[^FNHHH \^\/\ @I9-2FN[Z,BSBF800OUD
2 )P3[?S^G7T$  8 P*** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>drs_049.jpg
<TEXT>
begin 644 drs_049.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  : %8# 2(  A$! Q$!_\0
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L/^?63_O\W^-8WA_P4G]I37M]%BVCF86\#?Q $X+>WMW^G7O:* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>drs_050.jpg
<TEXT>
begin 644 drs_050.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ; $L# 2(  A$! Q$!_\0
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MI10!Q?\ PK?3?^?R[_\ '?\ "C_A6^F_\_EW_P"._P"%=I10!Q?_  K?3?\
MG\N__'?\*JZGX!L+'2KNZCN[EGAB:10VW!(&?2N^I" 1@@$>AH X;P?X/\CR
8]3U./][]Z&%A]S_:;W]!V^O3NJ** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>formdrs_018.jpg
<TEXT>
begin 644 formdrs_018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" @T"[@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWTKJH8ER?+(\_%X"/*YT_N/H"BD5@RAE(((R".]+7<>*%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ4G'0]?2N!L/&?C?QJ]Q>^#-,T>VT2*0Q176L&7==$'ED5.@[<_GG( !Z>>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB_Q%=GY]5N03VB/E_P#H.*HW-SJM_@75Q=W '3SI&;'YUIT5+K]D;QP$%U_
MQQ8W!_@Q]2*D&F3'JZ#\36I2U#KR-E@Z?4SAI?K-^2U(-,A'5G/XBKM%0ZL^
MYHL-270KBQMA_P L\_4FI!;PCI$G_?(J2BH<I/J:JG!;)&+=#%ZP'J*^AXO]
M2G^Z*^>;O_C];ZBOH:+_ %*?[HKN7PH^9S'X_FQ]%%%!YP4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC^E>E>E571EZ,ZW_ (6]XB_YX:=_WZ;_ .*K5TKXR3"0+J^FQLA/,EH2"O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=_\ 'ZWU%?0T7^I3_=%=Z^%'RV8_'\V/HHHH/."BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 0?KQ6;_ ,*G\3?W;/\ [_?_ %J]#VU&6[15T<Y_PE'B#_H.ZG_X%R?XT?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P!#1]M@_O\ Z&BS'SQ[EBEJO]M@_O\ Z&C[;;_WS^1I68^>/<GI:K_;;?\
MO_H:/MMO_?\ T-*S'SQ[EBBJ_P!MM_[_ .AH^VV_]_\ 0TN5C]I'N6*6JWVV
MW_O_ *&E^W6_]_\ 0T<K'[2'<L457^W6_P#?_0T?;K?^_P#H:7*^P_:0[EBB
MJ_VZW_O_ *&C[=;_ -_]#2Y7V'[2'<LT56^W6_\ ?_\ '31]NM_[_P#XZ:7+
M+L/VD.Y9HJM]NM_[_P#XZ:7[=;_W_P#QTTN678?M8=T6**K_ &ZW_O\ _CIH
M^W6_]_\ \=-+DEV'[6'=%D456^W6_P#?_P#'31]NM_[_ /XZ:7)+L/VL.Z+-
M%5OM]O\ W_\ QTT?;[?^_P#^.FCDEV'[6G_,BS2U5^WV_P#ST_\ '32_;[;^
M_P#^.FER2[#]K3_F19HJM]OMO^>G_CIH^WVW_/3_ ,=-+DEV'[:G_,BS15;[
M?;?\]/\ QTT?;[;_ )Z'_ODTN278?MJ?\R,^[_X_6^HKZ&B_U*?[HKYWG=9+
MLNIRI(Q7T1%_J4_W17:OA1\SF#O.Z[L?1110>>%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 45S>L^/O#&@3&"_U:%9QUBB!D8'T(4'!^N*YT?&OPF9_+(U
M +_SU, V_P#H6?TI.274UC0J25U%GHU>8?&6X=;#3+=6(1Y'9ESP< 8_F:Z_
M1/&_AOQ#+Y.FZK#)-VB<&-S]%8 G\*Y#XRVTCZ?IERJDQQR.K-C@$@8_D:WP
MS3JHGE<7:2L>05]&>"-$@T3PQ:11J/-E02S/W9B/Y=A7SG7T-X&\1VFN^'[=
M$E7[7;QA)XB<,".,X]#ZUV8SFY%;8)'44445YI 4444 %%%% !1110 4444
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M4JK2V"BBBM#E"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^SH_X5/_ -1O_P E?_LZ])HHNP^L5.YYM_PJ?_J-_P#DK_\ 9T?\*G_ZC?\
MY*__ &=>DT478?6*G<\V_P"%3_\ 4;_\E?\ [.C_ (5/_P!1O_R5_P#LZ])H
MHNP^L5.YYM_PJ?\ ZC?_ )*__9T?\*G_ .HW_P"2O_V=>DT478?6*G<\V_X5
M/_U&_P#R5_\ LZ/^%3_]1O\ \E?_ +.O2:*+L/K%3N>;?\*G_P"HW_Y*_P#V
M='_"I_\ J-_^2O\ ]G7I-%%V'UBIW/-O^%3_ /4;_P#)7_[.C_A4_P#U&_\
MR5_^SKTFBB[#ZQ4[GFW_  J?_J-_^2O_ -G1_P *G_ZC?_DK_P#9UZ311=A]
M8J=SS;_A4_\ U&__ "5_^SH_X5/_ -1O_P E?_LZ])HHNP^L5.YYM_PJ?_J-
M_P#DK_\ 9T?\*G_ZC?\ Y*__ &=>DT478?6*G<\V_P"%3_\ 4;_\E?\ [.C_
M (5/_P!1O_R5_P#LZ])HHNP^L5.YYM_PJ?\ ZC?_ )*__9T?\*G_ .HW_P"2
MO_V=>DT478?6*G<\V_X5/_U&_P#R5_\ LZ/^%3_]1O\ \E?_ +.O2:*+L/K%
M3N>;?\*G_P"HW_Y*_P#V='_"I_\ J-_^2O\ ]G7I-%%V'UBIW/-O^%3_ /4;
M_P#)7_[.C_A4_P#U&_\ R5_^SKTFBB[#ZQ4[GFW_  J?_J-_^2O_ -G1_P *
MG_ZC?_DK_P#9UZ311=A]8J=SS;_A4_\ U&__ "5_^SH_X5/_ -1O_P E?_LZ
M])HHNP^L5.YYM_PJ?_J-_P#DK_\ 9T?\*G_ZC?\ Y*__ &=>DT478?6*G<\V
M_P"%3_\ 4;_\E?\ [.C_ (5/_P!1O_R5_P#LZ])HHNP^L5.YYM_PJ?\ ZC?_
M )*__9T?\*G_ .HW_P"2O_V=>DT478?6*G<\V_X5/_U&_P#R5_\ LZ/^%3_]
M1O\ \E?_ +.O2:*+L/K%3N>;?\*G_P"HW_Y*_P#V='_"I_\ J-_^2O\ ]G7I
M-%%V'UBIW/-O^%3_ /4;_P#)7_[.C_A4_P#U&_\ R5_^SKTFBB[#ZQ4[GFW_
M  J?_J-_^2O_ -G1_P *G_ZC?_DK_P#9UZ311=A]8J=SS;_A4_\ U&__ "5_
M^SH_X5/_ -1O_P E?_LZ])HHNP^L5.YYM_PJ?_J-_P#DK_\ 9T?\*G_ZC?\
MY*__ &=>DT478?6*G<\V_P"%3_\ 4;_\E?\ [.C_ (5/_P!1O_R5_P#LZ])H
MHNP^L5.YYM_PJ?\ ZC?_ )*__9T?\*G_ .HW_P"2O_V=>DT478?6*G<\V_X5
M/_U&_P#R5_\ LZ/^%3_]1O\ \E?_ +.O2:*+L/K%3N>;?\*G_P"HW_Y*_P#V
M='_"I_\ J-_^2O\ ]G7I-%%V'UBIW/-O^%3_ /4;_P#)7_[.C_A4_P#U&_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1U"^9&,!@,  XX8'NK9Z"@#U:N#\<>,M0\/>+_!VD6*VYBU>\,5R9%)8(&C
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M$=ZEU?PE8:UXCT;7+F:Y2YTAI&@2-E"-O !W @D].Q% '._&S_DD6N?]L/\
MT?'72^#O^1(T#_L'6_\ Z+6G^*?#=GXM\.7>AW\D\=K<[-[P, XVN'&"01U4
M=JO:;81:5I5II\#.T-K"D",Y!8JJ@#.,<\4 6J*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKQGQW\7->\+^,K[1[*S
MTV2WMQ'M::-RYW1JQR0X'4GM7.?\+[\4?] _1_\ OU+_ /'* /HFBOG;_A??
MBC_H'Z/_ -^I?_CE'_"^_%'_ $#]'_[]2_\ QR@#Z)HKYV_X7WXH_P"@?H__
M 'ZE_P#CE'_"^_%'_0/T?_OU+_\ '* /HFBOG;_A??BC_H'Z/_WZE_\ CE'_
M  OOQ1_T#]'_ ._4O_QR@#Z)HKYV_P"%]^*/^@?H_P#WZE_^.4?\+[\4?] _
M1_\ OU+_ /'* /HFBOG;_A??BC_H'Z/_ -^I?_CE'_"^_%'_ $#]'_[]2_\
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M1_\ OU+_ /'* /HFBOG;_A??BC_H'Z/_ -^I?_CE'_"^_%'_ $#]'_[]2_\
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M1_\ OU+_ /'* /HFBOG;_A??BC_H'Z/_ -^I?_CE'_"^_%'_ $#]'_[]2_\
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MG)52?4;<9R.F* .>_9I_Y!'B#_KO#_Z"U3^"_P#DY;Q=_P!><G_H<%=)\)O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '.ZIX$\,:UJ,NH:CI$-Q=2XWRLS
MM@ #H?0"J?\ PJ_P5_T +?\ [[?_ .*KKJ* .1_X5?X*_P"@!;_]]O\ _%4?
M\*O\%?\ 0 M_^^W_ /BJZZB@#D?^%7^"O^@!;_\ ?;__ !5'_"K_  5_T +?
M_OM__BJZZB@#D?\ A5_@K_H 6_\ WV__ ,51_P *O\%?] "W_P"^W_\ BJZZ
MB@#D?^%7^"O^@!;_ /?;_P#Q5'_"K_!7_0 M_P#OM_\ XJNNHH Y'_A5_@K_
M * %O_WV_P#\51_PJ_P5_P! "W_[[?\ ^*KKJ* .1_X5?X*_Z %O_P!]O_\
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M'PQX?\/30>%M0-_9R7#/)<&=927P 1E0!P .,4 /_P"%7^"O^@!;_P#?;_\
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M?85#HWB;0_$*N='U:SO3'RZP2AF7ZCJ* ,;_ (5?X*_Z %O_ -]O_P#%4?\
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M^UN>,Q23J&7/(R.WXT 9W_"K_!7_ $ +?_OM_P#XJC_A5_@K_H 6_P#WV_\
M\574V]S!>6T=S;31S02J'CDC8,KJ>A!'!%9>L>+?#WA^98=7UFRLYF&1'+,
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M8^U[IE'D9Z;\GY>AZT 8?_"K_!7_ $ +?_OM_P#XJC_A5_@K_H 6_P#WV_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>$]"\++.NB:;%9"?;YHC+'=MZ9R3ZFO.M/\ ^3G]6_[!2_\ H,5>O4 5[_\
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ME1>%(V GH!ST/4'FNU\(^/[?QIJ%VNEZ5J"Z7 @V:E/&$CF?)!50>>.#GZY
MXR 5-6\+_#[2=>N]?\1?V=]LOCG=JTZNO  Q&DAQV[ D=!@<5Y[HNI^';?\
M:!TY?!<]N-,U&S:.\CM4VQ;PKG 7  ^XAX]3ZFJGAK7/"VC>+_$DGQ-A0^(/
MMF8YKRT>=!'_  ^6 K;0,9!P/E*X-:37[:U\>O"6KP:1<V&F2VTL-H]Q&(S<
M!4E)<)U4?,,9Y(P>] !XW%IH?QH&N^--,EOO#4MJD-G(T/G0P/@ [EZ=?,..
M3\P('IZ)X/M? =Y<S:_X2ATT3/$(97LU\LJN<X:/C:21GE03@5!X@^*&@>&_
M$4VB^(;>^LH3&&CO);5G@GR 2%VY)QG!XZYKC/AQ#8ZO\6M8\0^%].>S\,BT
M^S^8L/E132Y7[J\8Z$\=.X&: .8\*:]8>(/$6M>)_$?@_7?$D\MP8;9+73A=
MV]K&.0G) W8(ZC@8/<UJ:C(C>,O#^L^#_ /B71+J&Z6.]SI!@AEMV(#!@A(S
MC/./<G@5<T#5?^%+>)=5T77[6X3PYJ%R;BQU&-#(JD\8; SG  ('(*]""#79
M6/Q<T37=?L])\-V>H:R97 N+B&!HX[9"#\S%P#UQV'?!)P" <G\35@TSXHZ+
MKWBC2IM0\+):^3E8O,BAE);[Z]#U!YZCIG;BNV\'P?#S5M1.N^$X=,^V)#Y+
MFT3RF1&.?FBXP21]XKGCKBG>)?B5HOA/7TTS7K:^M;:6(-'?FW+P.>Z_+DDC
MCH#U[=^!\)IIWB3XV#Q!X+LVM-!M;5H[V>. PQ7,A!X"X'/*'&!]S)Z\@'N5
M>(>']-M?B-\9?$U[KT27=GH;BUM;24;H_O,H)4\'[C'!XRWM7M]>&0ZHGPF^
M+.O3:Y#.FAZ^_GQ7J1%E5]Q;!QZ;V!QD_=.,&@"/X^>$/#^E>$;/5--TFTL;
MH7J0%K6(1*R,CGE5 !.5'/6MKXWZY>67A?1M$LVN%_MB<0S&V3?(\8VY15[E
MBPXR,XQT)KFOC)XSM?&?@E!H%G=76DVUXDDVIO&8HM^UE5$# ,Q^8Y. !@>M
M=U\5_"^I:]X7TW4M$0R:MH\RW<$:C+.  2%'=LJIQWQCJ10!S=O/X+@TA=-_
MX4_XG>+R_+,CZ IE/&,^9NW9]\Y%:GPM&JVO@GQ!IE]8:K:6=K)-_9XU. Q2
M>0RDA<'TYZ9'-6;#X[>#VTL/JLUUI^I1KMFL9+:1G#CJ 0,=>F2/<"NETCQ)
M)XJ\'ZAJ3:1>Z;$R2K"EXH5I8]OROCL#_DD<T >>?!+PCHVL>$/[3U>SCU*5
M)Y88([Q1+% F[)V(V0"222<9IOB+2K3P#\:O#%_H=O'96FKYM;BU@&R-B2%/
MRC@#YD.!W6J'PC^(FB>$_!WV+Q!]IL8GN97M[LP/)%-R,J"@)# ]01TP<\UH
MV5S+\6/BMINMV%K<)X9T($I<3+M$\N2?E]\[>.P7G!(% &;XQU6'6_C7-9:S
MHNKZWI&C0J8=/TVW,V9"%.Z1<C*Y)SZX4'(S2>,_['UG0ROA_P"&/BC2=:@=
M9+.[M]#%OL8,#\QC.<8SC@X.*W?%B7OP\^*C>.A9SWFA:A;BWOS NYK<@*,X
MSC^%3D^K#TSL7GQP\*M$D6@K?:YJ4N1%96MK(K%L9P2RCCW&[Z4 <Y\9KN^N
MO@KX?O-0B>WOY+FVDGC92C1R&%RP(/((-=]9?#3PA'HWV.?0[6\:5#YUU=1B
M2XE9OO,93\VXDDY!&.V*X_\ :#D:;X8V$CQ/"SZC"QC?&Y"8Y.#@D9'M7KL/
M^HC_ -T?RH \8^#&KR:1X$\4)(S2V^CW$\L2LW10FXJ/09!/XFG?"#PEIWB7
M2+OQAXDM(-6U'4[F0J]W&LBH@;'"D8!R#VX& ,5'\%K)-3T/QG82$K'<W<D+
M$=@R$'^=5?AWXZLOAO9WG@_QIYVG36<[O;RF!W21&.>-H)/.2#C!!H =K_AW
M2?#_ .T!X3&DV45G'<QF62&%=L>X!UR%'"\ =/2F_%#5EUCXJ:;X>OM/U;4]
M&T^$7-QI^F0F22:0C() (^4 J,]N<=:-3UF;Q)\:/!FLQ:;<VNER"2*SEN5V
M-<A58EPG55^88SU'/>MKXB66I>%?'^E_$'3[*:\L8H3;ZG%;KEQ'S\_TQCT&
M4&2,T 8?B@^&=:\.W-E8?"CQ/87P0M:W-OH*PLD@'RY9#G;GJ.?SQ4GC;Q)X
MAA^!VBVMXES::QJ;K97(G5HY2HR#NS@@MA<^H)]:ZF;XZ>#39HVG2WNHWTN!
M'806C^:S'HN2 O7T)]LTWXG:#JGCCX9VUW9Z?/;:K;LEZMD^#*/E.Y./XAG/
MJ=N,9- &UI7PN\&V/AZ'3'T"PN1Y6V2>>!6F<D<MYGW@>3T(QVQ7+?%OPA#I
MW@33-1\/VXMYO#4J2VRJ2Q6/(SUR3@A3D]@:L:;\=?"QT2,ZC]LM]811'+IJ
MVKM(91P54XV]>F2#Z@5WNG3'Q-X6C?4]+GLA?VY6>RN#\Z!A@J<>Q]CZ@'B@
M#BO'GC9'^#BZIIY)N-:ACMK9%^8[I1\R\=PNX?7%=9X'\/)X5\&Z9HXP7@A!
ME8=&D;YG/_?1->)> _#^IWGQ#M_">H8DTKPE=3W2-M(#,S#9_P"/#>/H:^C:
M /._C7XBO/#GP[F>Q=HY[R9;02J<,BL&+$?@I'XU=\,?##PKI/ARTL[C0].O
MI_*!GN+FV21Y'(Y.6!(&>@[4OQ6\(W'C+P+<6%F-U[!(MS;H6P'=01MS[AFQ
M[XKG]$^-OAVUT6.W\3/=:9K5J@CN;22TD)9P.=N 0,^C$?UH S_ T0\%_&;6
M_!UE(XT:X@%W;P.Y;RGPIP,^S$9ZD**I>'?#>F^(_C7XQBU6)[FUMYDF%JSG
MR9'R0"Z]&QDX!X^8UK?#RRU#Q3\1-7^(5W8S65A/"+;3XIUP\B84;\?11[$L
M<=*/ /\ R6WQW]4_F: ,OXT>'])\*6NA>)-!T^UTW4+:_1 ;2)8E<8+#<% !
M^[CZ$BO;HF+1(QZE037D?[1'_(DZ;_V$D_\ 0'KUN#_CWC_W1_*@#R?]HK_D
MG5K_ -A*/_T7)3OCM_R2>#_KY@_]!:F_M%?\DZM?^PE'_P"BY*=\=O\ DD\'
M_7S!_P"@M0!M^%?AOH,5I8ZUJ=HM_KTFR[FOI';<9C\V5&0  >@ Z 5Q_@O3
M;/XC_$KQ-KOB"!;ZWTZ;[-8VLXW1(N6'*'@\ >V6)QGI[%HW_($L?^N"?^@B
MO';*]_X4]\0-<;6+6X'AO691-;WT,9=(7R3M8#ZD>OR@XP> "[\7/!NF:'X<
M3Q9X<L[;2-4TF:.02V<0B#*6VX*J,$Y8=1TR#57XSZLVL?!C0M74&-KJZMK@
M8/*EHG-,\=>-H?B;91^#O Z3Z@]W(C7=V8'CAAC!S\Q8 CD YQVP,DXJ?XYZ
M;%H_P?TC38/]5:7D$*?18I /Y4 =Q9?#3P@FB"SFT.TNC+&?-NKF,27$C,.6
M,I^;=DDY!&.V*Y/X 7$O_",:MIS2,\-GJ+I"&/W5(!P/QR?QKUBW_P"/:+_<
M'\J\B^ /_(-\1_\ 83;_ -!% 'L-%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 17%M!
M=P-!<P1S0N,-'(@92/<&LK_A#_#'_0N:1_X Q_\ Q-;5%%AJ36S&10Q6\2Q0
MQI'&HPJ(H  ]@*<RJZE6 *D8((X(I:*!&4?"_A\G)T+3"?\ KTC_ ,*3_A%_
M#_\ T M,_P# 2/\ PK6HJN>7<"."WAMHA%!#'%&.B1J% _ 5)114@%%%% !1
M110!\SWG_'[/_P!=&_G7=_";_D-7O_7$?SKA+S_C]G_ZZ-_.N[^$W_(:O?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@!&574JZAE/4$9%*!@8%%% #=B;]^U=^,;L<XIU%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)B+DA"Q,>-V.2O//MFK6N?!YK^PGU6X\6:Y<>(8XC+'<M.$C$@&0%0#*)GH
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MB25U+*F[Y2Q7HQ )(!XR!FH?%OPF&GZ%J'B.U\5:^^NV<#7/VJ>Z!#%%R1@
M$# (&#Q[T >RT5YA:^.-8O/@*_BBW4MJR6K*7V _.K^6TF!QV+>E<UX,^'6E
M>+_#UKX@C\:ZU)X@EC$D]Q!>@M;RD?=(QNXZ<L,XXP* /0?B7X1U3QEX:CT[
M2=3%C,MPDK%V95D49X)7G@X(]Q^(T=3FNO#'P\NY7O6N+W3]-;%U*.9)5CX8
M@]RP%<#\>!<Z?\+=.B:]FFGCOH4>X.%:0B.3).W YZ\5<^+.@QZI\+SJ,E_?
MPM86JNL,,VV*8L4'[Q<'=CMTH [/P-J=WK/@?1M1OY?-N[FU2263:%W,1R<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'S/>?\ '[/_ -=&_G7=_";_ )#5[_UQ'\ZX2[_X_9_^NC?SKN_A
M,1_;5Z._DC^==E3X&?7X_P#W27I_D>NT445QGR 4444 %%%% !1110 4444
M%%%% !1110!5U"PBU*PN;.5I$2XC,3O$=KA3Z&N(FTK6O VA:3I/A"P^W W/
M^E3SXP 3R6 .<<]1TQ^%>@T4 9-MXDTJXUR70Q>Q'5(4#R0#/3'8]#U^M:U8
M=QX:M(9=2U'2+>VL]:O(2ANRA/S=B0#USW'XYKF4U^_^'OA_2;;Q)<76LZC>
MW!BS#ABH] 2 6ZCJ><GGM0!Z%13(Y4DX!PP +(3\RYYY':GT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!>)=,@5FFEN96C11DLR!'"CZE0/QKM_@WXIT[5/ %A8_:H([[3H_(N+=G 9
MIP&P>Q&#GIG([5V7A[PSH_A6P>QT6T^RVSR&5D\QWRQP"<L2>PK$UGX5^"M>
MU*34-0T*)[J0[I'BEDBWGN2$8 D^O4T /UCQ'HWB'P1XI_LC48+T6ME<13&%
MLA6\HGKW'N,C\JR/@;_R2;2O]^?_ -'/786GAK1K#09-#L]/AM]-EB:)X(@5
M#*PPV2.22.^<^]2:'H6F^&])BTO2+;[-91%BD6]GQN)8\L2>I/>@#RT_\G/G
M_L&C_P! %3_%>-O"WBSPWX_@5C';3?8[X(,EHFS@X[G!?KW"UZ'_ ,(KHO\
MPE'_  DGV+_B;^7Y7VCS7^[C&-N=OZ5PGQCOIM5&C>!;!_\ 2];N5,Y50QC@
M4Y+$?49_X : +/P<TV>31M1\5WZ%;_Q!=-<G((VQ9.P<]N6(]F%95K_R<_?_
M /8+'_H,=>L6-G!IVGV]E;($@MXUBC0=%51@"L]/"VC)XHD\2+9XU>2+R6N/
M-?E, 8VYV]AVH \]_:&_Y$"Q_P"PI%_Z!)7I6I?\B[>?]>C_ /H!J#Q%X8T?
MQ7I\=CK=G]JMHY1,J>:Z8< @'*D'H36G+!'-;/;R+F)T*,N3RI&,4 >-_"K5
M9M#^!^JZI;P^=-:/<RHA&02!D9]AU/L*E\):)I_C/PE'XF\7^*KZ_6<,]Q;F
M_-O:6^#]THA7:0.O->FZ'X8T?PYI+:7I5DL%D[,S0L[2 ENN=Y)Y]*YZ/X/^
M HM0^VKX=@,N[?M>61H\_P"X6VX]L8H X/X'1:?#XX\:QZ2,::)4^R<L08=\
MFP@MR1MQR:U/AA_R5GXB_P#7VO\ Z')7IMGX?TO3]8O=6M;18KZ]6-+B16;#
MA!A1MS@8'H!4.E^%M&T;5M1U33[/R;W4GWW<OFNWF-DG."2!RQZ 4 ;%>-ZC
M(EI^TS8/<.L2S:=B,N<!CM(X_(_E7LE<[XE\"^&O&#P/KNEI=20 K'()'C8
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M^FV?D7.HR>;=/YKMYC9)SAB0.6/3'6MB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW-O_ +/W^3C/&-_.<=:CU_PW8>)(;2*_\W;:W*7,?EMM^=3D9XZ5KT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %<OXG_P"/V'_KG_4UU%<OXG_X_8?^N?\ 4U4-
MR9[&'1116ID%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5YA\2_^0]I_P#UQ_\ 9C7I]>8?$O\ Y#VG_P#7'_V8U<-R*GPG
MI_:O+_A?_P A6_\ ^N(_]"KU#M7E_P +_P#D*W__ %Q'_H5"V82^)'J%%%%0
M6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR##W$K#W<FH:*JR)NPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#R;7O\ D/W_ /UV;^=7?!W_ ",,7^XU4M>_Y#]__P!=F_G5WP=_
MR,,7^XU>E+^%\CI?PGIE%%%>:<P4444 %%%% !1110 4444 *.])2CO24 %%
M%% !1110 4444 ;'AO\ Y"9_ZYFNLKD_#?\ R$S_ -<S765E/<UAL%%%%24%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !65JNG0WDR/(S@A<?*1_A6K5:Y^\
MOTJH;DSV,3^PK;_GI-^8_P */["MO^>DWYC_  K4HK8Q,O\ L*V_YZ3?F/\
M"C^PK;_GI-^8_P *U** ,O\ L*V_YZ3?F/\ "C^PK;_GI-^8_P *U** ,O\
ML*V_YZ3?F/\ "C^PK;_GI-^8_P *U** ,O\ L*V_YZ3?F/\ "C^PK;_GI-^8
M_P *U** ,O\ L*V_YZ3?F/\ "C^PK;_GI-^8_P *U** ,O\ L*V_YZ3?F/\
M"C^PK;_GI-^8_P *U** ,O\ L*V_YZ3?F/\ "C^PK;_GI-^8_P *U** ,O\
ML*V_YZ3?F/\ "C^PK;_GI-^8_P *U** ,O\ L*V_YZ3?F/\ "C^PK;_GI-^8
M_P *U** ,O\ L*V_YZ3?F/\ "C^PK;_GI-^8_P *U** ,O\ L*V_YZ3?F/\
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MA6W_ #TF_,?X5J44 9?]A6W_ #TF_,?X4?V%;?\ /2;\Q_A6I10!E_V%;?\
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M% &7_85M_P ])OS'^%']A6W_ #TF_,?X5J44 9?]A6W_ #TF_,?X4?V%;?\
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M?\])OS'^%']A6W_/2;\Q_A6I10!E_P!A6W_/2;\Q_A1_85M_STF_,?X5J44
M9?\ 85M_STF_,?X4?V%;?\])OS'^%:E% &7_ &%;?\])OS'^%']A6W_/2;\Q
M_A6I10!E_P!A6W_/2;\Q_A1_85M_STF_,?X5J44 9?\ 85M_STF_,?X4?V%;
M?\])OS'^%:E% &7_ &%;?\])OS'^%']A6W_/2;\Q_A6I10!E_P!A6W_/2;\Q
M_A1_85M_STF_,?X5J44 9?\ 85M_STF_,?X4?V%;?\])OS'^%:E% &7_ &%;
M?\])OS'^%']A6W_/2;\Q_A6I10!E_P!A6W_/2;\Q_A1_85M_STF_,?X5J44
M9?\ 85M_STF_,?X4?V%;?\])OS'^%:E% &7_ &%;?\])OS'^%']A6W_/2;\Q
M_A6I10!E_P!A6W_/2;\Q_A1_85M_STF_,?X5J44 9?\ 85M_STF_,?X4?V%;
M?\])OS'^%:E% &7_ &%;?\])OS'^%']A6W_/2;\Q_A6I10!E_P!A6W_/2;\Q
M_A1_85M_STF_,?X5J44 9?\ 85M_STF_,?X4?V%;?\])OS'^%:E% &7_ &%;
M?\])OS'^%']A6W_/2;\Q_A6I10!E_P!A6W_/2;\Q_A1_85M_STF_,?X5J44
M?._B>)8?%&IQ*20MPX&?K6EX MTNO%<,3E@I1ON]:H>+?^1NU;_KZ?\ G6I\
M-_\ D<8/^N;UZ,OX7R.I_ >N_P!A6W_/2;\Q_A1_85M_STF_,?X5J45YQRF7
M_85M_P ])OS'^%']A6W_ #TF_,?X5J44 9?]A6W_ #TF_,?X4?V%;?\ /2;\
MQ_A6I10!E_V%;?\ /2;\Q_A1_85M_P ])OS'^%:E% &7_85M_P ])OS'^%']
MA6W_ #TF_,?X5J44 9?]A6W_ #TF_,?X4?V%;?\ /2;\Q_A6I10!E_V%;?\
M/2;\Q_A1_85M_P ])OS'^%:E% &7_85M_P ])OS'^%']A6W_ #TF_,?X5J44
M 9?]A6W_ #TF_,?X4?V%;?\ /2;\Q_A6I10!!IFF0VET9(WD)VD?,1_A6O56
MW_UGX5:K*>YM#8****@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4_@/<:***\XY0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )K?\
MUGX5:JK;_P"L_"K593W-8;!1114%A1110 4444 %%%% !1110 4444 %%%%
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M% &I_;MQ_P \XOR/^-']NW'_ #SB_(_XUET4 :G]NW'_ #SB_(_XT?V[<?\
M/.+\C_C6710!L)K[@?/;J3[-BK4.MVTA </&?4C(_2N=HH [)'21 Z,&4]"#
MD4ZN0@N);9]\3E3W'8_6NAL-2CO!M/R3 <KZ_2F(O4444 %4=3L1=P%E'[Y!
M\OO[5>HH XNBM'6+;R+OS%'RR\_CWK.I#.C\-7F0]FY/'SI_4?U_.NAK@;2X
M:TNXIU_@;)'J.X_*N]5E= RG*L,@CO6<UJ:0>@M%%%06%%%% !1110 4444
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MW;C_ )YQ?D?\:RZ* -3^W;C_ )YQ?D?\:/[=N/\ GG%^1_QK+HH U/[=N/\
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MW'_/.+\C_C6717FG,:G]NW'_ #SB_(_XT?V[<?\ /.+\C_C6710!J?V[<?\
M/.+\C_C1_;MQ_P \XOR/^-9=% &I_;MQ_P \XOR/^-']NW'_ #SB_(_XUET4
M :G]NW'_ #SB_(_XT?V[<?\ /.+\C_C6710!J_V[<?\ /.+\C_C2?V[<?\\X
MOR/^-9@[TE &I_;MQ_SSB_(_XT?V[<?\\XOR/^-9=% &I_;MQ_SSB_(_XT?V
M[<?\\XOR/^-9=% &I_;MQ_SSB_(_XT?V[<?\\XOR/^-9=% '2Z-J<UW>F-T0
M#83\N:WZY/PW_P A,_\ 7,UUE93W-8;!1114E!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5S^OV%U=W4300EU"8)!'K7044T[":N<3_ &-J'_/JWYC_ !H_
ML;4/^?5OS'^-=M15<[)Y$<3_ &-J'_/JWYC_ !H_L;4/^?5OS'^-=M11SL.1
M'$_V-J'_ #ZM^8_QH_L;4/\ GU;\Q_C7;44<[#D1Q/\ 8VH?\^K?F/\ &C^Q
MM0_Y]6_,5VU%'.PY$<3_ &-J'_/JWYC_ !H_L;4/^?5OS'^-=M11SL.1'$_V
M-J'_ #ZM^8_QH_L;4/\ GU;\Q_C7;44<[#D1Q/\ 8VH?\^K?F/\ &C^QM0_Y
M]6_,?XUVU%'.PY$<3_8VH?\ /JWYBC^QM0_Y]6_,5VU%'.PY$<3_ &-J'_/J
MWYC_ !H_L;4/^?5OS'^-=M11SL.1'$_V-J'_ #ZM^8_QH_L;4/\ GU;\Q_C7
M;44<[#D1Q/\ 8VH?\^K?F/\ &C^QM0_Y]6_,?XUVU%'.PY$<3_8VH?\ /JWY
MBC^QM0_Y]6_,?XUVU%'.PY$<3_8VH?\ /JWYC_&O*/BG:3VOB'34GC*,T&0#
MW^<U]&UX5\</^1LT?_KV'_HPUI3E>1G5BE$[_P#L;4,?\>K?F/\ &O)_A-:3
MW>KZ@L$9<K "0/\ >KZ.[5X3\"/^1@U;_KV7_P!"HC+W6$XKGB>@?V-J'_/J
MWYC_ !H_L;4/^?5OS'^-=M16?.S3D1Q/]C:A_P ^K?F*/[&U#_GU;\Q_C7;4
M4<[#D1Q/]C:A_P ^K?F/\:/[&U#_ )]6_,?XUVU%'.PY$<3_ &-J'_/JWYC_
M !H_L;4/^?5OS'^-=M11SL.1'$_V-J'_ #ZM^8_QH_L;4/\ GU;\Q_C7;44<
M[#D1Q/\ 8VH?\^K?F*/[&U#_ )]6_,?XUVU%'.PY$<3_ &-J'_/JWYC_ !H_
ML;4/^?5OS'^-=M11SL.1'$_V-J'_ #ZM^8_QH_L;4/\ GU;\Q_C7;44<[#D1
MQ/\ 8VH?\^K?F/\ &C^QM0_Y]6_,5VU%'.PY$<3_ &-J'_/JWYBC^QM0_P"?
M5OS'^-=M11SL.1'$_P!C:A_SZM^8_P :/[&U#_GU;\Q_C7;44<[#D1Q/]C:A
M_P ^K?F/\:/[&U#_ )]6_,?XUVU%'.PY$<3_ &-J'_/JWYC_ !H_L;4/^?5O
MS%=M11SL.1'$_P!C:A_SZM^8_P :/[&U#_GU;\Q_C7;44<[#D1Q/]C:A_P ^
MK?F/\:/[&U#_ )]6_,?XUVU%'.PY$<3_ &-J'_/JWYC_ !H_L;4/^?5OS'^-
M=M11SL.1'$_V-J'_ #ZM^8_QH_L;4/\ GU;\Q7;44<[#D1PDFG7D()>VE  R
M3MR!5:O1*S]0TBWOE)VB.;M(H_GZTU/N)P['%TJL48,IPP.01VJ6YM9;2X:&
M489>_8CU%0U9!U&G7HO(/FXE3AQ_6KE<I87/V6[20G"]&^E=73$%%%% %/5+
M?S[%\?>3YQ^'_P!:N7KM*Y"YC\FYEC&<*Q SZ4 15V.@W!GTM 228R4)_E^A
M%<=70>%Y,27$6>H# ?3/^(J)K0N.YTE%%%9&H4444 %%%% !1110 4444 %%
M%% !1110 4444 <SXFN-T\-N#PB[CSW/_P"K]:P:O:S*)M6N&'0-M_(8_I5&
MMH[&,MR2"(SSI$O5CBNO50B!5&% P!7/Z)%OO2Y'"+Q]3_DUT-42%%%% !6%
MK-]O8VL9^4??/J?2M:\G^S6DDO<#CZ]JY,DDDGDF@!***U-(TDZ@YDD)6!3@
MD=6/H*3=AI7,Z.*29]D4;.WHHR:M+I%^PR+63\>*[."WAMHQ'#&J*.P%25GS
MFG(<3_8VH?\ /JWYC_&C^QM0_P"?5OS'^-=M11SL.1'$_P!C:A_SZM^8_P :
M/[&U#_GU;\Q_C7;44<[#D1Q/]C:A_P ^K?F/\:/[&U#_ )]6_,?XUVU%'.PY
M$<3_ &-J'_/JWYC_ !H_L;4/^?5OS%=M11SL.1'$_P!C:A_SZM^8_P :/[&U
M#_GU;\Q_C7;44<[#D1Q/]C:A_P ^K?F/\:/[&U#_ )]6_,?XUVU%'.PY$<3_
M &-J'_/JWYC_ !H_L;4/^?5OS'^-=M11SL.1'$_V-J'_ #ZM^8_QH_L;4/\
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MK?F2:%D781DD5T=%%2W<I*P4444AA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH:&<:Q;_ / O_034O8I;G:4445B;!1110 4444 %%%% !1110 4444 %%%%
M!1110!P-V_F7D[_WI&/ZU#2L<L3[TE;F!MZ ORSMZ[1_.MFLO0O^/.3_ *Z'
M^0K4IB"BBB@#(UYR(H8^S,2?P_\ UUA5K:\3]HB'8)G]:R:0QT<;2RI&OWG8
M*/J:[VV@2UMXX8QA4&/K[UQNDA3JML&Z;_U[5V]9S-(!1114%A1110 4444
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.^)NHK8^#+B+J]TRQ
M9P1SDG]/UKL:\;^,&K"?5;32T(Q;)YC^NYNWY 5MAX<U1#6YYK7O'PLL/L?@
MZ.8JRO<RM(<CJ.@/Y 5X7!!)<W$4$0S)*X11ZDG KZ>TFQ33-(M+),[8(E09
M]A79C96BH]RI%RBBBO-("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)KKJYCPQ%NNII<_=0+CZG_ZU=/64]S6&P4445)04444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUW&EVOV33HHB,-C<WU//_P!:HF]"H+4N4445D:A1110 4444 %%%% !1110
M4444 %%%% !1110!R_B:';=Q3#&'3'XC_P#6*PZ[+7+7[3IKE1EXOG'T[_I_
M*N-K6+T,I+4FM9_L]U'+V4\_3O76@@@$<@UQE='H]SYUIY9^_%Q^';_/M5D&
MC1110 5SVKV9@G\Y!^[D//L:Z&HYX4N(6B<?*P_*@#CZ4$JP9200<@CM4EQ
M]M.T3CE3^=14AG:Z1J O[0,Q'FIPX_K^-7ZX73[U["[69>5Z.OJ*[B.1)HED
MC;<C#(-925F:Q=T.HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAD$=Z6N=MO<T"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH:[?3KU;ZS24?>Z./0UG-=32#Z%NBBBH+"BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR*BKLLT445D:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR#]U$?S;M76U!:6R6=JD"=%'7U/K4]8R=V;15D%%%%(84444 %%%% !1110
M4444 %%%% !1110 4444 %%%%  0""",@]J\N\=ZG%X:F:"W96N)EW1IG/E@
M]S_2NI\:>,K;PK887;+J$R_N8<]/]IO;^?YX\/M[?5?%VO[%+7-]<OEG8\*.
MY/HH_P#U5UX:C?WY;#Y4]RK:6EWK&HB*/=)/*VYF;MZL37J.BZ;%HEJD5O\
M?!W-)CEF]:;I>@1>'X6M0N9\_O9".6/^'H*OU=:MSZ+8RG.^B.LLKI;NV60<
M-T8>AJQ7+:=>&TN03_JVX;_&NH!# $'(/2L3,6BBB@"&ZMUNK=HG[]#Z'UKE
M)8FAE:-QAE.#78UCZW:;D%R@Y'#_ $]: ,.M/0[[[)>A'/[J7Y3['L:S**35
MQIV/1**S=%OOMEB YS+'\K>_H:TJQ:L;IW"BBBD 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5%<VT-Y;26UQ&LD,JE71NA!J6B@#ST_"#0S>>:+N]$&<^3N7\MV,X_7WKN[.
MT@L+2*UM8Q'!$H5$'8"IZ*N=2<_B87"BBBH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %<EXAO//OO)4_)#Q_P+O_GVKIKRX%I:
M2SG^!<CZ]JX-V+NSL<DG)-7!=2)OH)4D$+3SI$O5CBHZV=#MN7N&'^RO]:T,
MS8BB6&)8T&%48%/HHIB"BBF32K!"TKGY5&30!G:S>>5%Y"'YW'S>PKGZDGF:
MXG>5_O,<U'2&%=1X>T_RH3=R#YY!A >R_P#UZQM)L#?W@4C]TGS.?;T_&NT
M"@ # '05$WT+@NHM%%%9F@4444 %%%% !1161XC\167AC26O[TLPR$BB3EY7
M/110W8<8N3LC7HKQ.X\1>*O%=RP_M4:-:MDQ0P3"'D?PF8\EL$< @5F3W'B;
M1]0:-]?UF&[A."LUTTJY]2K95A7,\5!>AWQRZH]&TGV/?Z*\^\%?$&75+Q-&
MUM(H[]E)@N(^$N,=1CLV.WY5Z#6\9*2NCCJTI4I<LUJ%%%%49A1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !16)I7BK3=9\0ZOHMD99)]),:W,@
M4>7N8'Y0P/48((XP?QK;H ***Y[Q%XY\,^%)HH=;U>"TFE 98B&=\$XR54$@
M<'D\<&@#H'&Y& ZD8KCOAAX2O_!7@Y-(U*:VEN%GDD+6S,R88\<L ?TKL58,
MH93D$9!I: "BBB@ HK&\4>);'PEHCZOJ27#6D<B)(T$>\H&8+N(] 3_AD\5K
MQR)-$DL;J\;J&5E.00>A% #J*** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*<%&'((/K6KPJMOJ<:S*?,M-#ZAKG?%'C72/"0A6_::6>;E+>W4-)M_O$$@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "H+ZSAU'3[FRN5W07$30R+ZJP((_(U/10!YQ\'[R
M6TT.^\(7YQJ7A^Z>W<$$;XF8M&XSV.3CV ]15_XI>#=1\;^'++3M-FM8IH+^
M.Z9KEF52JHZD#:IYRPKL8[&TAO)[R*UA2ZG"K-,L8#R!?NAFZG&3C/3-3T '
M:N'\%^#=1\.>+_%^K7DUJ]OK-TDUNL+,650TA^<%0 ?G'0GO7<44 <)JW@O4
M;_XPZ%XNBGM1I]A9O!+&SMYI8K* 5&W&/WB]2.AJU\1/ X\:Z)$MK.MIK%E(
M)["[Y'EN,<$CD X'(Z$ \XP>QHH Q[=/$/\ PB7EW#V \0BV91(K,UN9@"%8
M_*#M)P2,<9(&>M>97G@OXJ7WBW3O$LVH>%?M^GQ/%"%,X3:P8'(V<_>/>O9:
M* .-U?Q%JO@_X:76K^))K!]8@B<?Z(&\F25F(B"AL$]5S]&/2G_#'PY+X8^'
M^F6%RN+QU-Q<@C!$CG<0?< A?^ UU%U9VM]$(KNVAN(U=7"2H& 93E3@]P1D
M&IZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@##\3RA;2&+NS[OR'_UZY>M[Q1)FXMXO[J%OS/\ ]:L&M8[&
M4MQ0"S!0,DG %=C&@CC5!T4 "N5L5+W\ ']\'\N:ZRK("BBB@ KR/QMXFF.I
MSV%A(4?/[Z9>"H[*OOC'/;ZUZQ<2&*VED'55)'Y5\Z3,\EY=22C$KSNSCT.X
MYK6E%2EJ<F,JRIP]WJ1HBQKM4 "G445V'BA1110!);_:?MUI]B_X_/M$?V?U
M\S<-OZUH>/-5DU?QOJ<CD[;60VD:G^%4.#^;;C^-7O *QO\ $#2%E56&92 P
MXW"-B#]:PO$P \8:Z <_\3"<_P#CYK)6=7T1Z%!-4+WW9F4445N,1E5AA@"/
M>NG^'^O7&@>*[**)W-G>S+;SP _*2QPK8]0<?AD5E:#H5]XDU==,T\P+,R-(
M7G?:JJ/H"3U' 'Z9KTWPS\)9-.U6TU'5M1CF:V<2I;VZ$+O!RI+GD@'MBN>M
M4@DXR-Z-.HY*43U&BBBO,/5"BBB@ HHJ*YN(;.UFN;B01PPH9)'/15 R3^5
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?TJE2&=!X7?]Y<(3U ('YUTE<GX;;&I,,\&,_P Q765E/<UAL%%%%24%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !17F?C#XO1>$O$EQH[Z*]R851O-%P$SN4-TVGUK"_P"&@[?_
M *%R7_P,'_Q% 'M-%>+?\-!V_P#T+DO_ (&#_P"(H_X:#M_^A<E_\#!_\10!
M[317C"?M P.ZK_PCD@R0/^/L?_$5[/0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 9/B:WU6[\-WT&B7"V^HO'B&0G&#D9 /8D9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSY"#IR,Y]JX'5OB+XEU;<EN\.D6S?PV_[R8C'0R,,#_@*Y]ZYA55%"HH51P
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M!1114%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KC_$"[=7D/]X*?TKL*Y;Q,N+Z)L<&/K^)J
MH;DSV,2M'17"Z@!_>4C_ #^59U6M-<)J,))P,X_,8K4R.JHHHIB"J.KH&TZ0
M_P!T@_K5ZH+U!)93*?[A/Y<T <E1112&=W8.9-/MW)R3&I)_"K-9N@R"328A
MG)4E3[<UI5B]S9;!1112&%%%% !7G'Q+\:RZ4HT;3)2EW(NZ>5#S&IZ >A/7
M/88]:]'KYBUR_DU;7[V\;.Z>9F )S@9X%=6%IJ<[OH.*)]#\,ZOXDF==.MC(
MJ']Y*S!57ZD]_8<TFN^&=6\.3(FI6QC5_N2*0R-]"._MUKZ#\.Z/;Z%H=K86
MZC"("[ 8+L>K'ZFK.IZ99ZO8265]"LT$@Y4]CZ@]C[UH\8^?;0?,>8>!?B5Y
M2QZ7K\_R#"PW;GI[.?\ V;\_6NQ\3^+]#L?#]X1J%K<2RPM'%#%(LA<L"!P#
MT]37F7B3X9ZQI-S))IT$E_9$Y1HAF1?8J.2?<?I6%;>#_$EU.(8]$OE8]Y86
MC7_OIL ?G5NE1F^=.P[(9X6MI;SQ9I<4*[G^U(^!Z*=Q_0&OI:O)M/T'_A -
M/EO))HY-?DA\Q<PO)%;P!T$K8&-Q4,">1TX[Y](T6[O+S3A)?P"*X5WC8JI5
M9-K$!U!Y"L!N R>#U/6N?%554E[NR);N:-%%%<PB"]:5+"Y>$$RK$Q0#^]@X
M_6OF.R2&;6+>.[;9 ]PJS,3C"EAN.>W&:^HZ^?\ QYX0G\-ZJ\\2;M-N'+0N
MN<)GG8<]Q^H_'';@Y)-Q?4J)[Y;Q106\<4"*D2*%15&  .F*X?Q/\,-.UNX>
M\L9C873\N FZ-SZXXP?<?E6/\,?&D]Q,F@:C(9#M/V65CD\?P'UXR1]*]4K"
M7/0GHQ:H\9M_@WJ[3@7.I6,</=H][M^1 _G7H_ACPAIOA:V*VBM)<./WEQ)C
M<WL/0>U;]%$Z]2:LV#;.,\>^#)/$<$-_ISI'JMHI"!\!9T/)1CV]0>F2<]<C
MQ^><V-P;74HI+&Z4?-%<J4/U!/!'N*^DZANK.UOH3#=VT-Q$>J2H'7\C7#6P
M\:FNS.W#8Z=%<K5T?.LNL"[,$'VF2\D5?+@AB)E;'95 S7H7@3P)=1WT>NZ]
M!Y,D>?LEFQ!,>?XWQ_%CH.WUZ>BV>G6.GQ[+*SM[9/[L,2H/T%6:5+#1@^9Z
MLJOF$JD>2*L@HHHKI//"JFIR^3IEP^,_(1^?']:MUD^(I?+TS:#R[@8]1U_P
MIK<3V.1HHHK8Q.HTI"FG1 ]\G\S5RHK>/RK:-/[J@5+3$%%%% '-ZRQ;46'9
M0 /RK/JQ?MOOICG/SD57I#-7P]&'U52?X$+#^7]:Z^N8\,1YN9Y/[J@?G_\
MJKIZRGN:PV"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^6OB]_R
M5'6/^V/_ *)2OJ0=!7RW\7O^2HZQ_P!L?_1*5]2#H* %HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!DT0F@DB8D!U*G'N*\_92CLK#!!P17H=<9KEO]GU27 ^63]X/QZ_KFK@R
M)HSJW=!ES%+"?X3N'X__ *JPJN:7/Y%^A/W7^0_C_P#7Q6AF=11113$<YXP\
M*1>)].4(XAOH,M;RGIGNK?[)_3K['Q:[M;K3KQK._MWMKE.L;CK[@]"/<5]&
M51U71M/UNT-KJ-K'/'VW#E3ZJ>H/TK6G4<=#EQ&%C5U6C/GRBK6J:9<Z'JLV
MF7@(EB8['(XE3LP^H_K56NM.ZNCQ91<79A78^!=9C\/Z3XKU%MOGPVL30[AG
MYLNH'TW,N:XQ6WRB*-7EE/2.-2S'\!7?3^#KG1/A9KMY?;5OKM(6,601%&LB
MD+GU/.?PK&LXVY7U.O!0GS\Z6R?Y'F: J@!Z]_K3J**Z#4*]!^$6D7-UXEFU
M892UM(FB+?WW;'R_@.3^%>?5>TG6M4T&Z:YTF^DM9' #@89' Z;E/!QDX],U
M%6+E!I%TI*,U)GU#17*^ O%<OBS0Y+FZ@2&Z@E,,HCSM8X!##/3KTSVKJJ\F
M47%V9[$9*2N@HHHI#"BBB@ HHHH **** "BBB@ K)\0>&=)\3V/V75;1)E /
MER='B)[JW4=![''.:UJ*!IN+NCR#4/@_JMH__$AUV.2#/$.H*<J/3>H.?R%4
M3\,_&Q<KYVB ?W_,DQ_Z#_2O;:*Q>'IMW:.R./KI6N>4:5\''F=)/$FL/<J,
M$VMH/+0G/=NI'X ^]>FZ?IUGI5E'9V%M%;6T8PL<2X _^O[U:HK2,(QT2.>K
M7J57[[N%%%%49!63K][]GL3"K?O)N/HO?_"M.65(8FED;:BC)-</?WCWUV\S
M< \*OH.PJHJ[)D[(K4459L+;[5=I'CY>K?2M3(W-(M_(LE8CYI/F/T[5?H P
M,"BF(**** ,C79L11P@\L=Q^G^?Y5A5;U*?[1?2,#\JG:OT%5*0QR(TCJBC+
M,< >IKOH(A!;QQ+T10H_"N1T*V^T:I&2!MC^<Y]NGZXKLJSF^AI!=0HHHJ"P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "H;N'[1:2Q8!W(0,^O:IJ* /.R,$BBKNK6_P!F
MU.9 ,*6W+@<8/-4JW,#H-#FWVK1$\HW ]C_DUJ5S6D7'DWH4GY9!M/U[5TM,
M04444 9>MV_F6HF YC//T-<_792(LD;(WW6&#7(W$+6\[Q-U4X^M R.NVTF[
M^V:?&Y/SK\K_ %%<36GHE_\ 8KS:YQ%)PWL>QJ)*Z*B[,[&BBBLC4***YSQM
MXC/AGP[)=0J&O)6$-LK=#(W<^P&3^'O2;LKLJ,7.2BMV3>(/&&B>&0%U&[Q<
M.NZ.VB4O*_T4=/J<#WKD;_XH:!J>GS6MWH.LRVLRE74PQY_+S,^]<CH.E6MV
MM]JFKW\OF*4WW#)YC/(Q."V?X1@\5J^(--":/%?S6UM;7/G>4OV7 BN8]H(D
M4#C\JXWB9_% ]6&"HQ:A-MLX/4K:RCF:73;HW%H6P!(NR6(_W74\@^_0]CP0
M.^\ ?$,V)BT?6ILVO"P7+G_5>BL?[OOV^G3B;VS6Y3>H43I]QCW]C[4VZT6X
MCT:TUF!'DT^Y& ^.8I <,C>X(.#W'/J!ZV$Q<,7#V=3XC#%X3V-FM4SZ9!!
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MBBB@ HHHH **** "BBB@#Y:^+W_)4=8_[8_^B4KZD'05\M_%[_DJ.L?]L?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?UKO:*CV<+WL;+$UDN52=B&TL[:PMDMK.WBMX(QA(XD"JOT J:BBK,0HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!\M?%[_DJ.L?\ ;'_T2E?4@Z"OEOXO?\E1UC_MC_Z)2OJ0=!0
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M9_4_T_.L2SM7O+I($ZL>3Z#N:[F&%+>%(HQA$& *B;Z%P74DHHHK,T"BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ?+7Q>_Y*CK'_;'_ -$I7U(.@KY;^+W_ "5'6/\ MC_Z)2OJ0=!0 M%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !6#XBT_P R,7D:_,@Q( .H]?P_STK>I&4,I5@"
MI&"#WIIV8FKH\\HJ_JVGFPNR%'[E^4/]/PJA6RU,7H;VCWWF1BVD/SJ/D/J/
M2M:N-1VC=70X93D&NGL+U;V'/ D7[RTQ%NBBB@ JG?Z?'>IGA91]UOZ&KE%
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MWV.V\V1<32C)R/NCTK5HHK)NYJE8****0PHHHH **** "BBB@ HHHH ****
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M:Z>LYOH:074****@L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:F)L!QRC>AJW10!Y]+$\$K12+M=3@BF5U^L:2+Z/S8@!<*/^^QZ&N1961BK
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'RU\7O^2HZQ_VQ_P#1*5]2#H*^6_B]
M_P E1UC_ +8_^B4KZD'04 +1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'RU\7O^2HZQ_VQ_P#1*5]2#H*^6_B]_P E1UC_ +8_^B4KZD'04 +1110
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M)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?Q*/*B_[Z89S]%Q[UY%8>%/&GCJY6\^SWMV' _TR]<A-OLS]0/1<_2O1M!^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^6OB]_R5
M'6/^V/\ Z)2OJ0=!7RW\7O\ DJ.L?]L?_1*5]2#H* %HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW_@6!7R0#@Y'6O0/"'PDUGQ790:B;JUL].E)VREO,=@,C(5?<8P2#0!TVO\
MQ\N9=T7A_2U@7) GO#N;'LBG /U)K@WN/&OQ#NRA;4=4.X911B&,XX) PB?7
MBO<= ^#?A71MLEU ^J7 P=]V<H#[(.,>S9KO8((;6!(+>*.*%!M2.-0JJ/0
M=* /!] ^ VI7/ES:]J$5G&<%H+<>9)CN"WW5/N-U>H:!\-O"OAW:]KID<]PN
M/](NOWKY'0C/"G_= KK** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^6OB]_R5'6/^V/_ *)2
MOJ0=!7RW\7O^2HZQ_P!L?_1*5]2#H* %HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!\M?%[_ )*CK'_;'_T2E?4@Z"OEOXO?
M\E1UC_MC_P"B4KZD'04 +1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\M?%[_
M )*CK'_;'_T2E?4@Z"OEOXO?\E1UC_MC_P"B4KZD'04 +1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\M?%[_
M )*CK'_;'_T2E?4@Z"OEOXO?\E1UC_MC_P"B4KZD'04 +1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1110 4444 ?+7Q>_Y*CK'_;'_P!$I7U(.@KY;^+W_)4=8_[8_P#HE*^I!T%
M"T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $-V-UE.-X3,;#<5W
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MN=S)]<5[I%+'/$DL3K)&X#*ZG(8'H0:YBT\ Z58:,=.M)[N NXDDN(W7S9"
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M5N5FZ! ;?0[6,QF-MN2I.3D\UI5$MV4M@HHHI#"BBB@ HHHH **** "BBB@
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MQ[&"?#]R!\NIR9]U/^-1G1-3!^2]0_[S$?TKHJ*.>0O9Q.=&DZN.EW#^)/\
M\336L=;0\&.3Z%?ZXKI**?M)"]E$YEDUF,?-9HWT(/\ (TT7&H+]_3I3_NJ1
M_2NHHI^U8O8Q.2;4$SBXLV7ZC/\ ,"F?:-,EX:'9_P !Q_*NPJ%[.VD^_;Q-
M]4!I^U\A>Q[,Y7R=+E^[)L_X$1_.GII\6=UK>,I]0P/\L5O/HNG2=;91_NDC
M^55I/#5DYRC2I[!@1^HI^TCU)]E);,HK_:\!_=7Y8#^^<_SS4JZMK<(.^**4
M>I'/Z$4X^'KB,'R+]AZ @@?S_I4;:?K,(&UXIO8$?U H_=L?[Q%A/%#QD"ZL
M73U93_0C^M78?$FFRCYI'B/HZ'^F16*\^H6^?M%@Q ZE0<?GR*@^UV$QQ+;[
M3W.W_#FE[*#V#VTUN=C#>6UQ_J;B*0^BN":FKA_LNGS_ .JGV'L-W^-6(TU.
MUQ]FOF91_"QX_(Y%0Z#Z,M8A=4=A17,)KVIV^!<V:RJ.I7@_F,C]*NV_B>QE
MXF$D+=]PR/T_PK-TY+H:JK!]3:HJ&"ZM[D9@FCD_W6!J:H- HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ^6OB]_R5'6/^V/_ *)2OJ0=!7RW\7O^
M2HZQ_P!L?_1*5]2#H* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** /EKXO?\E1UC_MC_P"B4KZD'05\M_%[_DJ.L?\
M;'_T2E?4@Z"@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKTO$_'G^E+]JUM/^6L;_ / 5_P !5@^';P?=U)C]01_6F'1-64_+>1$>Y/\
MA1S4PY:B&+J6M+U@A;ZX_H:4ZUJB_>LD/T4_XTK:7K:#B6%_8$?U%,%KKH_Y
M=D/_  )?\:/W8OWJ'C7K[OIY/T#4\:_==],D_,_X5%]GUS_GTC_[Z7_XJ@PZ
MV.ME'_WT/_BJ+4QWJ$I\1R+]_3I%^KG_  IR>)[;'[R"93Z#!_J*J,^JQG#Z
M>Q_W5)_EFHY+Z:-1]IL)$4_W@1_,4<L&+GFMS;@UJPGP!<!&])/E_7I5\$,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^6OB]_R5'6/^V/_
M *)2OJ0=!7R_\8EV_$[5#_>6$_\ D)!7TW:2>=9P2?WXU;\Q0!-1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$$;II=DKK@AA;H"#Z]*BU[PUI'B>V@M]8M/M,4$PGC7S'3:XZ'Y2,]>AXK5
M   Z"@#Q+XD:/HT7Q>T?4/%5OOT#4+3[,9VE>-(9@3C+(00.G7CYB>U;6J>
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M_P#7K5\3_P#(*'_70?R-8]Z<+9MW##^E=%/X#EJZ3.LHI%Y4?2EK$Z HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB/S/]*ZSI6E6;6B,Z,$_>8U$6- B*%4#  & *=117.=(4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT4G=ATHHHK(V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#7KK(9H[B%98V#(PR#7/.#BSIIU%-$E%%%0:!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG3+!KX7ILK<W8_Y;>6-_3'7KTXJW4/$M04*>EM_-EK#IS<ZFO;R1Y!J]A=>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M [-5O8QT//Z__7KHZYOPL&G-Q>,,!\ ?7J:Z2OGZGQ,]6E\""BBBH- HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7D_QYT<W?A>QU5$9GL;
MC8Y'18Y!@D_\"5!^->L5C>+='_M_PEJFEA \EQ;L(@QP/,'*?^/!: //O@+K
M!NO#=_I+LQ>RN!(F3P$D'0?\"5C_ ,"KUJOF7X-:R-(^($-O*P6*_B:V;<V
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M:]N[$8)/V*N<A\0O&DG@C2+:^BLDNS-/Y6QI"F."<YP?2O.?^&@KO_H7H?\
MP*/_ ,37K^O^&=(\46D=KK-I]IAC?S$7S'3#8QG*D'O7/?\ "H? O_0#_P#)
MN?\ ^+KD.LX'_AH*[_Z%Z'_P*/\ \31_PT%=_P#0O0_^!1_^)KOO^%0^!?\
MH!_^3<__ ,71_P *A\"_] /_ ,FY_P#XN@#@?^&@KO\ Z%Z'_P "C_\ $T?\
M-!7?_0O0_P#@4?\ XFN^_P"%0^!?^@'_ .3<_P#\71_PJ'P+_P! /_R;G_\
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M .!_X:"N_P#H7H?_  */_P 31_PT%=_]"]#_ .!1_P#B:[[_ (5#X%_Z ?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI9M8S<W S<2\\_PCT^M4-(M3J5^U[*/W,1Q&#W-=/15G]E"HP^TPHHHK$W.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JEJMG]MT^2(#Y_O+]15VBA.VH-75CC8MM]9FW<[9H^.:LV^JZA9((9[4
MSA1@,"<_GS6CJ6AK=2_:+:3R;CN>S?X5FM;ZW ,&V27'\0(.?R-=*E&2U.1P
MG!Z"R:KJMUE88! I[D<C\3_A5?[/#:GS[R7S)3SR<\_UJP+/6[C \I(%/<D#
M_$U=M/#D4;B6\D-Q)Z?P_P#UZ.:$=@Y)SW,Z"WO-9?$8,-KW8]_\:Z*QTVVT
M^/;"GS=W/+&K2J%4*H  X ':EK&4W(Z(4U$*J7VG6^H1;)E^8?=<=15NBH3L
M6U?<Y&6.YT>80W \RV;A7]O\]J;B2PE%[9',9^^@Z$5U=Q;Q74+0S*&1NU<M
M+#+HUUY,N7M9#\K5T0FI*S.6I3<'S1.ALKR*^MQ+$?J.X/I5BN4W2:7<BZMO
MF@?[Z#IBNFMKB.Z@6:)LJWZ5$X\K-(3YD2T445!H%8>N6+*1?VX_>)]\#N/6
MMRD(# @C(/!!JD[.Y,E=6.4G_P!(ACO;<[98^>.M=1IE^NH62RCAQPX]#7-R
MQ'2]3,7_ "[S<K[4^QG.DZN 3BVGX/H#6E2//&Z,:<N27*SK:*.M%<IV!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% 'RQ\0M-F\)?$N[EM"T>9UO[5\8QN.[CV
M#;@/]VOIK2-2AUG1K+4X 1%=0),H)&5# '!QW'2O*OCUH!N-+T_7H8P6MG-O
M.P'.QN5)/H&R/J]7?@7X@^W^%[C1I6'G:=)F,>L3DD?7#;OS% 'JM%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&<*;?=M!/ SO[#C\*J?\*H_ZC7_DK_\ 9UZ115+&5DK*7Y$O"46[M?F>;_\
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M:.WMHEBAC&%11@ 5+117,W?5G0E8**** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "J&N0FYT#4H!UDM94_-"*OTUU#HRGD
M$8- 'S!\(93#\3=.3_GH)4_\<8_TKZAKY9^%K!/BGI)/_/24?^0WKZFH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *YOQ QEU6R@[*-_Z_\ UJZ2N5O#YGB:8YR$08]N
M!6M%7D8UW:!'"OG^(H5QD1+DY^G_ -<5TU<_HJ^9J]Y*>J?*/S_^M705=1^\
M125HA11169J%<YJ;>=X@B3&1$G/\_P"HKHZYG/FZ]=OV7Y?Z?TK2FO>,JK]T
MDTQ1/XC=CG$2$CZ\#^IKIZY[PV"]U?2XX+  _G70U-5WD725HA11169H%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[M0Z^BBBN0[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?ZE/]T4^N8Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!@ >E+117(=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD9[]!\=M)U'6/ %O:Z787-[.M_&YBMH6D8*$<9PH)QR/SH [7P?_ ,B3H/\
MV#K?_P!%K6U61X5AEMO"&BP3QO%-'80(\;J0RL(U!!!Z$&M>@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"J%HQCM)[M_O.2<UN^&K<Q::96!W2L6Y]*UJ>["QA3]ZI<V:***Y3L"BBB@
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M4 %%%% !1110 4444 %<YK=\UU,-.MCD9_>L/Y58UG5C#_H=H=UP_!(_A_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 >*?$WX2^:9M=\-6_P"\Y>YL8Q][N6C'
MK_L_EZ5S7PW^*=QX8EBTK6'>?1B=JMC<]L?4>J>J]>X]#](5Y5\1_A+#KQGU
MC042#5#EY8.%2Y/<_P"RY]>A/7')H ]/M;NWOK6*ZM9HYH)5#1R1ME6![@U-
M7RYX)\?:MX U.2RNHI9+#S"MS9295HF!P2N?NL.XZ'H>Q'TAH/B#3/$NEIJ&
ME7*SP-P1T9&[JP['_P#7TH TZ*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-V?49.35Y? _B1H!,-+?85W8,B!L?[N<Y]L9K4\'1:?J?CD36UG]FMHHS+'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^T]@'_QKK7TVQ?.ZS@)/?RQ5.7PYIL@(6)HR>Z.?ZY%-5UU1+P\NC,1+:^@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*US7;^%'EMDDN+J<I$FXX&3T49) _&K?CC_D0O$'_8.N/_1;5YIJW_)K"?\
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M 1(QDF.(T.2EM"#W/8#/7N3ZFOI/PUX<L/"VAP:7IZ8CC&7<\M(YZLQ]3_\
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M'>0Y_3I6DJ*BA44*HZ # %+16;;>YJDEL%%%%(84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &3XI0/X2UE3T^Q3'_QPUX'\#6"_$!@>]E(!_P!]
M+7T#K\9F\.:I&!DO:2J/Q0U\X_"&?[-\2;-.GF+)'^F?Z4 ?3]%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *R[[PUH6IR-)?:-I]S(W5Y;9&;\R,UJ44 <%>_!SP5>*PCTZ6U=CG?!
M</G\F) _*L"^^ .BR0@:?K&H02YY:X5)E_(!/YUZY10!X/=_L_7Z#_0M?MIC
MZ36[1_R+5FGX"^*0"1?Z.?;SI>?_ "'7T510!\Q7'P9\:POMCL()Q_>CND _
M\>(-0'X0>.1_S!0?^WN'_P"+KZDHH ^63\(_'(_Y@1_"ZA_^+I/^%2>.?^@$
MW_@3#_\ %U]3T4 ?+'_"I/'/_0";_P "8?\ XNC_ (5)XY_Z 3?^!,/_ ,77
MU/10!\L?\*D\<_\ 0";_ ,"8?_BZ/^%2>.?^@$W_ ($P_P#Q=?4]% 'RQ_PJ
M3QS_ - )O_ F'_XNC_A4GCG_ * 3?^!,/_Q=?4]% 'RQ_P *D\<_] )O_ F'
M_P"+H_X5)XY_Z 3?^!,/_P 77U/10!\L?\*D\<_] )O_  )A_P#BZ/\ A4GC
MG_H!-_X$P_\ Q=?4]% 'RQ_PJ3QS_P! )O\ P)A_^+H_X5)XY_Z 3?\ @3#_
M /%U]3T4 ?+'_"I/'/\ T F_\"8?_BZ/^%2>.?\ H!-_X$P__%U]3T4 ?+'_
M  J3QS_T F_\"8?_ (NC_A4GCG_H!-_X$P__ !=?4]% 'RQ_PJ3QS_T F_\
M F'_ .+H_P"%2>.?^@$W_@3#_P#%U]3T4 ?+'_"I/'/_ $ F_P# F'_XNC_A
M4GCG_H!-_P"!,/\ \77U/10!\L?\*D\<_P#0";_P)A_^+H_X5)XY_P"@$W_@
M3#_\77U/10!\L?\ "I/'/_0";_P)A_\ BZ/^%2>.?^@$W_@3#_\ %U]3T4 ?
M+'_"I/'/_0";_P "8?\ XNC_ (5)XY_Z 3?^!,/_ ,77U/10!\L?\*D\<_\
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M^@$W_@3#_P#%U]3T4 ?+'_"I/'/_ $ F_P# F'_XNC_A4GCG_H!-_P"!,/\
M\77U/10!\L?\*D\<_P#0";_P)A_^+H_X5)XY_P"@$W_@3#_\77U/10!\L?\
M"I/'/_0";_P)A_\ BZ/^%2>.?^@$W_@3#_\ %U]3T4 ?+'_"I/'/_0";_P "
M8?\ XNC_ (5)XY_Z 3?^!,/_ ,77U/10!\L?\*D\<_\ 0";_ ,"8?_BZ/^%2
M>.?^@$W_ ($P_P#Q=?4]% 'RQ_PJ3QS_ - )O_ F'_XNC_A4GCG_ * 3?^!,
M/_Q=?4]% 'RQ_P *D\<_] )O_ F'_P"+H_X5)XY_Z 3?^!,/_P 77U/10!\L
M?\*D\<_] )O_  )A_P#BZ/\ A4GCG_H!-_X$P_\ Q=?4]% 'RQ_PJ3QS_P!
M)O\ P)A_^+H_X5)XY_Z 3?\ @3#_ /%U]3T4 ?+'_"I/'/\ T F_\"8?_BZ/
M^%2>.?\ H!-_X$P__%U]3T4 ?+'_  J3QS_T F_\"8?_ (NC_A4GCG_H!-_X
M$P__ !=?4]% 'RQ_PJ3QS_T F_\  F'_ .+H_P"%2>.?^@$W_@3#_P#%U]3T
M4 ?+'_"I/'/_ $ F_P# F'_XNC_A4GCG_H!-_P"!,/\ \77U/10!\L?\*D\<
M_P#0";_P)A_^+H_X5)XY_P"@$W_@3#_\77U/10!\L?\ "I/'/_0";_P)A_\
MBZ/^%2>.?^@$W_@3#_\ %U]3T4 ?+'_"I/'/_0";_P "8?\ XNC_ (5)XY_Z
M 3?^!,/_ ,77U/10!\L?\*D\<_\ 0";_ ,"8?_BZ[WX2>!?$GAKQ;/>ZOIIM
MK=K)X@YFC?+%T(&%8GH#7M5% !1110!\[>([QM4^(FNW3C'D2_9D&>,)\O\
M[+G\:@IMY\OB_P 11G[RW\N3_P #:G5]+125-)=CQ:KO-GH/AW4Y=&^'ES?V
M\4+RI=8 E7(YQZ$5G2?$?5I8GC-GIP#*5.(FSS_P*KVB3VEM\-KJ2]LOMD N
M^8?-,>?N_P 0YKG+_4]"N+*2*S\._9)VQLF^VO)MYY^4C!XR/QKEA3C*<N:%
M]=_N\S:4Y1C&TK:?UT(=(\/:GKTC_8;?<B'YY&.U%_$_R%.UGPUJFA!'O8 (
MG.%E1@RD^F>WXUV,]EIZ^ M(LY]7&FPW \YSY+2>:W7!P1TSW]O2J,D^BV/@
MS4-*CUY;YI&$D"_9V0HV1D#.>N/;J:I8B3E=;7M:S]+WV$Z,4M=[7W7Y'",H
M=2K %2,$'O7H7P5OG;0M2TN1F9K.Z)7/158=!^(8_C7GU=I\%5/VSQ(_\)FC
M _-_\:,<DZ+'A'^\/7****\(]01E5U*L RD8((R"*\O\2_"));F2^\,72V$[
MG+VLN3"WT/)7OQ@CGC%>HT5I3JSIN\63.$9JTCYTO-!\8:6XCN_#5U,>SVH\
MU<?\ W?KBJWV?7VXC\+ZNS>GV60?^RU]%?VE8&;R?MMMYO\ <\U=WY9JU7;_
M &C42UB<WU.#V9X)IGP_\9:XR^=;QZ/:M@F2=LR8[X4<Y^NWZUZKX2\#:3X1
MA)M$::]D7$MW+R[]\#^Z/8>@SFNFHKFK8JI5T;T-J=&$-@HHHKG-0HHHH S/
M$=I/?^%]6L[9/,N+BRFBB3(&YF0@#)X')[UY?X(D^(O@SPG::$/A\+P6YD/G
M?VS;Q[MSLWW><?>QUKV.B@#S#Q+H_B^\USPUXSL-$@FO[&%H[G19;Q!L+9R4
MD^[GD@GV'!INJZ!XS\2^(?#&NZC8V=G%87N\Z=#,)'@C9?F=Y3@,<J!M4<>_
M./4:* /.-?T'Q4OQ3C\3:':6LL$&E>05N90HG;S,F($'*,1R&((R,'KQ7&@^
M+/''BG2M1\4:9;Z'I.D3>?#8I="XEGE&,,S+\NT$9]>",<YKT^B@#B&T#4S\
M9UU_[-_Q*QHYMO/\Q?\ 6>8#MVYW=.^,4SPSX=U.Q^(_C#5+RT":?J(MQ;2&
M16\S:K!N <CKW KNJ* /+-+T?QM\.9+G3M!TBW\2:#+,\MK$;U;:>UW')5B_
MRD9)Z=3D\=*[3PPWBF:*XN/$T>FV[2L#;VEGN9H5QR'<G#'Z#''4YP-^B@#(
M\565QJ7A'6+&TC\RYN+*:*)-P&YF0@#)X')[UP^H^$M<G^ 2^&8['=K M(8_
MLWFH/F61"1NSMZ ]Z]/HH HVMDKZ%%8WD0*M;B&6,G((*X(X_&O.=&TWQU\.
MK:71=(T.V\2:,)'>R<7J6TL 8DE9-XPW)[>_/0#U2B@#B/!'A+4]-U75?$GB
M.>WEUS5"H=+8?N[>-1A44GD\8R?8=<9,/PC\.:MX8\(26.L6GV:Y-W)($\Q'
M^4G@Y4D5WM% '"^$O#VJZ9\0O&&J7EKY5EJ,D)M9?,5O,"AL\ DCJ.H%=+XH
ML[C4?">L65K'YEQ<64T429 W,R$ 9/ Y/>M6B@#E_AWI%]H7@+2=,U*#R+R"
M+;)'O5MIR>ZD@_@:D\=>$H?&GA:XTB27R921+;S=?+D7H?U(_&NDHH \S:^^
M*KZ:=#'AW3$NRAA_MP7X\D#&-XBQOSC]>V.*LS?"JSD^%J>$!='SXSYZ7A7'
M^D9)WX';)(QS@'VKT.B@#S-K[XJMIIT,>'=,6[*&'^W!?KY(&,;Q%C?G'MU[
M8XHUGX>W.G_!.\\):,OVZ_=$.25C\Z0RJ[G+$ #KC)Z "O3** ,_0K::ST#3
M[:X39-%;HCKD'#!0",CBN,^+$$EE8Z+XIA1V?0K])I=G7R'PLF!W/W:]#J&Z
MM8+ZTFM+F-98)D,<B-T92,$?E0!P/Q/TG5/%/AK1I_#EFNHR0W\-Z$6=(PR
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVC%=#7SLU:31[*=U<****D84444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY7^)\7V/XEZF1P3*LOY@&
MOJBOF'XRC'Q+O^.L</\ Z+% 'TQ:'-E ?6-?Y5-532Y1-I5I(.C0H?T%6Z "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "L?Q1XBM?"V@7&J76&\L;8XMV#*YZ*/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA\7H\AE;SDM)SEI&/.Z7/_H)Z]_2O;@ H    X %+10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %>!_'^$C7M*G[&V*?DQ/]:]\KQ3]H*,"'0Y>Y:5?R"_XT =
MO\*)S<?#C2F/\*LGY,17:5P/P:.?AI8>TLW_ *,-=]0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %>-_M QEM+T23LLTH/XA?\*]
MDKRSX[PA_!EI-WCNU'YJ?\* +'P.N/-\!F+/^IN77\^?ZUZ77D_P#8GPGJ0]
M+T_^@+7K% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4L<\22Q.LD;@,KJ<A@>A!I]9\^EKYS7-G,]I<-RQ3F.0_P"VG0]LD8; QN%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *X_XIC/PTUK_ *YI_P"C%KL*YOX@6_VKP%K47_3L6_(@
M_P!* /*OV?Y0NK:U%W>&,C\"W^->\U\Z? F4KXWN(NSV;$_@R_XU]%T %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0U6X89D,\VU7;U^7#?FQKMM(\.Z-H$7EZ5IEM:#&TM'& S#_ &FZG\36G10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !63XH4/X2U@'_GRF_] -:U4-<B,_A_4H0,F2UE7\T(H ^?/@<X3X@,
M"?O6<@'YK7TE7R]\)9C;?$NPCZ>9YD9_[Y)_I7U#0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7RAXO)L_BGJ<G]W4S)_X_FO
MJ^OE;XJ1?9_B7JX'!,B/^:*?ZT ?4Z',:GV%.ID7^I3_ '13Z "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *;(@DB=#T92*=10!\L_#@[/BOI@Z#[3(/\ QUJ^IJ^4
M/"TAT[XH6)/!2_*'\25_K7U?0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\W_'.'R_
M'J/C_6VD;?J1_2OI"OGCX]C'C2P/KIZ_^C'H ]J\%,7\#:"QZG3X#_XX*W:Y
M_P "MN\!: ?^G"$?^."N@H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRWXT>#_[9
MT-=<M(R;VP7]X!G+P]^/8\_0GTKU*FR1I+&T<B*Z."K*PR"#U!H ^):]A^!/
MAH7.I7?B"= 4MOW,&<'YR,L?P&!GW-<?\0?!LWACQ>]C;1.]M=,'L\#)8,?N
M_4'BOHSP7H">&?"=AI@QYD<>Z4CNYY8\^YH WZ*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KY[^/J$>+=-D[&Q _*1_\:^A*\(_
M:!AQJ6BS8^]#(GY$'^M 'IGPTF\_X=:*W]VW"?\ ?)(_I75UP_PA??\ #+23
MZ>:/RE85W% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &7JOA_3]:NM/N+V$2
M26$WG0DCH<8P?;H?J!6I110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7B?[08'E^'V[DW _]%U[97BW[0:DVN@-C@/./TCH
MZ[X.MGX8Z8/1YA_Y%:N[KP/X??%C1/"GA.#2=0M-1DFBD=MT$:,N&8GNX/?T
MKJO^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#
M6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H
M]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;
M_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\
M'*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#
M6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H
M]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;
M_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\
M'*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#
M6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H
M]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;
M_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\
M'*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#
M6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H
M]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;
M_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\
M'*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#
M6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H
M]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;
M_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\
M'*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#
M6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H
M]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;
M_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\
M'*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#
M6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H
M]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;
M_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\
M'*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#
M6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H
M]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;
M_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\
M'*/^%]^%O^?#6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#
M6/\ OS%_\<H ]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H
M]2HKRW_A??A;_GPUC_OS%_\ '*/^%]^%O^?#6/\ OS%_\<H ]2HKSS1/C'X>
MU_6K72[6SU1)[E]B-+%&%!P3SAR>WI7H= !1110!6O\ 4;'2K5KK4;RWM+=3
M@RW$JQJ#]2<51MO%?AV[LI[VWU[3);6WQYTR7:%(L\#<<X7\:\UN;"+Q]\;K
MVPU<?:-'T&!3%9N3L>1L<L.AYS]0 *J_&OP?H6F>$X+S2--@TV[FNH[0_88Q
M"LJ-D[75<!N5!Y]* /:4=9$5T8,C#(93D$55U>1X=%OI8V*NEO(RL.H(4X-9
M>KZAK6DZ/9MHGA\ZS,557A%XEOL&.N7X/TK/MM8\1:IHNLKKGA4Z(B6CF)C?
MQW'FDJV1A.F..OK0!D_#/Q-(?A4NN^(-1DD$+SM-<3ON.U9& &>_8 5%\/+S
MQ#XOU:\\7:G<W-KH\A,>F:<KE4*#_EHP_B/N?<XQBO'[:R\4R?"FSO9_(NO!
M]M?-)<6-LY2X<>8=Q=MN-N<]#W'U'T=IFLZ;+X+CU?1UC:P2S,L,<? "JN=N
M.Q&,8H LZIXDT/0W2/5=8L+%W&Y4N;A(V8>H!.2*L6VK:;>Z<=1M=0M)[%59
MC<Q3*T8"]3N!QQ@Y]*^?_!&J:5>07NN>(O _B'Q/J=_<.S7::0MU J@X"H2<
M<8YP!CIVKI_ T!/Q'U%-,\*ZUI'AG4;)FN;34K PP^<"!\H)*X()X_#&!0!J
MZ'\1-*F^)/B5+OQ18+I$<-NMGYM[&L1;!WE"3@\]<5Z0]_9Q6)OI+N!+,)O-
MPT@$87UW=,>]>.^"/#'A^[^*OC>SN="TR:UMFB\B&2TC9(LEL[5(PO3M5SQG
M:)XE^*OA_P &S@)H5M;&[FM$^19",@#CL/EX^OK0!Z+8>+?#>JW8M-/U_3+N
MX.<107:.Y^@!R:UI98X(GEED6.-%+.[G 4#J2>PKSCXA_#SPX?!=]=Z7I-EI
MFH6$9N;>YLX5A=63GJF">!W[\USWBW5K[Q#\$= U*Z,[VTLUNVK-"""T0.')
MQVS^N* /4[#Q9X<U6Z^RZ?KVF7=Q@GRH+M'8@=3@&N!^/Y!^'EL001_:4/3_
M '7KFOB19_#W4/"5G9^%8=%FUJ>>-+6/31&96SU$FSG'KN_QK5^,>D6>A_"/
M3=/L;2.U@BOX/W48P Q5R?QSF@#U/^UM-TVTT^._U"TM7N%5(%GF5#*V!PH)
M^8\C@>M7KBY@L[>2XN9HX((QN>25PJJ/4D\ 5X]\7?\ D(_#K_L(+_.*O0/B
M'_R3S7?^O1Z )/$?BO2=,\+7&HKK-A'YUK*]E(;E )F"$CRR3ACG'3/6L7X;
M^,M-U;PIH\%YX@LKC69HOG@>[0SLW)(*YW9Q[5BV.EZ?J'[/UI)>V-M<O;Z0
MSPM-"KF)MG521P>!R*T?A/X=T-? V@ZH-&TX:CY ;[6+5/-R1@G?C.<>] '8
MZIXDT+1)$CU76;"QD<;E2YN4C9AZ@$Y(JY8W]GJ=HEW87<%U;/\ =F@D#HWT
M(XKSC6Y/A3H/B.\;5K>ROM9O'+S120/?2!O3;AA'].*R/A!>68\<^+K+1TG@
MT<M'/!;2QF/RRV<X4\CH!^ H ]2E\2:%!:SW,NM:<D%O+Y,TC72!8Y/[C'/#
M>QYJ<ZQI@TH:H=1M!IY4.+HS*(MIZ'?G&*\:\ ^#],\3^*O%<VM1_;+2UU23
MR;23/EB1OO.0.IP .?2N]\6:-X#T[1-._P"$E2UM],TT_P"BP2RL$[# C!_>
M=N,&@#H-,\3Z!K4[0:7K6GWLRC<8[>Y21@/7 .<>]<1\2_'%OH^I:#IUGK<%
MO.VHI]M6.Y4-'$,9$@S\JG/?'2N#\5:SX/;Q%X6U#P78FPN4U"-&GMM/:UCE
MC9@".54-P3V[UT/QAT?3&\5^"YCIMGYMYJ)2Y?R%S.OR<.<?,.3P: /6M-UC
M2]9A>;2]2L[Z)&VL]K.LJJ>N"5)P:HW'C+PO:7K6=QXCTF*Y5MC127D:LK>A
M!/!]JXWXJ36_@?X:W@\.6%MIK7LZ6[?8H%BQN!RV% R<+C\:YC2F\'6?AZ'3
MI?A-XINR8MLEU+H2O+(2.6\S=N'M@C';% 'N:L&4,I!!&01WI:\Z^#?]KP^%
M;FRU.RU&TAM;IH[)-0B:.7R< @$-V&2/3BO1: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%_Z#-_\ ]\I_A1_PH#1?^@S?_P#?*?X5Z[10!Y%_PH#1?^@S?_\ ?*?X4?\
M"@-%_P"@S?\ _?*?X5Z[10!Y%_PH#1?^@S?_ /?*?X4?\* T7_H,W_\ WRG^
M%>NT4 >1?\* T7_H,W__ 'RG^%'_  H#1?\ H,W_ /WRG^%>NT4 >1?\* T7
M_H,W_P#WRG^%'_"@-%_Z#-__ -\I_A7KM% 'D7_"@-%_Z#-__P!\I_A1_P *
M T7_ *#-_P#]\I_A7KM% 'D7_"@-%_Z#-_\ ]\I_A1_PH#1?^@S?_P#?*?X5
MZ[10!Y%_PH#1?^@S?_\ ?*?X4?\ "@-%_P"@S?\ _?*?X5Z[10!Y%_PH#1?^
M@S?_ /?*?X4?\* T7_H,W_\ WRG^%>NT4 >1?\* T7_H,W__ 'RG^%'_  H#
M1?\ H,W_ /WRG^%>NT4 >1?\* T7_H,W_P#WRG^%'_"@-%_Z#-__ -\I_A7K
MM% 'D7_"@-%_Z#-__P!\I_A1_P * T7_ *#-_P#]\I_A7KM% 'D7_"@-%_Z#
M-_\ ]\I_A1_PH#1?^@S?_P#?*?X5Z[10!Y%_PH#1?^@S?_\ ?*?X4?\ "@-%
M_P"@S?\ _?*?X5Z[10!Y%_PH#1?^@S?_ /?*?X4?\* T7_H,W_\ WRG^%>NT
M4 >1?\* T7_H,W__ 'RG^%'_  H#1?\ H,W_ /WRG^%>NT4 >1?\* T7_H,W
M_P#WRG^%'_"@-%_Z#-__ -\I_A7KM% 'D7_"@-%_Z#-__P!\I_A1_P * T7_
M *#-_P#]\I_A7KM% 'D7_"@-%_Z#-_\ ]\I_A1_PH#1?^@S?_P#?*?X5Z[10
M!Y%_PH#1?^@S?_\ ?*?X4?\ "@-%_P"@S?\ _?*?X5Z[10!Y%_PH#1?^@S?_
M /?*?X4?\* T7_H,W_\ WRG^%>NT4 >1?\* T7_H,W__ 'RG^%'_  H#1?\
MH,W_ /WRG^%>NT4 >1?\* T7_H,W_P#WRG^%'_"@-%_Z#-__ -\I_A7KM% '
MD7_"@-%_Z#-__P!\I_A1_P * T7_ *#-_P#]\I_A7KM% 'D7_"@-%_Z#-_\
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MA1_PH#1?^@S?_P#?*?X5Z[10!Y%_PH#1?^@S?_\ ?*?X4?\ "@-%_P"@S?\
M_?*?X5Z[10!Y%_PH#1?^@S?_ /?*?X4?\* T7_H,W_\ WRG^%>NT4 >1?\*
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M>B?YX%>H44 8_AJXUZZTA)O$5E:V5\[$^1;2EPB]@QZ;@.N"16Q110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %>8_'<9\!6_MJ$?_ *!)7IU>>?&J'S?AW,W_ #RN(W_4C^M
M&)\ 9<^'M5A_NW8?\T _I7KU>)?L^.2FO)G@&$X^N_\ PKVV@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KB/BZ@;X9:L?[OE'_R(H_K7;UQGQ8&?ACK7^[%
M_P"C4H X']GL_O\ Q /]FW_G)7N->#_L_2[=4UN+/+0Q-^1;_&O>* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BD) &2<"HFN[9#AKB)3[N!0!-15?[?9_\_<'_ '\'^-(=1LA_R]P?
M]_!18+EFBJ9U2P'_ "]1?@U,.M:<O6Y7\%)_I3LQ71?HK._MW3?^?G_QQO\
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M_M]G_P _<'_?P?XU(MQ _P!R:-OHP-*PR2BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?_OX?\::;Z[;K=3GZR&H**=A7)#/,WWI7/U8U&23U.:** "@44HZB@!****
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M5P:5AW)J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HJ*2Y@A.)9HT/HS@5 ^JV$8RUU$?\ =.[^
M5%@N7**S'U_3E&1*S^RH?ZU WB:T'W8IC^ ']:?*Q<R-JBN=;Q3UVVGT)D_^
MM4#>)KLGY880/<$_UI\K%S(ZFBN.D\0:@[9654'HJ#'ZYJ"35K^3[UU(/]T[
M?Y4^1BYT=Q2%@HRQ 'O7!27=S*N)+B5QZ,Y-0T<@<YWK7UHIPUU #Z&05 ^L
MZ?&<&Z4_[H)_E7$T4^1"YV=@_B#3U&1([^RH?ZU WB:T ^6&8GT( _K7+44^
M1"YV=&WBD?PVA_&3_P"M4#^)[DM\D$2CT;)_PK#HHY4',S6?Q%?MT,:?[J?X
MU$==U(_\O/Y(O^%9U%.R%=EIM1O6.3=S_@Y%1/<3R??FD;_>8FHJ*=A7"BBB
M@ HHHH ***<J.YPBLQ]AF@!M%3"SN3TMY?\ O@U(NG7C]+=_QX_G0!5HJZ-(
MO2?]3C_@8_QJ4:)=GJ8Q]6_^M0!FT'DUJC0;C/,L0^F3_2I1H!QS<\_[G_UZ
M ,6BMQ= 0?>G8_1<5(-"MN\DOYC_  H Y^BNC31;13SYC?5O\*D_LFQ_YX?^
M/-_C0!S%%=4NG6:]+=/QYI_V.U_Y]H?^^!3 Y*BNQ2*-/N1JOT&*?0(XX12-
MT1C]!3Q:7)Z6\I_X :ZZB@#DUL;ICQ;R_BI%2#2KT_\ + _]]#_&NHHH YD:
M1>G_ )8@?\"'^-/71;L]0B_5JZ.B@#G_ .PKKC]Y#^9_PIRZ#-_%,@^@)K>H
MH Q!H#=[D?\ ?'_UZ7^P!_S\_P#CG_UZVJ* ,A=!C'WIV/T7%/\ ["MO^>DW
MYC_"M2B@#,&AVH_CE/\ P(?X4\:-9C^%S]6K0HH HC2+(?\ +(G_ ($?\:7^
MR;'_ )X?^/M_C5VB@"F-*L@>(!^+$_UJ06-HO2WB_%0:L44 0_8[7_GVA_[X
M% M+8=+>(?\  !4U% $8@A'2)!_P$4X(@Z*/RIU% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5'<)YEM+&>C(1^8J2B@#YF^&'
M'Q-TK_?E'_D-Z^F:^8OAP_E?$O2B?^>TB_FC#^M?3M1#8N>X44459 4444 %
M%%% !1110 4444 %%%% !1110 4444 ! /44TQ1GJBG\*=10!&;> ]88S_P$
M4W[);'K;Q?\ ? J:B@"'[':_\^T/_? I#96K=;>+\$ J>B@"F=+LFZP#\"1_
M6D_LFQ_YX?\ C[?XU=HH HG1[(_\LB/^!&F'1;0] X^C5HT4 9G]A6O]^;\Q
M_A2?V%;?\])OS'^%:E% &0=!C_AG8?5<TS^P!_S\_P#CG_UZVJ* ,0Z W:X'
M_?'_ ->HVT&?^&6,_7(K?HH Y[^PKK_GI#^9_P *8VBW@Z*C?1JZ2B@#F#I%
MZ/\ ECG_ ($/\:0Z5>C_ )8'_OH?XUU%% ')M8W:];>3\%)IIM+D#)MY1]4-
M==10!QI1U^\C#ZBFUVE&* .+HKKVMH'.6AC8^Z TTV5J?^7:+_O@4 <E2C@@
MUU#:99MU@7\,BF_V38_\\/\ Q]O\:0SF**Z)M$M&/!D7Z-_C33H5OVDE'U(_
MPH Y^BMMM 7^&X(^J9_K3&T!P/DN%/U7% &/16H="N>TD7YG_"F-HMVHX"-]
M&_QH SJ.U7?[)OO^>'_CR_XU&VGW:];>3\!F@"M14IM;A1EH)0/=#41!!P:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HJNU_9I]ZZA!]-XJL^NZ<F?\
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MBH?M=M_S\1?]]BE^U6Y_Y;Q?]]B@"6BHQ/$>DJ'_ ($*>&5NC _0T +1110
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M: P'RW )]TQ_6H3H=T.CQ'\3_A0!F45>.D7H/^I!]PP_QJ%K&[4X-O)^"DT
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MW2O!]>/D>.[Q_P"[?%__ !_->[KRH^E1'J7+H+1115D!1110 4"BB@ HHHH
M**** "BBB@ HHHH *.E%% #A(XZ.P_&G"XG'2:3_ +Z-1T4 3"[N1TN)?^^S
M2_;+K_GYF_[[-044 3B]NL_\?,O_ 'V:D74[Q>D[?B :J44 7?[6OO\ GO\
M^.+_ (4HU>]'_+4'ZJ*HT4 :(UJ['=#]5IPUVZ'\$1_X"?\ &LRB@#4_MVZ_
MYYP_D?\ &GKKTO\ %"A^A(K(HH VO[?_ .G;_P ?_P#K4HU\=[8_]]__ %JQ
M.U% &Z->B_BA<?0@T_\ MVU_YYS?D/\ &N?HH Z)=<M#U$J_51_C4@U>R/\
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M<GW)%;Z'-/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT4 <7178/;PRG,D2,?\ :4&JSZ39/G]SM)[JQ% SF**WGT&$C]W,ZG_: /\
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MK:.LB[D8,I[@YJ;%7'4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM<NF'"Q+[A3_ (U ^J7KC!G8#_9 '\JJ44 2//-(,/*[?[S$U'1VHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?._Q[&/&EB?73U_\
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MZ#<,UR-% ':=:*XU79#E6*GU!Q4Z:A=QG(N)#_O'/\Z8CJZ*YM-:O$^\4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#A"/"G_0MZ3_X!Q_X4?\(1X4_Z%O2?_ ./_"@#Q3_A??BG_GPT?_OS+_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7*:MIMQ)JLS0PDHV&SD =.>OO75U7N1RI
M_"JAN3/8Y>/0KAL%WC0?7)%6H]!A'^LF=C_L@#_&M:BMC$IQZ79QX(A#'U8D
MU:2..(8C14'HHQ3J* "BBB@ HHHH **** "BBB@ HHHH **.G6H'O;:,$M/&
M,=@V3^5 $]%9[ZU9I]UG?_=7_'%5GU\9(CMR1V+-_2@#9HKG)-;NW&%V)[JO
M^-5I+^[D.6N)/P./Y4 =4[I&NYV51ZDXJN^I6<9^:X0_[OS?RKEB23DG)I*
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M!L3C)!XY-5?C=J%MJWA/P]?V<@DM[B1I$8>A0'\#[5M? ?\ Y$6[_P"P@_\
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M%S*UPTJF-E50" ,<_0T ?1E%>4Z!\:&\1^(;/2++PV^^YD"[VO!\B]6;&SL
M3C/->K4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 57N[ZTL8P]W<Q0*>AD<+GZ9ZUR_B?QJFF
ML]EIVV2['#R'E8SZ>Y_2O-[J[N+V=I[F9Y96ZLYR:Y:N*C!VCJSS\1CXTWRP
MU?X'LMCXATG4I/+M+Z)Y,X"'*L?H#C/X5IUX#6SI'Q"U;19_L]X?M]J#TD;]
MXH]F[_CG\*K#UG5NGN8T\TBM*JMYH]EHKEX_'VAS:)=:C%,S-;1&1[4C$O'H
M._U&0*R?"/Q7TCQ-="RN(6TZ]=L11R2;TD]@V!S[$#VS6[=G9GI1JPFDXN]S
MH/&W_(CZW_UYR?\ H)KP_P"!/_(_3_\ 7A)_Z&E>X>-O^1'UO_KSD_\ 037A
M_P "?^1^G_Z\)/\ T-*9H?1U%%% !37^XWT-.HZT ?+/PQ_Y*MI7_7:7_P!%
MO7U-69;>'-#L[I;JUT;3H+A"2LL5JBN">#@@9[UIT <=XV\&GQ BWED56^C7
M&&.!*/3/8^]<=;ZUXVT&$6)M[HI'\J"6V+X^C8Y'XD5[%16L:EE9JYP5L IU
M/:TY.,GO;J>/VGAKQ+XOU-;K6//AA& TLZ;"%]$3 _EBNX\5Z9Y/@6XT_3[=
MW$:(D<<:EF(##MU-=112=1MKR'2P$*<)1NVY;M[G&?#:TN;/0)X[JWE@<W!(
M65"I(P.<&M#QAX:3Q%I1" "]A!:%O7U4^QKHZ*3F^;F1K'"P5!4):JUCS3X:
M:9?V&IW_ -LLKBW!C4 RQ,H)R>F17I=%%*<N9W'A<.L/35-.X4445)T!1110
M 4444 %%%% !14%Y>6]A:O<W4JQQ(,EC7F'B'QI>:JSV]H6MK/D8!P\@_P!H
M^GM_.LJM:--:G/B,3"@O>W['H=[XBT?3WV7.H0J^<%5.\@^X7)'XU<M+VVOH
M1-:SQS1_WD8''^%>$4^._O=.;[387,D$R\[D/4>A'0CV-<]/%N4TFM&>>LTD
MG>4=#WNBO-M!^*4<FV#6X?+;I]HA&5_X$O4?AGZ5<\6?%+3?#4EBMO;'4EN5
M\PR0S!55,XX.#EN#QQ]:[9+EW/0HXJC65X/_ #.]HK(\.^)M+\4Z:M[ID^]>
MDD;##QMZ,/\ (K7H.C<**** "BBB@ HHHH **** "BBB@!&174JZAE/8C(JK
M)I=C*,-:Q?\  5V_RJW11<#)D\.V#_=62/\ W7_QS563PNA),5TP'8,F?US7
M044^9BY4<I)X:O%!*20OCH,D$_I5231]0B&6M7/^Z0W\J[:BJYV3R(\_E@FA
M.)8GC)_OJ14=>B5!)9VLIS);Q,?4H":?.+D."HKLGT+3GS^XVD]U8U5D\,6Y
M'[J>53_M -_A3YT+D9R]%;LOABX4_NIXW'^T"O\ C5.30M0CR?(W =U8'].M
M/F0N5F=14LEK<0C,L$J#U9"*BIB"E5BIRI(/J*2B@"RE_=Q\K</_ ,".?YU8
M36KM!\VQ_=E_PK.[44 ;::^.!);GW*M_2K,>M6;_ 'F=/]Y?\,US=% '6I>V
MTF-L\9)Z#=@_E4]<73TEDC.8W9#_ +)Q3$=C17+)J=Y&,"<D?[0!_G5J/79P
M?GBC8>V0: -^BLE->A/^LB=?]T@_X5:CU6SD('G!2?[P(H N44Q)8Y1^[D1_
M]TYI] !1110 4444 %%%% !1110 4A 8$$ @]C2T4 5I-/M)?O6Z#_=&W^55
M_P"PK9I!L:1>>F<BM&I8!F4>W-)[#6Y:4;5 ]!BEHHK W"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[;=]GMXHMWWO+0+G\JFHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[R04445SG %%%% !1110 4444 %%%% !1110 445#=W,=G:2W,IPD:EC[^U
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M;O71444F[C2L%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA:RV\GV/>5220JP5VP03M 8 =/F-6O$ND6FI_$[POX&:%4\.6-B;TV09MLK
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MO8IB)'"C:H;/)^HKMHP5C53U  H =1110 4444 %%%% !1110 4444 %%%%
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M8W(P<>>7(2:'%NEDF.>!M%;=4],@\BQ0$89OF/XU<HI1Y8)&>+J>TK2?R^X
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M<1KD<$+W'XD_E6LG9$9?3]IB(KMK]QZ)1116!]:%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5B^*YA#X>N!NPTA5%]^03^@-;
M5<UXW/\ Q)8O^OA?_06IK<VPZO5BO,X&BBBM#WPHHJ"YN! G'+GH/ZTTFW9
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MUQ7BC63>3_V=:$M&K8<K_&WH/7'\ZV,JDU"-RC*\_B?7@%!5"<#C_5QCN?\
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MYQ&_E 9_N\?TK$J2>1I9Y)'8LS,22>]1UXDGS2;/E:DN>;EW"BBBD2%4KZ?
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M^[_4_C7;4R*)(8DBC4*B *H'8"GUSMW=S[.A25&FJ:Z!1112-0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK+\37\^E>%=8U&V*BXM;
M&:>+<,C<J%AD?44 :E%>6?"+XJ-XWBGTS5S#'K,&9$\M=JSQ>H&?O*>H]"#Z
MX]3H **\\^'OC'5O$OBSQEIVH-";?2;WR+41Q[2%WRKR>_"+7H= !1110 44
M44 %%>/>$]0O9OVC/%=E+>7#VL=BS) TK%%.Z#D+G ZG\S7L- !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5@>,+=I]
M!9E_Y8R+(1ZCI_6M^F2Q)-$\4BAD=2K ]P:$73GR34NQX_171:OX2O;+?-9J
MUW"#D(G^L4?3O^'/M7&W%[(&:,(8V!P=W4?X5O&+EL>]"K":O%EFXN5@7 Y?
ML*RW=G8LQR3322223DFBNF$%$INX56OKZ#3K1[FX;"+T ZL>P'O3KN\@L;9I
M[APD:_F3Z#WK@[FYO?$^JK%$I"#[B=HU[DU1C4J<NBW"**\\4:R7;(0?>/:-
M/0>]=];V\5K;I!"@2-!A0*@TS3H=+LUMXN<<LY'+'UJY0%*GRJ[W84R65(8G
MED8*B LS'L*?7%>)]:-Y-_9UH2T:MARO\;>@]0/YTQU)J"N4KF:X\3ZXJ1!A
M'G" _P "#J3_ )]J[RUMHK.UCMX5Q'&,#_&LSP]HPTNSW2*/M4HRY_NCLM;-
M(FE!KWI;L*O:1IDVKZG#90@Y<_,V/N+W-4:]7\%>'_[(T[[5<)B\N0"05YC3
MLO\ 4_AZ5%2?)&XL16]E"_4Z.TM8K*TBMH%VQ1*%4>PJ:BBN \1N^H4444 %
M%%% !1110 4444 %%%% !1110 4444 ><^+X6C\02NW25%9?IC'\P:PJ].UW
M1(]9ME7=Y<\>3&^,_@?:O.M8TV^T0G[3:N8\X$R<H?Q[?CBM8ZZ(]G"XB$H*
M+>J*Q( R3@5G75YOS'&?E[GUJ&:YDFX)PO\ =%0UT0IVU9U-A116%X@\0)ID
M9M[<AKMA]1&/4^_H/\G8B4E%79#XFUW[%&;*V?\ TAQ\[ \Q@_U-5?"NA[=N
MHW2<GF%3_P"A?X?_ *JI^'=$?4I_M]Z"T&XD;^?-;/?VKN:1C"+J2YY?(***
MK7U[#I]H]S.V%7H.['L!3-V[:LH>(=872[(K&P^TRC$8]/\ :K$\)Z09YO[2
MN%RBG]T&'WF[M^'\_I5"VANO$^M-)*6$><N1T1.P'^?>N_BB2")(HE"H@"J!
MV%(YX_O9<[V6P^BBM'0](FUO58K.([0?FD?^X@ZG^GU(H;LKLZ)-15V=5\/M
M"\R9M8G3Y$RD /<]"WX=/S]*]%J*UMH;.UBMH$"11*%51V J6N"<^:5SPZU5
MU)N04445!D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '(>-/"-_K
MM[I&LZ+J,=CK.D.[VYGCWQ2!QAE<=1D=QZGV(QKWPGXX\7PKIOB[4]$M]&WJ
M\\&D12E[D*00K-)]T9&<BO2** $50B*JC  P*6BB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBO'_$WQ9U#PE\0M0TRXM8[W2T\O:@^22/*
M*3AN_))P?S H ]@HKG/#/CKP_P"+(Q_9M\OVC&6M9ODE7_@/?ZC(]ZZ.@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ JGJ[%=%OV'46\A'_?)JY45S"+FUF@/ D1D/XC%)ZHF2O%H\&HJ2:)X9Y(I
M%*NC%2K#!!%1UXA\J%,ED6)"['C^=)+,D*[G/T'K67/.T[Y;IV'I75AL,ZKN
M]C.<U'U&RRM-(7;\!Z4RBD)"J6)  Y)->TDHJR.;5L;-,D$32.<*HKGE$NJW
M^3D+W_V5IU[=2:A<K#""4SA1ZGUK9LK1;2 (.6/+-ZFL'^]E9;(]**6$I\S^
M.6WD3QQK%&J(,*HP!3J**Z#S6[N[&2R+#$TCG"J,FN>C5]4U$LV=I.3[+Z5/
MJUYY\HMHLE5/..YK2T^S%I;@$#S&Y8_TKGE^\G;HCT::^JT>=_%+;R7]?H6E
M4*H4# ' %+13HXWED6.-2[N0JJHR23T KH/.W.C\#Z!_;WB",2H3:6^)9O0^
MB_B?T!KW8   #@"L#PAX?7P]H4<# ?:9/WD[#NQ[?0=*WZPD[L^KR_#>PI:[
MO5A1114G<%%%% !1110 4444 %%%% !1110 4444 <'\2_\ 4Z=_O2?^RUY[
M7I7Q&M'ETNUN5/RPR%6&/[PZ_I^M>:UY6*7[UGS^/35=_(***J7-X(\I&<MW
M/I6=.G*I+EB<,I)*["\N?+'EH?F/4^E9M!))R3DT5[E"C&E&R.64G)W"L[5+
M[[/'Y49_>L.W\(JQ>WBV<.XX+GA5]:Q[*U?4+EIIB2@.6/J?2BI-_!'<[,+0
MC;VU7X5^)9T>R/\ Q]2#G^ '^=;%(   !P!2U<(**LCGKUI5IN;"L[5KSR(/
M*4_O)!^0J[/.EO"TKG@?K6!;Q/J=^7D^[G+>P]*BK)_"MV;X.BFW5G\,2[HU
MIL0W+CEN%^E:U(JA5"J, < 4M:0BHJR.>O5=6;FPKV+X:Z!_9^CG4ITQ<78R
MN>JQ]OSZ_E7GW@WP\WB#78XG4_98<23GV[+^/^->\JH50JC  P!4S?0];*<-
M=^VETV%HHHK(]\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "L'QO_P B#XC_ .P7<_\ HIJWJP?&_P#R(/B/_L%W/_HIJ /GC1?"
M%\OPOTGQYX:)AUO29YGF\OK-$KGG'<J,@@]5)!Z 5] ^!O&-EXW\,6^K6F$D
M/[NY@SDPR@<K[CN#W!'TKF/@/_R2JR_Z[S?^AFN2UNUG^"OQ"3Q#I\3-X3UA
M_+N[:,8$#=< =..67VW+QUH UO@[_P E!^)7_83_ /:L]7?#WB;6;OX_>(=!
MGOY'TNVM"\-L0-J-B'D<9_B;\ZS?@I<PWGC?XB75M*LL$VH+)'(AR'4R3D$>
MQ!J/POQ^T]XI!X)L3C\H* /2_'-]<Z9X$UR^LIFAN8+.22*1>JL%X-8OPU\1
MW%Y\);'Q!KUZTLB17$MS<..=J2R<G [*OZ5I?$C_ ))KXC_[!\O_ *":\]\.
M)-)^RM,L!._[#>$X_NB:0M^F: *NBW7CSXPRWVHVGB"7PSX>BE,5L+9"9788
M."596/!&3N SP!UQWG@W0_'&@:Q<6FM^(+?6M$\D&">6,K<B3C@]>.3G+-T7
M&,FJ/P+EAD^$VEK$REXY)UE [-YK'GWVE?TKT:@#Q;P?_P G,>+_ /KP;_T*
MWK9\?^-]</BFR\#>#/)&MW2B2>[EP5M4QNZ$$9VC)R#P1@$D8QO!_P#R<QXO
M_P"O!O\ T*WK%N]&75_VE-9T^YU?5-*>XME:WGTZX\F5R(8SMW8.5VJV1_L^
MU '1W7@#XD:/;W&J:5\1+O4=15=XL[F']U(>I5=SLH/I\H^HZUTOA7QTWC'X
M97FN1H+;4+>":.=$SB.9$SE<]B"K#KC.,G%0_P#"JV_Z'WQQ_P"#?_[&K&E^
M!=.\"^!]?L-,N+RX2YAFF8W3JS;O+QQM4>E &=\$/$.K>)?!%S>ZS>R7ERM^
M\2R2 9"A(R!P/4G\ZS_CEXHUOPS::$^C:A+9M<3R+*8P#N "X'(/J:9^SF1_
MPKN\]M3D_P#1<597[2'_ !X^&O\ KYE_DE ':_%SQK>^"/!PN]-1#?7<XMH9
M'&1#E68O@\$@+P#QDY.0,'G(OA_\3(;<:K!\1I7U9T5C9S1$VP8]5R25P.>1
M'S[5Z#XP\(:9XVT!])U02"/>)(Y8CAXG&0&&<CH2.1T)KRG4K3XD_"/2/M]K
MKMOK_AZTVJ\%U&0\:G"@X)+!1P %<@9SMQF@#VVQ^V#3[;^T# ;WRE\\P B/
MS,?-MSSMSG&><58K+\-ZW#XD\.:?K,$9CCO(%E\MCDH3U7/?!R,^U:E !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;C*SE[D=C0HHHKE. **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BL[7[^72_#NI:A J--:VLDR!QE2RJ2,^W%>!O\=_%;=+72D_W
M8'_J] 'T;17S3)\;O&+GY9;)/]VW']2:JO\ &/QNW35(T_W;6+^JT ?4%%?+
M?_"W_'7_ $&Q_P" D/\ \133\7/')ZZZ?PM81_[)0!]345\JO\5/&\F<Z]-_
MP&&-?Y+4'_">>-[EB%UO4V/I&Q'\A0!]8T5\H+KOQ!N"0FH^(W/?9)-_2ITF
M^)LO,<GBY_\ =:Y- 'U117RN4^)SYROB]OJ+DU&VF_$:;.^T\4/GKO2?G\Z
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MQ_T,<7_@(?\ XN@_L^7&?E\1Q$>]H1_[/0!WG_"W? O_ $'/_)2?_P"(I?\
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M-\%3P1ND]>HPOX-7M$,2P0I$A<JBA07<L<#U)))/N: 'T444 %%%% !1110
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MW/KZ<(TXJ$=D%%%%!84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>!DYY ./ER1C(%>R44 4-%TFVT'1++2;/=]GLX5A0MC<0HQDX[GJ?<U?HHH
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MO41X]1747?@'6X)]D$4=S'VD20+Q[AB.?SK9TCX<[9%EU:X5E'/DPD\_5O\
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M/_?;TA_: UC'&BV&?]]_\:/8S#V<CW^BOGP_'[7L\:3IN/?S/_BJ3_A?VO\
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M//6E[24]((\[ZG##KGKN_DC.L[*74)3/.3Y9/)/5OI6^B+&@10 H& !2@!0
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M:+I2]-,LQ](%_P *F33[*/[EI;K_ +L8']*L44K@(JJHPH 'H!2T44 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !16!XV\3?\(=X0O]>^R?:_LGE_N/,\O=ND5/O8.,;L].
MU2>$/$/_  E?A2PUS[+]E^UH7\GS-^S#$?>P,]/2@#;HK+\2:Q_PCWAK4=8\
MC[1]C@:;RM^S?@9QG!Q^1K+\'^+)O&/@B+7[;3UMYYEE$=LTV\;D9E +8'4C
MTXS0!U%%><?"G6O'6KC5_P#A,K"6W2.5?LK36WD,2<[E P-RCY<'W/)[>CT
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M2K&@)Z#+$"@"U145O<P7EM%<VTT<\$JAXY8F#*ZGH01P1[U+0 4444 %%%%
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MDZO8Z[I<&I:;<+<6DZ[HY%R,CZ'D'V- %VBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN!Q[8KHZ "O$?VD_^1;T7_K[?_T&O;J\1_:3_P"1;T7_ *^W_P#0: /:X?\
M4)_NBO#OAIY%]\>/%VH:/A])$<BM+$<QL[2*001P<E9"/:L;XB^ ?%GAWPH-
M2;QEK.MZ:K*+VUEGD7;&>^"[ C/'3C(.",X]=^&</AE?!-E<>%K58+*==[J3
MND\SHPD)Y+ \>G''&* /,_BKX>A\5?'#0=$GE:)+O2F42+R48>>RG'<9 R.X
MK=^$GBN]TV^G^'7B7$6JZ;E+-F/^MB SM&>N%P5]5^G,?BK_ ).9\(_]@YOY
M7%:WQ<\#7&MV4'B70M\?B'2<21&(?-*BG=M [L#R/7D8.1@ R_VB/^11TC_L
M)+_Z U>OI_JU^@KYO^('CJW\=?"O1+SY(]0@U)(KV!3]Q]C?,!UVMU'XCJ#7
MNWBO7H_#'@[4=9<KFUMRT8;HTAX0'ZL0* /+_)B^(?Q^NEF03Z/X>MF@967*
M/(<J00>^YGY[B,58^#-Q+X=\0^)O 5X[%[&X:XM=P.7C)"DCT&/+8#_;-<E\
M*?'VE>#=%O9-0T77KS4M0N#-+<VUHKJRX^4;BX)ZL>G\1J#6_'^G#XNZ+XQT
M[3M3T^ A;?4/MUN(Q(#E2WRL<X0CC_8% 'TQ12 AE!'(/(I: "BBB@ HHHH
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M@CAMXM@VC!!R^,9/'X]:J^!FN_A[\8+CP*+^XN]'N8R]JDISY;%=X/H.-P.
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M.E?M):/+$,'4[(QR^X /_P 0* /8:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML)[K@ @\GKR<BO3ZPO#'AM?#]O=/-=M?:C?3FXO+QUVF5SP !D[54  +G %
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M^'KKQG\6DO-27Q&_AW0DG\J&WL$_?/CJ3)PP[<YYYX%<UXX\-_\ "-_$SP?
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MED.6;'+,??Z?A7 _!^TFU[7/$'CN[0C^T)VBM W.V,'G!].@Q_LT >O4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A 8$$ @\$'O2T4 1
MPP0VZ;((HXDSG:BA1G\*DHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "J&EZ+IFBQS1Z;8PVJSRM-*(EQO=CDD_YX& .*OT4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !2$9!'K2T4 <QX,\"Z9X&M;
MNWTR>[F2ZF\YS<NK$-C'&U1QQ73T44 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 17-M!>6TEM<PI-!*I5XY%#*P/8@U'I^GVFE6$
M-C8P)!:P*$CC3HH':K-% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
:444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>formdrs_019.jpg
<TEXT>
begin 644 formdrs_019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Q K4# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !24M)0 M)2GI24 %58;G_2YK:1@'4AD!XR
MI]/6K596JRV$SBTF!DN6'RB/[\8_O9_A%-*XI.VI>BNDDN9;?[LD9Z'N#W%3
M,P498@#W-<*-2U&[U*TB8A)(OW+3H,$EL_>)Z' !'UJ&:Z,%T\<J[G4X9I"T
MAS^)Q71'#2D[(YI8J,5=G6SZA!;:FYFE58Q;&3.[L#S2Z3<1M;F229!/,WF.
MA897/08^F*Y?5]/BD\F=I&+_ &9I1A0!N7 7CTYZ4[4[9]/2!5-O*A4866$%
MAQW8<TU14O=3U$Z[C>36AV-]<+:V4L['[J\>Y[4LMPMM9^?+GY5!(]_2N.NQ
M?1:3 (%3-PX*QB0D,%^;^+[H&.:MV&J174J7>K%U+',2\B-%'0X_J:ATFD:*
MLFSK%)9 2-I(Y'I2TU'21 Z.&4\@J<@T%U#A"?F/(%8&X^DI:2@ I:2EH **
M** "BBB@ HHHH **** "BBB@"G+J5O%JD&GL6\^9"Z\<8%-M]5M;J_N;.)B7
MMRJNQ^Z6.> >YXK(U/3M1EU>34+6$&:)HXX"S#&W:P8_FWZ56MM'N]-NHYDL
MWN%6Y=\!U#,=FU6.3W)8GZT ;U[K-G8.%GD/^K:0E>0 I Q]<GI4ZWT!,F]Q
M&J-@,[ !N >.?>N571+XQ(;BT$F6B\Q003S(TDF,GUVBF):3G4I8WTQ;F1(Y
M&,>5VQO*YVYSVVJ.G2@#K/M\ NY;<MM,4:R.Y("@$D#G\#5E65U#*P93R"#D
M&N-;0M0B2-G2258Y%4K'L+,J1A5;#<$;MW!]:Z'2+*6RTA8'^64[FP2"$)).
M. !W[4 7Q-$SLBR(77[RAAD?6FBY@:/S%FC*9QN##&?K7*II-X^E^2--$=Q'
M$%EF,@#SDL"X!!Y! /)]:E&CRW>H)(VGK;V+S(S0';TC5L%@..21QZ"@#I5N
M8'("SQDD;AAQR/6E6XA=699HV5?O$,"!]:XR\TJ:QTR*46J13,LQ=EP#YDAV
M(GY-].*L-I%RS+-'IODVR>3'):!EW3*I)).#@\D=3SB@#K%FB=59)48-PI#
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M5G;<N1@*!P !^!_.K=/86Y6\J[_<_P"E)\O^L_=??^G/'ZT>5=_OO]*3YO\
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M(K8.1<R,S)*H;:!@R$$MQWX% #4\569B$TD%Q%$T7FQLZCYQD# YZY(ZT_\
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M#N?^@=#_ -_3_A5GXA_\>]A_OO\ R%<'7I8;#TYTU*2U/.Q->I"HXQ>AV?\
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M%)!&&!SP1FEMM3OEN_L:JLMYA82SRGRP50,['CK\P'O6@/#NG")XS'(59/+
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M>3W/^<U25V3?0ZF^U.QTQ%>^O(+96.%,KA<GVS2C4[$MM%Y 3Y7GX$@_U?\
M>^GO7%ZE!J-UKUEKUQX<FN[?[*]NUBY1GB?<<-@G&"*R;CP?KD'A[2UMX<7;
MF:WN(U8'RH)3G&?;G\Z:BNX79Z5%J5C,\"17<+M.I>(*X)=1U(]16!?>+;R#
M7;S2['0IKYK1$>1XYU4X89X!'-9O@SPS?Z7KMW)?HWV>R1K:P9C]Z,N6)_D*
M?+_;&D>-=8U"VT.XOH;J*)(FC=5&57G.3ZT65PN[&_8>*-+O=#BU9[A+6W<E
M3]H8*58<%3[U;FUG3(+)+V74+9+63A)3*-K?0]ZX"+POJFEPZ->W.G#41#-/
M-=64; [6DQ@@'AL8%0OX7U./2HIVTRYC9K^6XBBM9$+VB,  -AX;..F1BGRK
MN*[/1I-8TR&Q2^DO[9;5_NS&4;6^AJU#-%<0I-#(DD3C*NAR"/8UY=)X?\0?
MV=HES/9-BTEFWP6T47F!6QM<H?D+=<UVO@W39]*\.0V\\4D+EW?RI'5B@)SC
MY0 /7 Z9J7%);C3;-2?R?[2M-[.)=LFP#H1@9S^E6Z@D\[[7!L5#%AM['J#Q
MC'ZU/28T%%%%(9!9^=]DB^T;?-V_-LZ9]J@N=32VU.TL6C8O<AMK#H,#O3],
M\G^S;?[/O\K9\N_KCWK)UQ;B+7-,O(K.>XCA$F\0KDC( %:PBI2L_,SG)QC=
M>1O3316\9DFD2-!_$[8%-6Y@<H%FC/F E,,/F ]/6N:U-KC49;&]DTJZ:UMY
M&$MLZ#<<@8;;W%4FTK4(M,:\M;5XI4NFDM[?&62-A@C';MQ[5I&A%I7=G\C.
M59IZ*Z^9V0NK=@A6>,ASM4AQ\Q]!6=?ZV;/4EL8K*:YE,7F_NR.F<5B:'HE[
M:ZQ%%<*QM+53+&Q'!=E4$?AS^57=1-S:>*H[Y+&YN8A:^7^Y7/.XFCV4%.R=
M]/\ AA>TFX7:MJ:EAK%K?V;W )A$3%95E^4H1V-6A=VQM_/%Q%Y/_/3>-OYU
MR$NE7[V[WLUDSK+>^?): Y8Q_P!3STIDNESS6M[,FGW$-M).CQ0(!N3 .6V=
M_I5.A3;TD)5II:H[(7=LUN9Q/$81UD#C;^=/CECFC$D3JZ'HRG(-<.=-U*32
M/^/1A&EV)"JP!7D7'4Q]#]*W_#-K+;6MP7CEC664LJ2*$_$*.GTJ*E&,8MJ1
M<*LI22:-&V\G[=>["YDW)Y@/0':,8_"K=00^=]IN-ZH(\KY9'4C SG\:GK!F
MR,K6]!@UV.%)Y98_*)(,>.<_45C?\*^L/^?RZ_\ '?\ "NNHK2-:I%6BR)4:
M<G>2.1_X5]8?\_EU_P"._P"%'_"OK#_G\NO_ !W_  KKJ*?UFK_,R?J]+^4X
M+6O!EGINCW-Y%=7#/$H(#;<'D#TJAX8\+MJT@NKM2MBIX'0RGT'MZFO1;RSA
MO[22UN%+128#*#C(SFI41(XU1%"HHPJ@8 %:+%U%!QOJR'A8.:E;0$1(HUCC
M4*BC"J!@ 4ZBBN4Z0K,NM-N+L[6NU2+.<)",Y^IK3I*:=A-)[G&6NCV2:O<)
M)?R>8[,"54+N(P3G/&1GM6@;2*V(V:M/'Z95"!^E9WB2T>.[G:/*MN2Y5AU
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MY[DV>DHI*R"EI*6D,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @A\[[5<
M>8J"/*^61U(QSG\:GJI/LM;C[7LE;S-L3[!D 9.&(_']:MTV)!1112&%,FAB
MN('AFC62*12KHPR&!Z@T^B@#)TSPSHVCW+7%A81PS,NW?DL0/09)P/I6M111
M>X!1137=(T9W8*BC)9C@ 4 5IO*.IV@9V$H20HHZ$<9S^E6ZKP>;)/)*_E^2
M0!"5Y)&,DD^Y[>U6*;$@HHHI#(+/SOLD7GA1+M^8)T!]JGJI $M)_LBI+M?=
M*KD97).2N>W7//K[5;IL2"BBBD,*0@,"",@\$4M% &9:^']-L[E;B& AT)*
MN2%)] 3@5IT454I.6K=Q1BHZ)!114<DT<6T.ZJSG:@)QN/H*D9!;"+[;>E&<
MOO42 ] =HQC\,5;J&U69;=3<;/.;YGV#C/I[XX&?:IJ;$@HHHI#"LO7M<M_#
M^G?;;F.5XRX0",#J<XSD\#BM2LS7])@UK1I[*X=T0X</&,LI'(('?Z4 <U;>
M-]3U'6(+"ST)D+XD?SY-K"+."P! _F:[BO%(-2OH]3-Y;:A*K2H84U'40057
M/)5<D_SQ[5Z_I+L^DVK->)>,8ES<(,"0XZT 7**** "DI:2@ K$U**35(VCG
M46^FQG=+(QP[@>GH/>MNJ]S:B[*K*Q\D')0?QGW]JJ+L[DR5U8Y*TMQ'=":6
M*4Z>&+6=O*V/-;KDCUZXSUK&U[5I-0U$Q!),AMHC<;6'X5Z3/;PW,+0S1J\;
M=5(K$O?#_F!3YBS1QG*F4XDC_P!U^OYUU4,1&$^:2.2OAI2ARQ93BLQ::=I^
MFOA?.?S9CZ(GS'^E5[JY,.BR760)KR4RG/7;G"C\JJ7E]?37,C>29+>8&UBE
M4?P@Y(7U)'?I1JET][*(TMM\$8"J(W4D <=,UK37-44I>IC-J--QCZ&I,Q>V
MLYV8GY7@9O\ >7C]156>X:W32;GYMAA4$#L10^HP0^'UB9)/.CF1B&7' .>O
MT!JC)=1WNDV<5OE9HG;ANZGD#CV-$$E4N]KA)WIV6]C996,%U8QC,5XK3VQ_
MNR#EE_/FL[6UAOK6UNH#RZY;!P$/?)[<U+)8ZI)I*3@&,VI+J "A((P2,\GC
M/%7].TR'3KR/>OVFSN%0Q2,H^1P.X]_6LU-4Y<T6:.#J1Y9(;HFA)-;L]ZK2
MPL,(),C/N!V'ZFKUMI<"SO:S(^Z(YMY<X81^FX=<>AK;HP/2N:564FVSJC2C
M%)(9$C1QA&<N1_$>II]%%9FH4M)2T %%%% ",P12QZ 9-<5!\07FQ-_8%\;)
MWVQSQ_,#SCG@#]:O>(_%%K!H+26#QW;7$QLU*R857(.<GM@?TKE/!^B7D'B"
M73Y;ZZLI[-EF:&)\QRID''![Y'//!H ]2ZBBE-9=_,DLR6Y)7/)(."?:FE<3
M=BP^HQ*[QJLDCJ,D(N1^=$6H1/(L;*\;L,X<8'YTJ[/*"QL%53R,?I67=S-(
M[1X9(FX5C_'ZX]*I)/0F3:5S>HK,T>9FA:W;DP\;LY)!Z9K3J9*SL5&7,KE&
MZN ;I;<L50KEL'D_X5%Q%(9(69<<GGAO6C5+"6X99[<CS%&"IXR*@@M+^9P)
M_P!U&#\W/)]J:$;*D,H8=",TM48[\#69=-=0K"%9HCG[ZYP?R/\ .KU24%17
M,(N+66 L5\Q"NX=1D=:EHH YSP3J\NJ^'E2[8F^LI7L[K/7>AQG\1@_C71$A
M02>@K@='<Z)\8-;TL_+!K%JFH0CUD7Y'_I^5=EJLK16+LI8$\<#--*[$W9#C
M>.^3;Q"1,<.6P,^E$-\'D$4J&.0G"C.0?QJM;70:%47#8' I'.(B-V<<@YIZ
M"U[FK12*<H"1C(Z4M24%5CJ%H#@S+WY[<57OYO\ 2882"%/S'!ZTZ1T,>V->
MN/E]!5674F[Z%Y6#*&4@@]"*;'-'+O\ +<-L;:V#T/I5.UVPW&Q#A),G!]1Z
M5F>&+@S:CXCB[1:F5'XQH:30T=%1112&%%%% !1110 M%%% !1110 55^Q*B
MS?9Y)(7E.XL#N /J <@9JU11<+%?R)]\)^UOM08==B_O#ZGCC\*3[/<;)A]M
M?+G*-L7]W[#CG\:LT4[BL5_(GWPG[6^$'SC8O[SZ\<?A2?9[C;,/MKY<_(=B
M_N_IQS^-6:*+A8K^1/NA/VQ\)]\;%_>?7CC\*3[/<8F'VQ\O]P[%_=_3CG\:
MLT47"Q7\B?,/^F/\GW_D7]Y]>./PI!9JQE\^1YUD(.R7!5<'(P,59HHN%@HH
MHI#"BBB@!LD:RQM&XW(PP0>XJN+1XTA2"YEC2,\J</N'H2V35JBG<+%?R)]T
MQ^UOAQ\@V+^[^G'/XTGV>XV0C[:^4/SG8O[SZ\<?A5FBBXK%?R)]\Q^UOAQA
M%V+^[]QQS^--^SW&R(?;9,H<NVQ?WGUXX_"K5%%PL5_(GWS'[6^UQA%V+^[/
MJ..?QIOV>X\N)?MLFY#EVV+\X]#QQ^%6J*+A8K^1-YDK&[?:XPJA5^3W!QS^
M-+%:I&(RQ,LD8(663!;GKS4]%%PL%%%%(84444 %%%% '#>*- U)_$*:K9:=
M;ZE&;?R?(F(Q$W/S8) /7^=8GAGQ3<^'M($$NFR3:=#.4EN4?H['.%'?_P"O
MVKU2O/M;\!-&;FXL)Y7M%1YUL"21YV.-O;'Z\8[T =;X?U2?6=(COI[-K4R$
M[4+9RO9OQK4KP[0]?O\ 1M5%X//FC4$7"EFPQ(.%.>A!'Z5Z'I_CF+[1+9ZW
M9OIMS$N]RQW1A3C&3U!Y'YT ==25';W,%W"LUM-'-$W1XV# _B*DQ0 448HQ
M0 5!>6YN[5H-VU7X<_[/<58Q1B@"C'9 :@)B (X8PD"CHOJ:DETZRF.9+2%C
MUR4&:M8HQ3NQ<J,C4],M_P"RYH[>W178K@*O4Y%2:1;?9XIP4"DW#L!CH":T
M\48I\SM87(KW&D @@C(/6HK>VCMK=8$R44_*#VYJ?%&*DH2BEQ1B@!**7%&*
M $I:1B%4L>@&37/CQ;I=[IAEL=0MXKB7>ENMS\N7'3(/.,X_.@#H:Y7QMXCM
M]*TBXM8[PQ:E+'F%8QEASU]LX/)KFG\;:Q>Z=8VPDALI9)3;W=VR9,4@/IT'
M&.?8],5DRZ7J^OWTT+0>?JEJ_E7A:79O7I&W88&.W7@T 9<4+RM(,[[Z:XQ-
MI@3RQ(,9#)CC/7\^,@\^O>'?#ECH5N7MXI%GF53*TKAF''W<CC ]JB\.^%X=
M'MH&NC'=7T:[5N#& 8U_N*>N!SU]?PKH* "N?U0RQ:D'8@J5&T 5T!K/U+3_
M +;&#'A9U^ZY[4XB9367SXS&"1QC<#R*HK#>0K*DLZSPJ5*%N#D'J?;'%,>"
MXMYF1XW!3N <'\JFAM;B[=0JD1OU=NGUI\NJ?87-=-=R[I#>;<2N"0H X"X!
MK9JO9VHM+98@=Q')/J:L42=W<(QLK!1152\U*UL //DPQZ*HR<>N/2I*,7Q9
M)_9LNEZX.%L[D1SG_IC+A6S]#M/X5TM9^LV$>M:!>V).4NK=D!'N.#5+P9J<
MFK>$=.N9L_:!'Y4X/42(=K9_$&@#=HK$U'Q19:=+)'(DS&/[Q"X4?B>M46\4
M3WT0>QMS#'R3+*-Q/L%_QH P_B&/[*\7>#?$*\"*^-E,W^Q*,#/X\UZ#<0K<
M0/$Q(5ACBO)_B+>:OK'@/47ELXHQ:&.[1\D,I1@>!],UU%GXNNKVWM+NW%IY
M,T".(9)1O.5!SQT^E %U[*_LY2%1G4#.Y.F*N6EA<S2++=?)&ASL/\58J^([
MAKAC-++"Y.%;;B%3Z>I^IIUQJWVB-FN7$Q[JDI2,#TXZ_C57%8ZJTO[6]WBV
ME#^6<-@8JS7G5KK=Q;7LDMO/9H) %9 P(4#IQQ^E:L'B&]50T;I< ]0W]"*D
M9L:U;OOCNHTR5&&V]?\ ]54(M2Q'@]CR0:8WB*_@/F%()X\990K*5/L><U&F
ML^?FXAL]/PG_ "R\[,C$]3P,#\:J_<5GT-K3!-/(9Y%VQC[@QUSWK$\#R>=?
M>*IAT.L2+_WRB"M./Q-;L #:7,;*,L&4  ?7/-<K\--:L6TW696D;-QK%U-]
MP_*I; )/X4F"5CT:BJ*ZQI[R1QI=QNTC;5"'//OCI^-7J0PHHHH **** %HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#D?'&AZGJUM;G3B)(XV+2VP(0N>
MS GN.1^-<Y#X'UJY@M%O1N-W<![Z1I072->@/J3R>/\ 9]*]1HH \.NKF;3_
M !!<1:,)]-(N=D=NLS9!SC)4]CQ_]<5T&H>,?$-]I@DMHX(+>[F\BWEC8B4,
M,'U[]/QKTFXL+2Z>-[BVBE>-@R,Z E2.X-<S+\/-+^V+<VL]S;E2S+&&R@8C
M@C/(P<'KVH =8^.-,:X&G3&Z%Q$I0S2Q;5D91\WTZ=P*M>'/%EKKFFO<2&*"
M=-S-;B4,P5>^.M<7)\.]8LI&E@^RW1\IU!C<HQ)! )W<9Y]>U53HNKVUN9SH
M[V+6%I(DDB?,;AVW =.OWAZX - 'J.C:Q:Z[IJ7UGYGDN2H\Q<'(.#5V22.&
M-I)75$7DLQP!^->&7USJFEQ6=L9[BV6*V26&-'9"2^&) [G)(_#VKK_%4TMR
MGAFWUF1H;.9%>\.<#?A<Y].I^F: /08+F"ZC\RWFCE3INC8,/TJ6O(%U:VT?
M5[Z\\*N19&T5B'5BH8L!T;GN/S-=!<>-M0MKETVVKJFF1W!W_+^]8+GG/^UT
MH [^BO'M1\<:]J6DS0 PP%'4O-!N1BI!PN#SU[\5LKXO\4K<:A&T&EA=- ^T
M$E@.>!@YYYH ](HKR8?$/7C8W);[,)4V.C^21\I[8)YZCFI+WQ+XGM6O6?4H
M2=/=-ZI",2;SQVZ=/SH ]5HR,XSS7B\OBK7IM<9_M4ZF2?ROLP?";6X "=?Q
M^E=7\-;",65]>223->^:UO(SN3@#!XS[T =0_B314N9;=M2M_.B5F=-_(P,G
M\1Z5ST_Q'LS;3FUL[CS@F^W^T+L28 \X(ST&3^&*P;3PGK D&D2:3;",3/YF
MJ.%9C&P .WOGT_\ UUMZ?X&O!=V@U74([FRL5=;>)$P2&_O?Y/2@##N/$?B7
M5"BF\CLQ);/=P+:KRX7)V;CW^5OQ%8]I8SZA]I^RZ.;U[^$.DR# @<-\W/3K
MN&/3%>H:9X2TO38;-=CW$EH7,4LS9*[CD\# _3N:VHHHX(Q'#&D:+T5!@#\*
M .,L?A_#F1M0N#)'<V\0G@7C]ZN,N&_/_OHUV44,<"!(T"@ #WP!@9/?BI**
M "BBB@ -)2FDH * ,# X%%-=UC0N[!549))X H =161+X@@V,;5#/M&2S'8@
M'^\:QKO4M1OH<27<-K;-R?LY)9AZ;ST_ 4 ='J6IVVFP[II,,V0@'))Q7'RZ
MC;M;B3<%\SAY&ZRD^AZFHI+:T,J_9TM9Y<9VNQ;'N3VJ>*QV'S7*O<'_ ):$
M=/91V%,!(]2U2SC$7V^.*V'3*;F ] 37+Z%?FTUG7])BO[QL7*W<$<3;=ZRC
M+9]/F!KIUTJT\W=.GG2GG+R'] #P*YS4%M]'^(.A78ECBM]3MY;.1B_!9?F0
MY/XB@#3%A<7<XEG:,?-DQ[=_YD_T%:9TR6XZW#*.Z1OM_7K5MK&XE ^SRQ(/
MXGV[R/Z59M=,6WC"C+-_$YZL?6@##U'PU:WND7ML\\DAE@D0*\C, 2IQC-9'
MPZCM]2^'NDM+"CR1HT,F5'5&(_PKT&.U 8<<9KAOA?#]FC\2Z.PYL-7E"CT5
M_F% '1)I]O&I6*!4SUXZTQM.CV\0IQR!CC-= +:E^S#TH Y1M)D;:9&CQG)3
MR5('L#4RV 3Y415 [*,5TOV48Z56DT6WD4X4QOU$B,0P/UH P6L;EG)6]N8U
M/!1&&W]14)T.-W#R'S2/^>B@_P L5T)L+^$!8F@N%_O395A^76HB9+>94O6M
M(PW0(Y+$^PH QY-,M8K9WDB#+&C.6).1@9ZUB_#: Q_#_3Y)2P,_F2[4/)#.
M3S5_QKX@M-,T+6;50[7J:>\FU<90,"%)'U-6O"-F4\(:/;V=U;O)%91"2)N2
MK;03G!R.30!7O,PLY6V,4,HVS>8VY&';YEY&*6RLY[9TFMGDB!^ZR3F4#WYZ
MBMQK748U9V2V< 9*H&!/L*@73+21B\,<BYY:)24!^JT 6([[4XMKK,MP1]Z.
M0!0WT(Z5>T_Q)IU^&7SA;SH=LD$WRLI_'J/<5CB.XMI"+:UD>,_\LWXVGV.>
ME+);W+#[3+8PF5.1CYCCN".X^E '6JP90RD$'H0>M+7/6,NH( ;:!5M6.0C.
M&"YZ[<?PUMV\LKDK-&%8?Q*<JU(">BBB@ HHHH **** "BBB@ HHHH ****
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M1G&;J_2V5FV>7;+T]BYYS[@"@+<3\-]TD @=& Y/T-0N0)!%!$]Y=$$,L9'
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MNC+'USR.#4JIJ'E!KC1W5PQ)$4JN,GJ><9S6SI$(ATV)=P9C\SD'/S'DU=H
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M&LBO$P219$*D' /0^Q%6ZJ6-D;1KIVDWM/,TI.,8!P /P JW0 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
8!1110!QVN_\ (SR_]>4/_H<M%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>formdrs_020.jpg
<TEXT>
begin 644 formdrs_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $P FL# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF?7 Q4&I:;#JEL()LA0P8$ 9&/3- &7>ZM>VEY9S30M!:2OL9"5./]ICV/3
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M /HH!!&1R** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHNS1Q?A;X9:%X6OC?0B2YNP,)+-@[![#^M>?>._![ZM\6([5)$A74;8RHQP
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MMO:'X'O\O#O\U7\?\BU_PM/Q1_SWM_\ OW1_PM3Q1_SWMO\ OW57_A6_BO\
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M/<K<J!WKIQI<0AD6.\C>11G:#UK)D,X 5E(V]&%$Z4:D6D]?2_X,*<^65_\
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MTCT[@ULZ5J,^GRJUXAVW*"23:.IQ_K%'?(QN'4'FM^>RTW6(5DFA@NHR,*Y
M/'L:\S&X9U8\J=CT<)B%!W:/.O,TRV>Y::V6ZN95'[U>JGH< 4ZZEU2\58TF
MB^S(/]83A@/IZUUESX0L8+(C3(%CG5MX+,3N]CFL!?#^OZC,Z21I:1CC<QSF
MO%J86M"T+7]#U88BE*\[V-+P9HEEDZN+B2XN,E 7&-GK4S0IJNMWC--Y<:$X
MEX^4C 7KP>0W%.C\KPYI/]EV3F>\8_,RC.UC_7T%16^EQ6,CQ7D"33M )8E?
ME<C[P [D<5]!@J/LJ25K,\7%U?:5--4B2]L9;@@WT4L\><F>Q<D$^I3J/PS6
M/)I]FMS;+;7ZNK/M=&)79GNV>G?K5ZWO-)E.?LQMY@<$P.8V4_A2P6KW^J-?
M6Y_M&VA^1HYS\SK[=C@Y()YKT+U*:M+1'GM4ZCO'5G80S0RIF&5'4<91@14H
MJE9I;,QDBM?(D'!5DVFKHK@9Z*V"BBBD,**** "BBB@ HHHH **** "BBB@
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MIT>%:%4EMCGD.!D8]CT_&LU"]]"W.UM601V$%I<74EW=3;H"L:-"?+5&89)
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MFCY(1GVO'G^X_I['BNCHJXSE%W3(E3C)6:.'EF71+*UTV6"1HQ()GPH#%0>
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MR9@MVY[OQ7BEKXJ\:^%?$)37[EIDWYE@E *LGJAKU?4O&.F6/AV'5XYTE6Y
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M10!1UFVEO=$OK6  RRP.B G )(P*XJR\$7=E-X>N8XOW\$N^]W3Y5<'C:/\
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MF+9)<(%9L=CQ76T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>formdrs_021.jpg
<TEXT>
begin 644 formdrs_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %+ ?T# 2(  A$! Q$!_\0
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M/0B@!]%9UYKNEZ?#<RW-["B6I59\'<8RWW=P'(S6@&! (Y!H 6BBB@ HHHH
M*9-%'/#)#*@>.12KJPR&!&"#3Z* .#L_AA!9F.T7Q!K#Z'&Y9-):4>5@Y^0G
M&XIS]W-,M?A58P^7%<:SJ=Y:6MO+;Z?;SLI6T612I*X&6(4X!;.*[^B@#BA\
M-=.%KY'VZZV_V#_86?ESY6<[^GWOTKG$^&M_>^*M<@DU/4]/T:2RL[-6MW0"
M]C2+8X;()!&,9&/O&O6,TF: .%N_A5HMREZ([BZMFFFMY[9H2 ;1X(]B%..>
M.N<YIDGPKLK^-(M:UG4M4@WO-+%.559)"FQ6PH&-HZ <9YKOLT4 9VA:6^BZ
M):Z:][/>_9D\M9Y\;V4=,XZX&!GVK1HHH **** "BBB@ HHHH **** "BBB@
M HHHH *S+K2XIKS[9)NE*+Q"V"I(Z5IU4OKZ&PMO.FW')"HBC+.QZ*H[FFI.
M.J$X*>EC L;ZZL;D0FW7?/NGDMD^7R5[<_TKI(ITGMTF3(1U##<,<5P^H:FE
MR+GS((K.X78;HM,-S>B =<@8S5B2^N9?#M\;!8KBS" YCN,E$P"=N1DC&>N*
MTG*$H\RW)I4*T)\DMGU*?B36XI-8<,//M((U,,J)YB"0DC'IOSC!;Y0*UM&L
M-42#[2EM:+=2@-)=W3>9)(?8+P!^-4X[@^)M8@@L('TZWL8_,D>: !V)&%"J
M>,8R0QR.>*;>:7I5GI]]-8>(+J.:UB::1([O*' [H, <^F*F--O=_@=DYP24
M4K,T];%^^B7B7\0(@C,_F6WW90.JD$Y![]ZIV-J=92;6(/+>"6 QP)U+X4 $
M?CFN+76?$=QIT>B6S75YJDRK$TCS P3J0"SX8;@,9!(XS46CW>L)93ZC+IUK
M#<07!F@9)FWM%'@.L8^Z1@-E>ISFMXTIQGR)[?J8U*,)4W)K5_E_PYZ!I]O>
MPW\-M&%M9!9AG;9G>WH?QKHK"Y-W9QS,NUR,,OH0<&EL[RWU"UBN[619(9%R
MK#_/!]JG1%0$* !G/'K6-2?,]5J<].GR;,=11169J%%%% !1110 4444 %%%
M&: &R+NB902I((R.HK*M-)>SNFV3;[5QEXI/FRV!S5^\O;>PM)+JYD$<,8RS
M'M7,7GCF"*0&WM'EA5-\CLVTCC( 'J<CGH>G6JBWLB734FF=<!Q2UPB^--30
M%9=/B,K#S%P'5?+SU)([@Y]@#FMC3/&&GW\Z0$-&Y7/F=8\\Y^;TX."<9I.+
M+Y6='12!@0"#D'O2TA'*^,_!%IXLMHITE:QUBT.^RU"'AXF'.#ZKZBLSPAXV
MO)-2/A;Q9"EEXBA'R-TCO5_OQGIGV_\ U#O:Y'XAZ#H.L>');C7+D6 LQYL.
MH*=LEN_8J>I[<=Z ,7XP13/IN@20FZC$.JQ2/-;0&9X5 .7"X.<5@:G<R:MX
M8@AMM1U76)H=<LI&>ZTXVY1=W8!1D<9)[5>\$>+_ (@ZMX;BG3P];:E$K%(K
M^XN?LS7* X#["#U]>]='_;?Q!_Z$_3O_  :C_P")H \Y\/S>*V\6AOM=XNMB
M>Y^UP2+.R,F&V!@?W2K]W:5I^E6:ZSX;U&U,OB>XUN729SJD,Q<0&X'(!W=&
MR. G!'6O0_[;^(/_ $)^G?\ @U'_ ,31_;?Q!_Z$_3O_  :C_P")H XCP=H]
MS>:SIBVLFKP6EEH$,T4,CR1QO=JQRK@]0&[=,8[53\/W&KG4]*-C<>(&U]TN
M?^$@2=79$^5MNU6^3<&QM"]>*]#_ +:^(/\ T)^G?^#4?_$T?VW\0?\ H3].
M_P#!J/\ XF@#RK2H-1U70_$>F8U>]\S1WDD;?. UPK9 =)!\LA_NH2I%1:S<
MWT=A:PZ0NNPR66E6[V08S\N#F0HH&.#D'>?H*]:_MOX@_P#0GZ=_X-1_\31_
M;?Q!_P"A/T[_ ,&H_P#B: /.=9TR>RO_ !U-:V^IK?7:V4UO(@D(D0LAD(/0
MG)Z=0,CI6RTLC^/;U=6N/$4>L+J48TV.Q#>2;7:.H/R;/O;B>:ZW^V_B#_T)
M^G?^#4?_ !-']M_$'_H3]._\&H_^)H [:BO Y/B'\4(?&^H:?::"M['%, ;0
M1&1(N!\HE&/S->ZV4L\UA;2W4/DW#Q*TL0.=C$#*Y[X/% $]%%% !1110 4E
M+24 >>:EXXU"Y\776B:1);P+9'RV:6!IGN)L9V*H(P .IJFNL:[KUEJ%[/K$
MNA:AI[;/[,B56 ./ON6&6#<XQTQZUQVLZG+8?$'Q#XIT41)/IEQY,]F[8,R;
M</*,]\XX]!7-:S>>(=4NY?$VH07.G:;,%ADD0#>ZGD$*>H]_>N]9>_8N4I)2
M>VMM]OPZG93E!SC:.BM?2_J>^^ /$TWBKPPE[=+&MW%*\$XC^Z64_> [9'-=
M37@GPBAFE\<2W.@0WD&@+;E;MYV)6>3^$\\;L\\=!7O0KFKT'0ER2=W8Y9N+
MFW%:"T445B2%%%<#J_Q!UO3=7NK*#P%K=[%#(42YA'R2C^\..E '?45YK_PL
M[Q!_T37Q!^7_ -:C_A9WB#_HFOB#\O\ ZU 'I5%>:_\ "SO$'_1-?$'Y?_6H
M_P"%G>(/^B:^(/R_^M0!Z517FO\ PL[Q!_T37Q!^7_UJQ_%/Q9\36'ARZNH/
M!.JZ9+'L(N[Q T2?,/O# Z]/QH ]BHKB?ASXWU/QGI?VG4/#USIQ"Y%P?]3-
M_N9^;]"/>NVH **"<51N-4M(;.>Z$HD2 '<(SN.?0>YH#K8N,P52S$!1U)Z"
MO/;_ %5]:U*62&:7RPS6]C% K$L!Q),S#HH]N2![UU#6$U[:-=:GDR>662U!
M_=QG'&?[Q'J?PKE_#%Z+;3H[JVGM9 T8BABF9O,C0=<!0206R?RJ7J['70BE
M%RW9N"/2=*\,2R:>\<9A7'FF/=(\H[,",EB>WO6/>I_9.@V>II,D>I&,SBVB
MBW&8-\SH1W4 ]^!BI[J8:1#<ZSJL9N=2NW$=C9#"%FV[1A2>#U)8\@"LK5]:
MTKPEX0>*:[BU#7+R!;8^4V\@L-H''W47/3OCU-:TZ3GLB7/E>]]3F=7O[O3]
M6+ZO<2'3D"6IM--<B9P5+K'SR47NPZ9Q5ZTTO3M=<K96'F7LD8\B))7BAMHR
M0=S%N93QD\8..!5A+>WM-7BU+1YKS4=6@0137+0-B><C CY&% 7/R]@1W%3:
MQ<W][X>OTB@BTF*U?SDGNWR\+C[\*;?5NG/1NE=<9SA'E@VE]WX?TQ/EDTWJ
MRUH!NUUNZCMIEN-0M[5XM0O9\F(#(,7E#TQNXSCKR:L^'["34O ;:=>A6\ZS
M:ZB>/Y7C<E@.G?CK[XK#U.35=.M41(5TZ/4;)UF8DO/*% )8KVX)4?EQ5G3;
M6_TJ&#3I[*W,DD2RVMN+AHT6+&0K]F*DGY<\Y]JPE+52CTL7[.\;-K4VO#/B
M+3[26 7-W%;B_LH[EX6;[DX 5Q]2,$CU!KK+'7-.U*8Q6MR'DP3M*E20.N,C
MFN0TVWDOYY=8L@EY$L7V>%Y(54EBV9-J] %P%^N>M3)Y6EW<$T%O.;V/<UU'
M(, #IGT[]1VISCSRNMWT_KY')4E"$G&S?F=UFEK,T[5A>^6'@:$R)YB98$,.
ME:=823B[,F,E)704444B@HHHH **** "H+NY2SM9KF3.R)"[8&3@"IZY/QU>
M&+3H;:.<I+(Q?RP/]8JCD<D ]1QWII78TKLR(HK[Q?J\LN^YM;7RU(?'$6"/
ME&<?-D'/4=*[.PT>PTY2+:VC1BH5GQEFQZFH?#MA'I^B6L*+(NY?,82')#-R
M0?IT_"M:AN^@V^PTJ&!!&0>"#WKG]9\)V.H1F2!!;W"(P3R_E0DY^\,8[]>M
M=%2'I23L2G8XCPSJEUI^H#0[Y((E0$!?.R8VZA1D\K@C\37<=JXGQMIX66VO
M8H8\N=DQ4D2.1RF,=2.?IU/2NC&K*OAO^UEMYY0MMYWDH-TC8&=H]3VJGW*>
MUQ=<UW3O#FD3ZGJMRMO:PC)9NI/90.Y/85YSIVB:K\4=3AUWQ/!)9^&X6WZ?
MI#$AI_227V]OZ=;.B>&-3\<:M!XI\9PF*TB._3-%;[L0[22CNWL?_K5Z<!@8
MQ4DC8XTBC6.-%1$ "JHP% [ 5Y'XL\3:IX<\;^)[RP<2/!I]B(H9V)B!>;:3
MC/!P>M>OFL>^\+:'J=Q<W%[IL,\URD:3.V<NJ-N0'GL1F@#R_P 4^+O&$.C>
M(].DO+&VU#2[BS?[5:*P#1S,/E&3P0<9/<9JT_Q*\21Z]+!'807-G87D=A<K
M';OF9C@/(LF=J<G(4]17HUWX6T._.H&[TR"8Z@J+=[P3YP3[N?IVJG_P@7A?
M^TH-0_L:W^TP;-C<XR@PI*YP2,<$\T <4/'OBG^R=8U-O[(CMH-1?3;,.LA=
MY/,P"5'WB%Z*.2:;9?$;Q'?6D&EI;V,>M3ZN^FK<31.D2A$WEVCSD-@XVYKO
MKGP=H%WI4^F3:7"UG/<&ZDCR1F4G)?(.0V>XJN_@#PLVFRZ=_8UNMK),)V12
MP_> 8#@YR&QW% '%WFN>+I?%'A:";4M+C6;[7'=1V;F2*8QJ<G.>#CHO5357
MPYXN\07>BZ'H^ABPM[I]-EU":?4&>12JRLH1><D\<DG@5Z*O@OPXEII]JNCV
MPAT]S):J 1Y;'J0>I)[YZU!>> ?"]_86EE<:- ;>T#"!5+*4#'+ $'.">HH
MXA/B+XEUQ-..BPZ=:M<:-+J$WVI&<*T;E6"X(R#CCZUZ%X1UJ3Q'X2TO6)8E
MADO+=9713D*3UQ[5(GAK18I8I(]-@1HK0V495<;8#U0#TJYIVGVNE:?#86,"
MP6L"[(HDZ*/2@"R !G  R<FEHHH **** "BBB@ HQ110!P/B;X1Z!XFUB34W
MFN[.XFQ]H%LX"S?4$=?>J(^#>G&]B$VL:A-I41!6PD((./X2_4CVKTRLRRUR
MSU#6-2TR#S/M&G&,3[EP/G7<N#WXJJDY5%&,W=+;R-*=6=._([7+\4,<$8CB
MC6-%X"J, 5)114F84444 %%%% !1110 4444 %17-K;WD!@NH(YXB03'(H92
M0<C@^X%2T4      P!T HHHH 0]*YE])N&@U&>>V$EPXQ" WIG!'IVKIZ0BK
MA-QV,YTU/<XR2\O[1YHKF:XW1VZO\C9 8\#=GMVK*TELVD5G>:SJ5K!&H2+[
M+ (]RXSDOM+'GC(P*[Z_-FEG,]Z$\@+^\+#J*X"&_M[J%H)+JYA@LF9+<6!'
MGLK=%9LX!&<;1[53FIZ*.I=&FX)N4O=NC,N8=%L/%(>&2^N6CM?DENH?/ 8L
M=Q<R8P, #\:S+Z!KV]M[?1E>YU=B+QIX^5W X 7@!(QR 3^'2MQ-'UC4E4)#
M/;::3G:;J(3N/4@< GWR:=I>KZ-X4TW7+"]AN=/^T74GD?(<R@J%P)>06SG.
M3QS5TYSBTD_EK_7J=DO9\MXZFUX+@MK?2I+O<&,.]C%G#"3'SG!^@ /<<]ZY
MJW@N?$7B[4)HI[:[AM_+GO#YV((I #^Y  .2-JEF'/&,\U9N=,\/QZ1>:I<+
M<:G=?9BS/$)# B+S@'@$8'7^72JUC:65OH@EN-/FTN?6KKS8YXD"K;P$?*!M
M/0(!D$8^8YK914>:5W?]?ST,>9MFA+:R:]XSM+*1Q+,EF)[V;;PBR$85/[HV
MK@?[Q-:VHZC:VMI=37\;^3)<N+F40[Q"J<*O/W3C!!]S4F@WL-I?W-W<QQ0B
M](BFG7[@FB&W&>@5EP5[=:CNK?\ X2S6G73VDMM.BQ]JNTZ73C[J!3PRCN3]
M*XZDG&T5T-::4I<TOA(M+D\/V>C0Q3(MW=W1>5;:#,LGS'(7CH0".N*I6-MJ
M2ZY<6=PKBZOK=1#;>:9%L;??\V]O7CCW.*U7:^CO9K)+V1V&>+.".-W/'WFQ
MA1SU]J;H)_LM8&@@,MQ?F2:YD8EF8+D  GG ]Z%2J-IDSQ=)1E=WOI_7;]36
M_L%4N+J5OFC$ 2W&3E"!U^M;%H7:R@,N?,*#=GUQ618:Q+=6%N-R/>3R$;5'
MW%SR2/85OXJJCEM(X:2AO ****S-@HHHH **** "N.\>Q2&"TD6)C&-ZM,F=
MT9(&.QZ^GKCD5V-9NN:8NJZ:]NS.K AT9#@AAV_'D?C36XT[,FTRXCNM-M9X
MG9T>)2&88)X[^]7*X?PGKWV>7^RKYYM[.PAWQ[1'C@H?09!QGTKMP:&K,)*S
M%H-%0W-U!:0&:XF2*,$ LYP*0CEO'TL0L+..6)7#3%MY(^3 /."0#GTKH-&C
MFBT>S2>82RB)=T@.0W'6N+03^+/$45PUHPLU)BE#/P(QDCIQ\W!X/%>A*H50
M , # %4]$D4]%86BBBI)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N)\+?\ )1_&_P#UTM/_ $57;5Q/A;_DH_C?_KI:?^BJ .VHHHH
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M/1-=\0-#<:A*T<+3>9Y<_!B  ^ZH[YS@Y^HK=M_'/A:ZL;N]@URS>WM-IN)
M_P#JP3@$^Q/?I42?$+PA(Z*OB&P+/+Y*CS/X_3_Z_2GS=A\UMC9TS2K32;9H
M+2/:K.7=B<LS'N35ZN:7QIID"ZM+J=Q;6-OIUW]E,KSAM[$ C@<@\_=Y-/\
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M"G@?^R?B[XIUQH=MO*B&U;&!F3YI,?0C]:],HH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "D-+10 E%+10!'(F]&7)7<",CJ*Y&YA.E3X)GA@MP5CE
M7_63RMW]Q795!/:0W$D4DJ!FA;<A/8UI3J<N^QC5I<ZTW(].N?M5FCL<R  2
M C!#=QCM5L53LK=X3</)C?-*7P.PZ#]!5RHE:^AI&]M0HHHI%!1110 4444
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M*881@2-H9?2NI_X1SQS_ -#U'_X*8_\ &C_A'/'7_0]1_P#@IC_QH-#B]<\
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M]G/9P21021MITB3:>Q4@DOP%STQSZT#/9Z*** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S
M_B#PTVKZKHVK6ET+74-+G+I(4W"2)AB2,C(X(QSV(K0.AZ4R7Z'3[<KJ'_'X
M/+'[_C'S^O'%:%% %";1-+N$LDFT^V=;$@VH:,'R2!@;?3CBIK#3[/2K*.RL
M+:*VM8L[(HEVJN3DX ]R:LT4 9VL:#I.OVRV^KZ=;7L*-N5)XPP4^H]*SYO
MGA.>X2>;PYICRHJJK-;*<!0 HZ=  *Z&B@"I_9=A]N@O?L<'VFWC,4,H0;HT
M/50>PX'%5(_#&A1:I_:<>DV:7WF-+YZP@/O889L^I'&:UJ* *J:98QZG)J26
ML*WTL8B>X"C>R#D*3W%9?B'P7X=\4HW]KZ5;W$IC,:SE )$!]&ZC':MZB@#E
MK3X?:$FG6MIJ<!UIK4GR9]3"S2(I_A!Q]T # JS/X&\*W+(T_A[39&2$6ZEK
M=3B,<!>G85T%% &&O@WPTM]]M70[ 7.Y&\T0C.4^Z?J,"C4/!OAK5;V6]O\
M0K"YN94"22RP*S,!ZG\*W** ,NV\-Z)9K:K;:5:1+:RM- $B \IV&&9?0G-0
M7/@[PW>:;%IUSHEC+9PNTD<+0C:C,<L1Z9).?6MNB@#&G\/6T%G<_P!BP6FG
M7[VGV6&Y2 ?ND&=HP,9 )R!3_#6@VWACP[9:-:$M%;1[2[=9&/+,?<DD_C6M
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
B444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>formdrs_022.jpg
<TEXT>
begin 644 formdrs_022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "I ?\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ J.>9;>WDF?<4C4NVT9. ,\#O4E,FB$T,D3%@KJ5)5B
MI&?0CH: ,JP\26-];&=B;=,%@964AE W$@J2.!U&<BDG\4Z1"I(NA*0^PK&,
MD'#'_P!D8?450NO#%HDUJCW99Y[M))'FP'EV*Q" * #D9R3U&?:K-UX=TQ8U
M,MQ+$ =H;>!RSL<<CN9&'XBKM$G4MP^(M)G@AE6^B"RG"@G!SQU]/O+^8]:C
M@\3Z5/ )_M(CC) 4R<$YSVZCH>M5#X8TC47AOTE=PP4JX*L'7:@ Y!ZB->F#
MUIUKX<L&'G6=]=*RLT?FQNN0 2&3I^&>O'6BT0U.AHHZ"BH*"BBB@ HHHH *
M*1F5%+,0% R23P*%974,C!E(R"#D&@!:*** "BFI(DH)C=7 ."5.>:=0 444
MT2(SLBNI=?O*#R/K0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJKJ
M.HVFDZ?-?7TZP6T*[I)&Z ?U/MWK#\/^/=!\27S65E-,ER%++'<0F,R*.I7/
M7Z=?:FHMJZ6@G))V;U9TU%%%(84444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %!.!D]**RO$-G)?:0\$<+S$NC
M%$902 P/ ;Y6Z?=;@TUN#)-5LKFZ>RFLY(5EMIS*!*"58%&7''^]G\*P9/!]
MS-?W%W+=0R-)*LP5U)!(D1]I]AM('7@]N<UXK'Q3!]ECMP(($1ML<>P ?,Y^
M8;L D%.!D ],"K'V/Q-!=6JI-<3PK*I??(G(*Q[MQZX!\S P?PX(T5ULR-^A
M7N/ LS:>EI:W<$2>4BL/*ZR!"ID'OD@^O'6NJTNR;3[+R'D$C>;)(6 Q]YRW
M]:Y6STGQ#:,945O.2(.H:1-C.$A'EC^Z"4<'''(-%U9:Y9.VH332EX8V??&R
MX9_+C."HY(+*RC@GD4.[TN"TZ';T54TL70TV WK$W++OD']UCSM^@SC\*MUD
M6%%%% !1110!PGQ9CN)/""F&55A2=6N(RX7S$P>.>N#M./:H_A''<)X4E,DR
MM ]P6MXPX8QKM&>!]W)R<?CWKS/QMJS:KXTU RS&012O% I.0B(=IV^F2"??
M-1>$-7.D>,=/DBF:/?*B3A3@/&[;?F]0"<_A7K_4Y_5-UWVUVVN>/]<A]<V?
M;?3?>Q](5C>+([J7PGJ<=E,(;AK=@CEPGU&X]"1D9[9K9KQ3XNZNTWB2#3&E
M;[-!$A\K/RF5B3DCN0H7&>F37GX>DZM106AZ.)K*C2<VKEGX.1S?VOJ$D,J)
M9B'8\0< M)N&#MZ\#<,^XZU[%7RNMT]G<0SV\K0W2M^YD0X96 )X/X5].Z7>
MKJ.DV=\F-MQ DHQ_M*#_ %KIS&C*%3G;6O;0Y<MKQJ4N1)Z=W<LOG8V"%.#@
MGM7@_@>WOU^),2O<QB[BE<WLOG*?-!!SSGY]QP0!G'7C%==\8]8:STFRL%F:
M..X9Y9PIQNC0 ;3CJ"6!Q[5Y!(T4,>]\*BD<XZ<\5K@L+*=*4KI7TU5_F8X[
M%1A6C&S=M=';Y'U717,?#_5)=6\&64UQ*TL\>Z&1W.6)5B 2>YQ@UT]>9*+C
M)Q?0]6$E**DNH45D7/B"UMIIH'_UL<RQ;-W)RH.[Z<_I2R>(K*-%(\QW)4;4
MC8YRRJ<''."PX'-/V4^P<\>YK450DUFQC@AF:5MDP+(1&QX'4GCC'?-1_P!O
M:?DJLKD@D9\M@,YQUQC!((!Z$T<DNP<R[FG165'XBT]K2.=W>,.%RK1ME<@'
MGCISUZ5&?$EK]F:0(^]2^8V!4D+NY!(P?N'I3]E/L'/'N;-%9<>O6;3O%(6C
M* G>0=IP7XSZ_(:TD<21JZYVL 1D8J7%QW0TT]AU%%%2,**** .,^*&F7NI^
M#F6RB>9[>X2=X8QEG1<YP.Y&0V/]FO+O &GW>I^---ELXY#%9S>=/,%(6-0I
M&TGU.<8Z\GTIWBOQGJOB'4[F-+V:WTR.5XX8+=S&'56(W.1RQ.,XZ#T[USMI
M/<:?,)[&ZN;28'(>"5E.??G!_'->WAL-B%AW!6M+ON>%B<5AWB8S=[Q[;'U)
M17F&C?$#4[WP@ QA;6?MGV(3,GRX\OS/-*COM!&!@$CL*TM \1:K!K=K8ZE>
M?;K>]9HTD:)4>*0*6'W0 5(5NV0<<FO&G%PDXRW1[<)*<5*.S-/XC:M>Z+X(
MO;O3W:.X+1Q"5>L8=PI8>^#Q[XKQ?P7K.HZ7XPTY[>ZN'%U<I!/$\K,)E=@I
M)!/)&<YZ\?6O1_'WQ%TVS-WX>@TU-4E*F.Z$S;84R/NDCEF^F,>H->6>&-='
MAK7%U3^RK:]9"?+225P80>#L))&<9&2"?>O/KU(^UC[]K;H^LRK"57@*J^K.
M;FO=EIVZ7UT>NFY]/45B>%_%%AXLTK[=8[T*-Y<T,@P\3X!P>QX(((X-;==J
M::NCY>490DXR5F@HHHIDA1110 4444 %%%% !15*UU."ZU*^L$R)K,IO![AE
MR"/U'X5=IM-;A<*S]<U>WT'1[C4KD$QPKG:O5B3@ ?B:T*\W^*-Q+>P)ID#?
MN[8)<W./]IPB+^K'\*NE#GFDR)RY8MGH-G=Q7]E!=P-NBFC61#[$9J>N*^&]
MU*FAC2KELR6\<<T1/\4,@W+^1W#\*[6E4CRR:'%W5PHHJE+JD$6L6VF')GGB
M>48_A5<#GZD_I4I-[%7+M%%%( HHHH **** "J6L7$MIHM]<0-MEB@=T.,X(
M!(J[6;K[*/#^H!F W6\@&3C/RFJA\2N*6S/+/^$\\2?\_J_]^4_PH_X3SQ)_
MS^K_ -^4_P *Q_*'J*3RAZBO>]G1_E1YG-4[LV?^$\\2?\_J_P#?E/\ "NP\
M#ZUJ^L?:I]0N!)"A6- (U7YCR>@[#^=>;>4/:O4_"D4&GZ#9QF2,/*?.?YAW
M/'Z 5RXSV4*7NQ5V;T.>4]6SJZ*B^T0XSY@(]N::;R$?Q?I7E69V71/158WT
M0]33#J"=E/XT^5A=%RFR%A&Q0 N =H)ZFJ1U'GB/]::=0?LJ_E3Y&+F1\[:C
MH.H:7'!>ZG9S6]S<-(@21?F;;M+''NS'ZXHT_0-0U9+JZTVTFGNK8QHT:+\X
M#;^<>S*/IFN[^+%R\MUHF[''F]/K'3/A=/(FK:]M;&?+S_WW)7K^WG["^G?\
M;?D>/]6A]8MKV_"_WW/7X3(8(S*H60J-X!Z''->#^/-"U.;Q#K.L7UI)%;17
M,?DR,/E?)5$VGO\ (#GT->QFXE/\;?G7'_$J1F\'N"Q/^DP_^A5PX6\*BMUL
MOQ1WXN*G2=^EW^#/)]/TJ76KZ.V@A=K@(TT*$;2Y5"PQGU'3ZU[WX&2YLO!F
MG6^HQF">)67RW.&"[CMR.QVXXKR'P,3_ ,)OI7_7L/\ TFKV;)/4UMC)RJ-7
M\G^:,,#2C33:\U^3/._BEI-]K/B -]F=M-ATYG,X&47;O=@3V)P@Q[UYS#;Q
MW]U!9RAA'/-'$6*X!!=0<'OC(KW;Q+_R*VK_ /7E-_Z :\3L/^/W2/\ K]'_
M *,BK;#5)*DX_+\),QQ=&+JQE\_QBCU[X56.J:;I&H6NHVLEN!=;D$@QN.T!
MB/;*]>]=_5.PZ/\ 6KE>75DY3<GU/4I04(**V1E:A'I<-O=-=R!5WB>4!SG.
M H.!SV JK%H]G;W_ )\UXHB0!XH&8KL^93DY/JH[#WJ2Y\.I=74LK3@*[F0#
MRP6R=H()SR/EZ?X4_4M CU">2?S0DC%"I*9QM##!P0<'=ZCH*TC**5N833>M
M@N--L)/)C:Y\N&W5P\8EQD.1G<<]#_6GMIFELR N  NXH)L!UW%@2,\@$DBL
MY_"\D1W6]Q&W,7RR1Y'RLA)///"]!CWJ0^%4:,Q&Y&QLD_NAG<5*\'/"\_=_
M6G>/\X6?\I+_ &%HTR11F4R$@A"9R2R@ 8'/(&!_DFIX]$TR9&92TJ,6 /FE
M@,[L@<\#YFJM-X8CDNC*ESY:,7RJ1X.&SP#G'\1[?3%7](TL:5;/%YOF%WW$
M@$#H!W)]*4IZ74F"CKK$AN?#]K.FQ<JC.K2 DG< Y? YX.2>?0D5K445BY-[
MFB26P4445(PK-\0:B-(\.ZEJ)/\ Q[6TDH^H4D?K6E7,?$*ROM1\$:A:Z="T
M\[^63$GWF0.I8#U. >*<5=I,4FTFT?.2221WT%J,F-8"SMCJV0!_6I-0EDAT
MZXEB.)$0E?K5IO+73;>Y,-RK/<S"1W@941<1J@+8QRP?O6??MOC@62.1(G9&
M82+MW*P)4^X)Q7T4L7"-"I-.]KVMY+^F?/4,OG6QE&@].9Q3;VNWU_(Z7PEJ
M5M.M_;(;AY62&YMWM8O-\N9=PP_( #*[ Y(Z<<XKLO#VJ):ZQ#J/B2WN;1+;
M<8/*AWQ*Q!4N[*S'H2!Q@9.2:\]\,&2+Q39"W&"X=90O>/:3S]#M_&O2Y9H[
M>,RS2+&@(!9C@#)P/U(KYOZU]:;K6M<^NQN5_P!EU?JG/S62U]?(\BO-26^U
M26Y8DO?32W (]&8M_44R600PO*02$4L0/:KNOZ+ GBZ^W+MB7;)%&A*@;QEN
MGN#65.HA2[@+,T:Q;AN.2 0>,_A^M<6)RNK"BL4VK-_/5GUV4<4T*]9Y="#4
MHQT?3W8IM=_.^QTGA3Q1K&B74\>DWD<$=U&LQ#PB0,5X[].&'2O?O"6OGQ)X
M>AOY(EBG#-%/&IRH=3@X]CP1[&OF1&CM=2A%DXDBCN'MXV"GF/D X."> IQQ
M7T'\/-3T#^Q8M(TR^>2[B#23QW$9BE=F.6;:>V3V) &!FNW#J/U5*WO1;3_0
M^8SN[Q[JI^[4C&2^:5_Q3.THHHIGF!1110 4444 %%%% 'G_ )\FG?$N]U N
M?LLLL-C..P+Q@HW_ 'T,?\"KT"N-.F#6+[QA99VM(\(C;^ZXB!4_@<&M_P /
M:F=6T*UNW&V8KLF7^[(IVL/S!K:KJD^UOR,X:.QHNZQQL[L%102Q/8"O.+^-
MKSP?>:Q*I$NK7\,B@]1") L8_P"^1G_@5=1XNFDDTV'28&*W&J3"V!'54/,C
M?@H/YU!XQA2#P_96\2A8UO;:-5'8!Q@?I3I>[;S?Y!/6_D9.G'^S=-\)ZX.(
MC;QV-T?]AP-A/T?'_?5=]7*:'IZ:Q\-+.PD.!-9! ?[I['\" ?PK4\-:E)JF
MA6\TXQ=1YAN%])4.UOU&?QI5=;OLPAH:]>?Z5-)J/Q(35BQ-O/#<06P[>7$R
M#=^+%C73^*;^6QT*86W_ !^7)6VMA_TT<[0?PY/X5E+:6^C^)O#UE&RK%;Z?
M/&">,X\OG\>M%/2+?>X3U:.NHJG)J=M'G#%B.P%59-9/_+.,?5C7,ZD5U*<D
MC6I&=4&68 >YKGY-2N9/^6FT>B\569W8Y9B3ZDUFZZZ(EU.QT$FHVT?_ "TW
M?[HS56365'^KB)]V-8]%0ZTF2YLNR:I<OT8*/85@^((;J_L6*HTWEJ[MR/E&
MT\\UHU(HS8WX_P"G5_Y4Z,W[6+\R;M[GE?V27_GD?TH^R2_\\C^E;OD\T>37
MTO._Z1S<J,>VTVXN;F.&.!F=V"@#%=6-(O/M"HNFOP0 /D_QJSX7M1_:+W3#
MBWC+#_>/ _G72VK[KN/W8?SKAQ.(DI**.JA13BVQEC9SP:?;121,KI$JLN.A
M J8QNO5<5MT5R^T->4P]I]#28(K<*J>J@_A3##$?^6:_E3]H+E,:BM@VT+=4
M_6F&RA_ND4_:(.5GFWCSP[J>O3Z8VGQ1R" N)-\@7&2F#SU^Z:/ _AS4]#U#
M59=0ACC2XVB(K(&W89SVZ?>%=UJ<VG:3 LUY.T:LVU%52[.>N JC)X!IUFMI
MJ5HEU9W DA?.&VD<@X((/((/!!K3V_N\O3_@W,O8+GY^O_ L5ZY[QII5YK7A
MQ[.QC62?SHW"LX4$*V3R:Z_^SC_?%5KR)+"UDN;F:.*",99V/3_Z_M4QJ*+3
M3V*E#F3B^IYCX7\':UI?BBPO;N");>& *[+,&(;R=F,?6O2:BTZZM]6B=[*0
MR>6VUU92C*>V5;!%7#:3#^ U4JG-JV*--05D96M6LM]H6H6D !FGMI(T!. 6
M92!S]37F-IX#\0Q7&FR/:P 0W0DD_P!(4[5WQG/OPIKU]HG0$LI4 9)/  K,
ML-<T_4YVAM)R\BKO :-EWK_>7(&X=.1ZBJC5<59/^K-?J3.E&;N_ZU3_ $.@
MT_H]7:I:>,*WX5=KEGN=$=@HHHJ1A1110 4444 %%%% !1110 53U>WGNM&O
MK>U?9<2V\B1-G&&*D _G5RN&\5:Y?RZO+H]A=-:001HUQ-%_K79LD(I/W0
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M_ANW?G0!O>"-1MDO;A[XM97ETJ116\H(!"EC]_[I8[CP.P^M=TUU;KUFC'_
MA7C^JW?ELEFJGS98I)HF!Z-%M8#]?TKM(YA/"DRG*R*''T(S0!L:[J>EIH]S
M#=WGE)<QM "BEF)92/E4#)/L*X3P_JL-MK<5UJR/9PVX98Y"AV2LPQDG'R+C
MLW?'IS'XAOH[;5TDD&X0QQQ* ?XYI,?R4?A4=_=QV<47FIN2:9(#[;SC- 'J
MMK=Q76XQ @#&<BK%<OX%D,F@Q!CEHE$+?5"5_I744""BO.-<\.>(;G5-9%HC
MFRU&XCF8B< CR5CVA1G@,<@_[GO4MS;^,I;>:-_MQB<%9Q&\(<N1(!Y)/ CS
MY6=W./QH ]"HKSNRL?&XE6UEN)H;8>3&6C\OY(PT8.UB2=VSS,Y'7\*@:T\=
MSS/*1<JT4OF6ZO+%@.8YE^;!^9,F+L/IUH ]+HKA6F\26OANV6\>_-S+J21_
MN5C$_D$<CJ5Z@\D]*B:U\;+;^;+<7;3L-HCMVA 5Q"FP\C[OF>9NY],#% '?
MT5YRMIXQM;:YAMDO!OGD9_WL1 +3,P:+G.W:1D$@\CT--L=.\7[G-Q%<>;/+
M#+<B1XC"<)"&*@'(;<KY[8'':@#TBBO,%L/$6AVB7\AGA%G;,0JR(5=A'!A7
M');<R2(#R02*]"TA;Q=)MCJ#EKMDWS=/E8\E>.PSC\* +M>+:_K,D5Y=7T."
M]]K*VZDC/R*PB)_[YC/YU[/)O\I_+ +X.W/3/:O$?[-O&TJ%[JSNH%TX0K,9
MX2@-PT\2G:3][CS#D9'(YYH WA][%<#K%V^L>$DOI<&:RU%XG(&.-[(/T*FN
MT74+<ZD;$&3SA_TS;;T!QNQC."#C/>N4UMX--\-S6\X?_B;6K2VP1"<RI(R-
MG'3&(SD^IK.HDX-,ZL'.<,13G!7::=EY,X\0/J+QVEM$;J21Q^[0CD @MD]
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M5R^J3ZTVKW4&FM.?+A4H-J>7DJ^<D\[LA<=OUJK>VWB%A)!YEY,BNI+CRAE
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M45V=0<%\@$@'DBMOQ]X=O]?\:>&TM(+<Q);W8EGN[+[3#'D)C<N0,G!QD]J
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M/7FNTH **** "BBB@ KB=>BCFU*YCE171B,JPR#P*[:L&_T*:[O9)UEC <Y
M.?3Z4T3)71YKH7V>XU[7P?+D(NTD0<'HN,CZ&L#4FWZEK!.UK!=0@>Y:,9D1
M0!\R^V>#7L'_  C%Q_SUB_7_  H_X1B?_GK%^O\ A6ZK).YGRL\_U2XMY/%G
MAZ198V5A,0P/4%>/S/2J<=WI\.N>)Q=O$8W$8"-R7(0@@#N<\5Z9_P (Q/\
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MOQ&66SB+A"1%\^Y_D+"4?],R0!Z\_A762PQS*%E17"L' (Z$'(/X&GTN2?\
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D0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>formdrs_023.jpg
<TEXT>
begin 644 formdrs_023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %S D,# 2(  A$! Q$!_\0
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ME_:1%9PC]4PV"C^@/KVIBKONH99;M93%DX6/&<BJERJ+=E1^\MW/FE<<QGU
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M,CH91L8'OZ'\*5/$J_*U_7];'14P$N7FOZ_U^9UQU #RX;N-Q>VP,-S@]8F
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MG8 .%%8AU.$SEXI'4N/+8'^('O\ A65/$J_+;^OZV-*F ER\U_7^OS.M^WF
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MP2L>BHJ*L@HHHH&%%%% !1110 55L/\ CW;_ *ZO_P"A&K55;#_CW;_KJ_\
MZ$: +5%%% !1110 4444 %%%% !45SYWV:3[.4$VT[-_W<^]2USWBV_N+*QB
M-OYRLS\R(,H!Z-]<_I50CS220#(O%UM%B&_B>"[601N@Y'/\0/IWI9_%$4.L
M+$V/L(+1-*.?G !S_N@<5YW)*0,NQ(4 98]OK422Y8-%(2/NGG(YX/Y@UVO#
M12N:4XJ4K,[#6?$%K.\]HLDEU;/+'*L@Q^[QRP4_AQ]35W3_ !(UR^7NO*A\
MYYIFD4?NH\@+'[Y)ZUY9J^I75K>+'$=B!0V<?>KHM G:2ZL9W!5V() CW\X_
MN]_6HE22B=LJ$.6RZ'L%%06<SSVJ22121L>")!@G'?';/6IZXSSGH4]._P!7
M<?\ 7Q)_.N?OO^2I:-_V#+K_ -#BKH-._P!7<?\ 7Q)_.N?OO^2I:-_V#+K_
M -#BH ZRBBB@"O>VD=[:O!(.".#Z'UKA-7T:2W BNU&TGY'7O_GTKT.J&L1?
M:-.> +N>0JJ>QSU_#K42I*;29M2Q,J*=M3S&#3)#=VZ11%C,Y$1DXP!W)].]
M=Y9:3 C06,85H[<B2Y?'^LD(Z?UJI([Q:L'94E@M(C;Q@KC)(&3Q^ _.NCL+
M;[+:JC',C?-(?5CUKI<53BDOZ_K\V<OM'6DV_P"OZ_(IZK8K+8RKY2S!I5?R
MV'!Z#!K-G:?2+QKLO';Q.J372!3(6Q\I"CMVKIR,BJ\MLLEU%/@94%6R.H/;
M\ZA3Z,JUMC/CDN8Y_(LP7!N%>5[@XRC#)V>N*V*IW&F6USJ-I?R*WGVN[RB&
M( W#!R.AJY4MEL*\*^(\V?BI#O!9(;:-L#K_ !&O=:\_O?AQ+>^.)_$,FI*4
MD92L#1YV@ #&?P/YUE5BY*R.S 584JCE-]&>1ZYKE_KMR?,F\NU#?NH$/;W]
M370>#?#=U;W"ZE.K01QJ?+0\&3([^U>GQ>!+""X:>**W65CN+>7WJS<>%Y)K
M>6-;L(SH5#;>A(ZUG[.6[/0J9E3</9TU9'G'PB)?QUK+D9/V7K_P-:]KKC/
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M[=H8GN[;B#^0KV6O'/A%X6GDF;7[II$MD)6WCW$"1NA<CN!T'O7L=2,****
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M2)\1-'6XNTN7>***4QPR;"1-@1\#ONS(!CVS0!UU%<JGQ"T-P,?:PSOY<*M
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M 'S5_0OAU<Z3X0U;16OX_,O8E02QAL95<;F![MWQ0!W(O[-EB9;N!A-D1$2
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M4A3OYDB&0;TR>,_(W/KS7;44 9'AJ349-'1M4CD2YWL/WG#%<\'';Z5KT44
M%%%% !1110 4444 %%%% !1110!3T[_5W'_7Q)_.N?OO^2I:-_V#+K_T.*N@
MT[_5W'_7Q)_.N?OO^2I:-_V#+K_T.*@#K**** ,JTN=#N5GGMC9L"SI,ZJHR
M5;YL^N"1GZTVY?0[B65))K,7#YA9P5$@)^7&>N>U8UUX.NI$FCM[N"-96N5.
M8_X)G1S^(*8^AI\G@F-TN<RQ>9-#<1AS'RK2S&0-]1D#\* +]C8>'M*@FBC-
MJ?)E\V5I2I9'.!D^AX _ 5KM;6LTR7+01/*H^20H"P'L?QKF%\&,UPIEN(FA
MC<%0(_FE'G"4^9ZGY<?C77  # & * *\EA9S($EM('08PK1@@8&!^E'V&T$K
MR"U@\QQM9O+&6'H3WZ#\JL44 11VT$4CR1P1H[_?94 +?4]Z8EA9QNCI:0*\
M>=C", K]/3J?SJQ10!%+:V\RLLL$3JQW,&0$$^IJ/^S[+S#)]CM_,8;2WEC)
M&,8SCTXJS10!"EG:Q($CMH44=%5  .<_SYJ:BB@ HHHH **** "BBB@ HJN;
M^S%N;@W4/DA]AD\P;0V<8SZYXJ07$+7#6XE0S*H=HPPW 'H2/3B@"2BC(SC/
M/I4:7$,DTD*2HTL6/,0')7/(R.V: )**AN+RVM=OVB>.+<"1O8#( R?R%3 @
MC(Y!H **0D#&3C/2EH *3:I8-M&X# ..<4M% #418UVHH49)P!CK3J** "BB
MB@!JQHC,RHJLYRQ QD^].HHH **** "BBJ.H:O9Z7+9Q74FQ[R801 #.6/3/
MH,X&?4CUH O453L]1AO([A@&C:VE:*9'X*, #^H((]B*HQ>+=$DL;6\-]''%
M=!S#YGRE@@);CV H VJ*S8O$&D3VR7$>HVQC>-9 ?, ^5ONG\:=>:YI=@DC7
M5_;QB./S6!<9"^N* -"BJ@U73SO_ --@^2/S6_>#Y4QG<?;%54\2:4VG?V@U
MVB6GV@VXE;@,^_9Q^- &K14$-[:W,TL4-Q%))"<2*K E#[^E0'6=,",_V^VV
MJ_ED^:.&]/K0!>HJI_:=@)I83>0>9$I>1?,&44=2?0<C\Z1-5T^00E+VW;SL
M^7B0?/CKB@"Y145M=6]Y L]M-'-$WW7C8,#^(J6@ HHHH *JV'_'NW_75_\
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MHT9UDA69UB)PPW<U=FA6>%XFX##G%28XQVHN'*QD1!B0KC! (QTI]( %  &
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M=U<-<1&.9;.W,TD<:LH+%<F-L_Q#:0#ZFO0JIKI=BEO+;K:QB*5MTBXX8^]
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M>G?ZNX_Z^)/YUS]]_P E2T;_ +!EU_Z'%70:=_J[C_KXD_G7/WW_ "5+1O\
ML&77_H<5 '64444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M44$@ DG % !152QU2PU.W>XL;N&XA1F1GC;(##J*BTS7=+UD2'3KZ&Y\H@/Y
M;9*YZ4 :%%%&: "BH+F\M[-$>XE6-7D6-2>[,< ?B:GR/6@ HHR** "BBB@
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MHEI(CK ED;)$5L;8R4(_$>6M9K^ -/D6)?M5RJ(0S(K8#'>&SCUR /I76T4
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M&77_ *'%60SK**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT4*)))_?8* 3^)H LT444 %-DD2*-I)&"H@+,QZ "G57O[<W>GW-LK!6EB9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *SK6[@@C>.1RK"1\C:?[QK1HP* *O]HVO
M_/7_ ,=-']HVO_/7_P =-6L#THP/2@"K_:-K_P ]?_'31_:-K_SU_P#'35K
M]*,#TH J_P!HVO\ SU_\=-']HVO_ #U_\=-6L#THP/2@"K_:-K_SU_\ '31_
M:-K_ ,]?_'35K ]*,#TH J_VC:_\]?\ QTT?VC:_\]?_ !TU:P/2C ]* *O]
MHVO_ #U_\=-']HVO_/7_ ,=-6L#THP/2@"K_ &C:_P#/7_QTT?VC:_\ /7_Q
MTU:P/2C ]* *O]HVO_/7_P =-']HVO\ SU_\=-6L#THP/2@"EIIW0S, <-,[
M#(ZC-8%]_P E2T;_ +!EU_Z'%765R=]_R5+1O^P9=?\ H<5 '64444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5$UK;O=)=-!$;A%*),4&]5.,@'J <#CVHHH EHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>formdrs_024.jpg
<TEXT>
begin 644 formdrs_024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $U G0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^O-/B_K^
MJZ#::4^EWTMJTKR!S'CYL!<?S->EDXZUY#\=2#8:+@_\M)?Y+6^&2=5)DS^$
M\\_X6)XN_P"@[=?I_A1_PL3Q=_T';K]/\*YBBO8]G#LON,+LZ?\ X6)XN_Z#
MMU^G^%'_  L3Q=_T';K]/\*YBBCV<.R^X+LZZW\<>-[J.XDM]5O94MT\R9D
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M56UL(76;RG94V?.<NV O8X!;-#G37V?P_P" %GW//F\?>,EA29M8O1$Y*HY
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MUBC(C3& 2HSVKE+;QYXTO+F*VMM8O)9Y6"1QI@EB>@'%7_B^<_$&Y_ZXQ?\
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M;[*K)]D-QO&S(!V;MN>,XJKXB.D6_A?Q%;V+V<=Q)]@:Y@MG'EB?YO,$8!Y
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M13Q>:F <&I:* /'O&WPRU[Q#XEEU"SDM/):-%'FRD-PN#Q@USO\ PI;Q0?\
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M7?>L(8]TJ*B'[0V, C=QZG'7I[4VV\.ZG%);.^PR*L:O*9B2H64MCW^7'Y4
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M&:VBE9=C.@8KZ$CI4-IIUI8*ZVT(0/C=R3G'3KZ5:H *0D 9-+45Q_JC^/\
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MJ6BBNPY2"6]M8)XX);B..63[B,V"WTJ>O(?&WAWQ+>>,S/:K-)!+M:(P[CM
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MDJ72[)M6OE?)%E:R!F;'^ND!X4'T4C)/KQV-*;2CJ.*;>AV%%%%<ATA1110
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M **** "HW@BD^_$C<@_,H/(Z5F7FN+%<M:V4'VN=/];A]J1^S-Z^PR?I5?\
MM;58\LUI:3#^XDK*?IDC!_2H=2*=FRU3DU=(T[JZLM*M5\V6&UC/R1Y  SZ
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M#D#+*9KN9VE5U=V"C.[:#V_V13I?#L$LDK?:)T\XOYH7'SJQ!*].!D=1S2U
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M9%1P"X;*N,@\5IU!:QVHC$MJL6QU4!H\890,#D=@*GH **** "BBB@ HHHH
M*:8T8L2BDL-I)'4>E.HH B%K;JNU8(@N,8""E:W@8@M#&2&W#*C@^OUJ2B@!
MOEIL*;%VG.5QP<]:8]M!(,/#&PQM^90>/3Z5+10!$UK;N,-!$PXZH#TZ5#!I
MMI;R3/' FZ9BSDC.<@#'TXZ5;HH A%K;A446\06,Y0;!\I]O2IJ** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K#\0*J7&GSHV+@RF(+_?1AEORV@Y
M]O>MRN<OG^T>()<_=M(E11_M/RQ_(**SJM*#N:4DW-6%HHHKSST#.U#7+#2I
M62]E,2K#YY?&1MW!?J3DBL@>/M$^0N\J(=V]BOW,9QQWS@8QZUT4]G:W+*UQ
M;0S%1A3)&&('MFF?V?8[2OV*VVG.1Y*\YZ]JI./4AJ70Q[S7_#\>I*UXJFYM
ME5XI3 6*JZ@Y!Q\O!_G4Y\7:*MFMTUXPMVE,0<Q,!N !STZ8(.?>M1[2UDSY
MEM"^<9W1@YQT_+ ICZ?92/$[VD#-"Q>/*#Y6(QD#UQ1>(_>,6R\0^'FU$+IZ
MJ;N]E5)&2'8S-S]XD<X]/<5)XQN#;:%YJY602 ))VC.#R?7(R,>];$=E:0LK
M16ENC* %*Q*" .@''N:DEBCGB:*:-)(V&&1QD$>XIQ<%).2NNJ[D5(U)TY1C
M*S:T?8^;=0DED>6296-S."V] H&-H/4'CO\ A3],LTNKF.$W+(/++*8X0-S[
M/NJ/Z_C7I_BSPM?3Z@Z:1I=MY%RBIN2! (R!@Y/;U[U7T[P)?2:DJ74$=E#;
M0E%N(BK%VQ@8[D=SG%=E.%)IRE+ECI97N[?HT<E7&5TE2ITW*6JOM%.VCZW3
M+_@>QFCGCGMED6T176XEE<;I9, ;<#TX/_ZZ]!T.;R+VZT]ONL3<Q'V8_,/P
M;G_@58^@Z)%H.G&TBE>9G<R22.,%F.!T[# %:FC(UUJTMZJD6T,1@1STD<ME
ML>PV@9]<^E8P?[YN+;6NKW^9?*XX>*FDFDM%M\CH:***ZS **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (;JT
M@O8?)N8A)'D':?455U'2[?4+FUFN=C1P;_W;J"K;ACOZ5H5SWBJRFNXK;RK>
M6786^XH<9(P-R$C(]P>* *MQX8GM887LI/.FB\M0&"@ *K*3@Y!^]5K3O#7V
M:&T::8>?$T3L%7(RB%<9].:SQ;ZQ;32,J7D:2+!YH@(<JH0@A-W<-C/M4V/$
M'V2:6=KGSML2".';@9 WMTY(]O>@#5?0XWU<W[3$YE$GEE!CB,IU_'-4X/"D
M<4D+/=%Q R>6/* ^56+8/J<GK62VI:S%=V5O-/*MTWDKY?R8.2V[>.N>!TXQ
M6]X<;5&@F_M/S-^Y=OF* 0<?-C';/2@"_IEB--T^*T5RXCSAB,9R2?ZU;HHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:Q83:AK%AJ &JM+:26\.!9VAC90C\#N1QSTS0JS:NH_U]W]>8<OF>2?;[O\
MY^IO^^S1]ON\X^U3Y_WS7IUGJ^BZ'IUE;QZQIUQ=6FG:@OF1+N7SG=6C'(Y/
MI]*D3Q-IES')-!K-A9Z[<:7:![^:(%=ZLQF0X4_,1CMS3]J_Y?Z^X.7S.#U7
M2/$.BPO+?-(B),('*S[MCE X!P>,J01^-9/V^[_Y^I_^^S7H_BS4;._TOQC?
M6UPD]G=WEA':RJ/E>14RV/H.M9W@[Q);:)X>M8A>P07#ZW&TX= 6^S;0'/(.
M%['%$:DN2[6HFE<XC[?=_P#/U-_W\-+]ON_^?J?_ +[->JV&O^'8(0(=3TZW
MTN*XO#J5@\&Y[Y69O**<<C! '(Q5:V\96=O>Z5;17]JFG6^AME&12!=["%5B
M1RPX&.E'M7TC_7W#Y?,\R^WW?_/U-_WV:N:7%J^LZC%86,LTES*"40R[<X!)
MY)] :]!O/%NGZGI<EI>ZE:LDVB0-*?)4DW@<;B>.7"CITK<N/$_AX:AI4C:W
M93&UO92)@X)$+0,HZ(H4;L?*,XXJ76DE\/\ 7W!RKN>07@U.P%N;BXD N(1-
M'LGW?*<@9P>#QT/-5OM]W_S]3?\ ?9KUCP_K^D6HLKA?$&GVY@TB*$VDPPDM
MP"_^L.TG"Y[<G-16_B'0D\)W=M<ZAITUP5NQ?*,J+N5R2CHNS+#IM.1MQ3]L
M_P"7^ON#E\SRS[?=\?Z5/ST^<U=L[;6[^)9;8W#Q-<);"3S"%\U_NKDGJ:[C
MQIK>CZGX)@AAU*U>Z1H?)M[7E2 N&)0KF+'IN.35+P?KT%KX0DT^?5H+0Q:M
M;W+12\&2'(WA>.N0#^%5[1N',H]16U.-O)=1L+V>SN;B9)X)&CD7S2<,#@C.
M>>:A%]>,P474V2<8\P]:]7A\8:%>:G%<ZQ>VL_V?6[DVS&,?NH#&1&_ ^YNP
M<G//-<?X]U&QU#6["2VGMKB6*W5;FX@<N'8-GEMJ[B!W HA4;=G$&O,RY=-U
MZ#Q"N@RM*NI-(L0B\_C<P! W9QW%:=MX-\8W=J+B"-G4M(BK]L4.Y0E6"J6R
M<$'I70ZHVBR_$J'Q3%XGTI[07L$AA5V\P*-JD],<8)Z]*9J7C>QTNQTF;3;?
M3M0U"WN+UTEFW%K7?*2I ! ^8'/-1[2;MRK\!V74X6R35=0N)8(+B3S8HWD<
M23[,!?O=3U]NM5!J%V1G[5/_ -]FMSPEJ%K;ZSJ%SJ,T:":PNE#2=&E=>!]2
M:ZG6O%&GWVBZSIHO;62V&E68LXPBY-P,;\'&=P[UI*;4K6%;0X,?VL=-;40]
MS]C640&;>=OF$9V]>N!FJ_V^[_Y^I_\ OLUWOA'Q':67A"VM+K4X8!:ZU%<2
MV\BY:2WXSM&.?FY/T-:]CJV@:-<6P_MG3;AEO;^Y+1@E5$D9\L'(YYP/3/%2
MZK3:Y?Z^X+'E?V^[_P"?J?\ [[-)]ON^/]*FYZ?.:]+E\86.H:,;;4;ZVF6;
M00;B/RU#27@<<$@??VCBM&Y\2Z UY#)/JVGW-@VH6DNF6\4.UK")2/,W\# Q
MD8YS1[5K[/\ 7W#Y?,\D^WW?_/U/Z_?-'V^[_P"?J;_OX:]8\/>,[.ZO-7;5
M=5L84:\(B? B<6XR%V_(5D7G[A&>]<5X,N=/M/&,UQ+J*VL"QS_9YY%50S'[
MH)*D)D=P..U-5'K>.W]=A6.<^WW?3[5/_P!]FK&GG4]4U"WL;2>9[BX<1QJ9
M2 6/3DGBO3=5\7:9:-J5YI>I67VR<Z?AXP')*EA,067KCJ< X-6=/\2Z';ZQ
M-)I^MZ=I]NNM/<78>/\ X^H&4;=AVGHV?3'6I=:5K\O]?</E7<\DENKZ">2&
M2YF#QN48>8>"#@TS[==_\_4W_?PTNH2)+JEY)&P9'N)&5AT(+$@U6KH2T(+M
MM?79NH@;J;&\?\M#ZU]=#H*^/;7_ (^X?]\?SK["'05YV/\ L_,UI]1:***\
M\U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHIK@E3CK0 ZOFKXJ_\ )1=3_P"V?_HM:]^N;BZ@8\9%?//Q
M(E:?QWJ,C=3L_P#0%KMP/\1^AG4V.4HHHKU3$**** "BBB@ HHHH *D6XF2W
MDMUE=89"&>,,=K$="1W(R:CHH **** "BBB@ HHHH DGN)[J4RW$TDTA !>1
MBQP!@<GVJ.BB@ HHHH LVZWM^8--M_/GW2$PVR9.7/!(7U..OM6H?!?B47_V
M$Z-<BX\OS=I QLSC.[..O'6H?"^MCPYXDL]5,'GK 6#Q@X)5E*G!['!XKI=/
M\5>%]+N'2WL-5DB%N$BGN9$FD5]^XXC;* =LX]\5E.4T_=122ZG+GPWK0E2(
MZ;.)'N3:*I !,P&2GUQS3F\,:XNF2:BVF3BSCW%I<#@*<$XSG (QG&*[7_A8
M>ASZFUW=6&HXBU4:E;")D&28PA5\GMC(QU]JJKX^TO\ X1J:PFL+FYG*RB%)
MPACC9G+*P<?. /[O(J.>K_*%EW.7D\)>(86M%DT>[#7;;8!LY<XSCV..><<5
M3U/2-0T:X6#4;22WD=-Z!L$,OJ"."*]"O?B?8SWEO=0VNH0L]TMS<K&8DVD(
M5^5@I+]?XNW%<IXR\06'B&_M9K"T>$0P^7)*Z+&TS9SDHORC\*<)U&US*P-+
MH<W1116Y(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!+:_
M\?</^^/YU]A#H*^/;7_C[A_WQ_.OL(=!7G8_[/S-:?46BBBO.-0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** &O&LBX89KCM7^&/AW6M3FU"\CN3/+C=LFVC@ =,>U=G151G*#O%V$TG
MN>?_ /"G/"G_ #SO/_ C_P"M1_PISPI_SSO/_ C_ .M7H%%7[>K_ #,7*NQY
M_P#\*<\*?\\[S_P(_P#K4?\ "G/"G_/.\_\  C_ZU>@44>WJ_P S#E78\_\
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M//\ _A3GA3_GG>?]_P#_ .M1_P *<\)_\\[S_O\ _P#UJ] HH]O5_F8<J['
M'X.>$NT5V/\ MX//Z4'X.>$L<078]_M!KOZ*/;U?YF'*NQY__P *;\)_\\[S
M_O\ _P#UJ4_!SPD3Q#=K]+@_U%=_11[>K_,PY5V//_\ A3GA/_GG>?\ ?_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
..*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>formdrs_025.jpg
<TEXT>
begin 644 formdrs_025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #> H0# 2(  A$! Q$!_\0
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MY5<["BJU@T[V,+7((F*_.#ZU9JBT%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%-:1$959U!8X4$]30 ZBBL.^\2
MP6-\()(\INV,P89SQT'XTG)+<3DH[FY15#5M3CTK3GNW4OC 51QN)IFC:NFK
MVHE$+PO@$HWH>A'MQ2YE>PN97Y>II4445104444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M10!N45B_:]8T\_Z9:K>P#_EM:##CZH>OX&M"RU&TU&,O:S*^.&7HRGT(/(H
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M#*LO0BI: "BBB@ HHHH **** "BBB@ HHHH *HZCJUGI40:ZEPS<)&HW.Y]
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M@NSNOIKBZ<]2\A _!1@"D4=,LL;G"2*Q] <TX,IZ,#^-<!JFAVFFK%>V47E
M,(Y5!)&UN-W7@@XYJ_;>'M.%K#N@;S-B[G61@2<<G@T =C17,0VVH60*V6IO
MY6<K%<IY@'MNSG%:5CJLDDPMKZ%8)S]QD;,<GT/8^QH U:*** ,_5M8M=&MA
M/=;PAX&U2<GTSVJ>POH-2LHKNW8M%(,C(P?I3-2TRUU:S:VNXPZ'D>JGU'O4
MMG9P6%JEM;1B.%!A5%7[O+YD+GY_[OXW'SQF6(J" W521T-8-Y;?;+*2TN-T
M:$Y5E;!1AR :Z*H9K9)B&R5<?Q+UQ6;5U9FB;3NCD--T5TDD.H3%H0F$1GZ>
MOX8K?MXO-F0*A5%*G'8*O0?G5A--19"[2;C_ +@!ISSPVF8XP"_?)Z<<9-*,
M%%61$8I%RBL[[=*,,=A'IM(_6K,%VLQV%2CXS@]#]#WJBBQ6/J%C9VM[::IY
M4<;PR%7=5 ^5N"3^)!S6Q45SL^RR^8 R;#N!'48YH E!R,BBL_0VWZ%8-DG,
M"'GZ44 <YXG'G^-/#]N?NABY'X__ %J[.N&UR7/Q)TA/[BJ/S+5W- !37=8T
M9W8*JC)8G  IU<GXEDEU74H="A<K %$UXZ]=N>%_&@!;CQ3=ZA,\&@6@F53A
MKN;B,'V]:KFR\0S_ #3>(3&Q_AAA  J\;FRTXQ68*Q *-J*/NKTS5RDFGL-I
MK5F'_9&L@Y7Q+=Y]T!%2K%XG@_U>M6\WM-!_45KXHIB,U?$&N6 SJ.DI<1#K
M+9OD@>NTUNZ9J]EJ]OYUG,' ^\IX9#Z$=JR[O4+>Q:)9WVF0X4>M4=0T=S<?
MVCI<@M=13G<.%E]F%*Z>@VFE<["BL30?$":L'MYXS;ZA#Q- W\QZBMNF(R=:
MT./68T5YFB*\94 \9S6C&BVULB;CLC0+D]< 4V[O(+* S7$@CC'&34%W,LUK
M&T1#QR L&'0C&14I*]^I3<FDGL(UY*Y)CX4>V?S)H2[F1@)%W ]@,'Z]<5DZ
MBE_'&R11Q2V/DX92^UBW?FIEMKN&XC*R(+%(%"(3E@WU_K2YM;6'R:7N6I@R
M2>8@W0R ].#@^GO5)=,L%TMK"6:22-F+$R/ALUKP!%LF$V BE@=Q[9JH[P(^
M[9(2.BLY_E5.*>Y*DUL.M(M\R;%(2/&,]@!Q^/>M2JEO=0X"A/+!.!Z9]*MT
MQ!7->-@/[+LV[K?0X_.NEKF?&Q_XEMBO]Z^B'ZT =-1110 4444 %<;X1_?>
M)?$-R>IGV@^V3_A79$X&:X?X?R>;=ZTYZM,&_5J .XHHILDBQ1M([!44%F)[
M 4 4M5UBST:U\^[DVYX1%&6<^@%<^=3\2:K\]M%#IEN?NF8;Y"/IT%0Z;$VL
MZA)KMZN0Q*V<;=(XQ_%CU-;E &,=.UY_O^))A_N0@4BV/B&+_5^(F;VE@!K:
MHH RUN_%5MR7T^]4=B#&Q_I5JU\6Q+.EMJUI+ITS\*TAS&Q]F%22W*0N%;//
M<#I2W%M#=P-#<1+)$PY5AD47'8W00P!!!!Y!%8]ZKB4DABY;CCH*PH+J[\)2
MA9#)<Z*QQD\O;?XK74Q7XO(EDL5$L3C*S$X0CV[FIDKCB[:D]KO^S1^9G=CG
M/6G23PQ?ZR5$_P!Y@*A^RO)S/.[_ .RGR+^G/ZU+':P1?<A0>^WFF(9]NM?^
M>RGZ5%--9S8)G5&'1@<$5=H(!&#0(SH["&23S1,D@[%57^=2O+#9Y1!ESUR>
MGIDTZYM[=87E,"[E&<KP?S%<WJ,EQIT\=V+L-'$&_P!'D4L96P.0W\./?-*4
MK*[&K=S<34'?+*T3 '! !X/?)JU!=K,=I4H^,X/(/T/>N*EU633[>VNX+9;9
M)I/-F1>DI/7&:V;5V4W DO!/*K&4*HVF'(R%('M3C*,K\O0ANSY7N=)39!F)
MP>A4T1DM&I/4@&DE.(7/HIIE'/\ @?CPO"/220?^/&NCKG/ _P#R*T!]9)#_
M ./&M^::.WB:69U2-1EF8X H DHJO;7MO=JS02APN,]L9YIK:E9)%YC74(39
MYFXN,;<XS],\4 6J*JQZE933K!'=0O*R[@@<9(QG/Y4Z2^M8GE22XB5HDWR
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M+7--M('2XN54NI"C!.[CM6D\,<B;)(U=?1AD5EZA::?IVFWEQ':0QN8F&40
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M?PKIZ'JT>\_B2?ZU7\7Z5=:G8Q?9BS>6V6A'\6>X]Q6_;PK;VT4"#"QH$'T
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M",'^=<QH?R07D!^_#>2JWXMD?SKK:Y65#IOBB>-^(-1 EB;_ *:*,,OXC!H
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MB,.AYP>Q]0>Q]ZSR;[2L%F>]LAU)&9HAZ\??'Z_6M:F2K(R$1N$8_P 1&<4
M8TMQ)=WYDMYAY&V.)&7G)8Y;'N% ^G-:UQ:6]W#Y5S#'-'C&UUS6&^EW<.M1
M&RG"(D#R RIN5Y6;YBV,8.,<BKT>K^0XAU.'[)(> Y.8G^C=OH<4 1GPQIF"
MJ+.@/&$N' Q^=-CT2X@@6&'4 J(-J P*<#\ZV@00"#D&B@#!;2M8SA-1M<>K
M6QS_ .A4^V\.1>:)]2N'OY@<J)!B-?H@X_/-;=9&IZC-!>1V=J%:>8!5W#(7
M)Y8_0 F@#6&,#&,=L4M,AC\J%(]Q;:H&3WI] !6:TGEZ\@N!Q)'MMCVSU?/H
M>GX"I+VZ\J]L(%R7FD;Y?50I)/X<52TB)#JFHO<9:]28A2YR5B/*[?0=>E &
MW4-TLCVSK%]\CCG'UJ:J5YJ^G6&?M5[!$1_"SC/Y=: )K>:*13&@*&/ :-A@
MKZ53U#4=)S+IU[=PHSIAD=]O!]^U8B:C?WFMW#Z+#)+;74:JUQ/&42%AQN7/
MWA@]/6N@M-)M;:W>)U^T&1M\KS@,TC>IH P; :SJMNUHE\B:?&WEB]13YLZC
MTSP/3=W[5T=C8VVG6JVUK$(XU[#J3ZD]S5A55%"J J@8  P!2T %%%% !111
M0 4444 %96M>'[#78-EU'B11\DJ\,O\ ];VK5HH X0P^*?"J_N&&J6"]%()9
M1_,?AD5IZ9XZTJ](CN6:RGZ%9NF?K_CBNHK,U/P]I>KJ?M=JC/\ \]%^5A^(
MH T(IHYD#Q2*ZGHRG(I]<0_@.YL9#+HNKS6[=E?./S'^%1R3^.M-^4QQ7B#^
M)5#9_+!H [NBN%C\9:] ,7?AZ4D=2BLO]#4H^(MN@Q<:7=Q-W'']<4 =K17$
M'XEZ?GBQN#_P)?\ &I%^).ED?-:W0/T4_P!: .SHKC/^%CZ<W$=E=N?0 ?XT
MA\7ZU>?\@[P[.0>C2YQ_(?SH [2J]U?6EDA>ZN8H5'=W KDUM?&NJC$]U!IT
M1ZA -V/PS_.K-EX"TZ.3SM0EFOYNI,K$#\O_ *] #[CQI;RR&WT:UFU*XZ#R
MU(0?4U&OA[5=;82^(+W9!G(LK8X7_@1[UT]O:P6D0BMX8XD'\** *EH @M+.
MWL;=8+6%(HEZ*@P*GHHH **** "BBB@ HHHH **** "BBB@#%UKPOINMC?/&
M8[@=)X^&_'UKGS!XM\-MBW?^U+)>BMRP'\_RS7=44 <I8>/M+G/E7J2V4PX9
M9%) /U_Q%=);7MK>QB2VN(IE/=&!J"_T;3M3&+RSBE/]XK\P_'K7.7'P]L=Y
MDL+RYM']FW#_ !_6@#L:*X/_ (1SQ?9M_HNMB51T#R'^1!J??X\M@"8[2X [
M?+D_RH [6JE];/.H:-B&'!&<9%<A+K_C*$'=H:<=UC+?R-51XP\4(V'T<'V\
MAQ2:N-.VIV]M8A(&28*VX@E>PJQ':P1?ZN&-3ZA17$1^*_%,W$>@9/KY;BK*
MWOCB\&(["UM1ZOC/ZDT)6!ML[.J5]K&G::,WEY%"?[K-S^76N8_X1OQ-?G_B
M8:^8T/5(,_TQ5^R\#:/:N))TDO)>[3MG/X4Q$3^-8[IS%HVG75_)_>"[4'U)
MIHT/6=<._7+W[/;'G[':G /^\W>NIBAB@C$<,:1H.BH, 4^@"K8:;9Z7;B"R
MMTAC']T<GZGO5JBB@ IL@)C8#J0<4ZB@#,M&.6#C##'\A5IF 4DGBF366Z0R
M1G!)Z9Q^M1"SGDP)"N >A;(_+ S0 V*)IFDVC :-MN?]KI_*L./3M81M.M,O
M#&L'ES>5*2/W8RI!Q\I)./PKJXH5A4@9))R2>YJ2@#DX=(UU3;;Y\;,?,+AO
MDPQ)R/XBPP/04BZ/KODP(9R-C-@_:&RIW AV_O' (QTKK:* .430]7299A>2
M"0,K<W#%<[VSQTQL(&*T_#]C?V5O*M_,\DC,"-TF\=.2/3/I6Q10 4444 %%
M%% !1110 4UT21"CJ&5A@JPR#3J* ,S^QU@_X\;J>T']Q2&3_OELX_#%-:TU
MD<IJL)(Z!K7K]<-6K10!@7EUXDL(O-6ULKY%^\D)9'Q[ YS6''XD2XUJ#5)+
M5;,11M%*DTP$D@[ +Z@^M=W36C1CED4GW% ',CQUIQ8JMK?.?]B'=G\C5Z/7
MIY5$B:'J)C/0LJJ?R+9K9  &  /I2T <;K^K/>P);K87%I/&XDBGN/D\MAW
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DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>formdrs_026.jpg
<TEXT>
begin 644 formdrs_026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #$ >L# 2(  A$! Q$!_\0
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M&,TZ3+IQUH'8$<"4$\BEE ,A*]*KPQRLQXJRL+*N>IZFF@ND5VE5.6[4X$N
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M]6W^%="H4K5#4IDL[.2;:K.%)13W(%"2'=F$VO:<>?M!!_ZYM_A33X@TY?\
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MJ9<L&VC.WK42ED/'%0V;)$<L:X&WGBHPFWUJ[Y2R88'GN*/*(+ CI2L.Z(4
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M,S'@5H\%<G/6H4<AE0\;35I\J<9ZU7F4*-V.:BY;C;4NON>'Y.?45TO@YO\
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M-^,]:8R@J64Y%,:9"0 _(I-_!'.*>P)&YNW%0,[*.G%,:&F7J#49DXIC,2_
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MWE C!'3O4AF+#+'CM4PTC5%7:-.N/^^#47]C:P&/_$OGQV^0U-GV+]HD1B?
MP%R:C$F3C%7$T;5EY%C.#_N&D_L35,Y^PW&?]PTN5C<UW*HP7&>15A%C5AGG
M-21Z'JFW)L;C_O@U*='U12!]AN#]$-'*QJ<>Y4E &6V$<U/&J^3EN]22Z5JL
MI ^PW 4=MAISZ9JK  6$X'^X:.5]A\\>Y3\M>A/'I4)  .!TZ5>?1]5(!%C/
M_P!\&F?V+JN[_CPN/^^#19B=1=RB8V;FI8H>@-:2:+J17FRG'_ #4R:'J.>;
M.;_O@TK,7.NYG+ "*DCME%:BZ/?C_ESF_P"^:D72+\#)M)O^^:+,.:/<S?*
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MDN1ZGJE<WXW_ .0 ?^NJUTE87BVUFO-%,4$;2/YBG"BN^I\+/*I_&CS(':*
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,0 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>formdrs_027.jpg
<TEXT>
begin 644 formdrs_027.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $4 @ # 2(  A$! Q$!_\0
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M/&* '44TNJC+, /4F@L%QN8#)P,GJ: '44TNH(!8 GH">M&]=P7<-QY SS0
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M><4!U+%=PW 9QGF@!U%-#*20&!(ZC/2@.K9PP.#@X/0T .HIJNK#*L".F0:
MZE-X92N,Y!XQ0 ZBFF10F\LH7KNSQBAG51EF 'J30 ZBFEE7&Y@,G R>IH+J
M" 6 )Z GK0 ZBF[AN"[AN/(&>:-PW;=PW8SC/.* '44T.I)4,,CJ,]* ZL2
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M#1_^1O\ $?\ O6W_ *+-=%0 Q8U3.Q%7)W':,9/K2+$B)L1%5>?E P.:DHH
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M1Y:;_,V+O(V[L<X],T^B@!@C179PBAFQN8#DXZ9H6-$+%452QRQ QD^II]%
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MTI98(YH_+D7*Y!QGTZ5+10!')"DI0NN=C!EYZ$4/"CR1R,,M&25.>F1BI**
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M,]I'!*C1RS%F+.P8]NG'3/IZ5NZGH]CK$<<=]"TBQG<H61DP>G\)% &9H_\
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MP?P.#0!>I:R?#6I/JOA^SNI1BX*>7./213M<?]] UK4 %%%% !1110 4444
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MO_19KHJYW1_^1O\ $?UMO_19KH<T +129HS0 M%)FC- "T4F:,T +129HS0
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M/5C^&*Z04 -1%C1410J*,*JC  ] *=110 4444 %%%% !1110 4444 %%%%
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M_P (LO\ T'-<_P# T_X4 ;]%8'_"++_T'-<_\#3_ (4?\(JO_0<US_P-/^%
M&_17%>&]%EU/0XKJXU[6FE:6925O"!A964=O0"M;_A%E_P"@YKG_ (&G_"@#
M?HK _P"$67_H.:Y_X&G_  H_X19?^@YKG_@:?\* -^BL#_A%E_Z#FN?^!I_P
MH_X19?\ H.:Y_P"!I_PH WZ*P/\ A%E_Z#FN?^!I_P */^$67_H.:Y_X&G_"
M@#?HS6!_PBR_]!S7/_ T_P"%9-SHLL7B?3K!==UKR)[:>1P;PY)4H!SC_:-
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M:?*)[B>"$#+M Y5R/0$<\GTK 74]3\.^%M,GU)EG(N%BO)IW^>*)W(5F(ZL
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MO;;3XOL<26<K"60B0I/V Q@%?UJG?:IJFHNYE,!^R>)H[:UV;E^4$<,1UZT
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MZGIS[444 11>&]&@>*2+3X5>*8W", <K(1M+?7 Q3)/"VARHL;Z; 529KA,
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M* &CPOHBI$BZ; %AB,$> 1L0G)4>@SS6A:VD%E"(;:)8XP2<*.I/4GU)HHH
'GHHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>formdrs_028.jpg
<TEXT>
begin 644 formdrs_028.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #H =T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\9P<^U-U3Q#IND:?>WD]PKK9IYDT<+!G4?[N?>@#4HI$8.BL.A&12T %%%%
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MB32+>T^.G@_4HWF,UZ+D2*\A*#9#@;1VZ\^M>IUYWXN_Y*]X!_[??_15>B4
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MB[_DKW@#_M]_]%5Z)7G?B[_DKW@#_M]_]%5Z)0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%11W5O-(T<<\3NOWE5P2/J* ):
M*** "L[7=<L/#FC7&JZE(T=I  9&5"Q&2 .!SU-9FO>/O"_AO*ZGK-M',/\
ME@C>9(?^ KDUYK\0_&FJ>+O ^I6FB^$=7.G2!=]]<Q^7D!@?D3DM0!N)\<O
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MPC'9!*<I?$[A1115$A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2C_A7GB/_HI&N?\ ?"5Z$QPI/H,UA^&M9N-7CN6N!&#&R[=@QP1GU/'Z^PH
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MX/AYXCP,_$?7,_[B4?\ "O/$?_11]=_[X2O0Z9*2L3LI4,%)!;H/K[4 >?\
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MLK08Q:PC!R/W8X/K4]% !1110 4$9&#THHH @6RM5(*VT((.X8C'!]:GHHH
M**** "H!96JG(MH0<[N(QU]:GHH **** "BBB@" V=J5*FVA(8[B"@Y/K4P
M50H  '  [4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &<=!TAKN>[.
MF6AN+A2LTIA4M(",$$XYR.*@'A;1DNK&>*QBB^PF4P1QJ%0&1=K$@=21Q110
M!H65A::;;"WLK:*WA!+;(E"C)ZGBK%%% !1110 4444 %%%% !1110 4444
;%%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>formdrs_029.jpg
<TEXT>
begin 644 formdrs_029.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Y =4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *YO[,3R0?:X/.C&Y
MX_,&Y1C.2.HXJ*#6-,NEMFM]0M95N@Q@*2JPE"_>*X/..^.E8,O@Z&UO=4U2
MUGGDN+JWN$$+!-N9,,0#C/W@.I]J\UT_X<^)[(V.GVT1BL)-&N&5F<9L[R:
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M:RGS()""C<*<'@\'D5T7_":Z#_S]3_\ @'-_\17044 <_P#\)KH/_/U/_P"
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MU!P1(O\ > Z\=_7- 'G"VTK-M",3G'3O6W::)J-C=0S7%O<0("&#A>17H_\
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M+$'!('R^G>NEM/$>E7TT<,-T?-E*[(Y(V1FRK," P'!"L<].#6K5&9PEK+K
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M#_DGG_;_ ''_ *'0!Z/7G'QM_P"1"B_["-M_Z'7H]><?&W_D0HO^PC;?^AT
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MKH*;)%'-&T<J*Z,,,K#((]Q0!\G!E_O#\ZG@MY;@D0HTA')VC.*^GO[&TO\
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M:W%[;0W$Q BBDE57<GCY03D_A5?_ (2'1?LLEU_:]A]GB?RY)?M";5;^Z3G
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M9]H$>.!@<\UZ-7%^(_AW:^(M:DOGU*ZMH+I(8]0M8E4K=+$^] 21E>>N.HH
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MQ-&4^TWNW[F?DB_WO4^PH R!S[TM23($2V;=N9X@TF1C#=_PJ,?6@#N_ _\
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M2=9S$BR$'=Y:[0Q]2.F:K]* .\\$G.F7'_7;^@KIZY?P.<Z7<?\ 7;^@KJ*
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MZ%H=GX>TM;"R$A3<TDDDK[Y)9&.6=V[L3U-:5 !1110 4444 %%%% !1110
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1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>formdrs_030.jpg
<TEXT>
begin 644 formdrs_030.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #W IP# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,].U._X3GPW_ -!1/^_;_P"%'*^P71T-%<]_PG/AO_H*)_W[?_"C_A.?#?\
MT%$_[]O_ (4<LNP71T-%<]_PG/AO_H*)_P!^W_PH_P"$Y\-_]!1/^_;_ .%'
M++L%T=#17/?\)SX;_P"@HG_?M_\ "C_A.?#?_043_OV_^%'++L%T=#17._\
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M?)JEC%J<&FO=1B]G1I(X,_.RKU./3WKG-%TB_ABU^>]T\E-0=9$LIKH2NS;
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M'#F"59 I]\'BK=<)\-=;&KQZK&=(TO39+:5$DCT]2!NP<ASM'S#&,=OQKNZ
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M(A..@\L ?G704 %%%% '%^(O^2H>"_\ <OO_ $4M=I7%^(O^2H>"_P#<OO\
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MF3[-]JABD2"$"*/:$?8RD@$GY@220#@CBO7%SM&[KCG% &3_ ,(WI_\ ?O\
M_P &$_\ \71_PC>G_P!^_P#_  83_P#Q=:]% &1_PC>G_P!^_P#_  83_P#Q
M='_"-Z?_ '[_ /\ !A/_ /%UKT4 <G:^'[%O$^IH7OL+;VY'^GSYY,G??[5J
M_P#"-Z?_ '[_ /\ !A/_ /%T6?\ R->J_P#7M;?SEK7H R/^$;T_^_?_ /@P
MG_\ BZ/^$;T_^_?_ /@PG_\ BZU)=_E/Y?W]IVY]>U<'X,$]C<"22UU&)7L[
M>&]\Z*0[[TLV]N>O7EQ\N,<\4 =1_P (WI_]^_\ _!A/_P#%T?\ "-Z?_?O_
M /P83_\ Q=<6B;K2Z@>WU273%UWS;E)(9RTEN8N#R-SKY@!(&>G3%6]#2XM-
M:\-_:H]3\XV,\4OF)*Z(I93$'/*AMH.2>>.: .I_X1O3_P"_?_\ @PG_ /BZ
M/^$;T_\ OW__ (,)_P#XNM>B@#DT\/V/_"631[[[:+&,_P#'_/G_ %C]]]:O
M_"-Z?_?O_P#P83__ !="?\CC-_UX1_\ HQZUZ ,C_A&]/_OW_P#X,)__ (NC
M_A&]/_OW_P#X,)__ (NM>B@#(_X1O3_[]_\ ^#"?_P"+H_X1O3_[]_\ ^#"?
M_P"+J^'O/MY0PP_8]F1+YIW[O3;MQCWS^%6* ,C_ (1O3_[]_P#^#"?_ .+H
M_P"$;T_^_?\ _@PG_P#BZUZ* .2D\/V/_"76\>^]VFPE/_'_ #Y_UD???FM;
M_A&]/_OW_P#X,)__ (NDD_Y'.V_[!\O_ *,CK8H R/\ A&]/_OW_ /X,)_\
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MQ.U*^\3:7IK65ILO%M2R*) X$MOYS.&/R87IM/)% '<?V[-_T =6_P"^(_\
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M '5O^^(__BZ72_$5KJ^K:EI]M'+FP*!IF V2$E@=O/."C ^XK7H Y&36IO\
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M01^A8 ?=;;\N1T&<=35O_A'V_P"@UJW_ ($#_P")H_X1]O\ H-:M_P"! _\
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MX)/WLX[UUG_"1VW_ #YZI_X+Y?\ XFC_ (2.V_Y\]4_\%\O_ ,30!L45C_\
M"1VW_/GJG_@OE_\ B:/^$CMO^?/5/_!?+_\ $T *G_(XS?\ 8/C_ /1CUKUR
M2:_;_P#"632?9-2Q]A08^PRY_P!8_;;6K_PD=M_SYZI_X+Y?_B: .;\7S7JZ
M^4BDO4F^SP'3%@+A'F\X^9NV\'Y=N=W&TGWJ/7K^>X\0EK::^$H%NNFK$)%1
MW$[+/N'W3\H&=W&WD>M=1_PD=M_SYZI_X+Y?_B:/^$CMO^?/5/\ P7R__$T
M<9;3ZK&NKV.E+<ZB\K O?PR2*\2M(VY0LS!0ZKTVD=B1P*GTVUN=4T_P>DB:
MG#?F&.:ZEDN) 5BBP2' ;:6=BHYY(+>E=9_PD=M_SYZI_P""^7_XFC_A([;_
M )\]4_\ !?+_ /$T <K\/[C4)M;U'[9)=.CQ;P)&D.P^:_$H;A9,$#"?+@?2
MO0JQ_P#A([;_ )\M4_\ !?+_ /$T?\)';?\ /GJG_@OE_P#B: "3_D<[;_L'
MS?\ HR.MBN1DU^W_ .$NMI/LFI8%A*,?89<_ZR/MMK6_X2.V_P"?/5/_  7R
M_P#Q- &Q7">.)KM-2"++?1_Z"QT\6Q<!KO>, [>"<8X;C!:NC_X2.V_Y\]4_
M\%\O_P 31_PD=M_SYZI_X+Y?_B: .=\6ZAJTU[IAT^WOGL;:\A\^2T(7S)?.
M561@2#L"[CT(.1S@4GA>:[D\2C?+>M<;+O\ M))B_EHPF AP#\H^7.-O5:Z/
M_A([;_GSU3_P7R__ !-'_"1VW_/GJG_@OE_^)H V**Q_^$CMO^?/5/\ P7R_
M_$T?\)';?\^>J?\ @OE_^)H 2]_Y&[2/^O:Z_G%6S7,C4XK_ ,8:6L<%W'LM
M;DGS[=X@>8NFX#-=-0 4444 %%%% !1110 4444 <7XB_P"2H>"_]R^_]%+7
M:5Q?B+_DJ'@O_<OO_12UVE !1110 4444 %%%% !1110 4444 %17-M#>6TM
MM<Q++#*I1T<9# ]0:EHH3L[H#B;.ZG\"WL>EZC*\OA^9MEE>N<FV8](I3_=_
MNM^!KL8YX9S(L<B2&-MCA3G:< X/X$?G46I6L=[IES;2VT5RDL;*89?NOQP#
M7EWA:PU_X;7%Q<ZW$)M&NR//DMG,OV9AT=@1G;C@GGH*]&-*&+A*=TJBZ?S>
MGGW[OS,FW!I6T_([:5)/"]R]Q C/H\K;IHE&3;,>KJ/[OJ.U=#')%<PJ\;+)
M%(N01R&!IMO<6]]:I/;RQSV\JY5T(96!K"DM;KPW*UQ81M/I;'=+:+RT/JT?
MJ/5?RKR&G1>VGY?\#\B-:6J^'\O^!^1R]]97'PY\0OK-A&\OAZ]<"^MD&?(;
MLZCV_4<>E>C6US!>6T5S;2K+!*H=)$.0P/<5##/9:QI^Z-H[FUF4J1U!'<$5
MQ<27/PZOV7]Y/X7N'SD?,UDY/_H!_P ^XFH:KX?R_P"!^1ZJ:Q<;KX__ $I?
M_)?GZ[]_13(9H[B%)H9%DC<!E=3D,#W!I];'$%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5BC_ )'9O^P</_1AK:K%'_([-_V#A_Z,- '.W/Q(
M%KXKO-%.FJX@DDB#I<@R%E@\[<8\9"8^7=GK5?3_ (I+?>(=.TH:6H-XML<+
M<@RKYT/F[MFWE%Z%LUUL7AO389M6F2-O-U5BURY//*!,*>PP!QZUE+\.]#2-
M!$;N.2,P&.9)L2(8HO*7!QW3@^M $6A_$&RU=M<:6W:U@TQ6F25G!%Q;@L/-
M4=AE&&/IZU5T;QY>W6L:7I6I:?;6EQ=V:7;-).8\APS!8U(.\J N[Y@<GI3K
MKX6Z&+..WTI/[/W0I:W+1C/VF .K,K^K';C<?[Q]:UM9\%Z?KM\MS>W5^5C&
M8H$GVQQ/L*;U&.&P3[9YQ0!AV/Q.AOM-O+M=,D0P7UO!'&THS+#/($CF'' .
M2<>W6NB\4>(9?#EG:W*:>]W'+=102,) @B#N%#'/)Y8< ?E64_PP\,B-DM+:
M6Q#111-]D?R]WEN'1SQRP(Z_6M/5O"=MK.CVNF7>H:D8K=U?S%GQ)(RD%2QQ
MS@@'\* (?$OBX:%IEY=VVGS7K64T<5PI/E*@?'S!F'S#YA]W/--\6>,H?"=U
MI*7%H\MO?3-'+,K8^SH,9<C'(&1GVJ?5O"-KK6GW%C>:AJ9@N'1W5;G'W5
M'' ) 8@=3S5B^\-:?J:V8O\ S;G[+#)"/-?/F+(FQ]_J2* ./NOBNMM)8_\
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M **** "BBB@ HHHH *RKW1Y+G4EO[?4;BSF$/DGRDC8,N<_Q*><UJT4 8_\
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MX:DU*6_.CV@FDMOLS*(E";,DY"XP&YZ]:N,9I:N_R..I3=_W<FEYV?Z(Y?\
MX7-HHX-MD^@NX3_[-7*ZOX^U'4-5:]T^[FAME.8H_,!V\8/*DCU]:]#/PO\
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M=.M/*BG/[P&1F+#&T#+$G ' '85>T^PMM+TZWL+./RK:WC6*),D[5 P!D\T
M6:*** "BBB@#BM3\:W5CXUCTB.RA>Q2XMK6>5G(D\R<.5*CIM&T9SZ^U:?C'
MQ!>^'-)BO++3Q=;IXXY&>0*L2LX7<>Y/. !5NY\,:1=Z[#K4]F&OX0-DF]@,
MC.TE<X)&YL$C(S4L^@Z?=6$]E/"TEO//]HD1Y6.7W!\@YR!D X'% &E1110
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M1110 4444 %%%% !1110 4444 %%%% !534M2M-(LGO+V7RX5(7A2Q9B<!5
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>formdrs_031.jpg
<TEXT>
begin 644 formdrs_031.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "G D # 2(  A$! Q$!_\0
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **,T4
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M]0\2M=QW,*07XCAM[D /"OEJ<8'OS^- '94444 %%%% !1110 4444 %%%%
M!1110 4444 %%,\Z(/L\Q-W]W<,T2%A&QC 9P#M!. 30 ^BN6\)>(=6\02Z@
MUY8VMK!:7+VO[N4NSNO4]!@5U- !117'^--9U*S\NST^&[ ,9GGGMPN50'&
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MQ#\-1>'39VCSW-\+B5Q:6MLS2/N<D$ #'3')Q0!UGQ%FBC\&70DD1"TD6 S
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M=XR3]T^8HS^M=H.E<+\3M/BE\*03.TV^TNH"FR0@',BCYAT/XUW0Z4 %%%%
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MXF@!EZ]Q'93O:"-KA4)C$I(4GWQSBN3LO'(A\&6>LZU%$EY>DBWLK,EWF;.
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M..M?0O\ PC_C#_H<QC_L'1_XUF1^"/$L>O2:@OB"P65HP/M2Z7'YQ;N"?3%
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MO$WPDL=9T"YLK34]2BN' ,;3W;R)D=F4GD5=@^%^D)>7,LM[JDL,A7RH3>R
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MP50LJ\\#<1BNBT6ZGO=#L+JZ39/-;I)(N,88@$U;EACG7;+&LBYSM=01^M/
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J?R0MI\42,L<8S(4R>6]"2200?;%%% ';T444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>formdrs_032.jpg
<TEXT>
begin 644 formdrs_032.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "Y Q,# 2(  A$! Q$!_\0
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MM0&+XPZ<;D'KYGV8;L^^:Q/B3=Z)J&M69U2ZMIM'72]0$;&4&,7:A0 "#CS
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MK PJ5<2.<L7^]N! QCCZUV?PMN]9U?PK%K6KZS)?O>%MD1BC180KLO!4 DG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K)UO1?[9?2V^T&'[#
M?1WGW-V_:&&WKQG=U]JUJ9)+'%L\R1$WL%7<P&YCT ]Z .9T/P5;Z/J$\YG$
M]N8IH(+=H@ D<LIE<,<G=\Q]!P*V=1T?3-1C4WNGVMSY2D1^;$&VCVSTZ"IY
M-0LXDN'>ZA"VPS.=X_=\9^;TIT=Q#=V0N+>19(I$W(Z]",4 <U\,69_AGX>9
MF+,;-,DG)-=97)?"_P#Y)CX=_P"O-*ZV@ HHHH **** "BBB@ HHHH ****
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M:#R6EG>9D\[S<$]\X &<9P!CF@#6HHHH **** "BBB@ HHHH **** "BBB@
MHHHH SM?TZ'5M!O;*>#STEA8>42?F.,@?GBO-[#PUK,4/AV*33Y@XT_2HBY
MQ;-!(6E#'.1P>W4G%>LT4 8D^BW\6FWL6DZJ+2]NKIK@W4UN)MN2/EVY&<*
MHY[5G>#+_69[W7]-UJ_BOIM-NTA2>.W$(96B1_N@GNV.M=97(>$_^1M\;?\
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MA<:C?K'#?NB1I<$* #D<>QKH/A]Y\'BG5[1[V[N8H[:)E^T3%\$DYZUE0?\
M(P^(_P#L)/6OX&_Y'?6_^O2#^M>%/^&>G0;^LKU?ZGHU%%%<1[@4444 %8_B
M7Q)9>%-';4]02=X!(D>($#,2QP.,BMBO/OC-_P B ?\ K]M__1@JX)2DDQHY
MC3_$WAG0O$NIZZ_AK5H( B- _P!EYB.&\TD%\#.17>>,;R/4/AK>WL(817%H
MDJ;A@[6*D9]^:\R\4?\ (L:M_P!>[UZ!J_\ R1A/^P7!_P"@I7H*FH5Z37=?
MFB,0K4Y>C_(X^X_X]YO]QOY5T^EW<]C\$(KJUE:*>*P9DD7JIW'FN8N/^/>;
M_<;^5=#:_P#)!?\ N'M_Z$:]',_X$?\ $OR9\GD+LJOH9=O_ &E.+>\?7M3\
M]H0-XD7(#8) ^7ID#\J[[P7=7%[X1L+B[G>>=@^Z1SRV'8#/X"N&L?\ CRM?
M^N2?R%=GX"_Y$K3OI)_Z,:O%KI<IZ^7RDZCN^ATE%%%<IZX4444 %%%% !11
M7!^/O$^IZ%JFEVUC=V]K%<QRM))-$' *XQU(]:WP^'EB*BIPW_R,JU6-&#G+
M9'>45XW/X^UZ*WDD37].=D4L$%LN6/I]ZO4O#]Y-J/AS3;VX*F>>VCDD*C +
M%03Q6V*P%7#14YVLW;^M$8X;&TL3?V=].ZL:5& .@KADU[4=/NS/J=TR1O\
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M%Q[#C\* -VBBB@ HHKS/7[S6],UJ:RB\3Z[<R[?/,-AHD<X@1F.T$X]B!]*
M/3*Y?Q5JFL:9JWA];)[9+"ZU".VN2REI6W!CA>P'')Z]*Z.V+-:PEBQ8H"2Z
M[6)QW'8^U1WFGVE^;<W4"RFVF6>'=_!(,@,/?DT <#H_B?6-:>]A>:5%N[.[
MG@6"$&6W,5RT "#C<2 #SWK9/BA-!T'3UUFTU,W,\3<0VDMPP . 7*@[200<
M$^H[5OV6B:;IU[<WEI9QQ7%R<RNN<MR2?IR2<#N<U=DXB?Z&@#BO &HVFD_"
M+0[Z_N$M[6&Q1I)7/"C..?SK+_X3_P (?\)\;_\ MVR^S?V9Y7F[N-_FYQTZ
MXYK+F_Y-AC_[!<?_ *&*R[;3; VD!-C:DF)23Y*^@]JZ\/151-ME15SV>VU:
MPN])75;>ZCDL&C,HG4_*4'4_3@UP.J:YX1O?%%A=C608&61KDI=2JFY0OE\
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M-97P_M;JRUOQ?;WNH2:A<)J,6^ZDC6-I/]'B/*J !@<<>E ' ^'?^0!:_P#
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M_ :E'A6W6,P"\NOL@F\Z*WRNV-M^\XXR1GU/ -7H==TNX5VBOX&"!F;#= I
M)/XD?F/6FOKVF+/) MY$\T<BQNBN,J2<?H>#0 FGZ);:;,LD3R,5M(K3#D$;
M$+$'Z_,:@TSPY#I4HD@N9V*1K!"),'RH0V?+''3MD\X ]*NZ?J^G:J'-A>0W
M 3&[RVS@'H?H?7VIFG:U9ZK<7L-H[N;.412L5(!8J&XSU'/6@"2WTZ*VU*\O
MD9S)=B,.">!L! Q^=8Z^#;1;GS3=W3(N?*B++MC!F68@<9/S*.O;BK^F>(+3
M5;DPP).N4,D3R)A9D#;2R^V?7'4'O2:AXDTO3K%KR6X#Q@%L1#<Q4.$) [@,
MP!H ;IOARSTNZ6X@>8LIFQO;/$C!L?0;0!Z 8K8K/76;-]:72D9FN6M_M/"_
M*$S@<^I]*T* "BBB@ KQ_6-7NM=T'4]8O/$.BK%:2W#P:%<P1.K"%F4!F)WA
MVV]1C&[BO8*\6U+3[.6RUCQ MUOT^UOGBEE7P];2<!L.X)Y9$.06Z\&@#UK1
MX;5--BFM+9+=;H?:711U=_F)/J<GK5^H;3;]C@V.LB>6NUU  88Z@"N4\;6,
MDNK>%KR.6Z/E:M$C0QL?+VD-EF4=2, 9/3)]: .ODD2*-I)'5$099F. H]2:
M9YB2VQDC=71DRK*<@C'4&O,_"5EJ4NLZA'+$/M+VUTM]]H1C$\YNF,._U_==
M,?PX]JZ233_%6DZ'IUAH3:*ZP0E)S?>:/IMV=>,Y)H XV;_DV&/_ +!<?_H8
MJI:_\>=O_P!<D_\ 015R;_DV&/\ [!<?_H8JG:_\>=O_ -<D_P#017HX/X6:
M0.M\+?\ )$H?^P7-_)JXG1_^0-8_]<5_E7;>%O\ DB4/_8+F_DU<3H__ "!K
M'_KBO\J]'+/X=3_%^C/E>)-H?,]$^'?_ "*<O_7Y<?\ H9KAO#'_ " (/]Y_
M_0C7<_#O_D4Y?^ORX_\ 0S7#>&/^0!!_O/\ ^A&N"M_O-7U.FO\ P*/I^B.V
M\ ?\QS_K^'_HI*[*N-\ ?\QS_K^'_HI*[*N"K\;/4PG\"/\ 7<****S.D***
M* .!^,G_ "3:\_Z[V_\ Z-6N3N_^/*X_ZXO_ .@FNL^,G_)-KS_KO;_^C5KD
M[O\ X\KC_KB__H)KTL'\#-(;'63_ /)"HO\ L"1?^BUKD;+_ (\[;_KFG\A7
M73_\D*B_[ D7_HM:Y&R_X\[;_KFG\A7HY9_ E_B?Y'R7$GQ0^9U/P_\ ^2:Z
MA_UUNOZUSWAW_D7+#_KD/YFNA^'_ /R374/^NMU_6N>\._\ (N6'_7(?S-<6
M)_WJKZG9B/X5+T.I^&OWO$/_ &$#_P"@BN[KA/AK][Q#_P!A _\ H(KNZ\VK
M\;/4P?\  B%%%%9G2%%%% !1110!7O[./4+">SE++',A1BO4 ^E<R/A]IZ@
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M#O\ R +7_@?_ *&U=7\(O^/CQ9_V$_\ V05Z>)_A?<:2V.5T7_CTG_Z^IO\
MT,UW7PX_X^M>_P"NT/\ Z+KA=%_X])_^OJ;_ -#-=U\./^/K7O\ KM#_ .BZ
M]?,_X%3Y?FCXS*_^1E+_ +>.?@_Y&'Q'_P!A)ZU_ W_([ZW_ ->D']:R(/\
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M.!)LW*KXW%0?XB*]LJGIVEV>E68M;.$)"'>3;G/S.Q9CS[L: )[;R?LL/V<
M0[!Y>.FW''Z5+17-^)->U'1]4T.WMK**2TOKU+:>XD?[FX' 51R2<'GH,=Z
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MR!%BG*@94=JRCB;TU/EW=MSTJ.5*I7G2<[**3O9];=+^9Z=;-XESJ/VJ/20
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M[&I9*]_^ ?19/@UB</=RM:W2^[?^1Z1;GQ!]OOOM*:8+/:?L9C>3S">WF9&
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MW>JKJMO!'I<;V3J#+<FZ ,9YX"8^;MSD=:9#>ZR\E\)='BC6($VK"[#>>><
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M=S[UWM%;GD'+^%()XIY2L%Y!9_98%*7.[F<!MY4,20,;0>Q(KJ*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N=\3Z'+JMYH=S;0PF
M:RU&*>61L!A$H;< >O4CBNBHH X;PIX2U#2-7D>\*&V@M[FVBD$FYIA-<M-N
MQCY< A<>M:FH>%'ETZQM-/U[5M*@L8/*1;.1/G4  ;BZMD@#VZUTI.!DTR0@
MPL0<C:: /))O^388_P#L%Q_^ABJ=K_QYV_\ UR3_ -!%6YO^388_^P7'_P"A
MBJEK_P >=O\ ]<D_]!%>C@_A9I ZWPM_R1*'_L%S?R:N)T?_ ) UC_UQ7^5=
MMX6_Y(E#_P!@N;^35Q.C_P#(&L?^N*_RKT<L_AU/\7Z,^5XDVA\ST3X=_P#(
MIR_]?EQ_Z&:X;PQ_R (/]Y__ $(UW/P[_P"13E_Z_+C_ -#-<-X8_P"0!!_O
M/_Z$:X*W^\U?4Z:_\"CZ?HCMO '_ #'/^OX?^BDK!M?^/O4_^OZ7^=;W@#_F
M.?\ 7\/_ $4E8-K_ ,?>I_\ 7]+_ #KY[-/XD?G^2/K>'O\ =Y>B_-G0>$/^
M0QJG_7*'_P!GKD+W_D=O$?\ UWC_ /0*Z_PA_P AC5/^N4/_ +/7(7O_ ".W
MB/\ Z[Q_^@5C#^#'U?ZGN83_ 'JM_@C^:-?P=_R/!_[!K_\ HU*](KS?P=_R
M/!_[!K_^C4KTBNW#_!\SR<Y_WA?X8_J<#\9/^2;7G_7>W_\ 1JUR=W_QY7'_
M %Q?_P!!-=9\9/\ DFUY_P!=[?\ ]&K7)W?_ !Y7'_7%_P#T$U[.#^!GFPV.
MLG_Y(5%_V!(O_1:UR-E_QYVW_7-/Y"NNG_Y(5%_V!(O_ $6M<C9?\>=M_P!<
MT_D*]'+/X$O\3_(^2XD^*'S.I^'_ /R374/^NMU_6N>\._\ (N6'_7(?S-=#
M\/\ _DFNH?\ 76Z_K7/>'?\ D7+#_KD/YFN+$_[U5]3LQ'\*EZ'4_#7[WB'_
M +"!_P#016+I/_'F_P#UWD_]"-;7PU^]XA_["!_]!%8ND_\ 'F__ %WD_P#0
MC7S>:?Q8_/\ 0^NX>_W27_;OYR-[P9_R,&L?]<X?Y&L#5/\ D;=>_P"OB/\
M]%)6_P"#/^1@UC_KG#_(U@:I_P C;KW_ %\1_P#HI*QH_P "/J_U/:H?[Y5_
MP1_0D\'?\E(?_L%G_P!&+7J5>6^#O^2D/_V"S_Z,6O4J[,-\#]6>;GG^\1_P
M1_4****Z#Q@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** *>K62:AI-U:O#'+YD3!4D *EL<=??%>?67@K6H(=#@>./:ECIL%
MRWFC]PULY=L#^+/08[UZ;10!BW?AU9X-06TU*^T^:^G6>2>V90ZE55<+N4@
MA1GCUKG_  !92:?KGB^TEOKF^>/48@;BZ*F1_P#1XCSM ''3IT%=R"#G!!QP
M:Y'PG_R-OC;_ +",/_I-%0!YMX=_Y %K_P #_P#0VKJ_A%_Q\>+/^PG_ .R"
MN4\._P#( M?^!_\ H;5U?PB_X^/%G_83_P#9!7IXG^%]QI+8Y71?^/2?_KZF
M_P#0S7=?#C_CZU[_ *[0_P#HNN%T7_CTG_Z^IO\ T,UW7PX_X^M>_P"NT/\
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M;< ;_P >U>G45S0PU.#O%'H3QM>:Y9/K?;JCQ/3]$\<6.GPVI\'%S&N-PU.
M9YSZUT'AJY\:Z!97-N_@628S73S@KJMN,!@..OM7IE%7&E"+ND77S#$5XN-2
M5T]7HO4@LI9Y[&":ZMC:W#QJTD!</Y;$<KN'!QTR*GHHK0X@HHHH **** "B
=BB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>formdrs_033.jpg
<TEXT>
begin 644 formdrs_033.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #* 7,# 2(  A$! Q$!_\0
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M92&Q^.,5\K3SO'(R2 HZG#*1@@U]9:!XBC\0->M;VTBVUO+Y4<Y.5F]QZ?\
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M*M]1LWW0SH& [J>X/N*^IP.*]O3UW6YPS24M"]1117<0%%%% !1110 4444
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M_P"R&KB+C]S$L\;MNSY",.IB_P"6C?CRWX"O"S!NHO91?G_D34Q$:;LRY;W
MAGO)E0?O0&MU'<9VX'U;#?C2*/LVE75I_K)=[(@)^^SC</U)/T%).1_:5J4
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MK20FWE("K'*0KGIEMBL,$=1P1C(!6@G\>7>E6-S:FX"RJCL9TA\WS"BDD@$
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M7;0?;%EECB$:A%$SJ%&.2A0H3DD\9Z\57M_'6M7UXUM!I,$+O)'&GG%B8MS
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M=6U/1I48XVFXSE:<5H^K71>JM9/>SMV//P)9K7SY<[K9LJAZY7JQ]R.W;-2
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MMD8.?8<?E6M'96Z>'(M;B8EVD%NT,:C!8^I^OKZUEQ0Y6\69E#G)SGY45AG
M]LYJ<KPN'CSNC+F:;BV]+-6=OQ6IW\09[C,V4(XB*A!:I+6][J[?]6]62?\
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M*><L9 =% !W8P!@Y'(ST/M]T^M2QW,3#YO+7=\Q(C7(/]Y5X(]Q6=+"\;89
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M99#<%F!#>8K.S-DX* ]R, =.*@BE\#P:M)>)) MPRB[,QD?;\TAY&3C.\,2
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ME:EI]O=+C \V,$K]#U'X4W2M!TG0X?*TO3K:T7&#Y,84M]3U/XUHT4[NUKZ
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>'=\O .W('R#ICC(KI*** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>formdrs_034.jpg
<TEXT>
begin 644 formdrs_034.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #J S # 2(  A$! Q$!_\0
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MZQK^GSW,ESJ@M(YU=$63>S?= Z!-N,=ZZO6OB/;:-K&OZ>^G32MH^GK?.ZR
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M9B3_  C'3_>KW*QLH=.T^VL;9 D%O$L4:CLJC _E5C SG'-% !1110 4444
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M'K[5Z910!Y1)\([Z?09I9=:C/B:755U;[8(<0B5<X3;UV\G_  J76OA_XO\
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M;HR2&*)9F<B,D@1'#G'XC'KD59TK6K;5_.6**YADA(WQ7,)C< \JV#V.#^5
M&C1110 4444 %%%9EUJ$L/B'3]/54,5S#-(Y/4%-F,?]]&@#3HKF%\7)!=75
MM<VUS-.MU+%!%9V[2,T<83+''3[XKH+.\@O[.&[MI/,@E4,C8QD?0]* )Z**
M* "BBB@ HHHH **** "BBB@ HHHH **HRWTD>HBW\K]WC.><G@G([8& /QJS
M;W,-U'OA<, <$="I]".H/UI71;IR2NR6BH;BZAM45I9$4NP5 S %V/0#U-5]
M/N9KO=)(-@7C:!P3C/<9R.E%^@E%M.78O4444R0HHHH **** "BBB@ HHHH
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MW&%., 8P,5T.GV,.F6$-G;[O*B7:"YRQ]23ZDY-<9_PAFF?\^6O_ /@WF_\
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MI[^YIA)QU/YT]_\ 5Q?[I_F:8>E04=!&3Y4?)^XO\JEA)\Y.3]X5#'_JH_\
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M>9O6L!MK2& RO*8T">9)]YL#&3[U-115EA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 9.KK*+NSF2"694W[A&,GD8KS[_A6.A9_X]=>_P"^T_\
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M7(BFKMR_JP4445H:A1110 4444 %%%% &=K>GRZEIC00.B3+(DL9D!VED8,
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M F"L/,0,0K<JI/RXYP,]>]=%110 4444 %%%% !1110 4444 %%%% !1110
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MKD=%UR*+4KJW;5I=1LQ#'*DVT2[&)8$%HUQC@=?>NCBU6PF.([R GTW@'\J
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MY)/F-A#^7?ZU8^&GAT&,Z[=1\L"ELK#MT+_CT'XUSGB-X](U_4[&U3;#*X(
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MQ@8%%?(&H4444 %%%% !63:>&-#L+TWMKI=M%<[F;S G(9N21Z$Y/(]:UJ*
M,JY\-:)>06\%QI=K+%;AEA1XP0@;J!['TK+D\%6\_B*+4[B2!XX)4EAC6U59
M%*#"*9 >57J.,]LXXKJ:* (;BUM[L1BXA201R+*@89VNO((]Q67KMA<WDD!@
MCWA0<_,!Z5M5Q_C7QC<^%I[..WM(IQ<*Y)D8C&,>GUIJ?(^8:INH^5!_8FH_
M\\!_WV*V;>RN([:)&CPRH 1D5YY_PMS4?^@5:_\ ?QJZ%/'=VUK:S&RAS- L
MI&\\$]JTC.6(?+$)TGAUS2.F^R3_ -S]17,'P_JF3_HPZ_WU_P :7_A.KO\
MY\H?^^S5W_A+;C_GUB_[Z-9UJ3IVYRJ-5SOR%!_#VJ&WN%%L-SP2(HWKR2I
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MS:RQ3Q6RJ\;K@J<G@BMI;>;</W3=?2O5I_ O0^?JZU)>K_,Y=OOM]35S2O\
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MS?T36[-GFMW,D4DD\DJ+*A4LK,2" >U=$"",@@@]Q7'M9VSVRV[0H8E^ZO\
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MHMI9(3$KQG.SC%:JE&"Y8K_@FT:$:<>2"T_/YGBEY"EMJ$L@>8V*S&(SA-V
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M- H*J(M\9.UL\D\C(QC XH LT5%&)Q+*9'0QDCRPJD%1CG)SSS]*EH ****
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MZ-X9OKQHFGN+5I&:'[ISM((],C'':HG@,*DVJ:^XVHU:DYI.3-#_ (3[0_\
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M3'-=R222+G!8\G/7.. /85MB&,2F4(N\]6QS3Z%374%32W#H****T- HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>formdrs_035.jpg
<TEXT>
begin 644 formdrs_035.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #K ;$# 2(  A$! Q$!_\0
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M,( B/_ 0 !2V/AO1=-U.?4K'2[:WO9]WFS1)@MDY;V&2,G'6M_RU]*/+7TH
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M<DCL,D# )P,D9QS6A5_R4]!^0H\E/0?D* *%%7_)3T'Y"CR4]!^0H H45?\
M)3T'Y"CR4]!^0H H5Y)XVT2RT3XDP>,M9TRYU+0G@43+ N\6]P@PCNG\2XZ9
MXR?P/M7DIZ#\A1Y2<\#G@\"@#Y?\0^---\8V%_JNKW+W%ZT;0:-HD$;LEL7^
M7S96QAI,9(Z]![ =SI7Q.OO"L6D>';CP1JFZ*R0*BS*]P41<,YB R!P3R16K
M\:(9].\/Z+?:;;6X6UU>&:3>@$8.&",^!]T,1^==7X+\&0^&8)[R[N#J&NWQ
M\R^U"0?-(W]U?1!V'_U@ #HK&[34+"WO(XY8TGC614F0HZ@C.&4\@^U6***
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M!*-G!]#Z5)YT7G>3YB>:5W;-PW8]<>E%@N/HHJ*:YAM_+\Z14\QQ&FX_>8]
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MJMS=W#Z?9>='%N+V[1\QHO&_<#@Y.< 9X^E=/"UGX@TNWNUC5LC?'O!_=O\
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M11%XCTF<6QBUFSD%TQ2WVW"GS6!P0O/)S0!T&]?[P_.FO*B(6)! ]*I>8_\
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M 6KK*NUCGO<R?$F?['<CL<_H:\-6:SN4M9;K49B;RX\VYB 954 $JN0,G&%
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MF2-5DE"[0[  %L=LGG% $^]_[S?G1O?^\WYTVB@!V]_[S?G1O?\ O-^=-HH
M1[E8V17G",YPH9\%C[5@:/';1^,/$*PV\<<D0MSO48/[Q"S?F1FD\10VQU/1
M3/YF^YNQ:KM8 #Y6?/\ XYC\:AT23=X_\7K_ '18_P#HIJR@YN<E.-DMO/\
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M\0:ZL9/#L^NS^(-0'C 7ORQ9(^7(YSCCOW[8Q7U6JA4"CH!CFLIO"^@OJ?\
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MA_2_['TE;5HXHW:629Q%*\BEG8L3N?YB3G)]ZZ/R4_NC\J/)3^Z/RH JV_\
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M#+D,"2.H/TKN**T^LU>5P;NF9^QA?F2"BBBN<U"BBB@ HHHH **** "BBB@
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434J1Y9!1115G.%%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>formdrs_036.jpg
<TEXT>
begin 644 formdrs_036.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #( ?\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ\VANIK51-8V4EHSQ;P(&4?.A^8%,X(/3'M78Z#K]OK44@1@)XL;P. P(!#
M=<<]#R#Q6>!S.GBWRVY9=G^C0YTI0U9L4445Z9F%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%,EE2"%Y96"QHI9
MF/0 =30 ^BJ]C?6VI64-Y9RB6WF7=&XZ$58H:L 4444 %%%% !1110 4444
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M'J==%+'/$DL3J\;J&5E.00>A%/IL<:11K'&H5$ 55'0 =J=6904444 %%%%
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MY.$$H*!_H3Q^%=-5--;DQG&2O%W"BBBD4%%%% !1110 4444 %%%% !1110
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M[I/_ (!Q_P"%'_"&>%_^A=TG_P  X_\ "MRBH&8?_"&>%_\ H7=)_P# ./\
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M@%%%%2 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,#TI,#T
F%%% "X'I4!LK=KY;TQ@W"H8U<D\*3DX'3\:**!IM;$]%%% C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>formdrs_037.jpg
<TEXT>
begin 644 formdrs_037.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "7 =T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "D8[5)P3@9P*6D90ZE6&5(P0>XH P[#Q597<3R3J;7:3@2,"
M> 6(('*L #E3SZ9IMUXOTNWB+H9IL;LA(6'"ACGD#CY6&?44RZT'3()K",F4
M>9=1E=[-(6,:LR)N8G:HP?Y=ZAU!?"]JNVXD7="?**1RL6!P[;2 ?=^M:6BV
M3=EVX\6Z/;QNQN69UC9_*$;;_EW97!'#?*W!YX-6K36[.\G6"-V\YBWRA&(7
M!(^8XP"=IX//%8\D/A2<&^,L+FY60_),<R9W%N >3\S8^OTK5L-(T^-H;VU2
M52R[QF5L/G)RPS@GYCU]:344@5S4HHHJ"@HHHH ***1F5%+,0% R23P!0 M%
M4-+UO2]:25M-OH+H1-M?RGSM/;\#V/>K]#5MP3OL%%-DD2&-Y)'5(T!9F8X"
M@=23Z53TO6M-UJ%YM,O8;J-&VL8FSM/O18+EZBBH[BXAM;>2XN)4BAC4L\CM
MA5 ZDF@"2BJ>FZM8:Q:_:=.NXKF'<5+1MG!]#Z&KE&P)W"BBB@ HHHH ****
M "BBB@ HHHH **** "BBO+O$GQ4N].\07%AI>GVTT%I(8I7G=@9''W@N/N@'
MC)SR#QZZ4J4ZLN6"NS.K6A2CS3=D>HT50T35H-=T6TU2V#+%<QAPK=5/0J?<
M$$?A5^L]C1.X445SEGX]\,ZAK/\ 9-KJL<EV6*(-K!'8=E<C:Q^AI-I;E1A*
M5VE>QT=%%%,D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "H;JZALK9[BXD$<2#+,>U355U&T^W:?-;&01B1<;F0.!]0>"/6A 5)Q
M::S#:R17LD#12M)$R *X90RL"KCL&.016:_AC1_W\QO)?WY=RR.I)^\7Q@9.
M=S9ZX[8JD_A2QD:)GUI6**RD;OE4$L0$!;Y0-W0YXJ27POIS3AX=4A@4!EVH
MJ\!D"X'. .,]._:M4K;,BY.WA_1-4NFE2]F;8VYE20;0P^7TX(V\]ZW;*ZLC
M$+:WN%;[.BAE)^91C )_*N=_X1K33OSJD8#2!ALVJ=NYRZGGG<'92?3%'_"*
MQR3PM;7,<D)G5IV7 .P;BR<=0V5&.,8S0U?=@O(ZZBBBLBPHHHH *P/&=YIM
MOX8O;?4K\6:7<+P(X4LQ)4CY5'+?05OUXI\8M3W>);&T0%_(A52/0R-S^B*:
MWPU+VM51;L<^*J^RI.25V/\ A5?Z;9:Y<F\OA!<W"BW@B96"R?-G.XC&>  #
MSR?6O:*^4Y)I(I81&#N<D!O[I R#^8%?4>G7BZAIEI>I]VXA24?1@#_6NK,J
M/)4YKWO_ %^1R996YZ7):UOZ_,P?'UYIL/A6\L]0U!;1KN,QQ?*79F'.-HY(
MZ9]C7!_"6_TZTU&[6ZOO(O;L+##;NI <*2<[B,$G/ Z]?7C.^+>I&3QG%;*"
MRP11PX]"V7)_(I7$_:Y+2\MVC4E@QD5AV9,,/U%=&'PO-A7[V^MOR,,1B^7%
MKW;\NE]?F?55<;\2;S35\+3Z?>:@+:XN-KP(%+LY1@V"J\[21@GH,UUMM<)=
M6L-Q&<QRHKJ?8C(KP7XFZD;GQ[/$ 66(); ]E"IO/ZN17!@Z7M*R3=K:_P!?
M,]#&U?946TKWT_KY'3_"+4-.MQ=V\UZ(]1O&7;:NI'" ]&/#,<G@=@*]8KY<
ML=1;3=;LK@ @0R+<;O38RG'XC-?42D,H93D$9!%:YC2Y*M[WO^9CEM;VE'EM
M:WY?U<6BJ6J7$]M:H]NF^0S1IM]06 (]N#UK$;Q%>6PN3/ @*,^ [850"_&0
M.20H KDC2E)71W.:6YU%%<_#KETEG>37$"'RHWFC(8C*AV4!N..@Z9II\0W6
M"?LT"QJ=IF:1MA.6Y!V_=.S&?4BG[&8O:1.BHKEQXFN8XIFDMT+;CL4D@QC(
MP'XXZ\'O@TU/$=Y*DF(ERQW)MY:,84X88_VN#WQ3^KS%[6)U5%<RGB"\A+O+
M )(P%  !#[BS*.W3<%'MNKI5SM&X -CG%1.FX;E1DI;"T445!04444 17-S!
M9VTES<S1PP1J6>21@JJ!W)/2OG;Q;/I-SXGN+K1+R2>TNYC+([6S@1.>6*YQ
MO!.3VZ]:] ^,M\5T[2M.#86:=YY%_O+&N!GVW.I^HKR1'65%D1@RL,@CN*]C
M+<,Y+VJE;II_P3QLSQ2B_9.*?76_Z'T#X$U'09O#MMIVB7_V@6<8619%*2@G
MDLR'D9.3Z>E;:ZQIC:B=.74+0WPZVPF7S!_P'.:^?/!^HO9^+[&6UD43&1K0
MGWD0JH/MO,9_"ND_<?V!'';X^VX A3CSOM?;W\SS.O?KGBN#%T/85.6]^IWX
M.O[>ES6M;0]>UJUGOM"U"TMGV3SVTD4;YQM9E(!_,U\VZ1H.K7?B.VTF"QN(
M+Z*9"ZM&1]GVL#O)Z #&0>^!C-=Y\5/%FJ1:LF@6EW);01VZ27+0,5:1VS\N
MX<A0 #@==W->7*BI()$RD@.1(I(8'UR.<UXF*K4_:).]XGW^09;C?JE2I3<5
M&HK:IM]5?3Y[W[GUK17D_P .OB)$MG=:?XFUF%7@*&VFNG =T;(()/7:0.3S
M\PS7JR.LB*Z,&1AE64Y!'J*]"$U.*DMF?(XK#SPU:5"I\479CJ***HP"BBB@
M HHHH ***YOQ)K;:+K.@EI"MM<SO#,.V" %)^A(_6JC%R=D)NRNSI****D9S
M7CK7W\/>&9;BW<+=RL(H#@'#'J<'T -:7A[5DUS0++45(S-&"X'9QPP_,&N)
M\=@:N=2<G-OI:Q6\?H9Y'4N?P3:/^!&M/P.?[-:+3>D%[917]OZ!BJK*H_':
MW_ C72Z:]C?J9*3Y_([:BB@D $DX ZDUS&H45S?A#6I->AU2\9RT(OG2 'M&
M%7;^?7\:Z2JE%Q=F).ZN@HHHJ1A1110 57OQG3KD?],G_D:>]S#'G=(N1V!S
M61K6N16VG2>7$93("GWMH&0>:(R7,D2VK'BK0G<>O6D\D^]6FDRQ_=]_6D\S
M_8_6OI?:,\OE16\D^]>R^#;'^SO#UI$1AI4,SG'4MC'Z8KRBV'G7,<8C)W,!
M][%>EVOBD_:8XEL B$K&,39V@D <8^E<&.E*45%(Z<-%)MLZZBLXW\F> ,?2
MFM?2GH<?E_A7F<C.OF1IT5DF[F(^]3#<2D_?/YT_9L.8V:\P^(?A2!%U;Q*]
MX7=TA1+<J,(V^-"<YY^4'C'<UVAD9NI_2N9\?LQ\%7HW'&^+C/\ TT6MJ"<:
MBL^J_-&&(M*G*ZZ/\F><>%-#BUK74TV>X"_:+-I$D5,^6VU''&><'CMGVKW3
M1K6#1-$L]-6=I5MHA&'9<%L>W;Z5XM\/_P#D=+'_ *\6_P#12U[!6V+<IR7,
M^B_4QP<(P@^5=7^AY_\ $+PS:6L>I^(?M;S2W4\*I$RC]T2R@\YYX08X&.>M
M<GX2T6'7-8FTRXG,9>R\V.94^X_[IQQGD<D'D9]J[_XD_P#(G/\ ]?4/_H5<
MC\.O^1T'_8/_ /9(:UI3FJ#L_P"ERV^XQJTH/$*Z_I\U_O/8-,,>E:39Z?&S
M3+;0I"'<\L% &3Q[5Y5X^\/1:5!>ZR+AIY+Z^#(C)CR@5D9AG//./3@"O4*X
M?XJ?\BM!_P!?8_\ 1<E88;W:JMU:_,Z<2DZ,K]$_R..\+>'1K]]J.ES7(BDC
MA5UG6+."' /RD]PQ'6O?[&$6UA;0!F<11*@9NIP,9/O7CGPW_P"1PU7_ *]O
M_9UKV>+_ %*?[HJ<7.4I*[[?DAX2$8Q]U=_S9!?7@L8!(4+LSJBKD#))P,D]
M!61_:2:G:3SSV*30)-$D$1(W%F"]3G'5_P O6M^2..:,QRHKHW56&0?PI!%&
M!@1J!D'&.XZ?R%<\912VU.EIMG/_ /"36ES$$DLY/*D<(=^ NT]S_A^M2CQ/
M$4!-JX.WS"/,7_5^O7[W^SUK8^QVN<_9H<[]^=@^]Z_7WID.G6<$"0QVT0C1
MMR@J#AO7Z^]5S4NWXDVGW,IO$T:;"]I(H=A@EUP$)(W'TY4\5=TK5XM5,WEQ
M21B,C!<?>!S@_H:N-:V[[=T$3;2"N4!P1T_F:='#%$7,<:(7.YBJ@;CZGUJ9
M2@UHM1I2OJQ)(8IBAD16V,'7(Z$=ZDHHK,L**** "BBB@#P_XJ2OJOC>/38B
M28[>*U4#M)*QS^A2N#M8A#:PQ*<JB!03Z#BO8?'>C6-UXPTZY5);>[C@,[SP
MRLC2;6"H.#CC).>OW>:\QUC2+/1[N^C\^4PPV<5S;AY3N0FXC0J<??&W=C.3
MR?2O5P>-A3M%KI;YWN_Z\CR<9@*E6\HO5N_RM9+^NYS=O+<174E] Y2-YTG
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ME#,/PSC\*> UOX(\.ZY&"9-,BBE? Y,)4+(/^^3G_@-:WC,;M)M$_O7]N/\
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M:VC^G+S_ '\SL>SV=D+^PM[R.4%+B)95[<, ?ZUX5\0KB67QU>(BAHX&6W+
M\ *F?_0B:^B=.L8-+TVVL+8,(+:)8HPQR=JC R:\I^)_A;3]%TBZU:U,QN=0
MU!6D\Q@0F5D8A>. 3SSGM75B8<U-_P!?UJ>#D>+]GC8WW=DOFU>_RO\ >>5P
MW,UGJ-M<HIV0,)2P[,K @?C@U]76S![6)E^ZR C\J\+\#^%K#7-9U;1[QYS
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MPWRXXS]:=#X6U)888C<1)'%MQ'YKN,@H=PR.,[>G05+):>)H_),=Q)*3(KR
MR(!G+9&<<+C;Z_C6EH,6LQM=_P!K2;\L/+QC'4Y(P>F-O!Q1&$6[69-7$U8P
M<U.#]%KN9MCHNI6.IV\8F?R'D,URR.Q5@%3:.>A+ YQU6NKHHK>,%'1'F5\1
M*NU*6X44451@%<7J'A77H_$>I:AH&LVUC#JWD_;#-;F26)HQMW1<[<E>,,"!
MUKM** /*M6^%>JZIJNKW;ZM9[;V.ZBC/DE2%FVD;@.,KMZ]6SDFK>H?#*Y;4
MI[[3IM+7-X\\5G=6F^V"O;K"VY!@;@5W#ZD'K7I5% 'D]Q\(;N:^U&7^U+8Q
MW4,VQO)9&222 0X"JVT(,9QSQ@=LUUFN>#$U+X?#PO:-;VJ[8%+)'M3Y'5FX
M&.NT_B:ZRB@#SSQ-\,8;[28=.\/M:Z? 9)GN5F1I&F9X]@;>3OR/3.".#Q5.
M'X77J2[&O[-(3<6UPTD4)64-':F!P#GH2=P]R:]/HH \JT3X23:?_9_VR[LK
MA;6\MY701,5ECAB=!D,2-Q+YZ8&.],3X27D6G?9!=Z;*K:=':.9('!#QW#2J
M596!488#U&T=>E>L44 8/@_0[KP[X;@TV\NTNI4=VWHFT ,Q(7U.,_>/)ZUO
M444 %%%% !1110!7NK.&\0),"0#D8JK_ &#8_P#/-OSK2HH%9&;_ &#8_P#/
M-OSH_L&Q_P">;?G6E13N%D9O]@V/_/-OSH_L&Q_YYM^=:5%%PLC-_L&Q_P">
M;?G1_8-C_P \V_.M*BBX61F_V#8_\\V_.KMO;QVL(BB&%'2I:*0604444#"B
MBB@ J*YD,-K-*H!9$9@#Z@5+1UH&MSBX_&<UI!&;CR=0,L4<@>V^18V968HQ
MR1D!>/7/..M6CXS!G:*/3V<C+!?.&\*-^=RXX;$9P.^13$UUA/-!_94)LDNF
MB9E1E5")0@))7:2<D\'C'--LM?T**[DN+6QG6XN)2CR-C&[ 8?,6P,[^ /4U
M@I/^8]-TH.[]E]S_ #ML2VWC:.YN+2'^SY5:=PI/F @ E0"/7[W(XQCOQE^H
M>)YUO)+"SMT$_GK"LDCYQ\Z!B5Z@8?Y3GG^;;7Q):26@D&FE)(D,Q544B %0
M<DY[EL?+FK5CX@M+N[6&2S>*ZFD*1_*#YJJ6&[/H-N3Z9'K33;TYB)4XQ;E[
M+;S-^BBBMCS@HHHH *Y'XG?\D^U/ZQ?^C4KKJBN;:"\@:"Z@CGA?[T<J!E/?
MD'BIE'FBUW-:%3V56-2U[-/[FF>(?#<C_A8%AS_S#1_Z*2O=*IV^D:9:3K/;
M:=:0S*FQ9(X%5@O3&0,X]JN5-.'(K&V,Q/UFHIVM9)?=?_,X;XM_\B'-_P!?
M$/\ Z&*XKX7D'XB-@C_D$K_Z!!7M%U:6U] 8+NWBN(203'*@=21TX-0V^E:=
M9W!GMM/M8)BNSS(H55MO'&0,XX''L*4J5YJ=_P"M?\S6ECO9X:6'Y=[Z^O+_
M /(_B7*\[^,W_(FVW_7\G_HN2O1*@N[&TU"'R;VU@N8@=VR:,.N?7!JJD>>+
MCW.?"U_J]>%:U^5I_<>4?"\@^.=8Y_Y=O_9EKUZJMOIEA9SR3VUE;032##R1
M1*K,/<@<U:HA'E5O4,37]O-3M;2*^Y)?H%%%%6<X4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% $)M+<Q&(P1F-GWE2HP6SG./7/-5H]$TN$H
M8]/ME*-N4B,<'CG]!^0]***5D4IR6S :+I85%&GVV(\[1Y8XR,'] /RI8])L
MXM06]CB"R*K*H4 *"V-S8]3M49]J**+(?M)]V7J***9 4444 %%%% !1110
B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>formdrs_038.jpg
<TEXT>
begin 644 formdrs_038.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %" B4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BF2 %,$
M C(X/UI/*C_YYI_WR* )**C\J/\ YYI_WR*/*C_YYI_WR* )**C\J/\ YYI_
MWR*/*C_YYI_WR* )**C\J/\ YYI_WR*/*C_YYI_WR* )**C\J/\ YYI_WR*/
M*C_YYI_WR* )**C,<0ZH@_ 53:[MP6$=J\A4@$I'P<^AZ&FDV)M(T**IV\]K
M<$J(PCC^"1-K?E5CRH_^>:?]\BDU8$[DE%1^5'_SS3_OD4>5'_SS3_OD4#)*
M*C\J/_GFG_?(H\J/_GFG_?(H DHJ/RH_^>:?]\BJ$NI6,&N6^D2H$N+F%YH"
M5&V0(0' /]X;E./0^QH TZ*C\J/_ )YI_P!\BCRH_P#GFG_?(H DHJ/RH_\
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MMM9%,;QLDA&U_O =>:R_.WW%P%2%8WE9EW8#[L\Y!&<?2KVD(LCRN9!O#X4
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M0^'J@\F:]_+R0/ZUWU>;>+V,OQH\ 0#_ )9I>R$?6/']*])J2@HHHH ****
M"BBB@ HHHH **** "EI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQO=5SZG%>>R>7?1Q%MKX^Y(K[2![,ISBI([>V9'^UVB7DSC&Z1=P4#CC.?\
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M"FKM8%OHMW#>V;,T+0V]U+.7+DNP=&&,8[%@.O0>U;] !1110 4444 %%%%
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ME3^E,^TRM&CK',%C&VY"GF4[\8/UY/XT]KIBT@/FE&5GME &%;/4>N21C\:
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MU+02*X!P=IZ'T-9_B1))=$FCB7<69 P_V=Z[OTS5/PSY*O>!"WF&0-(.V=H
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MUDCV[9Y+5I?+ &-H,088//?O1::II%\'BM=1C02 +.'D!D#<G[AY )]L<]*
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M>C-C']*71K::TTR&&=]\H!+'.>I)Q^&<5?I-@D%%%%(84444 %%%% !1110
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M-(WEEOWMP_\ (>_MVKJHX=->TJ:1_,Y:U=I\E/67Y# NJ^+M6S]]NYZ)$O\
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MZ>M4HY9C<%?,78H& 5Z^O/K_ (U>$J@!B0!TR>U25N B'FM*6?)&"N<C\O\
M/6G*'W.6;*D_*,8P*ABF>2=F(7RU/[LCJ2,YS['BB==DL;M(XV D*#@'/KZB
MCU#T([QO($<K MLF5@%K5@N%G7(*?17R:R);A9+VUBCW.YD\PJI )VCW('I6
MXK;ER5*D]CUIOX42OB8M<KXS9Q<:#Y0_>_;RRMTZ12<?C755@^+;*YN=(BN;
M*(RW=A<1WD48ZOL/S*/<J6%51:4U<FLFZ;L/U&*:*U@N$NG6&(#(&U3@C'4C
MCM52-"T4@EDD 8@LRL>/3)./U_ =ZT[*]L/$5A'=6LF^%AZ88 ]O;N/P-95]
M:?8[V)IY"\$8 @B5?E5L\,P_Q[UI!_9EHS*HOM1U1-/;6FKQQ0WSR6MW$"J2
M*VTL,X/7@]/\*QWT"[>]5;O<;1'P\[7>,H/8'.<<"M57297 2.0(ZQK(PW9)
M!R![#CZXS3=EM]F\U+<.J9=5=B> #_4&N6M@*=6?,U9_GZG12QLZ<;+4DB$:
M;3:1R06MNGEP* 1D=2<]1VY_.DM8GN]155E"F,>865CR>P*]<]\YJ&262^D2
M.U=A<N T<S9 '8Y]\8X]O>KFH7-GX<LFN9GW.1EW9<[G/ ( _B/0*.OYFNKE
MY4HQWVL<]^9\SV[E'7'%]X@T725<NPG\^9>H"1?-DG_>V"NLKFO#&EW8N+C7
M-40I>W:A(X6ZP19R%/\ M$G)_ =JZ6LZK2M%=/S-:2>LGU_+H%%%%9&I7OK;
M[792PABK,,JPZJPY!_ @5S3F&<+<S:?'B>-9=YEPH;'*\@<CTKK:YW4[1H=2
MMDM,I&RR2NF?D!!7)&<X/S'[HK:C*SL85HW5R,%S!')'"F(OFPN1Y:>PQ@ G
M'7DXST%6-9TB76_)N+.[C4;=ICE3<C#.<^H(JHEW#-=FV@7ST16:1CD+G&
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M:!2TAEC(RW;&:[Y$2-%2-0J*,*JC  IU%.A0C1C9:BK575=V%%%%;F04444
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MRG XH W:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%7AMMA!+%20-V[ YZ\<^U7]-N9+F%O.EC>5" RK"T94X'!5B33GTRU>8RE9
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? "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>formdrs_039.jpg
<TEXT>
begin 644 formdrs_039.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "Z +L# 2(  A$! Q$!_\0
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M\(O98_Z_KW_X_6#LD9@@ )]JO66BWMVY\N-C]!0!HG6=' .?#%G_ .!M[_\
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M! <_]/\ >?\ QZLX3/'@-@9[T]+ID&-VUCW- %\V/A>,!I?#\84\9_M"[_\
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M&W<H<\#/%;-L\EJ^QXR#ZGH:XW0_$%O<Q)-%*F[/W<]ZZ<7:796225^.N"*
M-DRB4%4?!SR <_K5<M(T;*.<G@GM63<W\=L3\TBJW()'6F#6K6.!O,=2W8$9
MS0!H+-*W!;>@/I6+XBN()K9E=QO Z+S56^\66\<;".)@V,<' KSG7?%TD2-M
M(!8]* .(\7^6+Y]I&,GI7-*2PPAYQ5W4[U[^Z8GYF)Y-;&A>'FO'4E2JXSG%
M &7:6,\V-J%L\# K=@\,W3 ;8OFZ]:[[1_#2@+'';G<!R1S7>Z/H=@A3SH Q
M YSP30!X2_A6^VGY3GU%59=$O+8X>-L^I%?2MSI^EHA+0!.P KF]5TJ*?='#
M"-I'\>#G\: / RDD)VL#US4A<D88@-UKM-9\-I&[GRBKCD*.]<3=*8)MIXYX
M'I0!8B<KD;N!4R2!,A<$GDG-45E 0G.:(YB.C?AB@"^L[[N^W/0=ZTH]WRY<
M8_NG@UDV[;FR#@^O>M"*9=^2V>W- &G$6.0<*<84XYJ5,\KN')Z]ZI),S</U
M'3FK,1PP(.[V(H M+$69=[# KUCX0_\ ),=,_P"NMU_Z4RUY*S;_ )2".>!F
MO6OA#_R3'3/^NMU_Z4RT ?,NHW/E:5HBYQ_HLIXZ_P#'S/5.*\Z,&(;V-.UE
M<Z;HI[?9)/\ TIGK$9CN]O>@#KK/Q#-:.'BD*,#T%=EI7Q$:-,3C=CC*G!KR
M+SBA !YQWH65MQ&['TH ]KO?B/#<Q",.<^_4"LF?QK%L!,O3L*\J:Z=2 CG/
MO2&YE=>9#D=J .XO_&$KN5&<-T)-<O>:K<3R$LVX^]9;2%AG)R>^:;M/ - &
MUI<)GG4MSSDUZQX>B3"$#Y1C&*\GT679.H#$KGD5ZOX>O8OE!/'OVH ](L!#
M':AEW ]\=36JD.Z .3A3T)/.:Q])N]/G@$<;[9!VQUK76X$K;1(,]L\8H ;(
M3L 8ENV0.]491YC%'R HQD&M*1@(V7<,CT[U0DY( !QC.>M &)J-B94?* YZ
M%J\L\3Z=MF+X5 *]@OV-O:G#;F8<9[5Y)XHD/F.=X))_*@#D0-DF&&0/0U,!
MG(/ ZBJHD8/Z^Q/6I4E)X?IZ 4 6XB& "'IUK2L[=B#GCW-4(7*#@9./2M")
MV 3+<]/>@"\L:HI);YATH21L$* 1WQUJO+*<JH( 'K5E%0Q@= >I)H D@D=C
M'CNW->T?"'_DF.F?]=;K_P!*9:\:ACCCD3RRP)ZU[+\(?^28Z9_UUNO_ $IE
MH ^7=: _LK13G!^RR?\ I3/7//G)SUKH]67.E:*<#'V63K_U\SUAN@. <9-
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M1?\ KSD_]*9ZQ<9. : +EI,4.%&?KVK>M9V.W:Y!'8US 5L\<X'8U=M+EH6
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M;Q;D.\C/\JOQ0YPH/RCN: "*(*J[E&6/'->W_"'_ ))CIG_76Z_]*9:\8BB
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B .)K8L;"STRSCL["T@M+6/.R&",1HN22<*.!DDG\: /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
